cvm_10q.htm

0001354488-14-000595.txt : 20140210 0001354488-14-000595.hdr.sgml : 20140210 20140210161633 ACCESSION NUMBER: 0001354488-14-000595 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 9 CONFORMED PERIOD OF REPORT: 20131231 FILED AS OF DATE: 20140210 DATE AS OF CHANGE: 20140210 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CEL SCI CORP CENTRAL INDEX KEY: 0000725363 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 840916344 STATE OF INCORPORATION: CO FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-11889 FILM NUMBER: 14588864 BUSINESS ADDRESS: STREET 1: 8229 BOONE BLVD . STREET 2: SUITE 802 CITY: VIENNA STATE: VA ZIP: 22182 BUSINESS PHONE: 7035069460 MAIL ADDRESS: STREET 1: 8229 BOONE BLVD. STREET 2: SUITE 802 CITY: VIENNA STATE: VA ZIP: 22182 FORMER COMPANY: FORMER CONFORMED NAME: INTERLEUKIN 2 INC DATE OF NAME CHANGE: 19880317 10-Q 1 cvm_10q.htm QUARTERLY REPORT cvm_10q.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended December 31, 2013

o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _______________ to ______________.

Commission File Number 001-11889

CEL-SCI CORPORATION

Colorado		84-0916344
State or other jurisdiction		(IRS) Employer
incorporation		Identification Number

8229 Boone Boulevard, Suite 802

Vienna, Virginia 22182

Address of principal executive offices

(703) 506-9460

Registrant's telephone number, including area code

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports) and (2) had been subject to such filing requirements for the past 90 days. Yes þ No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes þ No o

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check One):

Large accelerated filer	o	Accelerated filer	þ
Non-accelerated filer	o	Smaller reporting company	o
(Do not check if a smaller reporting company)

Indicate by check mark whether the Registrant is a shell company (as defined in Exchange Act Rule 12b-2 of the Exchange Act). Yes o No þ

Class of Stock		No. Shares Outstanding		Date
Common		55,940,156		February 4, 2014

TABLE OF CONTENTS

		Page

PART I FINANCIAL INFORMATION

Item 1.

	Condensed Balance Sheets at December 31, 2013 and September 30, 2013 (unaudited)	3

	Condensed Statements of Operations for the three months Ended December 31, 2013 and 2012 (unaudited)	4

	Condensed Statements of Cash Flows for the three months Ended December 31, 2013 and 2012 (unaudited)	5

	Notes to Condensed Financial Statements (unaudited)	7

Item 2.

	Management's Discussion and Analysis of Financial Condition and Results of Operations	22

Item 3.

	Quantitative and Qualitative Disclosures about Market Risks	26

Item 4.

	Controls and Procedures	26

PART II

Item 2.

	Unregistered Sales of Equity Securities and Use of Proceeds	27

Item 6.

	Exhibits	27

	Signatures	28

CEL-SCI CORPORATION

BALANCE SHEETS

DECEMBER 31, 2013 AND SEPTEMBER 30, 2013

(UNAUDITED)

	DECEMBER 31,			SEPTEMBER 30,
ASSETS	2013			2013

CURRENT ASSETS:
Cash and cash equivalents	$	13,494,028		$	41,612
Receivables		45,879			74,263
Prepaid expenses		988,699			780,523
Deposits - current portion		150,000			-
Inventory used for R&D and manufacturing		1,347,257			1,016,628
Deferred rent - current portion		585,156			598,717

Total current assets		16,611,019			2,511,743

RESEARCH AND OFFICE EQUIPMENT AND
LEASEHOLD IMPROVEMENTS-- less accumulated
depreciation and amortization of $3,010,439
and $2,967,345		463,053			489,336

PATENT COSTS--less accumulated
amortization of $1,161,540 and $1,151,852		317,460			318,195

DEFERRED RENT - net of current portion		5,285,781			5,448,381

DEPOSITS - net of current portion		2,120,917			2,070,917

TOTAL ASSETS	$	24,798,230		$	10,838,572

LIABILITIES AND STOCKHOLDERS' EQUITY

CURRENT LIABILITIES:
Accounts payable	$	1,627,765		$	1,924,482
Accrued expenses		346,401			113,496
Due to employees		280,464			386,337
Related party loan		1,104,057			1,104,057
Deferred rent - current portion		9,274			8,529
Lease obligation - current portion		11,463			8,212

Total current liabilities		3,379,424			3,545,113

Derivative instruments		6,143,278			433,024
Deferred revenue		126,545			126,545
Deferred rent - net of current portion		6,381			7,875
Lease obligation - net of current portion		24,445			20,925
Deposits held		5,000			5,000

Total liabilities		9,685,073			4,138,482

COMMITMENTS AND CONTINGENCIES

STOCKHOLDERS' EQUITY
Preferred stock, $.01 par value--200,000 shares authorized;
-0- shares issued and outstanding		-			-
Common stock, $.01 par value - 600,000,000 shares authorized,
55,852,992 shares and 31,025,019 shares issued and outstanding
at December 31, 2013 and September 30, 2013, respectively		558,530			310,250
Additional paid-in capital		231,049,613			218,550,408
Accumulated deficit		(216,494,986	)		(212,160,568	)

Total stockholders' equity		15,113,157			6,700,090

TOTAL LIABILITIES AND
STOCKHOLDERS' EQUITY	$	24,798,230		$	10,838,572

See notes to financial statements.

CEL-SCI CORPORATION

STATEMENTS OF OPERATIONS

THREE MONTHS ENDED DECEMBER 31, 2013 and 2012

(UNAUDITED)

	2013			2012

OTHER INCOME	$	113,144		$	15,000

OPERATING EXPENSES:
Research and development (excluding
R&D depreciation of $41,673 and $104,864
respectively, included below)		4,019,541			2,924,722
Depreciation and amortization		56,699			133,450
General & administrative		1,971,214			2,001,285

Total operating expenses		6,047,454			5,059,457

OPERATING LOSS		(5,934,310	)		(5,044,457	)

GAIN ON DERIVATIVE INSTRUMENTS		1,610,817			2,746,198

INTEREST INCOME		31,757			29,415

INTEREST EXPENSE		(42,682	)		(41,402	)

NET LOSS		(4,334,418	)		(2,310,246	)

ISSUANCE OF ADDITIONAL SHARES DUE TO RESET PROVISIONS		(1,117,447	)		-

NET LOSS AVAILABLE TO COMMON SHAREHOLDERS	$	(5,451,865	)	$	(2,310,246	)

NET LOSS PER COMMON SHARE
BASIC	$	(0.11	)	$	(0.08	)

DILUTED	$	(0.15	)	$	(0.18	)

WEIGHTED AVERAGE COMMON SHARES
OUTSTANDING
BASIC		48,215,919			28,311,602

DILUTED		48,215,919			28,311,602

See notes to financial statements.

CEL-SCI CORPORATION

STATEMENTS OF CASH FLOWS

THREE MONTHS ENDED DECEMBER 31, 2013 and 2012

(UNAUDITED)

	2013	2012
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (4,334,418)	$ (2,310,246)
Adjustments to reconcile net loss to
net cash used in operating activities:
Depreciation and amortization	56,699	133,450
Issuance of common stock, warrants and options for services	137,729	54,485
Modification of warrants issued for services	76,991	-
Employee option cost	510,278	966,585
Common stock contributed to 401(k) plan	37,887	39,711
Impairment loss on abandonment of patents	240	10,223
Loss on retired equipment	-	2,011
Gain on derivative instruments	(1,610,817)	(2,746,198)
(Increase)/decrease in assets:
Receivables	28,384	143,714
Deferred rent	176,161	139,536
Prepaid expenses	(210,367)	471,936
Inventory used for R&D and manufacturing	(330,629)	247,585
Deposits	(200,000)	-
Increase/(decrease) in liabilities:
Accounts payable	(380,943)	(192,358)
Accrued expenses	232,905	23,252
Due to employees	(105,873)	20,843
Deferred rent liability	(749)	688

Net cash used in operating activities	(5,916,522)	(2,994,783)

CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of equipment	(8,587)	(16,093)
Expenditures for patent costs	-	(125)

Net cash used in investing activities	(8,587)	(16,218)

CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock and warrants	19,380,190	9,807,375
Payments on obligations under capital leases	(2,665)	(1,025)

Net cash provided by financing activities	19,377,525	9,806,350

NET INCREASE
IN CASH AND CASH EQUIVALENTS	13,452,416	6,795,349

CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD	41,612	3,941,042

CASH AND CASH EQUIVALENTS, END OF PERIOD	$ 13,494,028	$ 10,736,391

See notes to financial statements.

CEL-SCI CORPORATION

STATEMENTS OF CASH FLOWS

THREE MONTHS ENDED DECEMBER 31, 2013 and 2012

(UNAUDITED)

	2013			2012
ISSUANCE OF WARRANTS:
Increase in derivative liabilities	$	(7,321,071	)	$	(4,200,000	)
Decrease in additional paid-in capital		7,321,071			4,200,000

	$	-		$	-

ISSUANCE OF ADDITIONAL SHARES
Increase in common stock	$	(15,631	)	$	-
Increase additional paid-in capital		(1,101,786	)		-
Decrease additional paid-in capital		1,117,417			-

	$	-		$	-


ISSUANCE OF COMMON STOCK FOR PREPAID SERVICES
Increase additional paid-in capital	$	(55,362	)	$	(236,165	)
Increase in prepaid expenses		55,362			236,165

	$	-		$	-

PATENT COSTS INCLUDED IN
ACCOUNTS PAYABLE:
Increase in patent costs	$	9,208		$	8,641
Increase in accounts payable		(9,208	)		(8,641	)

	$	-		$	-

NON-CASH EQUIPMENT COSTS
Increase in research and office equipment	$	12,126		$	36,622
Increase in accounts payable		(2,664	)		-
Increase in capital lease obligation		(9,462	)		(36,622	)

	$	-		$	-

CAPITAL LEASE PAYMENTS INCLUDED IN
ACCOUNTS PAYABLE:
Decrease in capital lease obligation	$	26		$	1,105
Increase in accounts payable		(26	)		(1,105	)

	$	-		$	-

OFFERING COSTS INCLUDED IN
ACCOUNTS PAYABLE:
Decrease additional paid-in capital	$	72,328		$	-
Increase in accounts payable		(72,328	)		-

	$	-		$	-

SUPPLEMENTAL DISCLOSURE OF CASH FLOWS
INFORMATION:
Cash expenditure for interest expense	$	56,509		$	41,878

See notes to financial statements.

CEL-SCI CORPORATION

NOTES TO CONDENSED FINANCIAL STATEMENTS

THREE MONTHS ENDED DECEMBER 31, 2013 AND 2012 (UNAUDITED)

A. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying condensed financial statements of CEL-SCI Corporation (the Company) are unaudited and certain information and footnote disclosures normally included in the annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been omitted pursuant to the rules and regulations of the Securities and Exchange Commission. While management of the Company believes that the disclosures presented are adequate to make the information presented not misleading, these interim condensed financial statements should be read in conjunction with the financial statements and notes included in the Company’s annual report on Form 10-K for the year ended September 30, 2013.

In the opinion of management, the accompanying unaudited condensed financial statements contain all accruals and adjustments (each of which is of a normal recurring nature) necessary for a fair presentation of the Company’s financial position as of December 31, 2013 and the results of its operations for the three months then ended. The condensed balance sheet as of September 30, 2013 is derived from the September 30, 2013 audited financial statements. Significant accounting policies have been consistently applied in the interim financial statements and the annual financial statements. The results of operations for the three months ended December 31, 2013 and 2012 are not necessarily indicative of the results to be expected for the entire year.

Summary of Significant Accounting Policies:

Research and Office Equipment and Leasehold Improvements - Research and office equipment is recorded at cost and depreciated using the straight-line method over estimated useful lives of five to seven years. Leasehold improvements are depreciated over the shorter of the estimated useful life of the asset or the term of the lease. Repairs and maintenance which do not extend the life of the asset are expensed when incurred. The fixed assets are reviewed on a quarterly basis to determine if any of the assets are impaired.

Patents - Patent expenditures are capitalized and amortized using the straight-line method over the shorter of the expected useful life or the legal life of the patent (17 years). In the event changes in technology or other circumstances impair the value or life of the patent, appropriate adjustment in the asset value and period of amortization is made. An impairment loss is recognized when estimated future undiscounted cash flows expected to result from the use of the asset, and from its disposition, is less than the carrying value of the asset. The amount of the impairment loss would be the difference between the estimated fair value of the asset and its carrying value.

Research and Development Costs - Research and development costs are expensed as incurred.

Income Taxes - The Company uses the asset and liability method of accounting for income taxes. Under the asset and liability method, deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating and tax loss carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company records a valuation allowance to reduce the deferred tax assets to the amount that is more likely than not to be recognized. A full valuation allowance was recorded against the deferred tax assets as of December 31, 2013 and September 30, 2013.

Derivative Instruments – The Company has entered into financing arrangements that contain embedded derivative features. The Company has also issued warrants to various parties in connection with work performed by these parties. The Company accounts for these arrangements in accordance with ASC 815, “Accounting for Derivative Instruments and Hedging Activities.” In accordance with accounting principles generally accepted in the United States (“GAAP”), derivative instruments and hybrid instruments are recognized as either assets or liabilities on the balance sheet and are measured at fair value with gains or losses recognized in earnings or other comprehensive income depending on the nature of the derivative or hybrid instruments. The Company determines the fair value of derivative instruments and hybrid instruments based on available market data using appropriate valuation models, giving consideration to all of the rights and obligations of each instrument. The derivative liabilities are remeasured at fair value at the end of each interim period as long as they are outstanding.

Deferred Rent (Asset) –Consideration paid, including deposits, related to operating leases is recorded as a deferred rent asset and amortized as rent expense over the lease term. Interest on the deferred rent is calculated at 3% on the funds deposited on the manufacturing facility and is included in deferred rent. This interest income will be used to offset future rent.

Stock-Based Compensation – Compensation cost for all stock-based awards is measured at fair value as of the grant date in accordance with the provisions of ASC 718 “Stock Compensation Expense”. The fair value of the stock options is calculated using the Black-Scholes option pricing model. The Black-Scholes model requires various judgmental assumptions including volatility and expected option life. The stock-based compensation cost is recognized on the straight line allocation method as expense over the requisite service or vesting period.

Equity instruments issued to non-employees are accounted for in accordance with ASC 505-50, “Equity-Based Payments to Non Employees.” Accordingly, compensation is recognized when goods or services are received and is measured using the Black-Scholes valuation model. The Black-Scholes model requires various judgmental assumptions regarding the fair value of the equity instruments at the measurement date and the expected life of the options.

The Company has Incentive Stock Option Plans, Non-Qualified Stock Option Plans, a Stock Compensation Plan and Stock Bonus Plans. In some cases these Plans are collectively referred to as the "Plans". All Plans have been approved by the stockholders.

Reclassification – Certain prior year items have been reclassified to conform to the current year presentation.

B. NEW ACCOUNTING PRONOUNCEMENTS

There are no significant new accounting pronouncements that would impact the condensed financial statements.

C. STOCKHOLDERS’ EQUITY

Stock options, stock bonuses and compensation granted by the Company as of December 31, 2013 are as follows:

Name of Plan	Total Shares Reserved Under Plans		Shares Reserved for Outstanding Options		Shares Issued as Stock Bonus		Remaining Options/Shares Under Plans
Incentive Stock Option Plans		1,960,000		1,573,597		N/A		145,703
Non-Qualified Stock Option Plans		5,680,000		3,674,544		N/A		1,443,537
Stock Bonus Plans		1,594,000		N/A		958,325		634,919
Stock Compensation Plan		1,350,000		N/A		791,145		558,855

There were zero and 1,437,466 options granted to employees and directors during the three months ended December 31, 2013 and 2012, respectively.

In December 2012, the Company offered employees and directors holding options that expire on April 1, 2013 the opportunity to forfeit these options and have new options issued with an expiration date of December 17, 2017. All twelve employees and directors eligible for this offer accepted the terms. This resulted in the cancellation of 387,466 options priced at $2.20 per share and the concurrent issuance of the same number of options at $2.80 per share. In accordance with ASC 718, the Company recorded the incremental compensation cost of the options. The incremental compensation cost is the excess of the fair value of the replacement award over the fair value of the cancelled award at the cancellation date. At the cancellation date, the incremental compensation cost was $477,879.

Stock-Based Compensation Expense

	Three Months Ended December 31,
	2013		2012

Employees	$	510,278	$	966,585
Non-employees	$	214,720	$	107,818

At December 31, 2013 and September 30, 2013, respectively, non-employee stock compensation expense excluded $55,362 and $57,553 of prepaid consulting expenses.

Derivative Liabilities, Warrants and Other Options

Below is a chart showing the derivative liabilities, warrants and other options outstanding at December 31, 2013:

Warrant	Issue Date	Shares Issuable upon Exercise of Warrant		Exercise Price		Expiration Date	Reference

Series N	8/18/08		2,951,420		0.53	8/18/14		1
Series A	6/24/09		130,347		5.00	12/24/14		1
Schleuning (Series A)	7/8/09		16,750		5.00	1/8/15		1
Series B	9/4/09		50,000		6.80	9/4/14		1
Series C	8/20/09 – 8/26/09		463,487		5.50	2/20/15		1
Series E	9/21/09		71,428		17.50	8/12/14		1
Series F	10/6/11		1,200,000		4.00	10/6/14		1
Series G	10/6/11		66,667		4.00	8/12/14		1
Series H	1/26/12		1,200,000		5.00	8/1/15		1
Series Q	6/21/12		1,200,000		5.00	12/22/15		1
Series R	12/6/12		2,625,000		4.00	12/6/16		1
Series S	10/11/13-12/24/13		25,713,095		1.25	10/11/18		1

Series L	4/18/07		25,000		7.50	4/17/14		2
Series L (repriced)	4/18/07		70,000		2.50	4/2/15		2
Series M (modified)	4/18/07		500,000		1.00	4/20/14		2

Series P	2/10/12		590,001		4.50	3/6/17		3

Private Investors	7/18/05-6/30/09		740,938		5.60-8.20	1/26/14 - 7/18/14		4

Warrants held by Officer and Director	6/24/09-7/6/09		349,754		4.00 – 5.00	12/24/14 – 1/6/15		5

Consultants	2/15/05-10/28/13		200,750		0.85-20.00	5/20/14 - 12/27/17		6

1. Derivative Liabilities

See below for details of the balances of derivative instruments at December 31, 2013 and September 30, 2013.

	December 31, 2013		September 30, 2013

Series A through E warrants	$	6,106	$	6,106
Series N warrants		531,255		41,501
Series F and G warrants		12,667		12,667
Series H warrants		12,000		36,000
Series Q warrants		24,000		48,000
Series R warrants		157,500		288,750
Series S warrants		5,339,750		-

Total derivative liabilities	$	6,143,278	$	433,024

The Company reviews all outstanding warrants in accordance with the requirements of ASC 815. This topic provides that an entity should use a two-step approach to evaluate whether an equity-linked financial instrument (or embedded feature) is indexed to its own stock, including evaluating the instrument’s contingent exercise and settlement provisions. The warrant agreements provide for adjustments to the exercise price for certain dilutive events, which includes an adjustment to the number of shares issuable upon the exercise of the warrant in the event that the Company makes certain equity offerings in the future at a price lower than the exercise prices of the warrant instruments. Under the provisions of ASC 815, the warrants are not considered indexed to the Company’s stock because future equity offerings or sales of the Company’s stock are not an input to the fair value of a “fixed-for-fixed” option on equity shares, and equity classification is therefore precluded.

In accordance with ASC 815, derivative liabilities must be measured at fair value upon issuance and re-valued at the end of each reporting period through expiration. Any change in fair value between the respective reporting dates is recognized as a gain or loss.

Series A through E Warrants

The Company accounted for the Series A through E Warrants as derivative liabilities in accordance with ASC 815. These warrants do not qualify for equity accounting and must be accounted for as derivative liabilities since the warrant agreements provide the holder with the right, at its option, to require the Company to a cash settlement of the warrants at Black-Scholes value in the event of a Fundamental Transaction, as defined in the warrant agreement. Since the occurrence of a Fundamental Transaction is not entirely within the Company's control, there exist circumstances that would require net-cash settlement of the warrants while holders of shares would not receive a cash settlement.

In June 2009, the Company issued 1,011,656 Series A warrants exercisable at $5.00 per share in connection with a financing. The cost of the warrants of $2,775,021 was recorded as a debit to additional paid-in capital and a credit to derivative liabilities. As of December 31, 2013, 130,347 of these warrants remained outstanding. As of December 31, 2013 and September 30, 2013, the fair value of the remaining Series A warrants was $1,303.

In July 2009, the Company issued 16,750 warrants to a private investor. The warrants were issued with an exercise price of $5.00 per share and valued at $43,550 using the Black Scholes method. The cost of the warrants was accounted for as a debit to additional paid-in capital and a credit to derivative liabilities. As of December 31, 2013, 16,750 warrants remained outstanding. As of December 31, 2013 and September 30, 2013, the fair value of the remaining warrants was $168.

In connection with a loan received and fully repaid in a prior period, the Company issued 50,000 Series B warrants with an exercise price of $6.80 per share. As of December 31, 2013, 50,000 Series B warrants remained outstanding. As of December 31, 2013 and September 30, 2013, the fair value of the remaining Series B warrants was $0.

In connection with an August 2009 financing, the Company issued 539,222 Series C warrants exercisable at $5.50 per share. As of December 31, 2013, 463,487 of these warrants remained outstanding. As of December 31, 2013 and September 30, 2013, the fair value of the remaining Series C warrants was $4,635.

In September 2009, the Company issued 71,428 Series E warrants with an exercise price of $17.50 per share to the placement agent in connection with a financing. As of December 31, 2013, 71,428 Series E warrants remained outstanding. As of December 31, 2013 and September 30, 2013, the fair value of the remaining Series E warrants was $0.

For the three months ended December 31, 2013 and 2012, the Company recorded a gain of $0 and $332,436, respectively, on the Series A through E warrants.

Series N Warrants

In October 2011, the Company sold 1,333,333 shares of its common stock to private investors for $4,000,000, or $3.00 per share. This financing triggered the reset provision in the Series N warrants, which allows for adjustments in the exercise price if subsequent equity sales are offered at a lower price. As a result, the outstanding 389,078 Series N warrants issued to investors in connection with a prior year financing, were reset from $4.00 to $3.00. In addition, the investors were issued 129,693 warrants exercisable at $3.00 per share at an initial cost of $220,478. The cost was accounted for as a debit to loss on derivatives and a credit to derivative liabilities.

On October 11, 2013 and December 24, 2013, in connection with public offerings of common stock on those dates, the Company issued the Series N warrant holders 2,432,649 additional warrants as required by the warrant agreements. As of December 31, 2013, 2,951,420 Series N warrants remain outstanding. As of December 31, 2013 and September 30, 2013, the values of the Series N warrants were $531,255 and $41,501, respectively. During the three months ended December 31, 2013 and 2012, the Company recorded a loss of $489,754 and a gain of $311,262 on the Series N warrants, respectively.

Series F and G Warrants

In October 2011, in connection with a financing, the Company issued 1,200,000 Series F warrants exercisable at $4.00 per share at any time prior to October 6, 2014. The Company also issued 66,667 Series G warrants exercisable at $4.00 per share to the placement agent for this offering. The Series G warrants are exercisable at any time prior to August 12, 2014. The initial cost of the warrants of $2,146,667 was recorded as a debit to additional paid-in capital and a credit to derivative liabilities. As of December 31, 2013 and September 30, 2013, the fair value of the Series F and G warrants was $12,667. During the three months ended December 30, 2013 and 2012, the Company recorded a gain on the Series F and G warrants of $0 and $640,000, respectively.

Series H Warrants

In January 2012, in connection with a financing, the Company issued 1,200,000 Series H warrants exercisable at $5.00 per share at any time prior to August 1, 2015. The initial cost of the warrants of $2,400,000 was recorded as a debit to additional paid-in capital and a credit to derivative liabilities. As of December 31, 2013 and September 30, 2013, the fair values of the Series H warrants were $12,000 and $36,000, respectively. During the three months ended December 31, 2013 and 2012, the Company recorded a gain of $24,000 and $600,000, respectively, on the Series H warrants.

Series Q Warrants

In June 2012, in connection with a financing, the Company issued 1,200,000 Series Q warrants exercisable at $5.00 per share at any time prior to December 22, 2015. The initial cost of the warrants of $2,160,000 was recorded as a debit to additional paid-in capital and a credit to derivative liabilities. As of December 31, 2013 and September 30, 2013, the fair values of the Series Q warrants were $24,000 and $48,000, respectively. During the three months ended December 31, 2013 and 2012 the Company recorded a gain of $24,000 and $600,000, respectively, on the Series Q warrants.

Series R Warrants

In December 2012 the Company sold 3,500,000 shares of its common stock for $10,500,000, or $3.00 per share, in a registered direct offering. The investors in this offering also received Series R warrants which entitle the investors to purchase up to 2,625,000 shares of the Company’s common stock. The Series R warrants may be exercised at any time before December 7, 2016 at a price of $4.00 per share. The initial cost of the warrants of $4,200,000 was recorded as a debit to additional paid-in capital and a credit to derivative liabilities. As of December 31, 2013 and September 30, 2013, the fair value of the derivative liabilities totaled $157,500 and $288,750, respectively. During the three months ended December 31, 2013 and the Company recorded a gain of $131,250 and $262,500, respectively, on the Series R warrants.

Series S Warrants

On October 11, 2013, the Company closed a public offering of 17,826,087 units of common stock and warrants at a price of $1.00 per unit for net proceeds of $16,400,000, net of underwriting discounts and commissions and offering expenses of the Company. Each unit consisted of one share of common stock and one Series S warrant to purchase one share of common stock. The Series S warrants are immediately exercisable, expire on October 11, 2018, and have an exercise price of $1.25. In November 2013, the underwriters purchased an additional 2,648,913 warrants pursuant to the overallotment option, for which the Company received net proceeds of $24,370.

On December 24, 2013, the Company closed a public offering of 4,761,905 units of common stock and warrants at a price of $0.63 per unit for net proceeds of $2,790,000, net of underwriting discounts and commissions and offering expenses of the Company. Each unit consisted of one share of common stock and one Series S warrant to purchase one share of common stock. The Series S warrants are immediately exercisable, expire on October 11, 2018, and have an exercise price of $1.25. The underwriters purchased an additional 476,190 units of common stock and warrants pursuant to the overallotment option, for which the Company received net proceeds of approximately $279,000.

The initial cost of the S warrants of $7,321,071 was recorded as a debit to additional paid-in capital and a credit to derivative liabilities. As of December 31, 2013, the fair value of the derivative liabilities totaled $5,399,750. During the three months ended December 31, 2013, the Company recorded a gain of $1,921,321 on the Series S warrants.

1.	Series L and M Warrants

In April 2007, the Company completed a $15 million private financing. Shares were sold at $7.50, a premium over the closing price of the previous two weeks. The financing was accompanied by 1,000,000 warrants with an exercise price of $7.50 and 1,000,000 warrants with an exercise price of $20.00. The warrants are known as Series L and Series M warrants, respectively. The warrants issued with the financing qualified for equity treatment in accordance with ASC 815. The cost of Series L and Series M warrants were recorded as a debit and a credit to additional paid-in capital.

In November 2011, the Company reduced the exercise price of 160,000 Series L warrants to $3.40. The additional cost of $86,826 was recorded as a debit and a credit to additional paid-in capital and was a deemed dividend. In March 2012, 60,000 Series L warrants were exercised at a price of $3.40, and the Company received proceeds of $204,000.

In April 2012, the 25,000 Series L warrants were transferred to a consultant exercisable at a price of $7.50 per share and were extended for two years from the current expiration date. The additional value of $43,910 was accounted for as a credit to additional paid-in capital and a debit to general and administrative expense. In June 2012, 10,167 Series L warrants with an exercise price of $7.50 per share, expired. In April 2013, 100,000 Series L warrants were repriced to $2.50 and extended for two years to April 2, 2015 in return for a reduction in outstanding warrants to 70,000. The additional cost of $59,531 was recorded as a debit and a credit to additional paid-in capital and was a deemed dividend. This cost was included in modification of warrants and increased the net loss available to shareholders on the statements of operations. As of December 31, 2013, 70,000 of the Series L warrants at the reduced exercise price of $2.50 and 25,000 warrants at the original exercise price of $7.50 remained outstanding.

In February 2011, 600,000 Series M warrants, exercisable at a price of $6.00 per share were extended for two years to July 31, 2014. This cost of $661,457 was recorded as a debit and a credit to additional paid-in capital and was a deemed dividend.

In November 2011, the Company reduced the exercise price of 600,000 Series M warrants from $6.00 to $3.40. The additional cost of $238,794 was recorded as a debit and a credit to additional paid-capital and was a deemed dividend.

In October 2013, the Company reduced the exercise prices of the Series M warrants from $3.40 to $1.00 in exchange for a reduction in the number of warrants from 600,000 to 500,000. The additional cost of $76,991 was recorded as non-employee stock compensation expense. As of December 31, 2013, 500,000 Series M warrants at the reduced exercise price of $1.00 remained outstanding.

3.	Series O and P Warrants

In March 2009, as further consideration for its rights under a licensing agreement, Byron Biopharma LLC (“Byron”) purchased 375,000 Units from the Company at a price of $2.00 per Unit. Each Unit consisted of one share of the Company’s common stock and two Series O warrants. All Series O warrants were exercised by September 30, 2012.

On February 10, 2012, the Company issued 590,001 Series P warrants to the former holder of the Series O warrants as an inducement for the early exercise of the Series O warrants. Series O warrants entitled the holder to purchase 590,001 shares of the Company’s common stock at a price of $2.50 per share at any time on or prior to March 6, 2016. The Series P warrants allow the holder to purchase up to 590,001 shares of the Company’s common stock at a price of $4.50 per share. The Series P warrants are exercisable at any time prior to March 6, 2017. The warrants were accounted for as an equity transaction using the Black-Scholes method to value the warrants. The fair value of the warrants was calculated to be $1,593,000. This cost was recorded as a debit and a credit to additional paid-in capital. As of December 31, 2013, 590,001 Series P warrants remained outstanding.

4.	Private Investor Warrants

In February 2011, 132,500 warrants issued to an investor with exercise prices between $5.60 and $8.20 were extended for three years. The additional value of $406,912 was calculated using the Black Scholes method and was accounted for as a debit and a credit to additional paid-in capital. As of December 31, 2013, 132,500 warrants remained outstanding.

In January 2009, as part of an amended lease agreement on the manufacturing facility, the Company repriced 300,000 warrants issued to the lessor in July 2007 at $12.50 per share and which were to expire on July 12, 2013. These warrants were repriced at $7.50 per share and expire on January 26, 2014. The cost of this repricing and extension of the warrants was $70,515 and was accounted for as a debit to the deferred rent asset and a credit to additional paid-in capital. In addition, 78,750 additional warrants were given to the lessor of the manufacturing facility on the same date, exercisable at a price of $7.50 per share, and will expire on January 26, 2014. The cost of these warrants was $45,207 and was accounted for as a debit to the deferred rent asset and a credit to additional paid-in capital. As of December 31, 2013, 378,750 warrants remained outstanding.

Between March 31 and June 30, 2009, 229,688 warrants were issued at $7.50 to the leaseholder on the manufacturing facility in consideration for the deferral of rent payments. As of December 31, 2013, 229,688 warrants remained outstanding.

3.	Warrants Held by Officer and Director

Between December 2008 and June 2009, Maximilian de Clara, the Company’s President and a director, loaned the Company $1,104,057 under a note payable. In June 2009, the Company issued 164,824 warrants, exercisable at $4.00 per share, to Mr. De Clara. The warrants are exercisable at any time prior to December 24, 2014. These warrants were valued at $65,796 using the Black-Scholes method. In July 2009, as consideration for a further extension of the loan, the Company issued 184,930 warrants, exercisable at $5.00 per share, to Mr. De Clara. These warrants were valued at $341,454 using the Black-Scholes method and can be exercised at any time prior to January 6, 2015. The first warrants were recorded as a discount to the loan and a credit to additional paid-in capital. The second warrants were recorded as a debit to derivative loss of $831,230, a premium of $341,454 on the loan and a credit to additional paid-in capital of $489,776. The warrants and premium are fully amortized. As of December 31, 2013, 349,754 warrants remained outstanding. See Note E for additional information.

4.	Options and Shares Issued to Consultants

As of December 31, 2013, 200,750 options issued to consultants as payment for services remained outstanding, of which 191,250 options were issued from the Non-Qualified Stock Option plans. On May 22, 2013, 3,000 options previously issued to a consultant from the Non-Qualified Stock Option plans expired.

On October 15, 2013, the Company entered into a consulting agreement for services to be provided through October 14, 2014. In consideration for services provided, the Company agreed to issue the consultant 100,000 restricted shares in three installments – 34,000 upon signing, 33,000 on January 15, 2014, and 33,000 on March 14, 2014. Accordingly, during the three months ended December 31, 2013, the Company issued the consultant 34,000 shares of restricted stock at the fair market value of $0.80 per share. The aggregate fair market value of $27,200 was recorded as a prepaid expense and will be charged to general and administrative expense over the period of service.

On October 20, 2013, the Company entered into a consulting agreement for services to be provided through October 19, 2016. In consideration for services provided, the Company agreed to issue the consultant 34,164 restricted shares each month of the agreement, with the first three months being issued in advance. Accordingly, the Company issued the consultant 102,492 shares of restricted stock at the fair market value of $0.82 per share. The aggregate fair market value of $84,043 was recorded as a prepaid expense and will be charged to general and administrative expense over the period of service. On December 28, 2012, the Company entered into a consulting agreement with this same consultant for services to be provided through December 27, 2013. In consideration for the services to be provided, the Company issued the consultant 50,000 shares of common stock and 50,000 options to purchase common stock at a price of $2.80 per share. The common shares were issued at the fair market value on the agreement date of $2.80. The aggregate fair market value of $140,000 was recorded as a prepaid expense and was charged to general and administrative expense over the period of service. The fair value of the options issued, as calculated using the Black-Scholes method, was determined to be $98,150 and was also charged to general and administrative expense over the period of service.

On October 28, 2013, the Company entered into a consulting agreement for services to be provided through April 27, 2014. In consideration for services provided, the Company granted the consultant 60,000 options to purchase common stock at a price of $0.85 per share. The fair value of the options issued, as calculated using the Black-Scholes method, was determined to be $24,294 and was recorded as a prepaid expense and will be charged to general and administrative expense over the period of service.

During the three months ended December 31, 2013 and 2012, the Company recorded expense of $137,729 and $1,985, respectively relating to these consulting arrangements. As of December 31, 2013 and September 30, 2013, the Company recorded $55,362 and $57,553, respectively, in prepaid consulting expenses.

D. FAIR VALUE MEASUREMENTS

In accordance with ASC 820-10, “Fair Value Measurements,” the Company determines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company generally applies the income approach to determine fair value. This method uses valuation techniques to convert future amounts to a single present amount. The measurement is based on the value indicated by current market expectations with respect to those future amounts.

ASC 820-10 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to active markets for identical assets and liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement). The Company classifies fair value balances based on the observability of those inputs. The three levels of the fair value hierarchy are as follows:

●	Level 1 – Observable inputs such as quoted prices in active markets for identical assets or liabilities

●

Level 2 – Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and amounts derived from valuation models where all significant inputs are observable in active markets

●	Level 3 – Unobservable inputs that reflect management’s assumptions

For disclosure purposes, assets and liabilities are classified in their entirety in the fair value hierarchy level based on the lowest level of input that is significant to the overall fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the placement within the fair value hierarchy levels.

The table below sets forth the assets and liabilities measured at fair value on a recurring basis, by input level, in the condensed balance sheet at December 31, 2013:

	Quoted Prices in Active Markets for Identical Assets or Liabilities (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total

Derivative instruments	$	-	$	-	$	6,143,278	$	6,143,278

The table below sets forth the assets and liabilities measured at fair value on a recurring basis, by input level, in the condensed balance sheet at September 30, 2013:

	Quoted Prices in Active Markets for Identical Assets or Liabilities (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total

Derivative instruments	$	-	$	-	$	433,024	$	433,024

The following sets forth the reconciliation of beginning and ending balances related to fair value measurements using significant unobservable inputs (Level 3) for the three months ended December 31, 2013 and the year ended September 30, 2013:

	(3 month)			(12 month)
	December 31, 2013			September 30, 2013
Beginning balance	$	433,024		$	6,983,690
Issuances		7,321,071			4,200,000
Settlements		-			-
Realized and unrealized gains
recorded in earnings		(1,610,817	)		(10,750,666	)
Ending balance	$	6,143,278		$	433,024

The fair values of the Company’s derivative instruments disclosed above are primarily derived from valuation models where significant inputs such as historical price and volatility of the Company’s stock as well as U.S. Treasury Bill rates are observable in active markets.

E. LOANS FROM OFFICER

The Company’s President, and a director, Maximilian de Clara, loaned the Company $1,104,057. The loan from Mr. de Clara bears interest at 15% per year and is secured by a lien on substantially all of the Company’s assets. The Company does not have the right to prepay the loan without Mr. de Clara’s consent. The loan was initially payable at the end of March 2009, but was extended to the end of June 2009. At the time the loan was originally due, and in accordance with the loan agreement, the Company issued Mr. de Clara warrants to purchase 164,824 shares of the Company’s common stock at a price of $4.00 per share. The warrants are exercisable at any time prior to December 24, 2014. In June 2009, the loan with Mr. de Clara was extended for the second time to July 6, 2014. At Mr. de Clara’s option, the loan may be converted into shares of the Company’s common stock. The number of shares which will be issued upon any conversion will be determined by dividing the amount to be converted by $4.00. As further consideration for the second extension, Mr. de Clara received warrants to purchase 184,930 shares of the Company’s common stock at a price of $5.00 per share at any time prior to January 6, 2015. On May 13, 2011, to recognize Mr. de Clara’s willingness to agree to subordinate his note to the convertible preferred shares and convertible debt as part of the settlement agreement, the Company extended the maturity date of the note to July 6, 2015; however, Mr. de Clara may demand payment upon giving the Company a minimum 10 day notice.

During the three months ended December 31, 2013 and 2012, the Company paid $55,203 and $41,402 respectively in interest expense to Mr. de Clara.

F. OPERATIONS AND FINANCING

The Company has incurred significant costs since its inception in connection with the acquisition of certain patented and unpatented proprietary technology and know-how relating to the human immunological defense system, patent applications, research and development, administrative costs, construction of laboratory facilities, and clinical trials. The Company has funded such costs with proceeds from loans and the public and private sale of its common and preferred stock. The Company will be required to raise additional capital or find additional long-term financing in order to continue with its research efforts. To date, the Company has not generated any revenue from product sales. The ability of the Company to complete the necessary clinical trials and obtain US Food & Drug Administration (FDA) approval for the sale of products to be developed on a commercial basis is uncertain. Ultimately, the Company must complete the development of its products, obtain the appropriate regulatory approvals and obtain sufficient revenues to support its cost structure.

The Company is currently running a large multi-national Phase III clinical trial for head and neck cancer with its partners TEVA Pharmaceuticals and Orient Europharma. The Company believes that it has enough capital to support its operations for more than the next twelve months and believes that it has ready access to new equity capital should the need arise. During fiscal year 2013, the Company raised $9.8 million net proceeds from several institutional investors. During the three months ended December 31, 2013, the Company raised approximately $19.4 million in net proceeds through the sale of common stock and warrants in two public offerings. These funds are expected to meet the Company’s cash requirements through 2014. To finance the study beyond the next 12 months, the Company plans to raise additional capital in the form of corporate partnerships, debt and/or equity financings. The Company believes that it will be able to obtain additional financing since Multikine is a Phase III product designed to treat cancer and because it has done so consistently in the past. However, there can be no assurance that the Company will be successful in raising additional funds or that funds will be available to the Company on acceptable terms or at all. If the Company does not raise the necessary amounts of money, the Company will either have to slow down or delay the Phase III clinical trial or even significantly curtail its operations until such time as it is able to raise the required funding.

Since the Company launched its Phase III trial for Multikine, the Company has spent approximately $11,300,000 as of December 31, 2013 on direct costs for the Phase III clinical trial. The total remaining cash cost of the clinical trial is estimated to be about $33,300,000. It should be noted that this estimate is based only on the information currently available in the Company’s contracts with the Clinical Research Organizations responsible for managing the Phase III trial. This number can be affected by the speed of enrollment, foreign currency exchange rates and many other factors, some of which cannot be foreseen today. It is therefore possible that the cost of the Phase III trial will be higher than currently estimated.

G. COMMITMENTS AND CONTINGENCIES

Clinical Research Agreements

In March 2013, the Company entered into an agreement with Aptiv Solutions to provide certain clinical research services in accordance with a master service agreement. The Company will reimburse Aptiv for costs incurred. In May 2013, CEL-SCI made an advance payment of $400,000. In October 2013, CEL-SCI made the second and final advance payment of $200,000. The funds advanced will be credited back in $150,000 annual increments from December 2014 through December 2017. As of December 31, 2013, $150,000 of the deposit is classified as a current asset.

In April 2013, the Company entered into a co-development and revenue sharing agreement with Ergomed. Under the agreement, Ergomed will contribute up to $10 million towards the Company’s Phase III trial in the form of offering discounted clinical services in exchange for a single digit percentage of milestone and royalty payments, up to a specific maximum amount. The Company accounted for the co-development and revenue sharing agreement in accordance with ASC 808 “Collaborative Arrangements”. The Company determined the payments to Erogmed are within the scope of ASC 730 “Research and Development.” Therefore, the Company records the discount on the clinical services as a credit to research and development expense on its Statements of Operations. Since the Company entered into the co-development and revenue sharing agreement with Ergomed it has incurred research and development expenses of approximately $2,017,000 related to Ergomed’s services. This amount is net of Ergomed’s discount of approximately $634,000. During the three months ended December 31, 2013, the Company recorded, net of Ergomed’s discount, approximately $1,179,000 as research and development expense related to Ergomed’s services.

In October 2013, the Company entered into two co-development and profit sharing agreements with Ergomed. One agreement supports the US Navy with the development of Multikine as a potential treatment in HIV/HPV co-infected men and women with peri-anal warts. The other agreement focuses on the development of Multikine in HIV/HPV co-infected women with cervical dysplasia. Ergomed will assume up to $3 million in clinical and regulatory costs for each study.

On October 31, 2013, the Company commenced arbitration proceedings against inVentiv Health Clinical, LLC (inVentiv, f/k/a PharmaNet, LLC), the Company’s former clinical research organization. The arbitration claim, initiated under the Commercial Rules of the American Arbitration Association, alleges (i) breach of contract, (ii) fraud in the inducement, and (iii) common law fraud, and seeks at least $50 million in damages. The Company filed this arbitration because, among other reasons, the number of patients enrolled and treated in the study fell below the level agreed to with inVentiv. In April 2013, the Company dismissed inVentiv and replaced it with Aptiv Solutions, Inc. and Ergomed Clinical Research Ltd, as noted above.

On December 12, 2013, inVentiv filed a counterclaim, alleging breach of contract on the part of CEL-SCI and seeking at least $2 million in damages. On December 20, 2013, inVentiv moved to dismiss certain claims. Given that this matter is at a preliminary stage, the Company is not in a position to predict or assess the likely outcome of these proceedings.

Lease Agreements

In August 2007, the Company leased a building near Baltimore, Maryland. The building was remodeled in accordance with the Company’s specifications so that it can be used by the Company to manufacture Multikine for the Company’s Phase III clinical trial and sales of the drug if approved by the FDA. The lease is for a term of twenty years and requires annual base rent to escalate each year at 3%. The Company is required to pay all real and personal property taxes, insurance premiums, maintenance expenses, repair costs and utilities. The lease allows the Company, at its election, to extend the lease for two ten-year periods or to purchase the building at the end of the 20-year lease.

The Company was required to deposit the equivalent of one year of base rent in accordance with the contract. When the Company meets the minimum cash balance required by the lease, the deposit will be returned to the Company. The $1,670,917 is included in non-current assets on December 31, 2013 and September 30, 2013.

The Company subleases a portion of its rental space on a month to month term lease, which requires a 30 day notice for termination. The Company receives $5,150 per month in rent for the subleased space.

The Company leases its research and development laboratory under a 60 month lease which expires February 28, 2017. The operating lease includes escalating rental payments. The Company is recognizing the related rent expense on a straight line basis over the full 60 month term of the lease at the rate of $11,360 per month. As of December 31, 2013 and September 30, 2013, the Company has recorded a deferred rent liability of $4,591 and $3,992, respectively.

The Company leases its office headquarters under a 36 month lease which expires June 30, 2015. The operating lease includes escalating rental payments. The Company is recognizing the related rent expense on a straight line basis over the full 36 month term of the lease at the rate $7,864 per month. As of December 31, 2013 and September 30, 2013, the Company has recorded a deferred rent liability of $11,065 and $12,412, respectively.

The Company leased office equipment under a capital lease arrangement. The term of the capital lease is 48 months and expires on September 30, 2016. The monthly lease payment is $1,025. The lease bears interest at approximately 16% per annum.

In October 2013, the Company purchased office equipment under a capital lease. The term of the capital lease is 36 months and it expires on September 30, 2016. The monthly lease payment is $299. The lease bears interest at approximately 9% per annum.

H. PATENTS

During the three months ended December 31, 2013 and 2012, the Company recorded patent impairment charges of $240 and $10,223, respectively. For the three months ended December 31, 2013 and 2012, amortization of patent costs totaled $9,703 and $23,905, respectively. The Company estimates that future amortization expense will be as follows:

Nine months ending September 30, 2014	$	25,252
Year ending September 30,
2015		33,795
2016		33,795
2017		33,795
2018		33,461
2019		31,758
Thereafter		125,604
Total	$	317,460

I. NET LOSS PER SHARE

The Company’s basic and diluted loss per share are as follows: For the three months ended December 31, 2013 and 2012, the computation of dilutive net loss per share excluded options and warrants to purchase approximately 865,000 and 578,800 shares of common stock because their inclusion would have an anti-dilutive effect.

	Three Months Ended December 31, 2013
	Net Loss			Weighted Average Shares		LPS

Basic loss per share	$	(5,451,865	)		48,215,919	$	(0.11	)
Gain on derivatives		(1,610,817	)

Dilutive loss per share	$	(7,062,652	)		48,215,919	$	(0.15	)

	Three Months Ended December 31, 2012
	Net Loss			Weighted Average Shares		LPS

Basic loss per share	$	(2,310,246	)		28,311,602	$	(0.08	)
Gain on derivatives		(2,746,198	)

Dilutive loss per share	$	(5,056,444	)		28,311,602	$	(0.18	)

J.	SUBSEQUENT EVENTS

The Company has evaluated subsequent events through the date these financial statements were filed and determined there are no subsequent events that require disclosure.

Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Liquidity and Capital Resources

The Company’s lead investigational therapy, Multikine® (Leukocyte Interleukin, Injection), is currently being tested in a Phase III clinical trial in advanced primary head and neck cancer. Multikine has been cleared by the regulators in eleven countries around the world, including the US. Multikine is also being used in a Phase I study with the US Naval Medical Center, San Diego under a Cooperative Research and Development Agreement (CRADA) in HIV/HPV co-infected men and women with peri-anal warts.

Multikine (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this report as Multikine. Multikine is the trademark that the Company has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with the Company’s future anticipated regulatory submission for approval. Multikine has not been licensed or approved by the FDA or any other regulatory agency. Neither has its safety or efficacy been established for any use.

The Company also owns and is developing a pre-clinical technology called LEAPS (Ligand Epitope Antigen Presentation System).

All of the Company’s projects are under development. As a result, the Company cannot predict when it will be able to generate any revenue from the sale of any of its products.

Since inception, the Company has financed its operations through the sale of equity securities, convertible notes, loans and certain research grants. The Company’s expenses will likely exceed its revenues as it continues the development of Multikine and brings other drug candidates into clinical trials. Until such time as the Company becomes profitable, any or all of these financing vehicles or others may be utilized to assist the Company’s capital requirements.

Capital raised by the Company has been expended primarily for patent applications, debt repayment, research and development, administrative costs, and the construction of the Company’s laboratory facilities. The Company does not anticipate realizing significant revenues until it enters into licensing arrangements regarding its technology and know-how or until it receives regulatory approval to sell its products (which could take a number of years). As a result the Company has been dependent upon the proceeds from the sale of its securities to meet all of its liquidity and capital requirements and anticipates having to do so in the future.

The Company will be required to raise additional capital or find additional long-term financing in order to continue with its research efforts. The ability of the Company to complete the necessary clinical trials and obtain FDA approval for the sale of products to be developed on a commercial basis is uncertain. Ultimately, the Company must complete the development of its products, obtain the appropriate regulatory approvals and obtain sufficient revenues to support its cost structure. The Company believes that, counting its cash on hand and access to the capital markets established over the years, it will have enough capital to support its operations through year end.

The Company estimates the total cash cost of the Phase III trial, with the exception of the parts that will be paid by its licensees, Teva Pharmaceuticals and Orient Europharma, to be approximately $33,300,000. This is in addition to approximately $11,300,000 which has been paid as of December 31, 2013. This estimate is based on the information currently available in the Company’s contracts with the Clinical Research Organization responsible for managing the Phase III trial. This number can be affected by the speed of enrollment, foreign currency exchange rates and many other factors, some of which cannot be foreseen today. It is therefore possible that the cost of the Phase III trial will be higher than currently estimated.

In April 2013, the Company replaced the clinical research organization (CRO) running its Phase III clinical trial. This was necessary since the patient enrollment in the study dropped off substantially following a takeover of the CRO which caused most of the members of the CRO’s study team to leave the CRO. The Company has hired two CRO’s who will manage the global Phase III study; Aptiv Solutions and Ergomed who are both international leaders in managing oncology trials. Both CRO’s will help the Company expand the trial by 60-80 clinical sites globally. As of April 2013, the last update given by the Company, the study has enrolled 117 patients and has been conducted at 39 sites in 8 countries, including three centers in Israel where the Company’s partner Teva Pharmaceuticals has the marketing rights, and nine centers in Taiwan where the Company’s partner Orient Europhama has the marketing rights.

Under a co-development agreement, Ergomed will contribute up to $10 million towards the study where it will perform clinical services in exchange for a single digit percentage of milestone and royalty payments, up to a specified maximum amount, only from sales for head and neck cancer. Ergomed, a privately-held firm headquartered in Europe with global operations, has entered into five similar co-development agreements, including one with Genzyme (purchased by Sanofi in 2011 for over $20 billion). Ergomed will be responsible for the majority of the new patient enrollment since it has a novel model for clinical site management to accelerate patient recruitment and retention. For example, they have almost 25 physicians who can directly call on clinical sites to aid recruitment and retention. Some of the Ergomed physicians also have experience of being clinical investigators themselves. The Company believes that this interaction on a physician to physician level is what is needed to help physicians increase enrollment in the Multikine study.

During the three months ended December 31, 2013, the Company’s cash increased by approximately $13,452,000. Significant components of this increase include net proceeds from the sale of the Company’s stock of approximately $19,380,000 offset by net cash used to fund the Company’s regular operations, including its on-going Phase III clinical trial, of approximately $5,917,000, purchases of equipment of approximately $9,000 and payment on capital leases of approximately $3,000. During the three months ended December 31, 2012, the Company’s cash increased by approximately $6,795,000. Significant components of this increase include net proceeds from the sale of the Company’s stock of approximately $9,807,000 offset by net cash used to fund the Company’s regular operations, including its on-going Phase III clinical trial, of approximately $2,995,000, purchases of equipment of approximately $16,000 and payment on capital leases of approximately $1,000.

In December 2012, CEL-SCI sold 3,500,000 shares of its common stock for $10,500,000, or $3.00 per share, in a registered direct offering. The investors in this offering also received Series R warrants which entitle the investors to purchase up to 2,625,000 shares of CEL-SCI’s common stock. The Series R warrants may be exercised at any time before December 7, 2016 at a price of $4.00 per share. CEL-SCI paid Chardan Capital Markets, LLC, the placement agent for this offering, a cash commission of $682,500.

On October 11, 2013, the Company closed a public offering of units of common stock and Series S warrants at a price of $1.00 per unit for net proceeds of $16,400,000, net of underwriting discounts and commissions. Each unit consisted of one share of common stock and a warrant to purchase one share of common stock. The warrants are immediately exercisable and expire on October 11, 2018, and have an exercise price of $1.25. In November 2013, the underwriters purchased an additional 2,648,913 warrants pursuant to the overallotment option, for which the Company received net proceeds of $24,370.

On December 24, 2013, the Company closed a public offering of units of common stock and warrants at a price of $0.63 per unit for net proceeds of $2,790,000, net of underwriting discounts and commissions. Each unit consisted of one share of common stock and a warrant to purchase one share of common stock. The warrants are immediately exercisable and expire on October 11, 2018, and have an exercise price of $1.25. The underwriters exercised the option for the full 10% overallotment, for which the Company received net proceeds of approximately $279,000.

The Company incurred $185,508 in offering costs related to the two offerings which were charged to additional paid in capital and netted against the cash proceeds in the Statement of Cash Flows.

The October and December 2013 financings triggered the reset provision of the Series N warrants which resulted in the issuance of an additional 1,563,083 shares of common stock. The cost of additional shares issued was $1,117,447. This cost was recorded as a debit and a credit to additional paid-in capital and was deemed a dividend.

Results of Operations and Financial Condition

During the three months ended December 31, 2013, grant and other income increased by approximately $98,000 compared to the three months ended December 31, 2012.

During the three months ended December 31, 2013, research and development expenses increased by approximately $1,095,000 compared to the three months ended December 31, 2012. The Company is continuing the Phase III clinical trial and research and development fluctuates based on the activity level of the clinical trial.

During the three months ended December 31, 2013, general and administrative expenses decreased by approximately $30,000 compared to the three months ended December 31, 2012. This decrease is primarily due to decreased costs of employee stock options.

The gain on derivative instruments of approximately $1,611,000 for the three months ended December 31, 2013 was the result of the change in fair value of the derivative liabilities during the period. This change was caused by fluctuations in the share price of the Company’s common stock.

Interest expense was approximately $43,000 for the three months ended December 31, 2013 and consisted entirely of $42,000 in interest expense on the loan from the Company’s president and $1,000 in interest on capital leases. Interest expense was approximately $41,000 for the three months ended December 31, 2012 and consisted entirely of interest expense on the loan from the Company’s president.

Research and Development Expenses

During the three month periods ended December 31, 2013 and 2012, the Company’s research and development efforts involved Multikine and LEAPS. The table below shows the research and development expenses associated with each project.

	Three months ended December 31,
	2013		2012

MULTIKINE	$	3,922,477	$	2,832,695
LEAPS		97,064		92,027

TOTAL	$	4,019,541	$	2,924,722

Clinical and other studies necessary to obtain regulatory approval of a new drug involve significant costs and require several years to complete. The extent of the Company’s clinical trials and research programs are primarily based upon the amount of capital available to the Company and the extent to which the Company has received regulatory approvals for clinical trials. The inability of the Company to conduct clinical trials or research, whether due to a lack of capital or regulatory approval, will prevent the Company from completing the studies and research required to obtain regulatory approval for any products which the Company is developing. Without regulatory approval, the Company will be unable to sell any of its products. Since all of the Company’s projects are under development, the Company cannot predict when it will be able to generate any revenue from the sale of any of its products.

Critical Accounting Estimates and Policies

Management’s discussion and analysis of the Company’s financial condition and results of operations is based on its unaudited condensed financial statements. The preparation of these financial statements is based on the selection of accounting policies and the application of significant accounting estimates, some of which require management to make judgments, estimates and assumptions that affect the amounts reported in the financial statements and notes. The Company believes some of the more critical estimates and policies that affect its financial condition and results of operations are in the areas of operating leases and stock-based compensation. For more information regarding the Company’s critical accounting estimates and policies, see Part II, Item 7 of the Company’s 2013 10-K report. The application of these critical accounting policies and estimates has been discussed with the Audit Committee of the Company’s Board of Directors.

Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISKS

The Company has a loan from the president that bears interest at 15%. The Company does not believe that it has any significant exposures to market risk.

Item 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Under the direction and with the participation of the Company’s management, including the Company’s Chief Executive and Chief Financial Officer, the Company has conducted an evaluation of the effectiveness of the design and operation of its disclosure controls and procedures as of December 31, 2013. The Company maintains disclosure controls and procedures that are designed to ensure that information required to be disclosed in its periodic reports with the Securities and Exchange Commission is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and regulations, and that such information is accumulated and communicated to the Company’s management, including its principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure. The Company’s disclosure controls and procedures are designed to provide a reasonable level of assurance of reaching its desired disclosure control objectives. Based on the evaluation, the Chief Executive and Chief Financial Officer have concluded that the Company’s disclosure controls and procedures were effective as of December 31, 2013.

Changes in Internal Control over Financial Reporting

The Company’s management, with the participation of the Chief Executive and Chief Financial Officer, has evaluated whether any change in the Company’s internal control over financial reporting occurred during the first three months of fiscal year 2014. There was no change in the Company’s internal control over financial reporting during the three months ended December 31, 2013.

PART II

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

Issuance of Restricted Stock

During the three months ended December 31, 2013 the Company issued 34,000 shares of common stock to a consultant for investor relations services and 1,563,083 shares of common stock to an investor per the reset provision associated with the Company’s Series N financing.

The Company relied upon the exemption provided by Section 4(2) of the Securities Act of 1933 with respect to the issuance of these shares. The persons who acquired these shares were sophisticated investors and were provided full information regarding the Company’s business and operations. There was no general solicitation in connection with the offer or sale of these securities. The persons who acquired these shares acquired them for their own accounts. The certificates representing these shares bear a restricted legend providing that they cannot be sold except pursuant to an effective registration statement or an exemption from registration. No commission or other form of remuneration was given to any person in connection with the issuance of these shares.

Item 6. (a) Exhibits

Number		Exhibit

31		Rule 13a-14(a) Certifications

32		Section 1350 Certifications

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	CEL-SCI CORPORATION

Date: February , 2014	By:	/s/ Geert Kersten
		Geert Kersten, Principal Executive Officer*

* Also signing in the capacity of the Principal Accounting and Financial Officer.

EX-31 2 cvm_ex31.htm CERTIFICATION cvm_ex31.htm

Exhibit 31

I, Geert Kersten, certify that:

1. I have reviewed this quarterly report on Form 10-Q of CEL-SCI Corporation;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15 and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) designed such internal control over financial reporting, or cause such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of the internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) any fraud, whether or not material, that involves management or other employees who have significant role in the registrant’s internal control over financial reporting.

February , 2014		/s/ Geert Kersten
		Geert Kersten
		Principal Executive Officer

I, Geert Kersten, certify that:

1. I have reviewed this quarterly report on Form 10-Q of CEL-SCI Corporation;

b) any fraud, whether or not material, that involves management or other employees who have significant role in the registrant’s internal control over financial reporting.

February , 2014		/s/ Geert Kersten
		Geert Kersten
		Principal Financial Officer

EX-32 3 cvm_ex32.htm CERTIFICATION cvm_ex32.htm

Exhibit 32

In connection with the Quarterly Report of CEL-SCI Corporation (the “Company”) on Form 10-Q for the period ending December 31, 2013 as filed with the Securities and Exchange Commission (the “Report”), Geert Kersten, the Principal Executive and Financial Officer of the Company, certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge:

(1)	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and results of the Company.

February , 2014		/s/ Geert Kersten
		Geert Kersten
		Principal Executive and
		Principal Financial Officer

EX-101.INS 4 cvm-20131231.xml 0000725363 2012-10-01 2012-12-31 0000725363 2013-12-31 0000725363 2013-10-01 2013-12-31 0000725363 2013-09-30 0000725363 CVM:SeriesNMember 2013-12-31 0000725363 us-gaap:SeriesAMember 2013-12-31 0000725363 CVM:CSchleuningSeriesAMember 2013-12-31 0000725363 us-gaap:SeriesBMember 2013-12-31 0000725363 CVM:SeriesCMember 2013-12-31 0000725363 CVM:SeriesEMember 2013-12-31 0000725363 CVM:SeriesFMember 2013-12-31 0000725363 CVM:SeriesGMember 2013-12-31 0000725363 CVM:SeriesHMember 2013-12-31 0000725363 CVM:SeriesQMember 2013-12-31 0000725363 CVM:SeriesLMember 2013-12-31 0000725363 CVM:SeriesLRepricedMember 2013-12-31 0000725363 CVM:SeriesMModifiedMember 2013-12-31 0000725363 CVM:SeriesPMember 2013-12-31 0000725363 CVM:PrivateInvestorsMember 2013-12-31 0000725363 CVM:WarrantsHeldbyOfficerAndDirectorMember 2013-12-31 0000725363 CVM:ConsultantsMember 2013-12-31 0000725363 CVM:SeriesFAndGWarrantsMember 2013-12-31 0000725363 CVM:SeriesRMember 2013-12-31 0000725363 CVM:SeriesMModififedMember 2013-12-31 0000725363 CVM:Level1Member 2013-12-31 0000725363 CVM:Level1Member 2013-09-30 0000725363 CVM:Level2Member 2013-12-31 0000725363 CVM:Level2Member 2013-09-30 0000725363 CVM:Level3Member 2013-12-31 0000725363 CVM:Level3Member 2013-09-30 0000725363 CVM:TotalMember 2013-12-31 0000725363 CVM:TotalMember 2013-09-30 0000725363 CVM:IncentiveStockOptionPlansMember 2013-12-31 0000725363 CVM:NonQualifiedStockOptionPlansMember 2013-12-31 0000725363 CVM:StockBonusPlansMember 2013-12-31 0000725363 us-gaap:StockCompensationPlanMember 2013-12-31 0000725363 CVM:SeriesAThroughEWarrantsMember 2013-10-01 2013-12-31 0000725363 CVM:SeriesAThroughEWarrantsMember 2012-10-01 2012-12-31 0000725363 CVM:SeriesNMember 2013-10-01 2013-12-31 0000725363 CVM:SeriesNMember 2012-10-01 2012-12-31 0000725363 CVM:SeriesFAndGWarrantsMember 2013-10-01 2013-12-31 0000725363 CVM:SeriesFAndGWarrantsMember 2012-10-01 2012-12-31 0000725363 CVM:SeriesQMember 2013-10-01 2013-12-31 0000725363 CVM:SeriesQMember 2012-10-01 2012-12-31 0000725363 CVM:SeriesRMember 2013-10-01 2013-12-31 0000725363 CVM:SeriesRMember 2012-10-01 2012-12-31 0000725363 CVM:ConsultantsMember 2013-10-01 2013-12-31 0000725363 CVM:ConsultantsMember 2012-10-01 2012-12-31 0000725363 us-gaap:SeriesAMember 2013-09-30 0000725363 CVM:PrivateInvestorsMember 2013-09-30 0000725363 CVM:SeriesCMember 2013-09-30 0000725363 us-gaap:SeriesBMember 2013-09-30 0000725363 CVM:SeriesEMember 2013-09-30 0000725363 CVM:SeriesNMember 2013-09-30 0000725363 CVM:SeriesFAndGWarrantsMember 2013-09-30 0000725363 CVM:SeriesHMember 2013-09-30 0000725363 CVM:SeriesQMember 2013-09-30 0000725363 CVM:SeriesRMember 2013-09-30 0000725363 CVM:SeriesHMember 2013-10-01 2013-12-31 0000725363 2012-09-30 0000725363 CVM:SeriesHMember 2012-10-01 2012-12-31 0000725363 CVM:PrivateInvestorWarrantsMember 2013-12-31 0000725363 CVM:PrivateInvestorWarrants1Member 2013-12-31 0000725363 CVM:PrivateInvestorWarrants2Member 2013-12-31 0000725363 CVM:ConsultantsMember 2013-09-30 0000725363 2014-02-04 0000725363 2012-10-01 2013-09-30 0000725363 2012-12-31 0000725363 CVM:SeriesSMember 2013-12-31 0000725363 CVM:SeriesSMember 2013-10-01 2013-12-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares CEL SCI CORP 0000725363 10-Q 2013-12-31 false --09-30 No No Yes Accelerated Filer Q1 2014

0.01

200000

0.01

600000000

55940156

There are no significant new accounting pronouncements that would impact the condensed financial statements.

The Companys President, and a director, Maximilian de Clara, loaned the Company $1,104,057. The loan from Mr. de Clara bears interest at 15% per year and is secured by a lien on substantially all of the Companys assets. The Company does not have the right to prepay the loan without Mr. de Claras consent. The loan was initially payable at the end of March 2009, but was extended to the end of June 2009. At the time the loan was originally due, and in accordance with the loan agreement, the Company issued Mr. de Clara warrants to purchase 164,824 shares of the Companys common stock at a price of $4.00 per share. The warrants are exercisable at any time prior to December 24, 2014. In June 2009, the loan with Mr. de Clara was extended for the second time to July 6, 2014. At Mr. de Claras option, the loan may be converted into shares of the Companys common stock. The number of shares which will be issued upon any conversion will be determined by dividing the amount to be converted by $4.00. As further consideration for the second extension, Mr. de Clara received warrants to purchase 184,930 shares of the Companys common stock at a price of $5.00 per share at any time prior to January 6, 2015. On May 13, 2011, to recognize Mr. de Claras willingness to agree to subordinate his note to the convertible preferred shares and convertible debt as part of the settlement agreement, the Company extended the maturity date of the note to July 6, 2015; however, Mr. de Clara may demand payment upon giving the Company a minimum 10 day notice.   During the three months ended December 31, 2013 and 2012, the Company paid $55,203 and $41,402 respectively in interest expense to Mr. de Clara. The Company has incurred significant costs since its inception in connection with the acquisition of certain patented and unpatented proprietary technology and know-how relating to the human immunological defense system, patent applications, research and development, administrative costs, construction of laboratory facilities, and clinical trials.  The Company has funded such costs with proceeds from loans and the public and private sale of its common and preferred stock.  The Company will be required to raise additional capital or find additional long-term financing in order to continue with its research efforts.  To date, the Company has not generated any revenue from product sales.  The ability of the Company to complete the necessary clinical trials and obtain US Food & Drug Administration (FDA) approval for the sale of products to be developed on a commercial basis is uncertain. Ultimately, the Company must complete the development of its products, obtain the appropriate regulatory approvals and obtain sufficient revenues to support its cost structure.   The Company is currently running a large multi-national Phase III clinical trial for head and neck cancer with its partners TEVA Pharmaceuticals and Orient Europharma. The Company believes that it has enough capital to support its operations for more than the next twelve months and believes that it has ready access to new equity capital should the need arise. During fiscal year 2013, the Company raised $9.8 million net proceeds from several institutional investors. During the three months ended December 31, 2013, the Company raised approximately $19.4 million in net proceeds through the sale of common stock and warrants in two public offerings. These funds are expected to meet the Companys cash requirements through 2014. To finance the study beyond the next 12 months, the Company plans to raise additional capital in the form of corporate partnerships, debt and/or equity financings. The Company believes that it will be able to obtain additional financing since Multikine is a Phase III product designed to treat cancer and because it has done so consistently in the past. However, there can be no assurance that the Company will be successful in raising additional funds or that funds will be available to the Company on acceptable terms or at all.  If the Company does not raise the necessary amounts of money, the Company will either have to slow down or delay the Phase III clinical trial or even significantly curtail its operations until such time as it is able to raise the required funding.   Since the Company launched its Phase III trial for Multikine, the Company has spent approximately $11,300,000 as of December 31, 2013 on direct costs for the Phase III clinical trial. The total remaining cash cost of the clinical trial is estimated to be about $33,300,000.  It should be noted that this estimate is based only on the information currently available in the Companys contracts with the Clinical Research Organizations responsible for managing the Phase III trial. This number can be affected by the speed of enrollment, foreign currency exchange rates and many other factors, some of which cannot be foreseen today. It is therefore possible that the cost of the Phase III trial will be higher than currently estimated.

Clinical Research Agreements   In March 2013, the Company entered into an agreement with Aptiv Solutions to provide certain clinical research services in accordance with a master service agreement. The Company will reimburse Aptiv for costs incurred. In May 2013, CEL-SCI made an advance payment of $400,000. In October 2013, CEL-SCI made the second and final advance payment of $200,000. The funds advanced will be credited back in $150,000 annual increments from December 2014 through December 2017. As of December 31, 2013, $150,000 of the deposit is classified as a current asset.   In April 2013, the Company entered into a co-development and revenue sharing agreement with Ergomed. Under the agreement, Ergomed will contribute up to $10 million towards the Companys Phase III trial in the form of offering discounted clinical services in exchange for a single digit percentage of milestone and royalty payments, up to a specific maximum amount. The Company accounted for the co-development and revenue sharing agreement in accordance with ASC 808 Collaborative Arrangements. The Company determined the payments to Erogmed are within the scope of ASC 730 Research and Development. Therefore, the Company records the discount on the clinical services as a credit to research and development expense on its Statements of Operations. Since the Company entered into the co-development and revenue sharing agreement with Ergomed it has incurred research and development expenses of approximately $2,017,000 related to Ergomeds services. This amount is net of Ergomeds discount of approximately $634,000. During the three months ended December 31, 2013, the Company recorded, net of Ergomeds discount, approximately $1,179,000 as research and development expense related to Ergomeds services.   In October 2013, the Company entered into two co-development and profit sharing agreements with Ergomed.  One agreement supports the US Navy with the development of Multikine as a potential treatment in HIV/HPV co-infected men and women with peri-anal warts.  The other agreement focuses on the development of Multikine in HIV/HPV co-infected women with cervical dysplasia. Ergomed will assume up to $3 million in clinical and regulatory costs for each study.   On October 31, 2013, the Company commenced arbitration proceedings against inVentiv Health Clinical, LLC (inVentiv, f/k/a PharmaNet, LLC), the Companys former clinical research organization. The arbitration claim, initiated under the Commercial Rules of the American Arbitration Association, alleges (i) breach of contract, (ii) fraud in the inducement, and (iii) common law fraud, and seeks at least $50 million in damages. The Company filed this arbitration because, among other reasons, the number of patients enrolled and treated in the study fell below the level agreed to with inVentiv. In April 2013, the Company dismissed inVentiv and replaced it with Aptiv Solutions, Inc. and Ergomed Clinical Research Ltd, as noted above.   On December 12, 2013, inVentiv filed a counterclaim, alleging breach of contract on the part of CEL-SCI and seeking at least $2 million in damages. On December 20, 2013, inVentiv moved to dismiss certain claims. Given that this matter is at a preliminary stage, the Company is not in a position to predict or assess the likely outcome of these proceedings.   Lease Agreements   In August 2007, the Company leased a building near Baltimore, Maryland. The building was remodeled in accordance with the Companys specifications so that it can be used by the Company to manufacture Multikine for the Companys Phase III clinical trial and sales of the drug if approved by the FDA. The lease is for a term of twenty years and requires annual base rent to escalate each year at 3%. The Company is required to pay all real and personal property taxes, insurance premiums, maintenance expenses, repair costs and utilities. The lease allows the Company, at its election, to extend the lease for two ten-year periods or to purchase the building at the end of the 20-year lease.   The Company was required to deposit the equivalent of one year of base rent in accordance with the contract. When the Company meets the minimum cash balance required by the lease, the deposit will be returned to the Company. The $1,670,917 is included in non-current assets on December 31, 2013 and September 30, 2013.   The Company subleases a portion of its rental space on a month to month term lease, which requires a 30 day notice for termination. The Company receives $5,150 per month in rent for the subleased space.   The Company leases its research and development laboratory under a 60 month lease which expires February 28, 2017. The operating lease includes escalating rental payments. The Company is recognizing the related rent expense on a straight line basis over the full 60 month term of the lease at the rate of $11,360 per month. As of December 31, 2013 and September 30, 2013, the Company has recorded a deferred rent liability of $4,591 and $3,992, respectively.   The Company leases its office headquarters under a 36 month lease which expires June 30, 2015. The operating lease includes escalating rental payments. The Company is recognizing the related rent expense on a straight line basis over the full 36 month term of the lease at the rate $7,864 per month. As of December 31, 2013 and September 30, 2013, the Company has recorded a deferred rent liability of $11,065 and $12,412, respectively.   The Company leased office equipment under a capital lease arrangement. The term of the capital lease is 48 months and expires on September 30, 2016. The monthly lease payment is $1,025. The lease bears interest at approximately 16% per annum.   In October 2013, the Company purchased office equipment under a capital lease. The term of the capital lease is 36 months and it expires on September 30, 2016. The monthly lease payment is $299. The lease bears interest at approximately 9% per annum.

The Companys basic and diluted loss per share are as follows: For the three months ended December 31, 2013 and 2012, the computation of dilutive net loss per share excluded options and warrants to purchase approximately 865,000 and 578,800 shares of common stock because their inclusion would have an anti-dilutive effect.   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 8pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="11" style="text-align: center; border-bottom: Black 1pt solid">Three Months Ended December 31, 2013</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">Net Loss</td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">Weighted Average Shares</td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">LPS</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="3" style="text-align: justify"> </td><td> </td> <td colspan="3" style="text-align: right"> </td><td> </td> <td colspan="3" style="text-align: justify"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%; text-align: justify; padding-bottom: 2.5pt; padding-left: 5.4pt">Basic loss per share</td><td style="width: 5%; padding-bottom: 2.5pt"> </td> <td style="width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</td><td style="width: 11%; border-bottom: Black 2.5pt double; text-align: right">(5,451,865</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 5%; padding-bottom: 2.5pt"> </td> <td style="width: 1%; border-bottom: Black 2.5pt double; text-align: left"> </td><td style="width: 11%; border-bottom: Black 2.5pt double; text-align: right">48,215,919</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 5%; padding-bottom: 2.5pt"> </td> <td style="width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</td><td style="width: 11%; border-bottom: Black 2.5pt double; text-align: right">(0.11</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt">Gain on derivatives</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(1,610,817</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-left: 5.4pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt; padding-left: 5.4pt">Dilutive loss per share</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(7,062,652</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">48,215,919</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.15</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-left: 5.4pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">Three Months Ended December 31, 2012</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">Net Loss</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">Weighted Average Shares</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">LPS</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-left: 5.4pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt; padding-left: 5.4pt">Basic loss per share</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(2,310,246</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">28,311,602</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.08</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt">Gain on derivatives</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(2,746,198</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-left: 5.4pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt; padding-left: 5.4pt">Dilutive loss per share</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(5,056,444</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">28,311,602</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.18</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table>

The Company has evaluated subsequent events through the date these financial statements were filed and determined there are no subsequent events that require disclosure.

The accompanying condensed financial statements of CEL-SCI Corporation (the Company) are unaudited and certain information and footnote disclosures normally included in the annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been omitted pursuant to the rules and regulations of the Securities and Exchange Commission. While management of the Company believes that the disclosures presented are adequate to make the information presented not misleading, these interim condensed financial statements should be read in conjunction with the financial statements and notes included in the Companys annual report on Form 10-K for the year ended September 30, 2013. <table cellpadding="0" cellspacing="0" style="width: 100%; font: 8pt Times New Roman, Times, Serif; letter-spacing: -0.1pt; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top"> <td style="width: 0"></td><td style="width: 0.5in"></td><td style="text-align: justify"></td></tr></table> <table cellpadding="0" cellspacing="0" style="width: 100%; font: 8pt Times New Roman, Times, Serif; letter-spacing: -0.1pt; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top"> <td style="width: 0"></td><td style="width: 0.5in"></td><td style="text-align: justify">In the opinion of management, the accompanying unaudited condensed financial statements contain all accruals and adjustments (each of which is of a normal recurring nature) necessary for a fair presentation of the Companys financial position as of December 31, 2013 and the results of its operations for the three months then ended. The condensed balance sheet as of September 30, 2013 is derived from the September 30, 2013 audited financial statements. Significant accounting policies have been consistently applied in the interim financial statements and the annual financial statements. The results of operations for the three months ended December 31, 2013 and 2012 are not necessarily indicative of the results to be expected for the entire year.</td></tr></table>

Research and Office Equipment and Leasehold Improvements - Research and office equipment is recorded at cost and depreciated using the straight-line method over estimated useful lives of five to seven years. Leasehold improvements are depreciated over the shorter of the estimated useful life of the asset or the term of the lease. Repairs and maintenance which do not extend the life of the asset are expensed when incurred. The fixed assets are reviewed on a quarterly basis to determine if any of the assets are impaired.

Patents - Patent expenditures are capitalized and amortized using the straight-line method over the shorter of the expected useful life or the legal life of the patent (17 years). In the event changes in technology or other circumstances impair the value or life of the patent, appropriate adjustment in the asset value and period of amortization is made. An impairment loss is recognized when estimated future undiscounted cash flows expected to result from the use of the asset, and from its disposition, is less than the carrying value of the asset. The amount of the impairment loss would be the difference between the estimated fair value of the asset and its carrying value.

Research and Development Costs - Research and development costs are expensed as incurred.

Income Taxes - The Company uses the asset and liability method of accounting for income taxes. Under the asset and liability method, deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating and tax loss carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company records a valuation allowance to reduce the deferred tax assets to the amount that is more likely than not to be recognized. A full valuation allowance was recorded against the deferred tax assets as of December 31, 2013 and September 30, 2013.

Derivative Instruments The Company has entered into financing arrangements that contain embedded derivative features. The Company has also issued warrants to various parties in connection with work performed by these parties. The Company accounts for these arrangements in accordance with ASC 815, Accounting for Derivative Instruments and Hedging Activities. In accordance with accounting principles generally accepted in the United States (GAAP), derivative instruments and hybrid instruments are recognized as either assets or liabilities on the balance sheet and are measured at fair value with gains or losses recognized in earnings or other comprehensive income depending on the nature of the derivative or hybrid instruments. The Company determines the fair value of derivative instruments and hybrid instruments based on available market data using appropriate valuation models, giving consideration to all of the rights and obligations of each instrument. The derivative liabilities are remeasured at fair value at the end of each interim period as long as they are outstanding.

Deferred Rent (Asset) Consideration paid, including deposits, related to operating leases is recorded as a deferred rent asset and amortized as rent expense over the lease term. Interest on the deferred rent is calculated at 3% on the funds deposited on the manufacturing facility and is included in deferred rent. This interest income will be used to offset future rent.

Stock-Based Compensation Compensation cost for all stock-based awards is measured at fair value as of the grant date in accordance with the provisions of ASC 718 Stock Compensation Expense. The fair value of the stock options is calculated using the Black-Scholes option pricing model. The Black-Scholes model requires various judgmental assumptions including volatility and expected option life. The stock-based compensation cost is recognized on the straight line allocation method as expense over the requisite service or vesting period.   Equity instruments issued to non-employees are accounted for in accordance with ASC 505-50, Equity-Based Payments to Non Employees. Accordingly, compensation is recognized when goods or services are received and is measured using the Black-Scholes valuation model. The Black-Scholes model requires various judgmental assumptions regarding the fair value of the equity instruments at the measurement date and the expected life of the options. The Company has Incentive Stock Option Plans, Non-Qualified Stock Option Plans, a Stock Compensation Plan and Stock Bonus Plans. In some cases these Plans are collectively referred to as the "Plans". All Plans have been approved by the stockholders.

Reclassification Certain prior year items have been reclassified to conform to the current year presentation.

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 8pt Courier New, Courier, Monospace"> <tr style="vertical-align: bottom"> <td colspan="3"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="7" style="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Three Months Ended December 31,</td></tr> <tr style="vertical-align: bottom"> <td colspan="3"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="3" style="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2013</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="3" style="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2012</td></tr> <tr style="vertical-align: bottom"> <td colspan="3"> </td><td> </td> <td colspan="3"> </td><td> </td> <td colspan="3"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="width: 26%; font-family: Times New Roman, Times, Serif; text-align: right"> Employees               </td><td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="width: 8%; font-family: Times New Roman, Times, Serif"> </td> <td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="width: 26%; font-family: Times New Roman, Times, Serif; text-align: right">510,278</td><td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="width: 8%; font-family: Times New Roman, Times, Serif"> </td> <td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="width: 26%; font-family: Times New Roman, Times, Serif; text-align: right">966,585</td><td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right; text-indent: -30pt; padding-left: -20pt"> Non-employees        </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">214,720</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">107,818</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> </table>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 8pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-decoration: underline; padding-bottom: 1pt; padding-left: 5.4pt">Warrant</td><td style="text-decoration: underline; padding-bottom: 1pt"> </td> <td style="text-decoration: underline; text-align: center; padding-bottom: 1pt; padding-left: 5.4pt">Issue Date</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">Shares Issuable upon Exercise of Warrant</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">Exercise Price</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="text-decoration: underline; padding-bottom: 1pt"> </td> <td style="text-decoration: underline; text-align: center; padding-bottom: 1pt; padding-left: 5.4pt">Expiration Date</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">Refer-ence</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5.4pt"> </td><td> </td> <td style="text-align: justify; padding-left: 5.4pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: justify; padding-left: 5.4pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 15%; text-align: left; padding-left: 5.4pt">Series N</td><td style="width: 2%"> </td> <td style="width: 15%; text-align: right; padding-left: 5.4pt">8/18/08</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right">2,951,420</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right">0.53</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 15%; text-align: right; padding-left: 5.4pt">8/18/14</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right">1</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 5.4pt">Series A</td><td> </td> <td style="text-align: right; padding-left: 5.4pt">6/24/09</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">130,347</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right; padding-left: 5.4pt">12/24/14</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 5.4pt">Schleuning (Series A)</td><td> </td> <td style="text-align: right; padding-left: 5.4pt">7/8/09</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">16,750</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right; padding-left: 5.4pt">1/8/15</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 5.4pt">Series B</td><td> </td> <td style="text-align: right; padding-left: 5.4pt">9/4/09</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">50,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6.80</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right; padding-left: 5.4pt">9/4/14</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 5.4pt">Series C</td><td> </td> <td style="text-align: right; padding-left: 5.4pt">8/20/09 8/26/09</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">463,487</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right; padding-left: 5.4pt">2/20/15</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 5.4pt">Series E</td><td> </td> <td style="text-align: right; padding-left: 5.4pt">9/21/09</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">71,428</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">17.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right; padding-left: 5.4pt">8/12/14</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 5.4pt">Series F</td><td> </td> <td style="text-align: right; padding-left: 5.4pt">10/6/11</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,200,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right; padding-left: 5.4pt">10/6/14</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 5.4pt">Series G</td><td> </td> <td style="text-align: right; padding-left: 5.4pt">10/6/11</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">66,667</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right; padding-left: 5.4pt">8/12/14</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 5.4pt">Series H</td><td> </td> <td style="text-align: right; padding-left: 5.4pt">1/26/12</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,200,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right; padding-left: 5.4pt">8/1/15</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 5.4pt">Series Q</td><td> </td> <td style="text-align: right; padding-left: 5.4pt">6/21/12</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,200,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right; padding-left: 5.4pt">12/22/15</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 5.4pt">Series R</td><td> </td> <td style="text-align: right; padding-left: 5.4pt">12/6/12</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,625,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right; padding-left: 5.4pt">12/6/16</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 5.4pt">Series S</td><td> </td> <td style="text-align: right; padding-left: 5.4pt">10/11/13-12/24/13</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25,713,095</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1.25</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right; padding-left: 5.4pt">10/11/18</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 5.4pt"> </td><td> </td> <td style="text-align: right; padding-left: 5.4pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: right; padding-left: 5.4pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 5.4pt">Series L</td><td> </td> <td style="text-align: right; padding-left: 5.4pt">4/18/07</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right; padding-left: 5.4pt">4/17/14</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 5.4pt">Series L (repriced)</td><td> </td> <td style="text-align: right; padding-left: 5.4pt">4/18/07</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">70,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right; padding-left: 5.4pt">4/2/15</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 5.4pt">Series M (modified)</td><td> </td> <td style="text-align: right; padding-left: 5.4pt">4/18/07</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">500,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right; padding-left: 5.4pt">4/20/14</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 5.4pt"> </td><td> </td> <td style="text-align: right; padding-left: 5.4pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: right; padding-left: 5.4pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 5.4pt">Series P</td><td> </td> <td style="text-align: right; padding-left: 5.4pt">2/10/12</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">590,001</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right; padding-left: 5.4pt">3/6/17</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center; padding-left: 5.4pt"> </td><td> </td> <td style="text-align: right; padding-left: 5.4pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: right; padding-left: 5.4pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 5.4pt">Private Investors</td><td> </td> <td style="text-align: right; padding-left: 5.4pt">7/18/05-6/30/09</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">740,938</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5.60-8.20</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right; padding-left: 5.4pt">1/26/14 - 7/18/14</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 5.4pt"> </td><td> </td> <td style="text-align: right; padding-left: 5.4pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: right; padding-left: 5.4pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 5.4pt">Warrants held by Officer and Director</td><td> </td> <td style="text-align: right; padding-left: 5.4pt">6/24/09-7/6/09</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">349,754</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.00 5.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right; padding-left: 5.4pt">12/24/14 1/6/15</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center; padding-left: 5.4pt"> </td><td> </td> <td style="text-align: right; padding-left: 5.4pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: right; padding-left: 5.4pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5.4pt">Consultants</td><td> </td> <td style="text-align: right; padding-left: 5.4pt">2/15/05-10/28/13</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">200,750</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.85-20.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right; padding-left: 5.4pt">5/20/14 - 12/27/17</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6</td><td style="text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 8pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; padding-left: 5.4pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">December 31, 2013</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">September 30, 2013</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5.4pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left; padding-left: 5.4pt">Series A through E warrants</td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">6,106</td><td style="width: 1%; text-align: left"> </td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">6,106</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 5.4pt">Series N warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">531,255</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">41,501</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 5.4pt">Series F and G warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,667</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,667</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 5.4pt">Series H warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">36,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 5.4pt">Series Q warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">24,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">48,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 5.4pt">Series R warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">157,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">288,750</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Series S warrants</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">5,339,750</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">  </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-decoration: underline; text-align: justify; padding-left: 5.4pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt; padding-left: 5.4pt">Total derivative liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,143,278</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">433,024</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 5339750 157500 288750 24000 48000 12000 36000 12667 12667 531255 41501 6106 6106 6143278 433024

6143278

433024

6143278

433024

7321071

4200000

433024 6983690 6143278 433024

-1610817

-10750666

317460

318195

125604

31758

33461

33795

25252

-2310246

-5451865

-5056444

-7062652

28311602

48215919

-0.08

-0.11

-0.18

-0.15

578800

865000

10223

240

23905

9703

585156 598717

1347257

1016628

988699

780523

45879

74263

13494028

41612

3941042

10736391

16611019

2511743

463053

489336

5285781 5448381

11463

8212

9274

8529

1104057

280464

386337

346401

113496

1627765

1924482

3379424

3545113

5000

24445

20925

6381

7875

126545

6143278

433024

9685073

4138482

-216494986

-212160568

231049613

218550408

558530

310250

15113157

6700090

24798230

10838572

3010439

2967345

1161540

1151852

55852992

31025019

55852992

31025019

2001285

1971214

133450

56699

5059457

6047454

0 1117447

-2310246

-4334418

41402

42682

29415

31757

2746198 1610817

-5044457

-5934310

28311602

48215919

28311602

48215919

104864

41673

688

-749

20843

-105873

23252

232905

-192358

-380943

-200000

247585

-330629

471936

-210367

139536 176161

143714

28384

-2746198

-1610817

2011

10223

240

39711 37887

966585

510278

54485

137729

-2994783

-5916522

-16218

-8587

125

16093

8587

9806350

19377525

9807375

19380190

6795349

13452416

4200000 7321071 -4200000 -7321071 0 0 0 0 0 0 0 0 0 -1117417 0 -1101786 0 -15631 -236165 -55362 -236165 -55362 -8641 -9208

8641

9208

0 0 -36622 -9462 0 -2664 36622 12126 0 0 -1105 -26 1105 26 0 -72328 0 72328 0 0

41878

56509

0 76991

15000

113144

24798230

10838572

2120917

2070917

41402

55203

107818 214720

966585

510278

1960000

5680000

1594000

1350000

1573597

3674544

958325 791145

145703

1443537

634919

558855

2008-08-18 2009-06-24 2009-07-08 2009-09-04 2009-09-21 2011-10-06 2011-10-06 2012-01-26 2012-06-21 2007-04-18 2007-04-18 2012-02-10 2012-12-06 2007-04-18 2951420 130347 16750 50000 463487 71428 1200000 66667 1200000 1200000 25000 70000 590001 740938 349754 200750 2625000 500000 25713095 0.53 5.00 5.00 6.80 5.50 17.50 4.00 4.00 5.00 5.00 7.50 2.50 4.50 4.00 1.00 1.25 2014-08-18 2014-12-24 2015-01-08 2014-09-04 2015-02-20 2014-08-12 2014-10-06 2014-08-12 2015-08-01 2015-12-22 2014-04-17 2015-04-02 2017-03-06 2016-12-06 2014-04-20 2018-10-11 2009-08-20 2005-07-18 2009-06-24 2005-02-15 2013-10-11 2009-08-26 2009-06-30 2009-07-06 2013-10-28 2013-12-24 2014-01-26 2014-12-24 2014-05-20 2014-07-18 2015-01-06 2017-12-27 5.60 4.00 0.85 8.20 5.00 20.00

1670917

1437466

55362 57553 2951420 130347 50000 463487 71428 500000 590001 16750 349754 200750 132500 378750 229688 531255 1303 0 4635 0 12000 24000 168 12667 157500 1303 168 4635 0 0 41501 12667 36000 48000 288750 5399750

332436

311262

640000

24000

600000

131250

262500

24000

600000

1921321

489754

137729 1985 55362 57553 11065 12412 4591 3992

150000

2924722

4019541

1025

2665

Basis of Presentation   The accompanying condensed financial statements of CEL-SCI Corporation (the Company) are unaudited and certain information and footnote disclosures normally included in the annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been omitted pursuant to the rules and regulations of the Securities and Exchange Commission. While management of the Company believes that the disclosures presented are adequate to make the information presented not misleading, these interim condensed financial statements should be read in conjunction with the  financial statements and notes included in the Companys annual report on Form 10-K for the year ended September 30, 2013.   In the opinion of management, the accompanying unaudited condensed financial statements contain all accruals and adjustments (each of which is of a normal recurring nature) necessary for a fair presentation of the Companys financial position as of December 31, 2013 and the results of its operations for the three months then ended.  The condensed balance sheet as of September 30, 2013 is derived from the September 30, 2013 audited financial statements.  Significant accounting policies have been consistently applied in the interim financial statements and the annual financial statements.  The results of operations for the three months ended December 31, 2013 and 2012 are not necessarily indicative of the results to be expected for the entire year.   Summary of Significant Accounting Policies:   Research and Office Equipment and Leasehold Improvements - Research and office equipment is recorded at cost and depreciated using the straight-line method over estimated useful lives of five to seven years.  Leasehold improvements are depreciated over the shorter of the estimated useful life of the asset or the term of the lease.  Repairs and maintenance which do not extend the life of the asset are expensed when incurred. The fixed assets are reviewed on a quarterly basis to determine if any of the assets are impaired.   Patents - Patent expenditures are capitalized and amortized using the straight-line method over the shorter of the expected useful life or the legal life of the patent (17 years).  In the event changes in technology or other circumstances impair the value or life of the patent, appropriate adjustment in the asset value and period of amortization is made.  An impairment loss is recognized when estimated future undiscounted cash flows expected to result from the use of the asset, and from its disposition, is less than the carrying value of the asset.  The amount of the impairment loss would be the difference between the estimated fair value of the asset and its carrying value.   Research and Development Costs - Research and development costs are expensed as incurred.     Income Taxes - The Company uses the asset and liability method of accounting for income taxes.  Under the asset and liability method, deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating and tax loss carryforwards.  Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.  The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.  The Company records a valuation allowance to reduce the deferred tax assets to the amount that is more likely than not to be recognized.  A full valuation allowance was recorded against the deferred tax assets as of December 31, 2013 and September 30, 2013.   Derivative Instruments The Company has entered into financing arrangements that contain embedded derivative features.  The Company has also issued warrants to various parties in connection with work performed by these parties.  The Company accounts for these arrangements in accordance with ASC 815, Accounting for Derivative Instruments and Hedging Activities. In accordance with accounting principles generally accepted in the United States (GAAP), derivative instruments and hybrid instruments are recognized as either assets or liabilities on the balance sheet and are measured at fair value with gains or losses recognized in earnings or other comprehensive income depending on the nature of the derivative or hybrid instruments.  The Company determines the fair value of derivative instruments and hybrid instruments based on available market data using appropriate valuation models, giving consideration to all of the rights and obligations of each instrument.  The derivative liabilities are remeasured at fair value at the end of each interim period as long as they are outstanding.   Deferred Rent (Asset) Consideration paid, including deposits, related to operating leases is recorded as a deferred rent asset and amortized as rent expense over the lease term. Interest on the deferred rent is calculated at 3% on the funds deposited on the manufacturing facility and is included in deferred rent. This interest income will be used to offset future rent.   Stock-Based Compensation Compensation cost for all stock-based awards is measured at fair value as of the grant date in accordance with the provisions of ASC 718 Stock Compensation Expense.  The fair value of the stock options is calculated using the Black-Scholes option pricing model.  The Black-Scholes model requires various judgmental assumptions including volatility and expected option life.  The stock-based compensation cost is recognized on the straight line allocation method as expense over the requisite service or vesting period.   Equity instruments issued to non-employees are accounted for in accordance with ASC 505-50, Equity-Based Payments to Non Employees.  Accordingly, compensation is recognized when goods or services are received and is measured using the Black-Scholes valuation model.  The Black-Scholes model requires various judgmental assumptions regarding the fair value of the equity instruments at the measurement date and the expected life of the options.      The Company has Incentive Stock Option Plans, Non-Qualified Stock Option Plans, a Stock Compensation Plan and Stock Bonus Plans. In some cases these Plans are collectively referred to as the "Plans".  All Plans have been approved by the stockholders.   Reclassification Certain prior year items have been reclassified to conform to the current year presentation.

Stock options, stock bonuses and compensation granted by the Company as of December 31, 2013 are as follows:   <table cellspacing="0" cellpadding="0" style="font: 8pt Calibri, Helvetica, Sans-Serif; width: 100%; background-color: white"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1pt solid; line-height: 115%">Name of Plan</td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%">Total Shares Reserved Under Plans</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%">Shares Reserved for Outstanding Options</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%">Shares Issued as Stock Bonus</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%">Remaining Options/Shares Under Plans</td> <td nowrap="nowrap" style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 52%; line-height: 115%">Incentive Stock Option Plans</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 9%; text-align: right; line-height: 115%">1,960,000</td> <td nowrap="nowrap" style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 9%; text-align: right; line-height: 115%">1,573,597</td> <td nowrap="nowrap" style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 9%; text-align: right; line-height: 115%">N/A</td> <td nowrap="nowrap" style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 9%; text-align: right; line-height: 115%">145,703</td> <td nowrap="nowrap" style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%">Non-Qualified Stock Option Plans</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">5,680,000</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">3,674,544</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">N/A</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">1,443,537</td> <td nowrap="nowrap" style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Stock Bonus Plans</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">1,594,000</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">N/A</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">958,325</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">634,919</td> <td nowrap="nowrap" style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%">Stock Compensation Plan</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">1,350,000</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">N/A</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">791,145</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">558,855</td> <td nowrap="nowrap" style="line-height: 115%"> </td></tr> </table>   There were zero and 1,437,466 options granted to employees and directors during the three months ended December 31, 2013 and 2012, respectively.   In December 2012, the Company offered employees and directors holding options that expire on April 1, 2013 the opportunity to forfeit these options and have new options issued with an expiration date of December 17, 2017.  All twelve employees and directors eligible for this offer accepted the terms.  This resulted in the cancellation of 387,466 options priced at $2.20 per share and the concurrent issuance of the same number of options at $2.80 per share.  In accordance with ASC 718, the Company recorded the incremental compensation cost of the options.  The incremental compensation cost is the excess of the fair value of the replacement award over the fair value of the cancelled award at the cancellation date.  At the cancellation date, the incremental compensation cost was $477,879.   Stock-Based Compensation Expense   <table cellspacing="0" cellpadding="0" style="font: 8pt Calibri, Helvetica, Sans-Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="6" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%">Three Months Ended December 31,</td> <td nowrap="nowrap" style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%">2013</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%">2012</td> <td nowrap="nowrap" style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td nowrap="nowrap" style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 78%; line-height: 115%"> Employees</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 8%; text-align: right; line-height: 115%">510,278</td> <td nowrap="nowrap" style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 8%; text-align: right; line-height: 115%">966,585</td> <td nowrap="nowrap" style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"> Non-employees</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">214,720</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">107,818</td> <td nowrap="nowrap" style="line-height: 115%"> </td></tr> </table>         At December 31, 2013 and September 30, 2013, respectively, non-employee stock compensation expense excluded $55,362 and $57,553 of prepaid consulting expenses.   Derivative Liabilities, Warrants and Other Options   Below is a chart showing the derivative liabilities, warrants and other options outstanding at December 31, 2013:   <table cellspacing="0" cellpadding="0" style="font: 8pt Calibri, Helvetica, Sans-Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1pt solid; line-height: 115%">Warrant</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; text-align: center; line-height: 115%">Issue Date</td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%">Shares Issuable upon Exercise of Warrant</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%">Exercise Price</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; text-align: center; line-height: 115%">Expiration Date</td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%">Reference</td> <td nowrap="nowrap" style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td nowrap="nowrap" style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 35%; line-height: 115%">Series N</td> <td style="width: 1%; text-align: center; line-height: 115%"> </td> <td style="width: 11%; text-align: center; line-height: 115%">8/18/08</td> <td style="width: 1%; text-align: right; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 11%; text-align: right; line-height: 115%">2,951,420</td> <td nowrap="nowrap" style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 11%; text-align: right; line-height: 115%">0.53</td> <td nowrap="nowrap" style="width: 1%; line-height: 115%"> </td> <td style="width: 11%; text-align: center; line-height: 115%">8/18/14</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 11%; text-align: right; line-height: 115%">1</td> <td nowrap="nowrap" style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Series A</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%">6/24/09</td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">130,347</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">5.00</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%">12/24/14</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">1</td> <td nowrap="nowrap" style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Schleuning (Series A)</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%">7/8/09</td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">16,750</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">5.00</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%">1/8/15</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">1</td> <td nowrap="nowrap" style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Series B</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%">9/4/09</td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">50,000</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">6.80</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%">9/4/14</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">1</td> <td nowrap="nowrap" style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Series C</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%">8/20/09 8/26/09</td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">463,487</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">5.50</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%">2/20/15</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">1</td> <td nowrap="nowrap" style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Series E</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%">9/21/09</td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">71,428</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">17.50</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%">8/12/14</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">1</td> <td nowrap="nowrap" style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Series F</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%">10/6/11</td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">1,200,000</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">4.00</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%">10/6/14</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">1</td> <td nowrap="nowrap" style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Series G</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%">10/6/11</td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">66,667</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">4.00</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%">8/12/14</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">1</td> <td nowrap="nowrap" style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Series H</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%">1/26/12</td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">1,200,000</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">5.00</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%">8/1/15</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">1</td> <td nowrap="nowrap" style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Series Q</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%">6/21/12</td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">1,200,000</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">5.00</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%">12/22/15</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">1</td> <td nowrap="nowrap" style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Series R</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%">12/6/12</td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">2,625,000</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">4.00</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%">12/6/16</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">1</td> <td nowrap="nowrap" style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Series S</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%">10/11/13-12/24/13</td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">25,713,095</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">1.25</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%">10/11/18</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">1</td> <td nowrap="nowrap" style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td nowrap="nowrap" style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Series L</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%">4/18/07</td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">25,000</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">7.50</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%">4/17/14</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">2</td> <td nowrap="nowrap" style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Series L (repriced)</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%">4/18/07</td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">70,000</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">2.50</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%">4/2/15</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">2</td> <td nowrap="nowrap" style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Series M (modified)</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%">4/18/07</td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">500,000</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">1.00</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%">4/20/14</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">2</td> <td nowrap="nowrap" style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td nowrap="nowrap" style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Series P</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%">2/10/12</td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">590,001</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">4.50</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%">3/6/17</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">3</td> <td nowrap="nowrap" style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td nowrap="nowrap" style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Private Investors</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%">7/18/05-6/30/09</td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">740,938</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">5.60-8.20</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%">1/26/14 - 7/18/14</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">4</td> <td nowrap="nowrap" style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td nowrap="nowrap" style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Warrants held by Officer and Director</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%">6/24/09-7/6/09</td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">349,754</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">4.00 5.00</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%">12/24/14 1/6/15</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">5</td> <td nowrap="nowrap" style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td nowrap="nowrap" style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Consultants</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%">2/15/05-10/28/13</td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">200,750</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">0.85-20.00</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%">5/20/14 - 12/27/17</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">6</td> <td nowrap="nowrap" style="line-height: 115%"> </td></tr> </table>     1.   Derivative Liabilities   See below for details of the balances of derivative instruments at December 31, 2013 and September 30, 2013.   <table cellspacing="0" cellpadding="0" style="font: 8pt Calibri, Helvetica, Sans-Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1pt solid"> December 31, 2013</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1pt solid"> September 30, 2013</td> <td nowrap="nowrap" style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td nowrap="nowrap" style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 78%; line-height: 115%">Series A through E warrants</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 8%; text-align: right; line-height: 115%">6,106</td> <td nowrap="nowrap" style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 8%; text-align: right; line-height: 115%">6,106</td> <td nowrap="nowrap" style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Series N warrants</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">531,255</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">41,501</td> <td nowrap="nowrap" style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Series F and G warrants</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">12,667</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">12,667</td> <td nowrap="nowrap" style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Series H warrants</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">12,000</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">36,000</td> <td nowrap="nowrap" style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Series Q warrants</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">24,000</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">48,000</td> <td nowrap="nowrap" style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Series R warrants</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">157,500</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">288,750</td> <td nowrap="nowrap" style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Series S warrants</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%">5,339,750</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%">-</td> <td nowrap="nowrap" style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td nowrap="nowrap" style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Total derivative liabilities</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt double; line-height: 115%">$</td> <td style="border-bottom: black 1.5pt double; text-align: right; line-height: 115%">6,143,278</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt double; line-height: 115%">$</td> <td style="border-bottom: black 1.5pt double; text-align: right; line-height: 115%">433,024</td> <td nowrap="nowrap" style="line-height: 115%"> </td></tr> </table>   The Company reviews all outstanding warrants in accordance with the requirements of ASC 815.  This topic provides that an entity should use a two-step approach to evaluate whether an equity-linked financial instrument (or embedded feature) is indexed to its own stock, including evaluating the instruments contingent exercise and settlement provisions.  The warrant agreements provide for adjustments to the exercise price for certain dilutive events, which includes an adjustment to the number of shares issuable upon the exercise of the warrant in the event that the Company makes certain equity offerings in the future at a price lower than the exercise prices of the warrant instruments.  Under the provisions of ASC 815, the warrants are not considered indexed to the Companys stock because future equity offerings or sales of the Companys stock are not an input to the fair value of a fixed-for-fixed option on equity shares, and equity classification is therefore precluded.   In accordance with ASC 815, derivative liabilities must be measured at fair value upon issuance and re-valued at the end of each reporting period through expiration.  Any change in fair value between the respective reporting dates is recognized as a gain or loss.   Series A through E Warrants   The Company accounted for the Series A through E Warrants as derivative liabilities in accordance with ASC 815.  These warrants do not qualify for equity accounting and must be accounted for as derivative liabilities since the warrant agreements provide the holder with the right, at its option, to require the Company to a cash settlement of the warrants at Black-Scholes value in the event of a Fundamental Transaction, as defined in the warrant agreement.  Since the occurrence of a Fundamental Transaction is not entirely within the Company's control, there exist circumstances that would require net-cash settlement of the warrants while holders of shares would not receive a cash settlement.   In June 2009, the Company issued 1,011,656 Series A warrants exercisable at $5.00 per share in connection with a financing.  The cost of the warrants of $2,775,021 was recorded as a debit to additional paid-in capital and a credit to derivative liabilities.  As of December 31, 2013, 130,347 of these warrants remained outstanding.  As of December 31, 2013 and September 30, 2013, the fair value of the remaining Series A warrants was $1,303.   In July 2009, the Company issued 16,750 warrants to a private investor.  The warrants were issued with an exercise price of $5.00 per share and valued at $43,550 using the Black Scholes method. The cost of the warrants was accounted for as a debit to additional paid-in capital and a credit to derivative liabilities. As of December 31, 2013, 16,750 warrants remained outstanding.  As of December 31, 2013 and September 30, 2013, the fair value of the remaining warrants was $168.     In connection with a loan received and fully repaid in a prior period, the Company issued 50,000 Series B warrants with an exercise price of $6.80 per share.  As of December 31, 2013, 50,000 Series B warrants remained outstanding.  As of December 31, 2013 and September 30, 2013, the fair value of the remaining Series B warrants was $0.   In connection with an August 2009 financing, the Company issued 539,222 Series C warrants exercisable at $5.50 per share.  As of December 31, 2013, 463,487 of these warrants remained outstanding.    As of December 31, 2013 and September 30, 2013, the fair value of the remaining Series C warrants was $4,635.   In September 2009, the Company issued 71,428 Series E warrants with an exercise price of $17.50 per share to the placement agent in connection with a financing. As of December 31, 2013, 71,428 Series E warrants remained outstanding.  As of December 31, 2013 and September 30, 2013, the fair value of the remaining Series E warrants was $0.   For the three months ended December 31, 2013 and 2012, the Company recorded a gain of $0 and $332,436, respectively, on the Series A through E warrants.   Series N Warrants   In October 2011, the Company sold 1,333,333 shares of its common stock to private investors for $4,000,000, or $3.00 per share.  This financing triggered the reset provision in the Series N warrants, which allows for adjustments in the exercise price if subsequent equity sales are offered at a lower price.  As a result, the outstanding 389,078 Series N warrants issued to investors in connection with a prior year financing, were reset from $4.00 to $3.00.  In addition, the investors were issued 129,693 warrants exercisable at $3.00 per share at an initial cost of $220,478.  The cost was accounted for as a debit to loss on derivatives and a credit to derivative liabilities.   On October 11, 2013 and December 24, 2013, in connection with public offerings of common stock on those dates, the Company issued the Series N warrant holders 2,432,649 additional warrants as required by the warrant agreements.  As of December 31, 2013, 2,951,420 Series N warrants remain outstanding.  As of December 31, 2013 and September 30, 2013, the values of the Series N warrants were $531,255 and $41,501, respectively.  During the three months ended December 31, 2013 and 2012, the Company recorded a loss of $489,754 and a gain of $311,262 on the Series N warrants, respectively.   Series F and G Warrants   In October 2011, in connection with a financing, the Company issued 1,200,000 Series F warrants exercisable at $4.00 per share at any time prior to October 6, 2014.  The Company also issued 66,667 Series G warrants exercisable at $4.00 per share to the placement agent for this offering.  The Series G warrants are exercisable at any time prior to August 12, 2014.  The initial cost of the warrants of $2,146,667 was recorded as a debit to additional paid-in capital and a credit to derivative liabilities. As of December 31, 2013 and September 30, 2013, the fair value of the Series F and G warrants was $12,667. During the three months ended December 30, 2013 and 2012, the Company recorded a gain on the Series F and G warrants of $0 and $640,000, respectively.     Series H Warrants   In January 2012, in connection with a financing, the Company issued 1,200,000 Series H warrants exercisable at $5.00 per share at any time prior to August 1, 2015. The initial cost of the warrants of $2,400,000 was recorded as a debit to additional paid-in capital and a credit to derivative liabilities. As of December 31, 2013 and September 30, 2013, the fair values of the Series H warrants were $12,000 and $36,000, respectively.   During the three months ended December 31, 2013 and 2012, the Company recorded a gain of $24,000 and $600,000, respectively, on the Series H warrants.   Series Q Warrants   In June 2012, in connection with a financing, the Company issued 1,200,000 Series Q warrants exercisable at $5.00 per share at any time prior to December 22, 2015.  The initial cost of the warrants of $2,160,000 was recorded as a debit to additional paid-in capital and a credit to derivative liabilities. As of December 31, 2013 and September 30, 2013, the fair values of the Series Q warrants were $24,000 and $48,000, respectively.   During the three months ended December 31, 2013 and 2012 the Company recorded a gain of $24,000 and $600,000, respectively, on the Series Q warrants.   Series R Warrants   In December 2012 the Company sold 3,500,000 shares of its common stock for $10,500,000, or $3.00 per share, in a registered direct offering.  The investors in this offering also received Series R warrants which entitle the investors to purchase up to 2,625,000 shares of the Companys common stock.  The Series R warrants may be exercised at any time before December 7, 2016 at a price of $4.00 per share.   The initial cost of the warrants of $4,200,000 was recorded as a debit to additional paid-in capital and a credit to derivative liabilities. As of December 31, 2013 and September 30, 2013, the fair value of the derivative liabilities totaled $157,500 and $288,750, respectively.  During the three months ended December 31, 2013 and the Company recorded a gain of $131,250 and $262,500, respectively, on the Series R warrants.   Series S Warrants   On October 11, 2013, the Company closed a public offering of 17,826,087 units of common stock and warrants at a price of $1.00 per unit for net proceeds of $16,400,000, net of underwriting discounts and commissions and offering expenses of the Company.  Each unit consisted of one share of common stock and one Series S warrant to purchase one share of common stock.  The Series S warrants are immediately exercisable, expire on October 11, 2018, and have an exercise price of $1.25.  In November 2013, the underwriters purchased an additional 2,648,913 warrants pursuant to the overallotment option, for which the Company received net proceeds of $24,370.     On December 24, 2013, the Company closed a public offering of 4,761,905 units of common stock and warrants at a price of $0.63 per unit for net proceeds of $2,790,000, net of underwriting discounts and commissions and offering expenses of the Company.  Each unit consisted of one share of common stock and one Series S warrant to purchase one share of common stock.  The Series S warrants are immediately exercisable, expire on October 11, 2018, and have an exercise price of $1.25. The underwriters purchased an additional 476,190 units of common stock and warrants pursuant to the overallotment option, for which the Company received net proceeds of approximately $279,000.   The initial cost of the S warrants of $7,321,071 was recorded as a debit to additional paid-in capital and a credit to derivative liabilities. As of December 31, 2013, the fair value of the derivative liabilities totaled $5,399,750.  During the three months ended December 31, 2013, the Company recorded a gain of $1,921,321 on the Series S warrants.   <table cellspacing="0" cellpadding="0" style="font: 8pt Calibri, Helvetica, Sans-Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px; line-height: 115%">1.  </td> <td style="line-height: 115%">Series L and M Warrants</td></tr> </table>   In April 2007, the Company completed a $15 million private financing.  Shares were sold at $7.50, a premium over the closing price of the previous two weeks.  The financing was accompanied by 1,000,000 warrants with an exercise price of $7.50 and 1,000,000 warrants with an exercise price of $20.00.  The warrants are known as Series L and Series M warrants, respectively.  The warrants issued with the financing qualified for equity treatment in accordance with ASC 815.  The cost of Series L and Series M warrants were recorded as a debit and a credit to additional paid-in capital.   In November 2011, the Company reduced the exercise price of 160,000 Series L warrants to $3.40. The additional cost of $86,826 was recorded as a debit and a credit to additional paid-in capital and was a deemed dividend.  In March 2012, 60,000 Series L warrants were exercised at a price of $3.40, and the Company received proceeds of $204,000.   In April 2012, the 25,000 Series L warrants were transferred to a consultant exercisable at a price of $7.50 per share and were extended for two years from the current expiration date.  The additional value of $43,910 was accounted for as a credit to additional paid-in capital and a debit to general and administrative expense.  In June 2012, 10,167 Series L warrants with an exercise price of $7.50 per share, expired.  In April 2013, 100,000 Series L warrants were repriced to $2.50 and extended for two years to April 2, 2015 in return for a reduction in outstanding warrants to 70,000.  The additional cost of $59,531 was recorded as a debit and a credit to additional paid-in capital and was a deemed dividend.  This cost was included in modification of warrants and increased the net loss available to shareholders on the statements of operations.  As of December 31, 2013, 70,000 of the Series L warrants at the reduced exercise price of $2.50 and 25,000 warrants at the original exercise price of $7.50 remained outstanding.   In February 2011, 600,000 Series M warrants, exercisable at a price of $6.00 per share were extended for two years to July 31, 2014.  This cost of $661,457 was recorded as a debit and a credit to additional paid-in capital and was a deemed dividend.     In November 2011, the Company reduced the exercise price of 600,000 Series M warrants from $6.00 to $3.40.  The additional cost of $238,794 was recorded as a debit and a credit to additional paid-capital and was a deemed dividend.   In October 2013, the Company reduced the exercise prices of the Series M warrants from $3.40 to $1.00 in exchange for a reduction in the number of warrants from 600,000 to 500,000.  The additional cost of $76,991 was recorded as non-employee stock compensation expense.  As of December 31, 2013, 500,000 Series M warrants at the reduced exercise price of $1.00 remained outstanding.   <table cellspacing="0" cellpadding="0" style="font: 8pt Calibri, Helvetica, Sans-Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px; line-height: 115%">3.  </td> <td style="line-height: 115%">Series O and P Warrants</td></tr> </table>   In March 2009, as further consideration for its rights under a licensing agreement, Byron Biopharma LLC (Byron) purchased 375,000 Units from the Company at a price of $2.00 per Unit.  Each Unit consisted of one share of the Companys common stock and two Series O warrants.  All Series O warrants were exercised by September 30, 2012.   On February 10, 2012, the Company issued 590,001 Series P warrants to the former holder of the Series O warrants as an inducement for the early exercise of the Series O warrants. Series O warrants entitled the holder to purchase 590,001 shares of the Companys common stock at a price of $2.50 per share at any time on or prior to March 6, 2016.  The Series P warrants allow the holder to purchase up to 590,001 shares of the Companys common stock at a price of $4.50 per share.  The Series P warrants are exercisable at any time prior to March 6, 2017.  The warrants were accounted for as an equity transaction using the Black-Scholes method to value the warrants.  The fair value of the warrants was calculated to be $1,593,000.  This cost was recorded as a debit and a credit to additional paid-in capital.    As of December 31, 2013, 590,001 Series P warrants remained outstanding.   <table cellspacing="0" cellpadding="0" style="font: 8pt Calibri, Helvetica, Sans-Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px; line-height: 115%">4.  </td> <td style="line-height: 115%">Private Investor Warrants</td></tr> </table>   In February 2011, 132,500 warrants issued to an investor with exercise prices between $5.60 and $8.20 were extended for three years.  The additional value of $406,912 was calculated using the Black Scholes method and was accounted for as a debit and a credit to additional paid-in capital.  As of December 31, 2013, 132,500 warrants remained outstanding.   In January 2009, as part of an amended lease agreement on the manufacturing facility, the Company repriced 300,000 warrants issued to the lessor in July 2007 at $12.50 per share and which were to expire on July 12, 2013. These warrants were repriced at $7.50 per share and expire on January 26, 2014. The cost of this repricing and extension of the warrants was $70,515 and was accounted for as a debit to the deferred rent asset and a credit to additional paid-in capital.  In addition, 78,750 additional warrants were given to the lessor of the manufacturing facility on the same date, exercisable at a price of $7.50 per share, and will expire on January 26, 2014. The cost of these warrants was $45,207 and was accounted for as a debit to the deferred rent asset and a credit to additional paid-in capital.  As of December 31, 2013, 378,750 warrants remained outstanding.     Between March 31 and June 30, 2009, 229,688 warrants were issued at $7.50 to the leaseholder on the manufacturing facility in consideration for the deferral of rent payments.  As of December 31, 2013, 229,688 warrants remained outstanding.   <table cellspacing="0" cellpadding="0" style="font: 8pt Calibri, Helvetica, Sans-Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px; line-height: 115%">3.  </td> <td style="line-height: 115%">Warrants Held by Officer and Director</td></tr> </table>   Between December 2008 and June 2009, Maximilian de Clara, the Companys President and a director, loaned the Company $1,104,057 under a note payable.  In June 2009, the Company issued 164,824 warrants, exercisable at $4.00 per share, to Mr. De Clara.  The warrants are exercisable at any time prior to December 24, 2014.  These warrants were valued at $65,796 using the Black-Scholes method.  In July 2009, as consideration for a further extension of the loan, the Company issued 184,930 warrants, exercisable at $5.00 per share, to Mr. De Clara.  These warrants were valued at $341,454 using the Black-Scholes method and can be exercised at any time prior to January 6, 2015.  The first warrants were recorded as a discount to the loan and a credit to additional paid-in capital.  The second warrants were recorded as a debit to derivative loss of $831,230, a premium of $341,454 on the loan and a credit to additional paid-in capital of $489,776.  The warrants and premium are fully amortized.  As of December 31, 2013, 349,754 warrants remained outstanding. See Note E for additional information.   <table cellspacing="0" cellpadding="0" style="font: 8pt Calibri, Helvetica, Sans-Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px; line-height: 115%">4.  </td> <td style="line-height: 115%">Options and Shares Issued to Consultants</td></tr> </table>   As of December 31, 2013, 200,750 options issued to consultants as payment for services remained outstanding, of which 191,250 options were issued from the Non-Qualified Stock Option plans.   On May 22, 2013, 3,000 options previously issued to a consultant from the Non-Qualified Stock Option plans expired.   On October 15, 2013, the Company entered into a consulting agreement for services to be provided through October 14, 2014.  In consideration for services provided, the Company agreed to issue the consultant 100,000 restricted shares in three installments 34,000 upon signing, 33,000 on January 15, 2014, and 33,000 on March 14, 2014.  Accordingly, during the three months ended December 31, 2013, the Company issued the consultant 34,000 shares of restricted stock at the fair market value of $0.80 per share.  The aggregate fair market value of $27,200 was recorded as a prepaid expense and will be charged to general and administrative expense over the period of service.   On October 20, 2013, the Company entered into a consulting agreement for services to be provided through October 19, 2016.  In consideration for services provided, the Company agreed to issue the consultant 34,164 restricted shares each month of the agreement, with the first three months being issued in advance. Accordingly, the Company issued the consultant 102,492 shares of restricted stock at the fair market value of $0.82 per share.  The aggregate fair market value of $84,043 was recorded as a prepaid expense and will be charged to general and administrative expense over the period of service.  On December 28, 2012, the Company entered into a consulting agreement with this same consultant for services to be provided through December 27, 2013.  In consideration for the services to be provided, the Company issued the consultant 50,000 shares of common stock and 50,000 options to purchase common stock at a price of $2.80 per share.  The common shares were issued at the fair market value on the agreement date of $2.80.  The aggregate fair market value of $140,000 was recorded as a prepaid expense and was charged to general and administrative expense over the period of service.  The fair value of the options issued, as calculated using the Black-Scholes method, was determined to be $98,150 and was also charged to general and administrative expense over the period of service.     On October 28, 2013, the Company entered into a consulting agreement for services to be provided through April 27, 2014.  In consideration for services provided, the Company granted the consultant 60,000 options to purchase common stock at a price of $0.85 per share.  The fair value of the options issued, as calculated using the Black-Scholes method, was determined to be $24,294 and was recorded as a prepaid expense and will be charged to general and administrative expense over the period of service.   During the three months ended December 31, 2013 and 2012, the Company recorded expense of $137,729 and $1,985, respectively relating to these consulting arrangements.  As of December 31, 2013 and September 30, 2013, the Company recorded $55,362 and $57,553, respectively, in prepaid consulting expenses.

In accordance with ASC 820-10, Fair Value Measurements, the Company determines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.  The Company generally applies the income approach to determine fair value.  This method uses valuation techniques to convert future amounts to a single present amount.  The measurement is based on the value indicated by current market expectations with respect to those future amounts.   ASC 820-10 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value.  The hierarchy gives the highest priority to active markets for identical assets and liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement).  The Company classifies fair value balances based on the observability of those inputs.  The three levels of the fair value hierarchy are as follows:   <table cellspacing="0" cellpadding="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="width: 96px; font: 8pt/115% Calibri, Helvetica, Sans-Serif; text-align: right">●  </td> <td style="font: 8pt/115% Calibri, Helvetica, Sans-Serif">Level 1 Observable inputs such as quoted prices in active markets for identical assets or liabilities</td></tr> <tr style="vertical-align: top"> <td style="font: 8pt/115% Calibri, Helvetica, Sans-Serif; text-align: right">●  </td> <td style="font: 8pt/115% Calibri, Helvetica, Sans-Serif">Level 2 Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly.  These include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and amounts derived from valuation models where all significant inputs are observable in active markets</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="width: 96px; font: 8pt/115% Calibri, Helvetica, Sans-Serif; text-align: right">●  </td> <td style="font: 8pt/115% Calibri, Helvetica, Sans-Serif">Level 3 Unobservable inputs that reflect managements assumptions</td></tr> </table>   For disclosure purposes, assets and liabilities are classified in their entirety in the fair value hierarchy level based on the lowest level of input that is significant to the overall fair value measurement.  The Companys assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the placement within the fair value hierarchy levels.      The table below sets forth the assets and liabilities measured at fair value on a recurring basis, by input level, in the condensed balance sheet at December 31, 2013:   <table cellspacing="0" cellpadding="0" style="font: 8pt Calibri, Helvetica, Sans-Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%">Quoted Prices in Active Markets for Identical Assets or Liabilities (Level 1)</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1pt solid"> Significant Other Observable Inputs (Level 2)</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%">Significant Unobservable Inputs (Level 3)</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%">Total</td> <td nowrap="nowrap" style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td nowrap="nowrap" style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Derivative instruments</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; line-height: 115%">$</td> <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%">-</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; line-height: 115%">$</td> <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%">-</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; line-height: 115%">$</td> <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%">6,143,278</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; line-height: 115%">$</td> <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%">6,143,278</td> <td nowrap="nowrap" style="line-height: 115%"> </td></tr> <tr> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td></tr> </table>   The table below sets forth the assets and liabilities measured at fair value on a recurring basis, by input level, in the condensed balance sheet at September 30, 2013:   <table cellspacing="0" cellpadding="0" style="font: 8pt Calibri, Helvetica, Sans-Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%">Quoted Prices in Active Markets for Identical Assets or Liabilities (Level 1)</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1pt solid"> Significant Other Observable Inputs (Level 2)</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%">Significant Unobservable Inputs (Level 3)</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%">Total</td> <td nowrap="nowrap" style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td nowrap="nowrap" style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Derivative instruments</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; line-height: 115%">$</td> <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%">-</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; line-height: 115%">$</td> <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%">-</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; line-height: 115%">$</td> <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%">433,024</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; line-height: 115%">$</td> <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%">433,024</td> <td nowrap="nowrap" style="line-height: 115%"> </td></tr> <tr> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td></tr> </table>   The following sets forth the reconciliation of beginning and ending balances related to fair value measurements using significant unobservable inputs (Level 3) for the three months ended December 31, 2013 and the year ended September 30, 2013:   <table cellspacing="0" cellpadding="0" style="font: 8pt Calibri, Helvetica, Sans-Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%">(3 month)</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%">(12 month)</td> <td nowrap="nowrap" style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%">December 31, 2013</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%">September 30, 2013</td> <td nowrap="nowrap" style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 78%; line-height: 115%">Beginning balance</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 8%; text-align: right; line-height: 115%">433,024</td> <td nowrap="nowrap" style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 8%; text-align: right; line-height: 115%">6,983,690</td> <td nowrap="nowrap" style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Issuances</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">7,321,071</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">4,200,000</td> <td nowrap="nowrap" style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Settlements</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td nowrap="nowrap" style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Realized and unrealized gains</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td nowrap="nowrap" style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">recorded in earnings</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%">(1,610,817</td> <td nowrap="nowrap" style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%">(10,750,666</td> <td nowrap="nowrap" style="line-height: 115%">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Ending balance</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt double; line-height: 115%">$</td> <td style="border-bottom: black 1.5pt double; text-align: right; line-height: 115%">6,143,278</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt double; line-height: 115%">$</td> <td style="border-bottom: black 1.5pt double; text-align: right; line-height: 115%">433,024</td> <td nowrap="nowrap" style="line-height: 115%"> </td></tr> </table>   The fair values of the Companys derivative instruments disclosed above are primarily derived from valuation models where significant inputs such as historical price and volatility of the Companys stock as well as U.S. Treasury Bill rates are observable in active markets.

During the three months ended December 31, 2013 and 2012, the Company recorded patent impairment charges of $240 and $10,223, respectively.  For the three months ended December 31, 2013 and 2012, amortization of patent costs totaled $9,703 and $23,905, respectively. The Company estimates that future amortization expense will be as follows:   <table cellspacing="0" cellpadding="0" style="font: 8pt Calibri, Helvetica, Sans-Serif; width: 100%"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 89%; line-height: 115%">Nine months ending September 30, 2014</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 8%; text-align: right; line-height: 115%">25,252</td> <td nowrap="nowrap" style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Year ending September 30,</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td nowrap="nowrap" style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">2015</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">33,795</td> <td nowrap="nowrap" style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">2016</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">33,795</td> <td nowrap="nowrap" style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">2017</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">33,795</td> <td nowrap="nowrap" style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">2018</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">33,461</td> <td nowrap="nowrap" style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">2019</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">31,758</td> <td nowrap="nowrap" style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Thereafter</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%">125,604</td> <td nowrap="nowrap" style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Total</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt double; line-height: 115%">$</td> <td style="border-bottom: black 1.5pt double; text-align: right; line-height: 115%">317,460</td> <td nowrap="nowrap" style="line-height: 115%"> </td></tr> </table> <table cellspacing="0" cellpadding="0" style="font: 8pt Calibri, Helvetica, Sans-Serif; width: 100%; background-color: white"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1pt solid; line-height: 115%">Name of Plan</td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%">Total Shares Reserved Under Plans</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%">Shares Reserved for Outstanding Options</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%">Shares Issued as Stock Bonus</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%">Remaining Options/Shares Under Plans</td> <td nowrap="nowrap" style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 52%; line-height: 115%">Incentive Stock Option Plans</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 9%; text-align: right; line-height: 115%">1,960,000</td> <td nowrap="nowrap" style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 9%; text-align: right; line-height: 115%">1,573,597</td> <td nowrap="nowrap" style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 9%; text-align: right; line-height: 115%">N/A</td> <td nowrap="nowrap" style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 9%; text-align: right; line-height: 115%">145,703</td> <td nowrap="nowrap" style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%">Non-Qualified Stock Option Plans</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">5,680,000</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">3,674,544</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">N/A</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">1,443,537</td> <td nowrap="nowrap" style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Stock Bonus Plans</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">1,594,000</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">N/A</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">958,325</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">634,919</td> <td nowrap="nowrap" style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%">Stock Compensation Plan</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">1,350,000</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">N/A</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">791,145</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">558,855</td> <td nowrap="nowrap" style="line-height: 115%"> </td></tr> </table>

<table cellspacing="0" cellpadding="0" style="font: 8pt Calibri, Helvetica, Sans-Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%">Quoted Prices in Active Markets for Identical Assets or Liabilities (Level 1)</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1pt solid"> Significant Other Observable Inputs (Level 2)</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%">Significant Unobservable Inputs (Level 3)</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%">Total</td> <td nowrap="nowrap" style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td nowrap="nowrap" style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Derivative instruments</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; line-height: 115%">$</td> <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%">-</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; line-height: 115%">$</td> <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%">-</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; line-height: 115%">$</td> <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%">6,143,278</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; line-height: 115%">$</td> <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%">6,143,278</td> <td nowrap="nowrap" style="line-height: 115%"> </td></tr> <tr> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td></tr> </table>   The table below sets forth the assets and liabilities measured at fair value on a recurring basis, by input level, in the condensed balance sheet at September 30, 2013:   <table cellspacing="0" cellpadding="0" style="font: 8pt Calibri, Helvetica, Sans-Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%">Quoted Prices in Active Markets for Identical Assets or Liabilities (Level 1)</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1pt solid"> Significant Other Observable Inputs (Level 2)</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%">Significant Unobservable Inputs (Level 3)</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%">Total</td> <td nowrap="nowrap" style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td nowrap="nowrap" style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Derivative instruments</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; line-height: 115%">$</td> <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%">-</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; line-height: 115%">$</td> <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%">-</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; line-height: 115%">$</td> <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%">433,024</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; line-height: 115%">$</td> <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%">433,024</td> <td nowrap="nowrap" style="line-height: 115%"> </td></tr> <tr> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td></tr> </table>

<table cellspacing="0" cellpadding="0" style="font: 8pt Calibri, Helvetica, Sans-Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%">(3 month)</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%">(12 month)</td> <td nowrap="nowrap" style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%">December 31, 2013</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%">September 30, 2013</td> <td nowrap="nowrap" style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 78%; line-height: 115%">Beginning balance</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 8%; text-align: right; line-height: 115%">433,024</td> <td nowrap="nowrap" style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 8%; text-align: right; line-height: 115%">6,983,690</td> <td nowrap="nowrap" style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Issuances</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">7,321,071</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">4,200,000</td> <td nowrap="nowrap" style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Settlements</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td nowrap="nowrap" style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Realized and unrealized gains</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td nowrap="nowrap" style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">recorded in earnings</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%">(1,610,817</td> <td nowrap="nowrap" style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%">(10,750,666</td> <td nowrap="nowrap" style="line-height: 115%">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Ending balance</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt double; line-height: 115%">$</td> <td style="border-bottom: black 1.5pt double; text-align: right; line-height: 115%">6,143,278</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt double; line-height: 115%">$</td> <td style="border-bottom: black 1.5pt double; text-align: right; line-height: 115%">433,024</td> <td nowrap="nowrap" style="line-height: 115%"> </td></tr> </table>

<table cellspacing="0" cellpadding="0" style="font: 8pt Calibri, Helvetica, Sans-Serif; width: 100%"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 89%; line-height: 115%">Nine months ending September 30, 2014</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 8%; text-align: right; line-height: 115%">25,252</td> <td nowrap="nowrap" style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Year ending September 30,</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td nowrap="nowrap" style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">2015</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">33,795</td> <td nowrap="nowrap" style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">2016</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">33,795</td> <td nowrap="nowrap" style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">2017</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">33,795</td> <td nowrap="nowrap" style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">2018</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">33,461</td> <td nowrap="nowrap" style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">2019</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">31,758</td> <td nowrap="nowrap" style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Thereafter</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%">125,604</td> <td nowrap="nowrap" style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Total</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt double; line-height: 115%">$</td> <td style="border-bottom: black 1.5pt double; text-align: right; line-height: 115%">317,460</td> <td nowrap="nowrap" style="line-height: 115%"> </td></tr> </table>

<table cellspacing="0" cellpadding="0" style="font: 8pt Calibri, Helvetica, Sans-Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="10" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%">Three Months Ended December 31, 2013</td> <td nowrap="nowrap" style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%">Net Loss</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%">Weighted Average Shares</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%">LPS</td> <td nowrap="nowrap" style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td nowrap="nowrap" style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 67%; line-height: 115%">Basic loss per share</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 8%; text-align: right; line-height: 115%">(5,451,865</td> <td nowrap="nowrap" style="width: 1%; line-height: 115%">)</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 8%; text-align: right; line-height: 115%">48,215,919</td> <td nowrap="nowrap" style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; border-bottom: black 1.5pt double; line-height: 115%">$</td> <td style="width: 8%; border-bottom: black 1.5pt double; text-align: right; line-height: 115%">(0.11</td> <td nowrap="nowrap" style="width: 1%; line-height: 115%">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Gain on derivatives</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%">(1,610,817</td> <td nowrap="nowrap" style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td nowrap="nowrap" style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td nowrap="nowrap" style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Dilutive loss per share</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt double; line-height: 115%">$</td> <td style="border-bottom: black 1.5pt double; text-align: right; line-height: 115%">(7,062,652</td> <td nowrap="nowrap" style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt double; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt double; text-align: right; line-height: 115%">48,215,919</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt double; line-height: 115%">$</td> <td style="border-bottom: black 1.5pt double; text-align: right; line-height: 115%">(0.15</td> <td nowrap="nowrap" style="line-height: 115%">)</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 8pt Calibri, Helvetica, Sans-Serif; width: 100%"> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="10" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%">Three Months Ended December 31, 2012</td> <td nowrap="nowrap" style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%">Net Loss</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%">Weighted Average Shares</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%">LPS</td> <td nowrap="nowrap" style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 67%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 8%; text-align: right; line-height: 115%"> </td> <td nowrap="nowrap" style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 8%; text-align: right; line-height: 115%"> </td> <td nowrap="nowrap" style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 8%; text-align: right; line-height: 115%"> </td> <td nowrap="nowrap" style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Basic loss per share</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">(2,310,246</td> <td nowrap="nowrap" style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">28,311,602</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt double; line-height: 115%">$</td> <td style="border-bottom: black 1.5pt double; text-align: right; line-height: 115%">(0.08</td> <td nowrap="nowrap" style="line-height: 115%">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Gain on derivatives</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%">(2,746,198</td> <td nowrap="nowrap" style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td nowrap="nowrap" style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td nowrap="nowrap" style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Dilutive loss per share</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt double; line-height: 115%">$</td> <td style="border-bottom: black 1.5pt double; text-align: right; line-height: 115%">(5,056,444</td> <td nowrap="nowrap" style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt double; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt double; text-align: right; line-height: 115%">28,311,602</td> <td nowrap="nowrap" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt double; line-height: 115%">$</td> <td style="border-bottom: black 1.5pt double; text-align: right; line-height: 115%">(0.18</td> <td nowrap="nowrap" style="line-height: 115%">)</td></tr> </table>

317460 -2746198 -1610817

I. NET LOSS PER SHARE (Details) (USD $)	3 Months Ended
Dec. 31, 2013	Dec. 31, 2012
I. Net Loss Per Share Details
Net loss – available to common shareholders	$ (5,451,865)	$ (2,310,246)
Less: Gain on derivative instruments	(1,610,817)	(2,746,198)
Net loss - diluted	$ (7,062,652)	$ (5,056,444)
Weighted average number of shares - basic and diluted	48,215,919	28,311,602
Earnings per share - basic	$ (0.11)	$ (0.08)
Earnings per share - diluted	$ (0.15)	$ (0.18)

EX-101.SCH 5 cvm-20131231.xsd 0001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 0002 - Statement - BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 0003 - Statement - BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0004 - Statement - STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 0005 - Statement - STATEMENTS OF OPERATIONS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0006 - Statement - STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 0007 - Disclosure - A. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 0008 - Disclosure - B. NEW ACCOUNTING PRONOUNCEMENTS link:presentationLink link:calculationLink link:definitionLink 0009 - Disclosure - C. STOCKHOLDERS EQUITY link:presentationLink link:calculationLink link:definitionLink 0010 - Disclosure - D. FAIR VALUE MEASUREMENTS link:presentationLink link:calculationLink link:definitionLink 0011 - Disclosure - E. LOANS FROM OFFICER link:presentationLink link:calculationLink link:definitionLink 0012 - Disclosure - F. OPERATIONS, FINANCING link:presentationLink link:calculationLink link:definitionLink 0013 - Disclosure - G. COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 0014 - Disclosure - H. PATENTS link:presentationLink link:calculationLink link:definitionLink 0015 - Disclosure - I. NET LOSS PER SHARE link:presentationLink link:calculationLink link:definitionLink 0016 - Disclosure - J. SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 0017 - Disclosure - A. ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (POLICIES) link:presentationLink link:calculationLink link:definitionLink 0018 - Disclosure - C. STOCKHOLDERS EQUITY (Tables) link:presentationLink link:calculationLink link:definitionLink 0019 - Disclosure - D. FAIR VALUE MEASUREMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 0020 - Disclosure - H. PATENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 0021 - Disclosure - I. NET LOSS PER SHARE (Tables) link:presentationLink link:calculationLink link:definitionLink 0022 - Disclosure - C. STOCKHOLDERS EQUITY (Details) link:presentationLink link:calculationLink link:definitionLink 0023 - Disclosure - C. STOCKHOLDERS EQUITY (Details 1) link:presentationLink link:calculationLink link:definitionLink 0024 - Disclosure - C. STOCKHOLDERS EQUITY (Details 2) link:presentationLink link:calculationLink link:definitionLink 0025 - Disclosure - C. STOCKHOLDERS EQUITY (Details 3) link:presentationLink link:calculationLink link:definitionLink 0026 - Disclosure - C. STOCKHOLDERS EQUITY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 0027 - Disclosure - D. FAIR VALUE MEASUREMENTS (Details) link:presentationLink link:calculationLink link:definitionLink 0028 - Disclosure - D. FAIR VALUE MEASUREMENTS (Details 1) link:presentationLink link:calculationLink link:definitionLink 0029 - Disclosure - E. LOANS FROM OFFICER (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 0030 - Disclosure - G. COMMITMENTS AND CONTINGENCIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 0031 - Disclosure - H. PATENTS (Details) link:presentationLink link:calculationLink link:definitionLink 0032 - Disclosure - H. PATENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 0033 - Disclosure - I. NET LOSS PER SHARE (Details) link:presentationLink link:calculationLink link:definitionLink 0034 - Disclosure - I. NET LOSS PER SHARE (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 cvm-20131231_cal.xml EX-101.DEF 7 cvm-20131231_def.xml EX-101.LAB 8 cvm-20131231_lab.xml Series N [Member] Class Of Warrant Or Right [Axis] Series A [Member] CSchleuningSeriesAMember Series B [Member] Series C [Member] Series E [Member] Series F [Member] Series G [Member] Series H [Member] Series Q [Member] Series L [Member] Series L Repriced [Member] Series M Modified [Member] Series P [Member] Private Investors [Member] Warrants Held by Officer And Director [Member] Consultants [Member] SeriesKwarrantsMember Financings2009WarrantsSeriesAToEMember Warrants2008SeriesNMember SeriesFAndGWarrantsMember SeriesHWarrantsMember SeriesQWarrantsMember ConvertibleNotesSettlementMember IncentiveStockOptionPlansMember PlanName [Axis] NonQualifiedStockOptionPlansMember StockBonusPlansMember StockCompensationPlanMember SeriesRMember Series M Modified Series O Level1 FairValueByFairValueHierarchyLevel [Axis] Level2 Level3 Total Outstanding Option Indexed to Issuer's Equity [Axis] Exercisable Incentive Stock Option Plans Award Type [Axis] Non-Qualified Stock Option Plans Stock Bonus Plans Stock Compensation Plan Series A through E warrants Deferred Rent Liability Gain Contingencies By Nature [Axis] Senior Convertible Notes Private Investor Warrants Private Investor Warrants Private Investor Warrants Private Investor Warrants Patent Indefinite-lived Intangible Assets by Major Class [Axis] Collaborative Arrangements Erogmed Legal Entity [Axis] Series S Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Is Entity a Well-known Seasoned Issuer? Is Entity a Voluntary Filer? Is Entity's Reporting Status Current? Entity Filer Category Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] ASSETS CURRENT ASSETS: Cash and cash equivalents Receivables Prepaid expenses Deposits - current portion Inventory used for R&D and manufacturing Deferred rent - current portion Total current assets RESEARCH AND OFFICE EQUIPMENT AND LEASEHOLD IMPROVEMENTS-- less accumulated depreciation depreciation and amortization of $3,010,439 and $2,967,345 PATENT COSTS--less accumulated amortization of $1,148,214 and $1,313,046 DEFERRED RENT - net of current portion DEPOSITS TOTAL ASSETS LIABILITIES AND STOCKHOLDERS' EQUITY CURRENT LIABILITIES Accounts payable Accrued expenses Due to employees Related party loan Deferred rent - current portion Lease obligations - current portion Total current liabilities Derivative instruments Deferred revenue Deferred rent-net of current portion Lease obligations - net of current portion Deposits held Total liabilities COMMITMENTS AND CONTINGENCIES STOCKHOLDERS' EQUITY Preferred stock, $.01 par value - authorized 200,000 shares, issued and outstanding, -0- Common stock, $.01 par value - authorized 600,000,000 shares; issued and outstanding 55,852,992 shares and 31,025,019 shares issued and outstanding at December 31, 2013 and September 30, 2013, respectively Additional paid-in capital Accumulated deficit Total stockholders' equity TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY Assets Accumulated Depreciation and Amortization for Research and Office Equipment and Leasehold Improvements Accumulated Amortization for Patents Stockholders Equity Preferred Stock Shares Par Value Preferred Stock Shares Authorized Preferred Stock Shares Issued Preferred Stock Shares Outstanding Common Stock Shares Par Value Common Stock Shares Authorized Common Stock Shares Issued Common Stock Shares Outstanding Income Statement [Abstract] OTHER INCOME OPERATING EXPENSES: Research and development (excluding R&D depreciation of R&D depreciation of $41,673 and $104,864) Depreciation and amortization General & administrative Total operating expenses OPERATING LOSS GAIN ON DERIVATIVE INSTRUMENTS INTEREST INCOME INTEREST EXPENSE NET LOSS ISSUANCE OF ADDITIONAL SHARES DUE TO RESET PROVISIONS MODIFICATION OF WARRANTS INDUCEMENT WARRANTS NET LOSS AVAILABLE TO COMMON SHAREHOLDERS NET LOSS PER COMMON SHARE BASIC DILUTED WEIGHTED AVERAGE COMMON SHARES OUTSTANDING BASIC DILUTED Expenses Depreciation Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES: Net loss Adjustments to reconcile net loss to net cash used in operating activities: Issuance of common stock, warrants and options for services Modification of warrants issued for services Employee option cost Common stock contributed to 401 (k) plan Impairment loss on abandonment of patents Loss on retired equipment Gain on derivative instruments (Increase)/decrease in assets: Receivables Deferred rent Prepaid expenses Inventory used for R&D and manufacturing Deposits Increase/(decrease) in liabilities: Accounts payable Accrued expenses Due to employees Deferred rent liability Net cash used in operating activities CASH FLOWS FROM INVESTING ACTIVITIES: Purchases of equipment Expenditures for patent costs Net cash used in investing activities CASH FLOWS FROM FINANCING ACTIVITIES: Proceeds from issuance of common stock and warrants Payments on oblgations under capital leases Net cash provided by financing activities NET INCREASE IN CASH AND CASH EQUIVALENTS CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD CASH AND CASH EQUIVALENTS, END OF PERIOD ISSUANCE OF WARRANTS: Increase in derivative liabilities Decrease in additional paid-in capital Total ISSUANCE OF ADDITIONAL SHARES Increase in common stock Increase in additional paid-in capital Decrease in additional paid-in capital Total EXERCISE OF DERIVATIVE LIABILITIES: Decrease in derivative liabilities Increase in additional paid-in capital Total MODIFICATION OF WARRANTS: Increase additional paid-in capital Decrease in additional paid-in capital EX-101.PRE 9 cvm-20131231_pre.xml EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0`!@`(````(0`:,QE5V@$``#$6```3``@"6T-O;G1E;G1?5'EP97-= M+GAM;""B!`(HH``"```````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````````````````#,F%UKPC`4AN\'^P\EM\/& MI)MSP^K%/BXW8>X'9,W1%MLD)-'IOU]:/QC2.63"SHU%FYSW,90'^@Y&JZJ, MEF!=H55*6-PE$:A,RT+-4O(^>>[T2>2\4%*46D%*UN#(:'AY,9BL#;@H[%8N M);GWYIY2E^50"1=K`RK[?9HII4'Y3N^GD&&@T>8 MBD7IHZ=5^'E#8J%T)'K8+*RS4B*,*8M,^$!*ETH>I'2V"7'8V:QQ>6'<5<`@ MM#6AOO-SP';?:S@:6TB(QL+Z%U$%#+HJZ:>V\P^MY_'Q(2V4>CHM,I`Z6U3A M!&)G+`CI<@!?E7%SC2M1J!WWD?QFL:/-A9T9I/Y_S>`3.3@2C@0)QS42CALD M'#TD'+=(./I(..Z0<+`N%A`L1F58E,JP.)5AD2K#8E6&1:L,BU<9%K$R+&;E M6,S*L9B58S$KQV)6CL6L'(M9.1:S*TG?'A$%@?0'[%K.M#=PGAGKT],"#.A+J`E:";,FF3>$[ M_`(``/__`P!02P,$%``&``@````A`+55,"/U````3`(```L`"`)?]=J>*V?5@^@8B)G:13'&HX<85?=WFQ?>*24FV+7^ZBRBXL:NI3\ M(V(T'4\4"_'L)MI< M3_3_MCAQ(DN)T$C@\SS?BG-`Z^N!+I]HJ?B]SCSBIX3A363X8<'%#U1?```` M__\#`%!+`P04``8`"````"$`_GO?E-(!```<%0``&@`(`7AL+U]R96QS+W=O M_%[)K?BL"EJL2UI0]@)88@((EL]X>W MKX40%*F=7J*]1+*C.*/)>KYX9XNOPS[[<#YLFSI7U.NKS-5%4V[K3:[>5L\/ M$Y6%:.O2[IO:Y>KH@EK,[^]F+VYO8WHH5-LV9&F5.N2JBK%]U#H4E3O8T&M: M5Z<[Z\8?;$Q#O]&M+79VXS3W^R/M?ZZAYC=K9LLR5WY9DE'9ZMBF5_^_>+-> M;POWU!3O!U?'7]ZA/QN_"Y5S,2UJ_<;%7%VF@C[=(=-+FI7^0T[R0U;.!,GA MD;`<'D$Y)"V'D!PS$)9C!DC.6%C-&(DA%E9##.5(FT/0'1X*N\-#Y(Z1#D$# M0U"Z='#E2$<@X0A,!!4%!/=1Y?!46LX4R9'F`\2#=.'`NB%Q:Z`W+(U.AN@T MTI%C8.:83FD5*NM=^1I]^ND.:;N>?TQOIM&FDF851!5)JR$HAZ7)R9B"'XJD MK2'H#4O#DB$LN5-87MHUUYRY3)T[.`R/=D8ZA/EWA MUI:F$H92TB_9\+L`6]_T-.??````__\#`%!+`P04``8`"````"$`<]PQ?(8# M``#;"@``#P```'AL+W=OFWX'A?<,_DR:9 M:`;QC+0*%E`G?7-#Y(PW07``8_+MNT#%%8AM7NF"^]SNL[\[[^[^;1,*KRQ) M>1QU1>5"%@46+>.`1\]=<>8-OUV+0IKY4>"'<<2ZXCM+Q?O>UR]W^SAY>8KC M%P$$HK0KKK-L>RM)Z7+--GYZ$6]9!&]6<;+Q,PB39RG=)LP/TC5CV2:45%F^ MDC8^C\12X3;Y'XUXM>)+-HB7NPV+LE(D8:&?0?GIFF]3L7>WXB&;EQT)_G9K M^1NH^RT4A=!/,Q+PC`5=\1+">,].'B2[;7_'0WA[H\F:*/6J)J>)$+"5OPLS M#]H[J(-?:D=5K_)?YE;,.=NGQZ0\%-X6/`KB??Y3L/:]BC0H8%^\6O`@6\-[ M69:K9R/&G]?9X2'(2TB_.5?KZ6+<,0MT1(9Z+LE24I9[/HE,_@=&L6<:7/IA>K:PA MC<)'87N`JKE!^,7C$$J#1A,&Z$'SKDN!9-A.NG.R(-X*2H/"'T!1WX5QP:*4S.M+ MXWV@M"!H.P^Z9?XN]@_-VT9,XA8P@DJ#P59XJ.<_A?`'<-S4'4R@TD#P0X@* M):R#650:,%8S:*D`,PAG;.U(:QM%BPA&46V@V&[&@&4^#[$;*L8"@EHM9V4H M&PO=V]R:W-H965T&ULE)A=;ZM&$(;O M*_4_(.YCV&7YLFP?!:*T1VJEJNK'-<%K&P58"TB<\^\[NX.!76*7W"0&7EZ> MG1EFO-Y\^ZA*ZYTW;2'JK4U6KFWQ.A?[HCYN[;__>GZ(;*OMLGJ?E:+F6_L' M;^UONY]_VEQ$\]J>..\L<*C;K7WJNO/:<=K\Q*NL78DSK^'*0315UL%A(A#H?K?8D M+K\TQ?ZWHN80;L MRW:;1EPLJ!IX9GO.9`V2-3A?5X8I2])YA*B*]*K0F8"Z`9$6/@4\?.@7TFD6)+()$BT!$^`]X!&C>?.%6$\ M2#02"-!R$BF&1$\>'+F#+;*AA$TDOJY([RDT-#!9CB;%6QO6/<0D,I*1H"12 MN23$(XP99)K`=]UQ;1H7U/=R+BDV0F8D*T$)/'Q`-T-V3Z&A!3J:+'T&-]^O M+WF3$3I/CTR"DD"%CKDD]ID1W'2JH#%E(1V7J2'"&[4\>E)LH!E)2U"":'X0 MQ&.=JX),I]>)YS'_1E;E8)MTC?LADV*#R\A9@A+D(G%(*#'(TZD"IA^!QC>$ M70M9_!4T*3;0@L$6WU&4(%K@LI#Y)MI4X;M^S/QP\-#0"`R>Y6%3:@-N-$:X M7H-T#W[L,8^,*<.<&AJ7L=N`L@4OSBO!AJVUD5G71TV?V8"X$3'6D/8V**$A M"T@\NNCQDYUZ.1[V=0W/J/>$H`:?[9%PDKD^>%,!C1FY475$-NKE:-C6IVBQ MD;9$.6[M/K6,!M'8(WHV=+DJ"'-'A1XWV:N7PV%GU^",!I80U%P?#9V"D3%I M/9ZFH5"8E(TOEPXH>_8$4+9B#UZ6^WU%?@,SWMYXC(""2'I-#TH("1F;%>!U M8LCO+6,:=,)/AL4"POFTB,UI05"#D_;!9SZ)@K'(^E!JFONA_-+((-CPH9"& M<1H;[2WI-9#-03/C0YO/)7HPV^OBRBQ(^)T<-334,CCY#@5B.$/:+69^[W%Z4V`,T4 M]YK[@-H,^1P0MYZX,ZMX<^0I+\O6RL6;W%92*.[A[+#E?50[7N-\`EMAM6]T MA@NP$SUG1_Y[UAR+NK5*?@!+=Q5"VVMP+XL'G3BK_>"+Z&`/JCZ>X#<'#KLH M=P7B@Q#=]4#NT89?,7;_`0``__\#`%!+`P04``8`"````"$`]Y\7S>@"``#3 M!P``&0```'AL+W=OR`"58!(]MIVG^_:YS00+JL?2&Q?7Q\SKGF,K]Y M;FKTQ*3BHLTP<3R,6)N+@K?;#/_Z>7=UC9'2M"UH+5J6X1>F\,WB\Z?Y7LA' M53&F$3"T*L.5UEWJNBJO6$.5(SK6PDHI9$,U#.7659UDM.@W-;7K>U[D-I2W MV#*D\CT6BZ8!BPVNN M7WI2C)H\O=^V0M)-#;Z?24#S(W<_.*-O>"Z%$J5V@,ZU0L\])V[B`M-B7G!P M8&)'DI49OB7I.L+N8M[G\YNSO3KYCU0E]E\D+[[QED'84"93@(T0CP9Z7Y@I MV.R>[;[K"_!=HH*5=%?K'V+_E?%MI:':(1@ROM+B9.'ABD7-0B` M)VJXN1D0"'WN?_>\T%6&9Y$3QMZ,`!QMF-)WW%!BE.^4%LT?"R('*DOB'T@" M4']8]QW_.B1A]'\6URKJ#:ZIIHNY%'L$EP;.5!TU5Y"DP&R(U86`<\W--K[<8ECY`+>LE,7E]4;\%3]1-O28JSZ M($RF!;#+EZ2?$LR2Y+4^(]W11W0;\%@W(=/4+<;>'4*\Z+7J?:(KNWY)^(C! M#\A4N6VBMLFI' MM^R!RBUO%:I9"92>$T.8TG9E.]"BZSO;1FCHIOW?"CZ>#'J*YP"X%$(?!^:` MX7.\^`L``/__`P!02P,$%``&``@````A`,/Y:^]_`@``W04``!D```!X;"]W M;W)K&ULC)39CILP%(;O*_4=+-\/!@)A)@H931*E M':F5JJK+M6,,6(,QLIWM[7N,$YJE2VX2;/]\_L_&]'DO&[3EV@C5YC@*0HQX MRU0AVBK'W[^M'AXQ,I:V!6U4RW-\X`8_S]Z_F^Z4?C,UYQ8!H34YKJWM)H08 M5G-)3:`ZWL))J;2D%I:Z(J;3G!;]2[(A<1B.B:2BQ9XPT?*;21O MK8=HWE`+_DTM.G.B278/3E+]MND>F)(=(-:B$?;00S&2;/):M4K3=0-Q[Z.$ MLA.[7]S@I6!:&57:`'#$&[V-^8D\$2#-IH6`"%S:D>9ECE^BR2+!9#;M\_-# M\)TY>T:F5KL/6A2?1,LAV5`F5X"U4F].^EJX+7B9W+R]Z@OP1:."EW33V*]J M]Y&+JK90[10"E%T1'E(?(2,P/WQ/`[BQS1*Q_^G$.^H#W!) M+9U-M=HA:!JXTW34M6`T`?(I,N]CB/5OH4*,#O+B*#G.,((H#)1G.TNR:$JV MD%-VU,QO-5>*Q4GA2@'V!H\0^;G'/V?]9,6)G157!>=M[C>`/7B++YTM;A79 MTR"Y<`(9NM^)$T.ESRY.LJNKYUZ3G&G2X>;>_N)?B@MO`+G?FQ/G&`(?DI)D MH\N;YU[SV)/PZAP&SC'\>1(EX>_8O"\_3K[;)-<57_"F,8BIC1N5&+C# M[C#%+[$KW-7^'*:[GP4R',!T=;3BGZFN1&M0PTM`AD$&XZ3]?/J%55W?XVME M8:[ZQQH^HQP:(PQ`7"IE3PO7=L.'>?8+``#__P,`4$L#!!0`!@`(````(0"E M*XQ#$@,``)\(```9````>&PO=V]R:W-H965TS`R98!8QLIVG__:YQ0B%IHY0'P'!\ M./?<:U\6M\]-C9Z85%RT&?8=#R/6YJ+@[3;#?WX_W*08*4W;@M:B91E^80K? M+C]_6NR%?%058QH!0ZLR7&G=S5U7Y15KJ')$QUIX4PK94`U#N755)QDM^DE- M[0:>1]R&\A9;AKF\AD.4)<_9OC]^,C`;TF02 ML!'BT4"_%>813';/9C_T"?@I4<%*NJOU+['_ROBVTI#M&`(R<B#Q8R<*XB3]"$MX8('KD85+:N'J;[JFFRX44>P2E!\I5 M1TTA^W-@/OICHQD<>\\P<,J0W!F6#"<8@1<*DORTC$BR<)\@,_D!L[(8.`\8 M?XI8GR,BD@X8%Q0/LL'*L>RWTWE49\!&G4FOD;NR#\92@N$S/6)]C@B]`3)1 M`J9=K\2`H81&'D1D-O!:<183C3#Q%+&^A)AH`Y+KM1EPAB'P(3]0Y-,OKRPF MM1D.0R^(IH#U&$!F:4AF[]@&J^=Z:09\*BVX20MVTT+72TM5R69\!3>6%P*L]B;/41 M/PJ#Y'5WL,MVC(BF]6D=M(W"[H`-DUNV9G6M4"YVI@GX4#W#TZ$_W05]BQE> M0'_HZ);]H'++6X5J5L)4STF@OJ3M,':@1=?OKQNAH3/TMQ7\"##8@3P'P*40 M^C@P/6SXM5C^!P``__\#`%!+`P04``8`"````"$`#5^:S+X"``"O"```&0`` M`'AL+W=OV`"58!(]MIVG^_8YQD&"J6WB0A>?SF.9X>:-LJ$"%H1!?ZR9*T\I]79-7$U$<^']B;C=0L1.U8Q]=:%(J?. MEH_[A@NRJZ#N5S\BV3F[NQC%URP37/)"N1"'C>BXY@5>8$A:KW(&%>BV.X(6 M*;KSE]L%PNM5UY_?C!YE[[,C2W[\(EC^C344F@W3I"=@Q_FS1A]S_14,QJ/1 M#]T$?!=.3@MRJ-0/?OQ*V;Y4,-LQ%*3K6N9O]U1FT%"(<8-8)V6\`@%X=6JF M5P8TA+QV[T>6JS)%8>+&,R_T`7=V5*H'IB.1DQVDXO4?`_FG*!,2G$)"L#_] M'KC!//;CY/\IV!AU!=X31=8KP8\.+!KX3]D2O03])23KRD+HS_N504EZS)T> MU`T%6L)LO*RC)%SA%VAA=F(V8R:PB>V8"+T+@L'O(@FE]R6GY32<(GCMR467 MW*Z`C6&B'A/;Q':*L-R@:=>[:=AVBWW[CS<&Z:M%0V8[S5AZ$'2]GH9MO2@9 M-&9CF+[?@-A.$98;K/WKW31LNPW;LC%(7VW@%_^XIRTP?>;T-9?I> MU;!MYH>#;6)CF*FN31&6V^(C;AJVW49=,\A\HFM]XMVNF3/';,DMV=,G(O:L MD4Y%"]B_/'<&"U:8$\=<*-YV6^^.*S@INH\E/!A0V)<]%^""0+)&ULE)I;;^,V$(7?"_0_&'YO;%UM!TF*E8AM"[1` M4?3RK-A*(JQM&9*RV?WW'6K&LH>D1V(?TDWT:70..>2193W\_.VPGWTMF[:J MCX_SX&XYGY7';;VKCJ^/\W_^_OS3>CYKN^*X*_;UL7RKM^Z$\=EBD*?=%!_K;M^K4GJL=ME/* M'8KFR_OIIVU].$&)YVI?==_[HO/987O_V^NQ;HKG/?C^%L3%]ER[_\4J?ZBV M3=W6+]T=E%N@4-OS9K%90*6GAUT%#O2PSYKRY7'^*;A7R6J^>'KH!^C?JOQH MK_X]:]_JCU^::O=[=2QAM&&>]`P\U_47C?ZVTW^"DQ?6V9_[&?BSF>W*E^)] MW_U5?_Q:5J]O'4QW`HZTL?O==U6V6QA1*',7)KK2MMZ#`/@Y.U2Z-6!$BF_] M_S^J7??V.(_2NV2UC`+`9\]EVWVN=,GY;/O>=O7A/X0"*H5%0BH2@WHZ'MZ% MZR1(TO$J"U34&U1%5SP]-/7'#+H&KMF>"MV#P3U4/CM#'8/76U;!HR[R25=Y MG*_F,W#1POQ\?8J3\&'Q%<9T2TQF,P$G\C.A!U"75?B'?A@6H'<0#4-Q+=H] M#6=M&M;:SE4S_`/4'L0:4G.;6&VX5F4CT7)`F-B(B]4C'$$'RJ+U28]SN,B@ M,4ZBH7X_.ADR<3_NN!YLK3^^ MV?OG0=&7??X#'LFR@*X\ALF_/)KDEA MLF$SF#[H&C9DAZ9L9*1!'R641##U.KFOMD6Y931LJ$^,<@($CTI$N`$=;-,-8`QR`V;W M!`CAAA.D:Z-[AL.N+07W^0'1=Q;7%;AT'6G3I6,`,NFA)5U*25RWP2BB1(1; M@$GTL*!I8P58&T^`$+9/LH3_S/%'`'[>S%FJX4:X`1UKT^<`0Y#-06+-P3DI M]>1;XL\'!?%GA)_/9>M8FRX;0Y#)#HVVS@(I*:EU1A$E5N$6=+9-MX!)R"S8 MK8,0MDZ<1O':F)L\D`*5UJZ$<`L5O3X]M/@3A^*^"V%PE.0'2!(@( M-^`5OJ$K?,T&(LA]LSP-<0_-CU8$"<.:CR-*1/C( M>T5OZ(C>Q-P_":*EN]ZL$L-D3H1@4HD(=P!E/"9!T\8D6)^S0H0$?3DA:#(* M@M#\$*S$(MR!SKG).Y!^9&0Y,&\]"4)YX2:!!6P&,"&"224BW()7#(>.&+;N M'@A""XE^X&9F`!&B`[P2]6*0+"];-=>OLV[Z%&`RLA!(C.=,62C%)]Y&C"-* M1+@%KQ`.72%L#'!&T(T]]#I>T]B^/U7#Z:Y=EFOWRN#0D<%V^R"$,P_+,S4" M(J"T[NGIXTM*#*VR(P@05T^CB@1X1:\$CAR);#9/031'J0; MQ/C\PH!4-Y!!*"+T5QI&EC"JP.(NC<09:ZG`"W.KP'934B[7$8`R[? M*X8C1PQ;CSH)$M3EXX@2$6X!KN2Q"#1MSH#500@)'70-N#L("?CI^(S,]7NE M<.1*86.+R0@2]&,5MSKJ($2P1KR^W4%>"1PY$MA\8IP1)*C+QQ$E(GP&O$(X M( ME@$DA%E2="7RN%Y?/XGD!KQR.+)S.`PNW^3THY<1),C+QQ$E(LQ"[)7%/3VV M#1%$3;0!C^'E-A*[B!#!I1(1;L$KBV-7%IMM1!!:2*(-?"@S^X@0T0)>RHUP M"UYQ'#OB.#7T902Y+TZS@'4$1(E5N`6O2(X=D6P]EB.(9@&VX`F.F)'&O:6`JQ-0D(N2].DS"**+J4NPJWX!7*^MMMTX(]"=>!FFQ@#JS% MC(1;7F]2T97<"'?@E MI^9$"":5B'`'1C!/>ZDI<01T;#D93=^D!W=-\1<3FRR@908*^?!Q1(L(GP2N@DRD!31"MB.72OE4E0C"I M1(0[,`)ZXHJP@SI.C1N)+$$(G031:A4:#XES3FS6QN=71V2WB3=7D'\$M==^=?X,*+X2WPI_\!``#__P,` M4$L#!!0`!@`(````(0!PIB,T"P,``#@)```9````>&PO=V]R:W-H965T-"2<- MEL`O:MJ+DUM;7&+78OZX[V\*UO9@L:4-E2_:%'EM,?^RZQC'VP;R?HY27)R\ M]<69?4L+S@2KI`]V@0$]SWD6S`)P6BU*"AFHLGN<5$MT%\TW48B"U4(7Z#U32+Z7Z"Q8'9ZL?]`E\YUY)*KQOY`]V M^$SHKI9PW!EDI!*;ER_W1!104;#QXTPY%:P!`/CT6JI:`RJ"G_7W@9:R7J(D M][-)F$0@][9$R`>J+)%7[(5D[1\CBHY6QB0^FB1`?XS'?CS-HBS_OTM@B'2" M]UCBU8*S@P==`WN*'JL>C.;@K#)+H#[_S@Q24FONU"*]%-0"CN-IE:;31?`$ M)2R.FO6Y)AXK-N>*)!PD`?`-D)"Z#?D^G!)#$LBSX&:#KTY@;32II8-W8\R>WXB&MR#9<2NUQNZQN-X8I3>U_=?AL[GD[M^(A+C3;K MN?'^+:G$#E?JU&-M-,=Z99/LK&"V()Y.03%TPHAL=@V9$KMD;NL;C2'+DF1F M[VQJ9A1P!UBW]:O+B`[&U!6%TVJ7+QGR-@^,H^CTQ$B3>.(THQJ.*D\C29,D MC-/!Q."9V6=&0X]WY!OF.]H)KR$5)!7Z$[B/N)E\YD*R7H^`+9,PL?3/&MY0 M",R'T`=QQ9@\7:C9.KSSK/X"``#__P,`4$L#!!0`!@`(````(0``)_N9J@H` M`+-````9````>&PO=V]R:W-H965T/*%G,XZ\_SJ?5]_;:'[O+-A'K-%FUEWUW.%Y>M\E__OWEESI9];?= MY;`[=9=VF_QL^^37I[_^Y?&CNW[MW]KVME(M7/IM\G:[O3]L-OW^K3WO^G7W MWE[43UZZZWEW4]]>7S?]^[7='3GNV\_= M_MNYO=R@D6M[VMW4^?=OQ_=^:.V\CVGNO+M^_?;^R[X[OZLFGH^GX^VG:319 MG?NNON^:3Z_4/(W7YHVWSC-7\^[J]=W[W>$=_,4/PQW5U:%]VWTZW?W4??V^/KV\W-=Z%ZI+N MVVWZN2JF;66:%;VGHFD]7^6W_KSO\#D<"FH)$,&U%?L1&1K;.Z$$6YW,H&SLAT\//N MMGMZO'8?*Q4;Y=F_[W0(Q8-J6?S4>WY]DEC]N MOJL2[E'SR==D=\5&F=_/0+F.SV#>68NWB?I[Y"SO[9JS^P0:.=(4=X7CG'.< MM5C59MQJ?6\6C$$28:PD\5W68K?+HBF),V@*,Q1Y4U;VS)P.J["-?>,&6Q]$ M_2OB#YK2^&=-(626WA7.&93N&
VXMAJ,;5M M[MT!6]!`P:6H2_MSQU=?`4:S:[Z[6NSZRLPF%WQ!$Q&QAN.LQ0O9!DF$L5#T MB.^S4;N=]M.-HB'>36U#X%1;_#F8`:G&3!$-#;AI>IM`PD6>YM(JW'/0](D> M<@&L1T'$=8\3=/`-5,0H,61W!Q%)YO- M,0X[H`V37E9%@.2"Q3:CIM9>T(%N\T%G@4T`ML9I$XT7=!!AT;-4!(J>L`*RB*B1N!VT+4@5=J,.^W!(7G#9H8;T*U MR+P!N-S:>WD#$>1-EKFLK<(M/@MQV13BO`*`"`)7K`.+"'WC%Q\XHZ9)IVQ% MT9VM1Y;1FM@6H14<\UA*+7;4:]<$5!38PW"VWY%-HLN;#C(+K7O`K,KIR@ M+6Z&FZ/XA*7;[.H) M-3'>++#)*;!1K*-H.>J$;)%1GR*@ MB?%F4:V8HIH7=1`->$EK>Q/C1+TD9(N+NCG*K;T?=11%1+UD,2!3>C=JUE3D<<11%Q*PG>YJ-NU`M41TV,-XMJ MI;]N\U?J*!JBGDD[*&[4"=DBHPZK-_?"8@$&F"E!!%'/U+L"P95ZR6*<4;L# M+QHOZL"XV05,R:*;45-;6U7L,^!MB'HE[!,:M^PLN)4^W#)!5^HHBHA;1?`V M'W6C7H@Z:F*\"=7B\E9-W9S2O*$(\U94ZM/2QE[ZG/)7+,@9-1UY&C@4X8,0 M]3K.]).WBL4XHZ;.-',HPLSE>6V7MFZG682KM-JU]A]UHFB@3#%Z`.Y:LP!7 M^8#S'W6B:+`N1P]I7&L"N(6P^V"3N1B"="M(G2+G.0^Y?SUDVEZ>!]BYI)2LQAGU&[8_4L*BF"&!Y]T MU@1P\WDS:FI,)SB*AJA7THZ+$_6:136C=JUE3JF&HHBXU2RP&?7"104U,=Y* M,[XU7:BY5KL=]]=/-8@6HUX3LL5%W1Q%3X%B!D5P/:O"SSEK%N&,FEI[PPZ$ M@ZAGH8?Z-8MN1DV-O:@#`C'J63IZX="-.@MNM0\WF7O6((J)&\';0MP`:[-4 MKT$3X=VPN&;4M.:6'K!F1=%BU!M"MKBHFZ/H*="HHPBB;EZ)"%Q9&A;BC)IZ MTZRC".X4`@\$&A;;7+RC"FJ=-Z*:X(6"+3#JPRST%+^D@PJ0WBNJA MR+$(U_B$\QA-YY$RJ(;R%US*6T](>V# M*B)R(B6(F\\[R!=6,8,HRI[0+2YW(M6'N67P%\Z#"I<3,FU&BSV'.")ET0[D MKKU_ISBH\"I3%Z%74T2J*A4//)`3=^^]F$&%[DW3!.Z11A[Z`"Z!1KN_@@ MF6/A3J0^[^3H/:O!&U3@7:\5F,9_;*'(J1``QLY"6,.-\2]'=VK#*46O]`1S M0P-N5IB]^D*;VR0&1G]V4T/,HSKA;&O(95,5-CCN:)A-"-'K'S&QL6$"1JBZ MXR"\L8.'PHG]#?Z3*X$JG)#A&SMAMB,P^J[)27'@P0CW.`PX"&^O,!L2&.X` M.3?_=HYA_G&7`[JK=][MXI2,.P^%$[L<)F"$JME/!03=X["`P8G-#1,H0M7L M1V^"N;5A8F^#'&T/&BH.$(R:\H1\2ST'EBT0)QYX=)]#)'@G-CQ,+']0!'\);\>#P.T,3NZ]=X('%1*GSD*XNQY$4846 M('3;PT(")O8[2'_Y@ZJ!.%45N-459GL"H^]3O/.(@WL>T%U])A1:@O"V/9@= MU!YM[54,9Q]N?(`E2+JN@X7GX6YJYX.__D$50,?;&0N[SF%3]OONM?WG[OIZ MO/2K4_NB=C2D:_T)RQ7VG,,WM^[=;+Y^[FYJK[CYYYOZY0"MVIFM=L`FJY>N MNPW?Z%WM]U\W\/1_````__\#`%!+`P04``8`"````"$`1SI=JKT"``#J!P`` M&0```'AL+W=OF92<=%FF'@!1JS-1<';;89__7R\F6.D-&T+6HN69?B5*7R[_OAAM1?R256, M:00.K3BZ8#BPVON7ZU MIA@U^?++MA62;FK(^X7,:'[TM@]G]@W/I5"BU![8^2[0\YP7_L('I_6JX)"! M*3N2K,SP'5G>DP#[ZY4MT&_.]NKD'JE*[#])7GSE+8-J0Y],!S9"/!GIE\+\ M!(O]L]6/M@/?)2I827>U_B'VGQG?5AK:'4-&)K%E\?K`5`X5!1LOC(U3+FH( M`+Y1P\W6@(K0%WO=\T)7&8X2+TZ#B(`<;9C2C]Q88I3OE!;-'R\6(##:G9-/-"/;$V[F;11D&QA#!/.C]701.,[>5"6/X]/^/^!#B*?]MKA%/ MN:3W=5RG22PWBM+%?_*&O78YUXBGW"$?QW6:=[G)-5PCGG*C2;Y.\RXWO89K MQ%/N;,)UFB-WE@Q]&/77C/V+SY013[E#_UR=G>;`)6D\G+D1=W$-UXC'W"@> M\G%T7&5CU&DVBZM0XB=Y8BDLZ2X;`YMIO6;IAU=,N^ M4;GEK4(U*^&(!EX*NU.Z6>T>M.CL\-H(#3/6WE;P3F4PV0(/Q*40^OA@W@;] M6WK]%P``__\#`%!+`P04``8`"````"$`;4R>>*0"``!R!@``&0```'AL+W=O M,?WQ]N,HR,I6U!&]7R'+]R@^^6'S\L#DKO3,VY1>#0FAS7UG9S M0@RKN:0F4AUO8:546E(+0UT1TVE."_^2;$@:Q[=$4M'BX##7UWBHLA2,WRNV ME[RUP43SAEK@-[7HS,E-LFOL)-6[?7?#E.S`8BL:85^]*4:2S1^K5FFZ;2#N MEV1,V49F!)R6BT)`!"[M2/,RQZMDOIE@LESX M_/P4_&#.GI&IU>&3%L47T7)(-I3)%6"KU,Y)'PLW!2^3B[&P8)!9LH]1A,-0``OT@*=S(@(?3%_Q]$8>L< MCR;1-(EGHRFX;+FQ#\)98L3VQBKY*X@2!]6;I$>3$=`?U],HS2;)Y!8V_8\+ M"40^P'MJZ7*AU0'!H8$]34?=$4SFX'R*+'#TL?XM5,!S)BOGDN,I1A"%@?(\ M+\?9[8(\0T[94;.^U"1#Q>:D<*4`O)X1(C]G_'/63RA.[%!A(GADJ?;3S.IKUO@`N:\9EF,E1L_J48L(')]6Q.G&,( MO$_*.,N&.Z^#)O/E3,?Q<'5SOIK$:3KJUP=4<#*OIW+B]U1OE0@9"YI`-9O& M;]OZ9;@%G,41>C2+W](9L$*/AQ:07%=\PYO&(*;VKG]3"+:?[:^65>I.T[OY M-5PYOD%)OP`MW]&*/U%=B=:@AI=@&4>NQW6X-,+`JLXWWE99:';_6,/=SN&T MQA&(2Z7L:>!ZH?]:+'\#``#__P,`4$L#!!0`!@`(````(0`@$9"=,P,``/T( M```9````>&PO=V]R:W-H965T)LA[/K(H6W."];N,O3KY\--@ARI2%N0FK/ MLJ)4.>#0R@Q52G4+SY-Y11LB7=[1%D9*+AJBX%;L/-D)2HI^4E-[@>_'7D-8 MBXS#0KS%@YQIQZJ0=.JV7! M(`*==D?0,D-W>+%)D;=:]OGYS>A!CJX=6?'#)\&*KZRED&PHDR[`EO-'+?U2 MZ$*M[\,2)\M#(F MP=%D!O3'\<`-D@A'\?]=/$/4!WA/%%DM!3\XL&C@G;(C>@GB!3B?(C,<0ZRO MA0HQ:I,[[9*A.7(@"@GE>5J%J;_TGB"G^5&SOM3@J6)S4NA2`-[`")&/&?^= M]1.*%FL4707-MC8/P'M@"ZSW7BKFZ2"9D$"&WDZBQ5#IT8O#U`IY;33A2!,- M;^[Q-]<4$S8P&;/I2LY@I5_/EIZ4(4C`D)PPM=*S-IJD+^M-%$8XB6W(B228 M83\(XR&."26L]S'E=3HMMNEF@Z\IK]'$A@['V$_P?"K93"3!/(QQF@R2"5W\ M'CHMMNG"P=?0&9%-:Y5L; MC58W)H-*FIL.]B M:P]MK''_E=JF[^'28IO+6E9KHSES65F%AJ0]SN,VEVDWYC1NJ-C1#:UKZ>1\ MKUM)`/$.3XM($S_ M,C>*=WT/V'(%?:>_K.`S@\+!Z;L@+CE7IQM]+`\?+JN_````__\#`%!+`P04 M``8`"````"$`K^EALA(&``!B&0``&````'AL+W=OR6=>'YU7X M]U^?[Y(PZ/KBL"YVS:%:A3^J+OSP^/-/#Z]-^[7;5E4?0(1#MPJW?7^\7RZ[ M+[\/.U7O?;52CT0L618"`/GJJN_UR;D&%0 MOG1]L__7BI@+98-P%T0`O3O.%SQ13.GK49:6:%C@IZ(O'A_:YC6`KH%K=L?" M]""[A\COKPB68K0?C7@X!6`[*,.W1YX^++]!YDHGR=Z18$4^58CH)%D"UHD- M5CR?S8@AKV%P8A/L%';`SZQ$>A*%%?DE!4*#Z\Q',^)5"+%'-(XOG%E),N24 M"9G*B"=8DOL2R30;0R`R6-Y\,B,F9`)?-K,2/9!)E<2DX+E_/)9VU(4(TUC9[;A@Q M02,7SJS$HJEAJ!$R)$B3F(T1$%AZ"Y@1$S"R[3(K<3G3FK&(T5;S)5PQ%LLS MO<:@B'[63&%C:-3+A1W.(I0$(7,:BRFUB-2(,`R_'"N25(BQ.U`"&;$$`RFO M0]JQ[@\Y.7:WG;]#Y%5H(06D21-%3A0)2\?MA2'-I)[=?\S.=01'S<%I7`>" MK\8)D>18(F4B/`G&N\D?V-0@Y#C=7>ZLQN)QQJ/4VP"NPD@2Q4B"\6XR"39U M":_!'9YO`US&:<(]5W=\OH9%D#T5C\O$@&9Z>^6=-P'-+1EL9TC#R6@E]0VG M`9239FPQQVG#O"_!F#>9!YNZAR37SIS&EIEI'L>:2'(L23GTX;DL$A^Y,F:F M!B+'$>'*[/N#D%I&DSWB*YBYE1ECX-S=Y"!L:B%R-``'YUL$3R+`(Q[BHK@! ME&@AQA@8[B8785,;D=1&G,85ED4RFGCO10G"X\1'+A=V4!/_&-=M<^CF.RFPR#3PU#$:_* MG,8UDXA3R2=9LV&<1$FX-QCQ,9Z9W=[`NY(X.^E]/U-D(V;<=P/-I.`QZ3F5+=!D?,+"@Q'O.)*ZNQP1W!C M31R`#3X9\Y#7TL=`UG#88>1!DS#XCS]^B@QK=*BHR'S&E@'YZ] M5;HHP7C$&>8]58BI0RCJ$$Y#DV,S=^8@1C-3VIMN!BV]^K@MS%FXJ/1Q)G,: MVU`*'FLG]\1((5C$/9O!D#<9A)@:A*8&X31N1L"UX5;-LR>7/]]%.$N4@CN7 ML5$PHIG87AXO#V)AY[L_B#5U":>QB'><:7@QEB9D9^=4!;I(Z7.0-[F%F+H% MO0')G,9",F/QC.[N'&ET#&,Q'0OG M'!^./;E_K2OOA7!!63/U41#Y'FD*5M)F/?7__'ZZ&_F>D+@I<<4:,O7?B/#O M9Y\_37:,/XL-(=(#AT9,_8V4[3@,1;$A-18!:TD#(RO&:RSAD:]#T7*"2SVI MKL(XBK*PQK3QC<.8W^+!5BM:D$=6;&O22&/"284E\(L-;<6[6UW<8E=C_KQM M[PI6MV"QI!65;]K4]^IB_&W=,(Z7%<3]B@:X>/?6#T?V-2TX$VPE`[`+#>AQ MS'F8A^`TFY04(E!I]SA93?T'-%Z@Q`]G$YV@OY3L1.^[)S9L]X73\CMM"&0; M]DGMP)*Q9R7]5JJ?8')X-/M)[\!/[I5DA;>5_,5V7PE=;R1L=PH1J<#&Y=LC M$05D%&R".%5.!:L``-Z]FJK2@(S@5_VYHZ7<3/TD"])AE""0>TLBY!-5EKY7 M;(5D]3\C0GLK8Q+O31*@WX_'03Q*49I==PD-D0[P$4L\FW"V\Z!J8$W18E6# M:`S.*K($\G,Z,@A)S7E0D_144`O8CI=9ED["%\A@L9?,CR6QK5@<*Y+H(`D! M[\`(D?<9+[,I,<3@>QU;=K#5^',C&?0D#OWBDL)"@W7Z:"I]V=7TJ4E3'];H M$(<.HI&,=&Z3"$6#)+<5B[XBSK-A,NB"L!`ASC[BY>PIL8,VLA>>&XE!0RA# MZ:#;-IW?A:U(T2CM]MY"@^*_'4V)G8UU#M8%@06F#KI> M%[E<8TKL@'7U8?ZA1C(PV7*83H]9./E'<)38P4GL)>=& MK7:`!@[07G.VG,Z/VV!.][^\;\AT['[?&CK_K_E>8THJTR5U7%571#:B:L4W MEQ8RC=M"=+O_7F,0TQ2:4YX[];>P-`F*XC1"7;.Q`9TCX$H.CWO_T.W]<)-1 M%7D9L*\Y`VBN,^:T;_&:_,!\31OA560%_3$*AM`,N;G,F`?)6GVJ+YF$2XC^ MNH%+)X$C/PI`O&),OC^HZ]+A&CO[#P``__\#`%!+`P04``8`"````"$`H-LJ MZ*M5``!_&`$`%````'AL+W-H87)E9%-T&UL['W;;B/)M>7[`/,/ MB8+.J2J`DGB1*,ENE\&2J"K:*E$M2M5C#.8A1:8DNGDSDZQ+/_D/SL-Y&`PP M`_2W]*?X2V:MO2,B(R,S*7:YNML#S,&QK6)F1NS8]UM$?//'3]-)]"%9IN/Y M[`_/&GOU9U$R&\Y'X]G#'Y[=WISO'C^+TE4\&\63^2SYP[//2?KLCZ_^ZW_Y M)DU7$;Z=I7]X]KA:+7ZWOY\.'Y-IG.[-%\D,3^[GRVF\PC^7#_OI8IG$H_0Q M25;3R7ZS7F_O3^/Q[%DTG*]G*\S;JA\\B]:S\=_6R:G^=%AO/'OU33I^]?8YZ,YT`<'^SOWKUS3Y?U==;T;OY;/68XM51,@J? MGB7#O:C5J$7->J,5/CQ/[O:B^H$\/`@?.C`Z6X'Q//S>0'Z=/(S3U3+&>B[C M:1*^]?RT>Q$-3GO1:?_Z*GQHAC@%,I;Q!$@8)9^B/R>?P_>>U_%_1\W#5KNP M1+>*F\^+XN2-^NZWX6#NBZMD.9Z3`J/H+%X5/NZ`1B.AT_DD?@A'>7X?3]+" M-Z?KY1*+B<['Z1`+^DL2+RO'?[Z[6S_9;=7#D7NDM#!%''V73":[W\_F'V?1 M((E3\.PHZJ7I.EG^,?SL^>4\_,D?Z?U\LIZMXN5GP#8I^=R]^SR-KI/%?+F" MS$2#5;Q:IY%95G'.OR1I.*F!76:)3H'7A_FR2-#.<)@`##P>*4`5PYS.I],Y M%K^:#[^O18/'>)FD47^]$B$&A.%GCKB&`H;&YQ"Y`J3/OVT\];D0L/QCR%M! MI%YW+CJ7I]UH\+;;O1E$+VX'9]'.RW"20;*`R-;+1;8S&.#3\)/3.'T4=3'D M'\G?UN,/\02,5EC3=3),\.QN4B3,U3)9Q.-1E'R"1DN+S\]`]72\2J/=:&C8 M6-B@J)%ZLP^8&V2-UBGH!\T57?][/%W\_DQ@G,:S]7T\7*V7901*[A/(R"@2 M.7ERJIOY"G)DX8G3-"E975WWWW?Y9+"[&P%-:10/H8_7$^'%40+=/AS'*RCB*/J-<.6B>R\)UF[:1]5&L='(;TN^K<$);3_H#3%F8MC-NH M-0Z.:\W&@8[;J+4:F.J@'8Y[UCWO7E]WSZ)K#K\;S9)5!+@LOBKH=]:]Z@]Z M12Z[Z=]T+J)R#KSH=5[W+GHWO>Y`4#JXZ9_^F2CM7@^>"[IO_A)"!R&G]4NC M1?R9+%GR?+D&*U1RY#J)5O,HF2XF\\])D6.O$R7:(E["A$[F<<%V7D!I)M'\ M;C)^$*)MP=PW.8Z;C..[\62\&A=G/X/Y^(!1/R31>`8+*#:]()!G&;]#:-8% M''C/9ZO=[>A7MJKMOG0R_IA,"JZ$KGS#BD_[[][U;D1VA`=.^Y/\^7X!W`)_*P:W(`H%2-0 MB\:T@Y!)R.4\,PBU:+>^&\)BK,@6D[1U$F^BWU=,%!T>UHX/(?$G30.2@`)7 MK-X\A%HXL;^6PQG%JPB^6S*]2Y;.?Y,18!Y6YF=C(VI0ENDB&9+7)@5;VAF- MP)_S&?0D]?ON>!8-X\48>C-$`^314W3WX^%X%;ZB/""(>IQ/1O"DGXNY616F M567Q)6HAM))7,.IP<)/5&#[3RRJKV2G5_?Z2P-R9[B9;='QU+58J2>&1#=64 M]N^!@23JPI@NG#LNHL651[WI8CG_D/!)0:C]60N37,&0E'PC+HS!J4Q:1&DF M#O*R=7>`G^@]Y2$D5L7['2[D:\K*WR\$N M>W,#S(,;F&95:?WSJ'_5O>[<]/J7E#KJ#WX6O7/N=]YW>1>?UA7Q%$XSE MR5#&^ZK\$%P$CS-[/WSQ=6?0.PU_/.M=W-YTS\*?O^OVWKS%[X`&$O*FFQMX M$/5O;R!(EV?P!L(OJP5L.[W?K0Y7G+;?/.=I9_`V.K_H?U+\4>"ZX0AL5W6-1\)K]AX8MR^WI!S.+M)?P(QI<, MDD4EALSQ!JDZO@CG9@O__05T.K)]:?)R?Y3H7W#W(XU$"P3*>?/AQ%"=$F"' MO]L9]E_8&5YR"L\1WSR/>[/@HY%%G^2R$)Q0&'J7[Z$B(=F;A.%J#;<*6`() M[JM1+[(,;W7-+`XY3&DI#%3@T`+P8Z0=4K$-F8@\!?QY[Q*:^"G@E_-ADHP` MTG(^%7>_3,A$M*R8A/->Q9]5XL%8"#=MM+E&1G-IW7%D&XBA\%.W3OJ;8Z1X MH[O/T?UX!AAH!ZO72O,#!^*:R0W\$0GAF`.1/Y@!>=^YZ"+1$MU] MT[N\)+Y@NV!`>OV"*=CP=5<2,!7?^5;QN\[U=0>0%1C;R@(%P!-03Q;"Q<`A M$_D4J=PZ%!)O(QS*A[!@MPLO&[W`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`%M8)!%,V6\"JC MQQAIT;LD@36TGE=D2@$<;GFT%SR,GE@]EU<5F"-#P<)4MCB`\L; MW4]P+F8/@K@I'%2\NA=]]TBG&L6&^$&#;?.M02YFGXP1&(,+'I%KXZ@^ZH`% MDAJ`D0;Q")H!I"-PT_A[_"]>]TF0O0XB1(`!MIQ!=HUO(L4LS#R>/L44Z>-\ MC=S2'9:/[TD!<-%?US.X_'`)#[Z-:04_W'&P2H13Z9_&YN+3/+$RBO(GE%].->R'K]Y2IY@N$[_1O[CVL M"P+R@I$Q]!,BPK"`O`X6Y@A+L*QR1.R%4"^2&`D[S/GQ<8P_5%!CH(&L#S2R MUD%^G:%2N4Q>(K)"M).RT$D',X[N$4Z`F3/!YEC$@8^R#-OBHG.5L?`S]'-) MBI:?8\3U!`$71F/1S,1O-NSB&ZO'90(&U>(]?I@IQO=(WAL\S[!S%R,20E@G M+05FYB)=N';QB4`U\50Y29`!Y?5_&E`Z8WZ6+>(AA1&*6'Y)GKU"% MR8$=NE)D2R8YEM0FT+3,!@C]77X1OZ]3RBB1RWSH^.%QM3L9SR`=">H[R%B@ M9R=B<(<>&WD[N5]/$-=2?0/3]RRR@5@I]/E,Z)(*]V39^K&7K17T65N MU)+@=%@V*)GPWO&(1/B1X0A\-+5?210GTZ-/`LI%518;@"`G:DI%4XV0Y0$G M)I_P,](>6/ID'`Y/VR..$=V(CU014.PLOH_VHAM\<3_^1*1*Z4.6M4P^C)./ M^(T:*H+-XGI`RSMQ88"B44)8B=KQ/:@@C,JYO3&`*X"-*53/@YMFORS<,W3/%;&!5;\UZGA.E))-<$D M>8"1\>EF(IT7C2/EPY?""<9"DCTA`.*KT$9'JV3X.(-T/H`.8#O,CFS`>(DR M'%0R-#Y>$F((>T`>4?/$>\7Y:E2^RSE\,CHIF7F4.2QU3=&42$$6G:U-$!T_ M/4])G<+5$9`[X#69.\NU&4&&<6"]5=@Q$Y'[->TKO%5Z42SKXQ7)+=U/YA_3 M3(F"!U6]9C8*B+7"(VR(U0!&3;;`=&)`:W59U=6F##AMZG4,D=D4?]N@1XVW MC"/KH)A@D0#(SA$NZZ/UN4A\9#U1)<`C(-?1Z> M*AG*:^4H(;Y%1245^L7M&9^>E'?6)[ M%D6+]+06=A-_LBFOWVR]9!$;%8`7&1$8A2A4MTZO`"A@86_% MQ0C7W4IB;_,X-2ACT]Z`#YT&!NO;&>EL$=LTGT;J.)L1-7Y$!PRA"?D5KZXT MB\Y>&IK#C)?3'#.7>&09VZJLB%E-/L&WH\ZTQB$$#?_&$B$/D&C3?T`!I0!$A/E\@&(<+YZ//\KQ.)FXAB0*W!*"` M).@[6TU@,JWOGD"+#*%QF*5\FL;4P\8LB,9VB\EK7("=7X!1XQ+`X@E#?&5> M08LH[A&0XJ"R3*[N&"@DBDP3#PBRYA_%/1$-/5I#`Q))9?#C#6%M5:LZ/4S' M'*PZ&7^/'A0\AGJF>X-7[WP&WHM^^K$##D9(1R4:SOT1^B1S%A_@-,%9K`)C M4PA6C'NJ5/%95N?IA7U:OY%*^L??_U/<.TLO5$X8=`BSP8VP[Y*UY2M8Y!^'V(X"VMVZ:&Y M$0P&-L0K#<@J*_GF;C!ZHP3H`5HNF>__X^_^)>L7Q/8W^ M!:FM%X#J3:=SA<%?4J^7E0X%H,?/=TLTV7H=@:&&)ZV1:X,G:-0N5N@;!.@4 M/(6.S>4$H%VIHYQZ1*`EF0WU5"1S)-(D_B-*H:"C9U6`;^C"&3`%Q>\<460A MEPF"CI3AE=$\B)L0KA"E!@[-JUC?RELYQBDNML`)+AY1Q>7!#*7HC99#&!9; M'%JL#I0Q2/LA'D]$WR,4_QXU3BC!V(28OI^<*:#I?)1,TEKT`";!TB2M@WRB>2B(J@],MU5N%3T;HS;T@B*98Z%5TWR6@:;-&2[I)!=9$@G,`D*@3IZ9"%NS#*2Q M#`E/8#G=@ZK`_\+]M_R>'Q8&&DV)0],=#JJU_LV^>(]0B`DY`9Y>@LIMKOL= M,HK6#V[PH;.$P8P5ER1:;B;&^_+<0&/$\>,8G`D#"[<5[A70$;4EEGU4"^H:4Y:AS3T`B2\A!UM=\(BMX)>%YI M<4!M:[%]-GDFR5)=KR?Q\/O=P1!=GU#'^C;K*E+7%Y7DILB_*L_`NVAA`6LZ M`_W7]>B!3A]2$F#W]=2T^622]&'..HKC-Y?8-%,SK^!F])$]]/A#28(E>>;# ML+9-W<%<(;]$A]+T#YDL'BV;8B\3-5D$MI4`9]J)1/MC^SC4ORWAX-6K+M8. MLOST1Y8TBI//->`G$R:KE?R4R<-\#KT`*&S[E'4`L#&'C*V* MP'%U%;L$QLO1[9_A%%3:$)!1YY*)BVQ-A@N0;@R5`=>%'+(,#N)XS$]:&<$P MA+5I`4T6Y%,%JUJD]A+K(O\,C4>'L"Y='5_"&8,!!GMUO42=" M^0*X+'LC-K_FU`R_%I#UB]?SV3K5(6D`HI3!/9)9D#6L"7ZMS"9T0VY]8COO M(1(VUH/+H`[-,WGUF9"G`QVF7V85%/%'2'?UF55SF#;P`#]0R*P0#"<0;M>; M]]NK:U.0AMX"3TOA$-(\]:M$T!0&9JP3,@3WBH$"_R2+2$(;SHA\NX!"HPIC M;%$J^*_WHLON=[D:_W7_$ITHI]JF'?*/%RN[Q&YFG&F%$(P-E[2D MQD8<,:)C(B$-JENK5]S\RP\I`"&-M+=[H+LWK\$`*"R-(LVAB<"$'X2O4JE[ M3?R1*H5"*YWYK*>&`L!ZXAY.<8W=W:AG0Q>:P?;-UQO`VJ2;PO$O]SN%GYY0 M7N'['O2J5\I?*&BZ\#7E[X]D\A^2)507.*&!78M'M8-VV_@EZ/*@&Z4"[-E6 MO#J"$S+$=D\XNVLIM9/-<\5MA#'XL(1E\#7+LOD-3`49@`9VW^KKG,'R(UQ> M28Q4`45E2C(:ME>QA%EB"1?&O`/%-<%R98.\2.A\L4`9$-OS8>J@HL!;]PC( M^0B:WXY"'(D6IPZP/]KDB;3*(*3F)!I#BO?IBTWC2&8\LOF(H(.NF^M&.&T$Z(A:;VQ$/C2T(P#S\'3X>,KTWH0N(=0.8UG&> MPG0]\3:TUDYSKUEGI*F;U(0C9`2TJK/\"&W-M4JZ$`/Q44KYGJUEOQI^LBC1 MP8Z]P63%("D59YC@@=NM#2.6N.`L+1QS"CBR2]&M<'"'OI21.;#%EPV:B4D&*<2GX,['/OE!25_Q M4-&P&7@F2W<.CHYJQT83],"ML^RC-]%MB6X%GWG[[OH@PU@ MIS0L"Q?\&ENT/C)>D$H`&K/0"_;1NN*C;'@OA52+P%_4RB8=)<-;P?-R0>1` MIT#M62`%`VU`#>$28UEZ`(9G3279MEXP-OJ4+(=C*LI[N_AP1/?*%?5-\:E3 MFF<0DO#Q-5ULEKO"!P.@"%[,9<7O!6.+L'N20,F#JB_,MYW";C;SX'7%H*?A M[\*^*5WOVXKW"\>:F/&O*]XO MM$HWZON-QGZCM=MH[C'T1_N-XWT$\NW]%DD1/C[<:]=WCV'=P@<-DJMQ@&XF&:%X M>(<39>Z-9[C6EYYQI*:@-LZ,#Q2.VB;N<(S+T7X9+QSL8;\Z>>40?X2?&KP? MR`L-?-\X#%]AWA2:B1H@?-3$ZT0#R-@\+J%>?>_X<+=9+YGWD#PLB"`$0,91 M?FP)0QMBO*S:]C+':_2/_2+-9Z_*5:S"!@!VK53R25J4NAHZ[5X<1U7=4R^<"]!OGGKM[5,O?/O4"]=/O3"H?*%P%H/&@AYE/(,7(N(& MKEOF*;+S#9:0I9KLO`J,QG^D?XB^YJ&FB+6\#O9` MM@@^,`,$T[&-"!J&>_5QOHMNV(5V8[$O&?%#HIFZA`U38J'YL232V.+X/=S$ MK!\CX\+H!5C7E7!-W1;[_E@BP"E8^`I#2V,QSGZ"(N3Q1_`6S=9N,Z=U'[)A MI0$<#@V]&7KQ&$G--968-C%(#B_+B#M'VO@:4?P`1U'1)6^--";)FLZ(,N-5 MF\'%#(@P#DVV:#2>K"6))RUQ2-R9[FW;Q``<90/:\;+H(M54@<0@#(K$]2`U MW7J,*V^!-A&0-N!)8H9O6]YA2S\*.08VD^64^`IHDH(WWS9M-R2_9.E1)YHC M:,92`6UN^#9($%##7A*-J.POZ MA<@=I*V'DG<$`OV4NM]=B)RG;9_*QF6(R*(&X'#=7PCXXHAU?-8/V$E50$R) M&?G.!`F;M*?)8E(9861RTX:!F.:K0#(@*XOK01>K1\".CJ='V@*--F4D['5# MAN$*`P_Q2U)8VN7!K`8#W>1#;5^RPE>BM;A*S;2[G3615/?!G\AO(*I2_D4H MSIY5*;8):JS:P,\(UGCBFJHDGT*B3`-U.'>I@?-+#ML99SL^-%9# MHEC0:X?NN)?]`DJ`A%S#$_8-V1W8EK'Q#A1,2'[\&\>^'1WAR*=F`YROXJQ[ M(2C,H^2.N45P4N7>7Y$`,!I:#?75.S+P^4*( ME!H4"C#D>4V;QA)P+P+@DL'%Y7;Y73$RQ93<]V M[>BPGND2$4887HD.]2B`^=+1)IN266[#$KJED7G:G)]"D@4<0!V4V8*=@Q9R M1'5OTXI(>&0K^5KN9L<&?C7R9R3`ZG<:[>,R MFA?EC,?V63T`2PQ"L'GT,WZ2Y!QD4[PQ6"TUQ*7"CZH^CX8S'/@ZXYH-+-#> M*V2M*Y%:.?ZOAMV2I1'-]:V0C"K(^H'N$:4MTVSEJ&R=U)K-IL7E:8;+HA:% MC+@:PB:54HL.VJW:P?'/4D_2>%'.Y?^LBO(6)2KJH-9N'99A,E.#E7KJ")6T MYK%%5Q;4J\\!WB[1/HVC/1]UUNGV:A`2O#UAEZIU0"5,OS:[^N@H9]=SXX[^ MS'HB+8]UT^@_J\$UKC/T>UU89*?5:J+.V<[7'VNV5<\9K&)*IL`,YMU+F_0N M).3@H/2'JSF/1=Y(362$T%UFVLC8>.#+.@,"7-'`8":L09I/'&ZP2/H)[$59Z4:T'/9/*FU3UH99*&>S%.*`8-$VSC>0.J\'!+AG*^9E//D6\Q M#U7PEQ=K]$H/X7VB>B,Y%?#VT.=K`*G[;R3LS4N')25D.F1'%SU0CINU]L&) MHPF09WF6(90)3%RCE7GFI;,LMP$TMRA;+<.":R>'5.7.B_!X3=7F5W&@Q;*E_N'`*NYN&A*C$&!X21,2^+D%SFBBD"K$+($^@#%D,;-:F[;^KB)O4="D)?SFQ6>EO`0XS7'! M;E+'+*%\BN0[/T;E$YTAV#=/54S[-'>J':8$DG'@I-3:(']O3;M=:[>/+&VS M]+SU!%P8&DR,:4B7T`O0A`TTNQ4N-[E9FC<#E6VP//95YM=B?$&VY>36@FZH MG$HB,`YI#)J:.)5]&V(F1.8A80@#2@KD*$5%8T^5,%`7%I')3V@3'I68IP\KG*^7B[R?GX M$T[=YZY&A>YKB$Q6-PIYJA`^TZ15L9EPV:%&RUNPV(&1VW]E%@OUMXY.0K&UV"]K"+Y1:SGS'M3=9Q+3@.XIW5<6Y,)_R\QH(`N3K9@F]D,\S:L6DH*&""Z$7#>T.KO,P MKT)""F&6<#>C%=YY)*&5-L<6;7,6*T`>LGY.*7AP'Z[)?//\+2GV9R5V4RJ5 M^C/W^<,*9X/!1\!!:B@X(<.[7M`S@2'C?0/0-MG2O/6;@K# MQCA(QCD0R!A+J&+T^IV6[!RBM;^U+>_03]):A(91SIDR>NY&UO"$Y!TXE^U? M6?),@MV+N'*;=U>\/028VVFPS]":@.;Q,9/9)3;@2RR`1UVR42'WT9#@P5@? MN.O"T!N5?\8#5<(WJ!2^DK@Q[QSQM$+R$A@W%R,2DPWTMC9A'Y$99#^VV-5< MV$@+ZGQ021]DK(;KW33_R$\E48&B%#,<>I@OO:Q&NV;\";2-XB%^0Q4N67[D MX8(H6=BS;#1JYLR(166?(">V#C=LD'24.K-OO'[A[B[;0`0"I![DL#1^B!`) M+=/L8N`_"DOB4R/X`[L^2?U8V:[\/!1?]SF6@,G&4^S/YR%!R*![@4"-2S`- M\39+9:)\-&1SK=+K7I&MW&NJ`>W-L/\*5V*8'!",G#-IATDJ/376F62MD>WY%+^>ENN@+%8?A:1\6L.+C4 M::XLD>%+TB8V/:@=M1NUD_KA%W!I?:_=DBQY-9>B?GABPH#_SZ24F$(J:DLF ME8K<5OQX<-2N-4Y0XGM:Z_PB?"K;`C_)<7>0U)WF$=*<]2+;5AE.3^JIYHYJ MK2;JWT>_<`&Z*C"OBL"SK&2YC417_@GS3'51:C_3%.:-3*D=K)T`*\!,D*_* MD%>P=MKV6I&WNA!%^:[2$D(]ZF8CI)[@'>64"W:S3'`R'\T@7`,<(#N9<),. MC)G4LUUB6C`QT.XW\>3%?87AVV')"*H:GR33\1JG$4)=RAQ47+1ESC!R8KSU M00YU05MC@)5DQ=N[ MOZO`GH$!#HI,Z!_!H4YH',6"C>V7#*9ZY@T3UCJP';(01*#H<5#7%(T'CNUM MV#ENTTT3?LD$[4M6)!(D;`<'&DVFW%S(.P]F>K(6UO=.CD?5)$K)LDWTFRBKB3Z#!J::S%,4/ MGA<&A(+`KG??$L/F?6UWJ6CN?"&8O&$6QU-##9=2AO4L,W?LK]VEEW4C\A`< MW7)&2?"HJ/UHG`QM+2<-MM2HV*]ENR?%@#]X_4?>QP%'"OV\1A9S,KC^G+O> MB0XG=V&)F`.;IGF+R$2(W9U#ZE:5Q8:=U9QS56[^*63`RO^9L*0ME- M*Z02MD&B#D^DZRFM!7SC'3.T9C&9W,(%,^LE6CV)-_P#,B?[+?'$+USZTG4D M`#F%YZ'72=CA20TUGU]>PN20&9F57*`-Y5@U@->=.B47`A$]>%$NV5#E0B=5 M2D7904Q`E$0[KME/,^#9P=,2$X&`LCE5C5%'XBGGEF>E.,47OZ``%^D(>><# MJ^^L(L@L8$97([2.&N937"F)8\.@<4N^%:-6VB@1^@5@:]RPC6/+->T.=6Q2 MK19FWV"9F8G>X9S9W@G'ZV(L+'*! M/Y/7W*B'$!:=G!3UD'_@SH8MMS)TI5C;%&QQS4\+M*!A*Z%L"1`AG.N`L,T8+'"_7@*].+79;,O0S?4D`M-5YK`X"3EA#=`"`9LG.5Z[B097 M*GU>PM-_/9XOX-9/X^CBXC3B<8+R.\\3])(F+?81(ZMU*V&IL_;6APD*I&R!(@WY/0Y&S))EDJ[CKX5EXIP6S=1[8YH4/-$N3G_5AQ3IS/DTO&@Z$`/2(^KF%NG&;M36@+I6ZR)7@8DYXN670)L%I. M^.=`/LBYLYL@0:P76L1"!5E%49>E!VEP698CE>^*;=9N,Y*XY+K)(FSE=H>R MF9/+@$-UDTEZ.X$#O]A;8%_!N["\V0&!&.U(Z*BULN:9;_]S M`90,N*$SMA99`AIN]:B_E?I4CR)4GU?!KNQ-"M2)-0PB_(`&VK98"'$HL]U> M")(HC[K-6[ME\]Y8=J@U^@W:II[!K=U6X_@ADMRU(D&2(YOG(7@Q4!T6#B7" M@'#!*6Q!J[^H17Y1Y#:SP8,>PW8AE(#7J7)]"]C:BFAP1+/V#V.X%CC-ERXT M\_#0=XPE]=A+MU/*IL7*3ZP,71E)+XVB5I@>RLA)V<%FPY2VD0$?M"HS851< M:(C(:09%J%R3H=$SMM&Z`H5\R4"1'I4D)?SM+/*^"^(X=M!,K>&A("HGN!T0P&7CL:,4!M[S10"VC(88QB>5DMDP@Q_LPA<#8 M6DQY6:221[4F6>2(4H]ZM@^I`N$\9"F#F2@].$3E%VP"Y&^4,;.JKX#22O%K M&?PZ`+<2O]?F(@FU5PCCN11)>&B/&B6RR2[AXV-OZ227$1['Q8YP<9H8$PU& M)"-54`^"5O1,,\8#?X#ZAY!4\H@Q7VHQMX_^\4)&SQ.+!)D$_M@\1%+>?<(&R=:O: MUNBGR%MHO#41D:3,?$5)9.>(8]F[<7Q0.VEE+D`16_GM>)78RJF.8)4MM$D? MH&4YL.2AIT?1Q`%>U7TNSJFVED/UF%;`;\!(][CR:>4HK[Y(X-29&W*<'N86 MMY^I]3E3BN8.48JV$L,E!U-98^/7VN0F;.1[C]D(0A7D58WPL\64T2RR`6][ MZ*A0M#_\*`LU,BX&O`OH#%:H6,_1O7SN2.[-RJ=UH%WG;K12Y8,X+$$?`D2V MJTG8;&.M=V-C,>#48[F$#@,ML/7<@<*G+EE?V-=3:2N@H&2'JCV0*W.$*#7F MV!ZF$(SF%6!3.$&P#J[I@]\7K,#"XML.$P7#21SS3+ M^M./?595X(L9CZH626CBA@:YI%0(N<^6D*M?;#VA<>+LS6+9J3D`P:;)>,5# M,54&Y0WF9J(9BM)-GLNDY/&'U^Y8W3)79ML=7&X67S]"G1<5F:.$'2.ONL1+ MAN4P-V:("R:/6-01`60*',GJMWT?`7UI%2);#$:J7,62Q%LZ@"C>(4JW%#TB.X8;TJL^:1^P$%%\P MK^S`J;(GV)26!#_V@/PA1/J!IGYNKZM5C5M:E,J*YTBOF(O2##\4]4;&NMBA M]6NP+KW%>D.5ZR_`NB!JHWT`!11RKIQ[(M>5VM#'A8K8+\IU`?BAK'V';Z$=#(D2T$LQYS6/7LI_!*QBN#S4Y60VF^DSK3+T-PI2Z9DWK&4%Q"ZEFG\7'G^N MZE>J;^PG7E>-`:Q:>VG0Y?A?BNOB^32ATYSS_I0F:^CNGFU9"PSXU=28)AZ- MBG4JF92S6%4<2)'#RV!N=I^A!P"DN]-'U"W,\,[)<:UA*ND2PK/#_:LM)4Q& M>LY$4X4EJ+MM(RS;B(0I_:L\:*A5*@].%LI="7>P-I#O":7I;K'DV);)>;!C MB9(KYJCMP%^3SFB=;:*^2AG]C=1ER`P_LVM00"^J5^=G6->"04X#!Z0?-;'A M&*M%UN#D&)XK#)+;Q(5_3%`.A.D#[2!9B$X->?F;9`;,Q6V;PAX9OE`P"SC: MP5=RE'$>*-FA8@V7!XY96/%`L;.]Z+S3NX[>=RYNN]&[;F=P>UU^T\(Y;T9] M+Y?4GB'"10?(&NBHO%>!YXA&GZ:3XHW2$"(FT@M-=LTZCC.M14IB[\S1\2]V MYBC*L-ZJWNG=D^*QUU"9+0#RBQQ\6HZCG/5W"A?UZ.QZ6FABZG-)S.,O&#-W MTRWX19O=P)DICH0'DYGD,\N&//2:+&M:UF!#[1F9?C&,S*L[>9XS5X#N(E[`(CW1YE!-MV)O MP68T^#>F:K?FM1:T;5J47_&RY3$N2Y4#*L'[Z)#%OA"]M]A>>XIUQ[CC`R$3 M,0>99=90[KETP/JKP&1Z'Q4"-(*JEA159-XHCW`#+;.V%<_@A8(V7&F;DWK- M1F>HEN`5I'F03,21/^)6SH@4>>#5Q$A,CE,H&(#NT?]QC'8J[`4#F4A\25QA M6\L/#JLXSS%%/DRC(K,J;P"WX&P@E@^4)H^X!@\SVU$Q!Q#'2Q:9BN:E>WHT MB*1=@0MPF+FD',K2@\HI-G@023K&=S'"2R_"#E M!SF3T@W2R@WBP+?,94^:Q*P>EMQYP#DZVCGTLBQH>SV<0N=S(VN4,^$*7/7> M&SK#&U-=$,>JNU'^\3__@_Y8:+LL:I@S:F@ND2-. MMB$#Q-RC0OG$33EYNL=C/[$ZD(/]$!#^_(3"6UR?11D$Q[9.:#W+FPMI"'.W MI>;@(>AX2G&!1EIA9[MQ2R$$IO`TU0LW,[&(B#PORQ&C%%3^P&[U/5 MV\/-A2(0")-XJ2"1@1-<"EN7.0>P5^Q.IG&B-PKE-P:98:YTO4(!\14))6PE MRF(==[3.Y,(-J`"TCRCBH)-#P>'>S>FSF20E=#9G'(]DF8_[2F9%<,E%; M55PVRG:%.Y=!#O+2E[9`P0OX##C?]K%`TQ?H`2I_\MJAP0A#@<_,S4B%4M%` M+HF7\"'\YCK!$<@_0,"(VO4,S?3Z3QX74QB'I)$#[:!$[+7-X8`O<-8M@J7C M\/:&U:N2I4JA"@?>M,-1NCDBAT^%?YQ*<1Z0\;=$V7IEQ^P0>F2(U,9PO7=0 MX6)'X,#`T([A$FQC1S.=O5*5!?-@'")X-T%G$/0UK-.^_YBV[V)H`-G_*4!?J`]V]Z*+?N1Q$Y]?] M=U'__+QWVBU( M5\1_@E=`YP?$I/,V7U9T8VSLL=`]95)B%J^)/1`CTP,!A1-CRSA*?G"<$`7` M@#4._TUR6R+DG)U>`8T831.L+9P3M#?!MO&T0=Z+@B/T&$R"?"545XNI(-@@ M830'D6?P[V3#.XV?]'`SO%FPO,1@BG$)_&":<6SID;X-"[-P$],JL&?>VI@, M,T?+`!S32F*+8U!6A`[V$`Z]MK7<85A^X[8=&7?'O.J:3U!"T-RV:4I^AQ=7/V=2+$G$J!F)"TO6=J>0_N,,\RE M\4%/C5DD;9X_ZDPQYZ:AS'U!ZPON"`K;=!S=)D%T3JHH^FW$5IZO5Q-PTF&T2\63)4PH@P33&;D->1,/>3*OD M+$#2*6M6_WOL@/B(3`75M$\D,ND(S28`S3:B"#\AU6,9Q>K&&/O29^,I6G>P M2W2$[S`/D@ZE":JODW>75"1SVLUZ2S38#KNXZDUXFUZ>'6Z0,Q(V00]R^,LL MF.7SO:A_U;WNW/3ZEX-:=-Z[[%R>]BX+UZS=9$H,)D&V1/)J!5R6X[FQW%O' M\)07+G#;#_^0=B+\18+GK@X@*>,A`D;<>F[:B(>0/%[JL0`-9=,MJ;&>N7^B M;@1/!O=8P1>1+.9\,G^`6<-;W!"_"\H"(Q._V!`]KD%3GO<"'QMOBSO$UEC> M?)A^QLZ?:4OXO=^+:WH MXLLI6J5L#0SHJ3WB)5"[PA4#?$2F.3>(_P26Y+R$%(/QHLQK^A`I@2G!HS\1Y/Y[&$7SLK4.T\`5)5D M.?4#,(5RT!K]S6R6D/UA%M?)/0-YQB6:(*>:IKY'9U;"\00I M0!'W&NN-/G9I\9V7P73F6('1(R<$A6!0*#FR5T`B0?+\3KCS%CXL[JZ/_CV> M+GX?G2W7#U''XPA0_\7Y6>>EYNF1_G+QFZ6&@5"4*4R.X2VL!9^RIPMG$^$R M*GPHV0CZ=KQ,6T1C+[K%#9Q0=CBX*(\9N1H&W\KY&;(8CV_MK3-2_[@W/).TD$Z;**="UW!1L^@X^JD@!_ M-%0XY54<7[M@N:94`)=MN3:1-L0)?4NX``?+WYU)+`X$7+Z"7H/PQ MB(YQHA0XLN8T69R19EJ.MF?$HIION^PX'PI[#88++N)"DUR7WH6JPSNX: MV)''ZHM8*<7->F.@@&4`V&1L)21O)KCX''?66>$`L_NHF;N-W0+@E'<[X6M- M@[)W[(Y@R9T@)8*68O4XB0JZ/<45<,#W_%#IS.QM19E)X5@05?V$L*CT`9YJM#^.^+3#SRG(^EU M6/!IDLX\(8CAX$"UMC*)0<6P1_%>6S#5U+J\F=ZPQG&79$AD4>C85X=S',PW MR:3C3V`L"MP2Y?8DN<-,#Y)+5P7:5U0?Q[^^J"\%%'H1E1AS0%CY+#>##6Q7LBN M!>J;[(W"3.85RAQ$`H)H!>4SK>H,V800V(#K6E0MU"7/$[,62]"='Z+N?H8T M9!G4.S9;R>1F)JXFJTC^8@TK42V-5G<-P\-)U_$8`A"[45/0Y>$;^$^-($6T9&:'PE$!'!,?9LT0?EC)!+CX`&.M,4U M'@'?0H$24M'SNI"!I36#?(L9-%O*U8(K3J`5B]+^0HW69!ILTQ!?>MB,-!M1 M/RE'0T4R4/>38;9[_9[F5_\>^7JY'9B[YMT)5)992VY2#3-#F4#%5L.%#];T M?!`X)EJE!<$;_P'43BYY8\V*P>\+"2<(B3C'L3HU'GMSAXA!(BI8F;,S!68H M9^`AY/O57%42S.5!`E:4Q0@D-=_\Q.[]X;6M58"9C>G;>&:1"R%VI"PK2ERV MC@6PB*8QJU4`1$JX-EPRGML&T,;KM6IS=V=GZV!G_/9@4BFXN;G[]@"?:XSG M-9[\RX.;C?(57U!U<69=M]P@V#3K&0,8,VS.@\LY2_G7$;$^(?+?.E-TT#E* M+G4KJ&X!U:VBO=23)H_!74`+UK3[!\BX-(_3S@AO[V,UF>E14^A#L@!.5.>J M_*IH9HGL7^6R0&BS'9;#U4;`@]P85"_H')C$IR$#:KDX6ERCO'T?HDQG9V2, M>:O@/"YYF,VS.=Y>G6QNL08;Q`R+@FR4RFW*BWX5?5'MRW1KPBVFQM=&Q'X/ M21I,^O"\=SY=AZD[:=T=M+Y^?_3=O5>OGKS4_^Y1W77]"N2KN.:[>P>\N\`S M[QA^^S.80+^>'E(0<.L_/](?'ESO":']-G>W?JPG;!X[>/Q<__NM=W``XX>9 MY97P6&?!5/[(G^3#(;:[T_,?""LH\POV\&NAM4'K0^_-A>CB35"X#7BX96F6 M=]9?LB\18&YLEG_]QJ*6?:KN/C6:J6[X3Y%+>7 M<(B$[,GGX(%A%R??W3,>^$U9)HN[^U7LS"E6$8WK,[(5J=LX_=&SFW(SP^?` MER@`8VY#6Z%`9!J"U#)#/G=55I(P+L]GX5G*S*P5)>]RT=Z4SEV4I1%)``F4 MO4@A(A[02[*F#?2SV\-S(J8A[5"#Q,U72C72Q,VJ$J3=MBOXBLJ]-I--( M]XRO9^_5/%%>G&R;@##@O#)X:,%ON'#+@MG0$61>8@M'M&]-[S3XERZ7;.K6W8WCWO0N%S7]BPH"R(,)\;1Q@&)BL-$ MC$2,C$6\;$X;F[&Q-8#IU=&T[Y_Y_;M?&W"(:H+<`;UO=>*WS;6Y)>\]B96_ M6(K397#(PBU+6!.O3;M#B.T5L`IG]/`@%M@IZ.Q(V+#WXYCR27[2?7V\*,_C6S,7I(LJ,H^F>!`@@JGQ;+.E$87/6/?;/WPX,W>#]HECHI' M5=!K)HY^0=![,EE2ZVR58CWKVA'18`[M9GZ]P=/9\6*.$12NS^".8/N^A8L% MC^VZ,>M-;^=$7.9GAVN)^%S`*XZ`4^$"\BN*9902$X?BG23CVM59CI_6CJ1= M&+2H3ZC0VOO=K6]-I@J>IHPY5C28^(6$&"\DX_AH65"J-``*$V!;;0RNS.4/ M`OG'Z@U%,_AQF[&O^]Y)+?V,6_7@PP,+R1#Q?'M"/H-.:U\W5C6&DQY"Y>;C M9>*>%:Z@B^)R:Y@09Z14/,NOJ!F.OVMN$6V*;.\OT$1B<1'SB+\2=L6,*(XX MHD$.07`=%Z8[/S]YSP^-:V+OW.?O_/#Z?7A0IZ)S5DW,/.4 M"R,8(F@"OO/#7WRT_X9/^`$XTJR3.A><<6YH%?CE,7+49RM$=HHF19S)L2T/ M'X$KIF69]T&P['>.,^00KC/99+447U;,6"ZO,(PF,';AWTE56:SP5-4X1.6( MZ0A>7A9J?&`BU01WPJ\Y*D/V&$)4+S?8_$$M3K40O6@,,6&3M?RX^[A-QVNV MOZ0?$G5567%NWTPYMZ5G=!;5,_61>[924^ M>RLA)0&,'DC.R&$59=Q($B+S*:R^5%*)4ISWE*"4`ES*CN@$Z);0C%2HN87YL\^Z,4*0D90LIDP_!5_MY`''9AO0W[P6!+K+8??S??\ZC%W M^,K=629C?>K.*;R.V MCJU7K.*F0)B<$6#B7J0%82#(B!@AZ7.T"$%RI;@/<,+U72CP0ZJIT$')(HV! MMD)M;F>1YB%%(Q82I5D>3972XZE64_7"?@2IR.KY,;U!&*ASBQMTF\5.\N82 M>]JZJQFSY'KH\.,4KL-(P*%BYR?*P"A.;^+,*[ENJB=_\B72$5DDQU!%%@1R M5<6%3#FW)5"5"!?^`Q+@WRQ_<_A)>6:R,A'YA@+59X2_*4Z)7K9X>+KHID0W MY04I4B)@$+SQ;'5Y6E;5.[<%WN!V"%<"3-7U)J=UK$^L`,.8G-)Y#1=8)OQY MU4XI[3Z;`FV\AJ)P2E]D^C%F`C3,%$J"2S[VM<&^0^0'?)Q`YK1GE>C.N.'? M:@%E/@B?"`7,*T_()N7?-6[$BSW584G;K%4__HRAHMG2BLH*.6A288A%@E.1 M>$9@T)$=P1DM^=XI[L%E`9IFN\`I5G!$<+GR&7W5GC_Z1M(%T_Q\,77N4M_9 MAJ]N1E$6:\FT,(KI5@/?"4V*?&R_B#,$%'?9T)^`R[/V>)8D`J[0'9+$!.OP M@XD@PY;^#S%&G-:#L35'T"&OJ)UQ*F$X@E)+-)D@"JCH@;9N]Z>AH%@!7!D_ M)89/NT7\:U=WGBR.Y2?IK_7`4LA%'&[''-*[.M:V[],K9-:5;U[W:HT;U\1A M1)J1/$&'^4>!.Z4#3`A(3^D@6H!>-*"PCXR_@F33Y[=@/ELWNM!+GT]E\7T9#B7]#7^2VU9]E9&7ZAR":NL(D>.J!$ES**STE+(& M"2AD&@H&WJ%RVR1F1S8^\]EL-(:7+Q8L*B&,2'[(JU_&J_[C$0:2A#,;B&+M M9L3@T;,_&2ID$EQTY--6[0]VRS)2C?'G0N4S()%(R"&!M?6K@/'X^?,O`<7S MNR#Q9JW:&QTH1>9!D=IG'GG@47)P;T8K<:7!AG-?OTT!9I99>&TR'LXP0,_P MC_DG*4DJD\QXY#G9:+_+E9/'CY^TR%V7.E]%K/1S"F*,.B$#V`9_$M7KZ5=) MQ]B&QQCR8XJTA4OUH2S..VRM#3142LI0RG!!Z->7K>N%DE9)U@G">^CJ[ENI MFF`JK#8AI\-,3]N8_$G.1-_H]D"$.Q;O*3S5_F5KK7H[/JBV=R>3BCK6:O)F MM#]N#>K/?Q4*P_P#Z[I#85.B,R)C^OX8`18"N4;\0E=+= MQS@P"[_\+FS:@@IT*^[96I7HOIMYJ4^)1%8N8BH-Z*:<^99VE@J]:O@Z[5J_ MY=]V#J-4-@"RHBPJHA:R*O`#S#;QVGDK04@O'NH6R6K>*86:J.)N.<>!-9C> M<>DZMAK6CAG:0L\&0:AJF]Q[\^_#F;*RLTX[S$1IZO?/+P[5'C]I_?(T+)UM[ MBA-%B2]$TP+;S<9+D:^H:-TJ<=$:*]=H;_F>3(NQ>3\??OT!_5^(<^ M+3+A9A16A23XF,HG_+=!';)4?EBJY`2_D@X;D"5.2)I:157F&M:5B79!`5:3 M:VQ5@:KT)3*4LCS6PC(B8?!N,[T58HC*MKY%$./A8*6;A81%NCQ*%&-W__7H M[=:_6MF_E:!,WNWLC/9_XF)>-=EZ_7:+ZWDC8#?:W-Q]9\4IU=[N]I;J4ZJ5 M]*_.#4I-7`2'JQ'[GRPNN,YX6^V>DK#B@@GF')+$6MXMD"BE$D_:O$T7DM3R MR"WHHR]PQ:=^#[L7@DC4%`C:TKDKSA(E"=#2@7ET2,SX0R24F2`%;? M7990Z>^GL]G-I:ZV*`4%3P%3!>V(GNM.7>F&:X$(]?1N[$JA%B^?Z808=,`` M"+78%/=<*2)5-(*Q:D*V"O]K';U>PG]9>M!$>D31H458_TAE3C/JAC0&NW&^ M$-#1%OKTVH+O.EJ4>P,=FT(_3G2-T.XJ&%#&J>0*P,6COPJ`$/Y6Z`V):#80 M$->W`5R%JHO2:/U2@@XHZ%J@H"YRGL*%"H,I:G#XP4MD2Q34PT$"$=PY=K;L M"W,L82(SM<\NEA%%75"')6%0A(K^3J6A130LZJV-]N)-H!(%-(,NQ8G-@`C, M@V-L-)%X#0WQ=5*LJ%A,->`)W%M+1]VV0U=#.L6\L+`9V;`8C1GT.\5!; M;(,4N8G(B@A8ZVI$PQ[C#UP.%\3=,ZE!DZ)S-`S"_O!ENTB1DV>Z%I19[8U6 MZ!F6!$E]HEJD*U5?2[Z2T9/[4O,L^ZMKG+'H8*3,\HG2^];(\+E#_C@$"@`N M`YY3:C\NY)<8`XLK4ZFRRL^BZ9,,D,!X6A$./](-UBBG3_A"%N!_&V]T6&`? M49$O8>UZ+&"<8P'BRVVE-_0&0+5U00R<9[>9KV4369G2KYNJ,#)[RN0@BM^G MX&BU:FR[$PV!.K-KBO:W>E5!A;@R?]>5'L+Y5M`NNDV!P54+#$9W,(L,)F=0 MHT]4"G\NRU((/!4BP9QN>UQZ;H.;_!GH.,(9Z$8.Y@M$43/:J>9 M6JS6S)(#XN646N'?%E]9`R!RO3U@428T7$Y-9Y9/*[,09^VYI7;"M<65DH!` MWT9]Z`$+G9Y]`FRV#Y9AL#I_G_S"WY#"A[11LC@BI.ZA58"3C31+&ZDBV65= M,8='#!!#+N6;OL,>B.JGVL8O?Q@1^BX<:!A,9@$),!%9RQT[(DSQF41G)-FB MC"0<,AD*>2[7*0'`4CXOT!E1D!42(M*L\Z\M^:UIS>Y6:(:R,6EM"(FF=WY= ME.F\DN3X[/J8O!C]$;@`$B$=TR"RY&W9[F*$8JZ4:O/K:Q!4_;9>R@SYIA(DRS(,0R3_5WEFPZM?1< M%JX0I8O=6FL!T@9=SB'W2SI?.A&R#%].F^E[P,V!7V[ M6N%X"TS,(/SVF7+'12%G>D;P@(@_9F>CFJ M(3:+>CYL5.YW="TMO(N3ZD"IT^9OICJVO/%B\?,?QHD'P"^9V2#4LXY.=,)F MG4))TAVCK?8LI'*1=3JKI8F+NMJ@W+Y)='DL\C1\E05CL9Q"L"XH/4>%`-!2 M0:SZ2':-N=MB-2HDK%HVW1>J":)^RTP4T6/HU+AW@C,==?*)5C-TCB*5?!28/B9<,C-QESWDG+W"X1, MZU=72CZ5E6>U#*QJ$`D,A:-GDDWBQ16<-V#$=<#+D%]=PBXIMG1;\4BJZUA: M6+I+ERC44R$L88_@>2QI.7;A0^IR_/:--I9/TI16_-3V2L+HNE4JKO32GV;N,N1Z3H0O4+L90[R M48"E*]5#MNU=`^\657'!@T@Q__=;7_"PMHP'A<3R*](8==`CWDRZ%VNL6V?P M(B.1W%1YR5.YS-,:'*<4E7C;=(FF'RC]POF"V\QXC$%93*`C@N MM?__R^SZ@Q0V_*ZJ<:_60&E>8>_Q27.MD*K9[61@RPTX\6F%%->K8BA5[=\OE'>B5;W;,52N;_$+[2.[^O M1Z,]#D8E:H'GLEF:!///MT?7=&5N_!FNEL`(>PD2B+NPH0R0>TDK"N^8\.+8 MEO?/U!*>66XK(98[NGE-I)792HI*,3!1L2:XQOS4%5#FS]8E\C%0$>/W( MA5_30D1M:5^L'AR'X4*6EF\M'KVMZWT]J:AS60"#Q5UVPN**,H45%\]`"Y$S M6C7SMDV*/%JPJ=ZGG[,X0HE!-S0&4`7BA%Z`K$5CVAL$QT4RQ2$0-2C!5M!( MRNG`.P65<@.$F`%!'!IR'S>M6AGI.E0K^@T+DGI)]D%WW!\LAO\Q\F)C4^&K MC'W\&FJ"(7TRF**-J':;*RU];K$)Z*.VO,S!1S*7,0T9`5F[6I50;>R&1P7A M@DO[+;SZ^MTBF]*B"'(-H0,\J<1ZS6E9E5*L8W4_T82JQ$P#_8YB;-[91#16 MEY[J;-'C!WJ"])C,3\UHA$-C)=&V_1Z["'L.0\2&YP68W3N7`Z M]%MT@&Z(]LJLN'+E3#&,\P4Y)C@,(6B"Z65 MXH@H5MT8HC+8NV:!&=P38\<.)]H)J&\'6OZVGS0E,4;SV]Q+Z"5P17NI:JYU M@P3$?.%,HKI7/*'SV>T)&EF2/.P0?A8-]6!?N%Y_N+[*'5C983Y],-!>U%Z* M_W@TL!JGJ>T6H$RV_$I7`U)-(%E$\3T=HLP82'?<;'>`TCL!AI#(E#Q$)2TU M^^L)A(P?EU%%<2+<+BF+SEK@#I4:>\TNFPDZ39))JXR6!3,$2NOBK0,^$+^K M?%_F^A91(-U:(JDB7N>"H]GC>WJ7\;Z0L/H]Z2FRQF"T;\1A_+4A0_2U;<^_ M>#&[7-!)1%-:@'"N^`=!,TB&_6.XVT^&H&/=Q)&AK6L6N6VAK!BWL>[9T'MX MB4@G_ZS.W9A]5-P7,,[RYXF[7=IL"^V=@D:W2PN_F7-[O;+\?[ MDXIBAJV#GZJ5`QEG\Y;QX<,%P%BN"K;QT>VY'2R!(OIE&.2/!"5Q$=*B0=WI M7::H7@_L=>94RQ82RV9V);ZQR9I,ZHN5"[1G^N__RGRGBKGA_W4_%+UD>=#^ ML#E<]EI_88>7^%1;2!DSA*T-Y/B3>K)!*Z@+GZA0F+]?V=&/YE/>Y!7SO=#A M[>>=YH^T4[F(O]\V]]34/J^7-WFSL2^#>%6A7O^U$`2'1]A:C6<6`"VF8Y0U M-9RVACO6GNE__N,_A>KVGU\./M@TR$3Z1%[?#Q;_WR')18S!8BZ$AL5V[35B MB-F+I2Q%^DAM1HK?5VMO)N\ MK+[Z7)V2/VQ#*HOM]@\-L=S^<0G@JL>#^YL@+%!8;ZN_[E@E3:?O40P8#0[8 MA%[/3Q:*W/C8D<_4WF-,]&)PHABP.3A`VD0V#J%$Y3!*YRL7J(XK$5ZI;W;/176DAG:1)5SG M^S8(3.^G!VGV_8'I8&_C-0+2S^&MF?S"R&_V94OO42Q MWEYC\(*81G3.N9^WY^Z!-.V3ENFD+LSKC]HKN!M6UHX= M^SW$]D#457VA#P_[ROPW"^YV9..`^[6,5OK]L`&RD<=FI35'?_OTD"ZUR?L MIE?=J6=N=[ZJ5:OW/`[KH'>2+",):,>MP?BJO5SOR(&MW8V6FD8Z#MR=B*F_ M:^\MV4:*!";]CP43]Q#-WD'&>;J[/BBO*\F4P43I7!.L%W@PG]]L_*\````` M__\#`%!+`P04``8`"````"$`X&ET6+T-```ZA```#0```'AL+W-T>6QE5*#;]M>D&OKU47^U(_>[FU[^ZCN)7U_[X;-NQ`B3\ M:*D^Q_'V2M,BZ]GVS.@\V-H^?+,)0L^,X6/XI$7;T#;7$0[R7&TR&EUHGNGX M:DKARK-XB'AF^&FW/;,";VO&SJ/C.O%K0DM5/.OJW9,?A.:C"U!?QKIIY;23 M#Q7RGF.%011LXG,@IP6;C6/9590+;:$!I9MK?^<97API5K#SXZ4Z*0XIZ3?O MUDOU0E52D5?!&D#\[M^[(/[V-^F?-W]X\V;TKV^^_<.C!&>%;A!J,1@99`O.>*;GIW^8F6ZSF/HX,\VIN>XK^GA"1Y('"/[ MG>>`F?"@EG(X+9]'1)/+-$<8C$Q3/$)E\D`D$P\VRV3^=$`FAM>LG=<0_3&\ M$BF:Y1+&J^H7%1T.X578BO`)GQZ7JF%`#AF/1JA6:K`C,5NL1L#O9,PN9B>3 M;&I,C4NADC&^6+4;,IP:(E79PM!X>WEW,G6*9U8G79:&3Q4!&'!BM>A`Z#;$ M]Z6!KU/XR8D+VE$L5JUE2>25J?'!\>Q(^6!_47X(/--'O=*:EOR:*H>O@1+4 MD\=4M9^L!"M("(L#$M0DHV`7.G:(\;L?N4F_E45N\B>"R'9/[QNH9GW88J'A+7T=RV_?@K-U_$D:6GY!D2!ZZP1Q=,J MF4)D3K:ZN#=6]PE?@HP710U1PUA='H'H_>UB)1[I:I&$L290_(D!+\%(W\[P M)9BH`?^MA.DTBQM=%,B"GA([..4?G5\N%HOY^&(^GR_TZ5C7$R4_9A[M^&O[ MQ<95`&%JJB*8`8+%=+ZXF`"0D3Y/6)T4P10`7,YF\]EX,='A_Z1M.#X"T3J= MJ;*M2A!(LBI!(,FJR:Q31.K+(@46X"3'*D$@R:H$@22K7@K.P)?2K4H02+(J M02#)JLGT1F"LPL*VY%@E""19E2"09%5AS6>6@6$W0;)5"0))5B4(3FW5;%J% MC;61K)Q5.S-A_7$^A5O=WW?GE*OE(_*_#2-A1Q,V+Y=J_.Q8GX`9 MLTN2ZB9E<2P.17SH.)O0+_71I3Z;7*03-D&L/7OM[+RJ=`7O@WX):D3=M@M. M=.@73#)W*!=M-;1"9C[.$8FI$TMS#@"?R%V"NR76P@\WT?0,;QGPT2A>+>?DT$R3`#WC,81!D3%6?K4,.:+1U M3%=9(;]48N-V@J^D.SX@:0[.F; M^7D_&,`H'9CCV4N"67XJ5VVYT]UA<5O)'Y"Z=4P_T;DE)I!`J($5=,^$W?2; ME6SH`"S;=3]B3?[[IF@#8&7MYOIE0TZ#@7.3\#P1/,L&W\+R=?8V+?GI!Y"I M;M"D=I!B;K?NZX>=]VB'1G+"4L(B.8K+Y.6GVZ17*3^_=9TGW[.3M4$U)?-] M&,2V%2\I``#.W'`$X:(D`X#1X MQ9`X&)-L!CY0L@3^QV().2:7DF%Y1"GKTB_P;Y#28-+O(#63?`N.7JH9/C0` M&,2R+L7*2C'$[!!II0K@0X,*#*BZ8DK>N"[G2U,(2;J`H=0(I($FC8CS2I)S M@6<)H%DCMP+[$.(4F(ID0P`X4B`00XPEU=\QQ2"I`E-OD%2"*02F!I\P)J@E MF`HI"0/@D1(599\P9BK&"=5`(,C*D,0;)K)2),4@*T>6IIC(2I$$@JP,22TA M*T52#+)R)#&%K!1)((!&I&1(:@E9*9)BD)4C2U-,9:5(`D%6AB26F!XY16IT MV31=1"7KIW!J8*\%5.5ET[J2.JZ;-8'A\^'I]"F=.H(QDLD4F4OCU85FOGBJ M/`>A\S/,,O$J0PM64^U0Q:M28\>B1[Z$YO;!?H&Y:+KW]+*I7^P%)/D"Q[XW ML@AK,97\8T@L#5'=D84-<9 M!N$N("A$,')EJPFJI'0,U%10,?ERA0&:P^33DLU:?94R1V5D*]YPF.E@V$1U M!.8XEY'&G)OW43*T:+73\/QI%\7.YK5CS2"(ILS,!A?EFES!2!8C_8(30JS25_-/ID#1-C)5;V;O1GFN&\J1#U= MT-!4R*)IT06WL;J@H;$_[=-@M*2"7L$'EU04,VZJKA:`1RIW0_-S"^J3]5:U M6F4*7L4)OU:M-J,^F59!7YM\#>W(,Z]>L52'[\CJ$QLT;;T`.QD3ERA!2>W& MK8+K'C+&9'/?2!9/";K M<=F5"DT*KFW-J(L.30-\@!KF-M3A^8BU-#0#MK;&HA?N!V#!LL"UC%]KYBY= MIG`K=&(N6NU=F`_7,PVG'AE?ZIZ)<+L/5,8I\`P(2@J/G341Z<.#C M384BK\2<69K=KQE7*JF0MJ15\+K.#XZ7%;(*[BLK\_1,A]HZ#[?)WK,?CQ2] M.L!>[<`Q^Y->6Y\37)[@*IZLK]:64IK5\"IK=H](P=NTX49^>D.QIK.()NBV M_W_(^EF1NS3WL&(_1&21="\+J,\.] MDP%XI`:5QI-(?9X`[E#O9-0KWOY"M0E8>68``W+]+PQN'^.398J35'\:6WWP MUNYVG""X>K@#52^ST7D"N`/5"]%/)ITMN8"[^Z/V[S,QH[6?15B94++52C[" M%A6>IH"R.A-U*@*UZN`:?WR((B-#J%4'+.,)7W(=;-,)N'.;>0$?Y(:UE=D@W=#F&3374_Y+#D`V:S M3=DGN4P:+HPFMYED;S)97$:MX(/2X+FNH]\J9\I;"XD6G3?FTL>=X\*=S?%< M#KS$W8++O`+O-CV879/<1*OH2'%7@=*"S->5%E!(%PBP$Z&TH`WH2@O8I[2F M("VA!7?@[$P+$DY&"V]*4>I+A^M.N^*"(1DM5O$=TA"671TD4B'+_@E*FPT9;6KM M:_IF'(2O"MX^I"#'&GW&2>Z/05#HB*4P@8\\@/YDFVO'?U)`+ZF&6!_&6T=T M(5/$`JL>O)E@%S(P.D7#^A^N2G8A`Z-3,FQ2Q?Z)A\P[?[LK+,3F4BS=/"3> M._XG>\UZ#JMA/.&$A]('>Q>'9N%_;$CAB@L7$;RA>$')_<'W>\8/ MQOI2?8[C[96F1=:S[9G1N>=881`%F_C<@H?@!)N-8]E:M`TAJ43/MAU[KC89 MC1;:0O/,Y/D30.0J6RID@\I_.01%0`;3EC(A=`BO$?_1V1R M\S\```#__P,`4$L#!!0`!@`(````(0#[8J5ME`8``*<;```3````>&PO=&AE M;64O=&AE;64Q+GAM;.Q93V_;-A2_#]AW('1O;2>V&P=UBMBQFZU-&\1NAQYI MF9984Z)`TDE]&]KC@`'#NF&7`;OM,&PKT`*[=)\F6X>M`_H5]DA*LAC+2](& M&];5AT0B?WS_W^,C=?7:@XBA0R(DY7';JUVN>HC$/A_3.&A[=X;]2QL>D@K' M8\QX3-K>G$COVM;[[UW%FRHD$4&P/I:;N.V%2B6;E8KT81C+RSPA,S*A/D%#3=+;RHCW&+S&2NH!GXF! M)DV<%08[GM8T0LYEEPETB%G;`SYC?C0D#Y2'&)8*)MI>U?R\RM;5"MY,%S&U M8FUA7=_\TG7I@O%TS?`4P2AG6NO76U=VJ^>?__J^5/TZOF3XX?/CA_^=/SH MT?'#'RTM9^$NCH/BPI???O;GUQ^C/YY^\_+Q%^5X6<3_^L,GO_S\>3D0,F@A MT8LOG_SV[,F+KS[]_;O')?!M@4=%^)!&1*);Y`@=\`AT,X9Q)2"M.69EN`YQC7=70/$H`UZ?W7=D'81BIF@)YQMAY`#W.&<= M+DH-<$/S*EAX.(N#UO5D"53,+2L?VW9`X8NXS'"L< MD)@HI.?XE)`2[>Y1ZMAUC_J"2SY1Z!Y%'4Q+33*D(R>0%HMV:01^F9?I#*YV M;+-W%W4X*]-ZAQRZ2$@(S$J$'Q+FF/$ZGBD".S1P1%H$B)Z9 MB1)?7B?-AOZ'&(KA\1JCX_M\+H>SHX;.1DC M56#.M!FC=4W@K,S6KZ1$0;?785;30IV96\V(9HJBPRU769O8G,O!Y+EJ,)A; M$SH;!/T06+D)QW[-&LX[F)&QMKOU4>86XX6+=)$,\9BD/M)Z+_NH9IR4Q>Q,O91&\\!)0.YF.+"XF)XO1 M4=MK-=8:'O)QTO8F<%2&QR@!KTO=3&(6P'V3KX0-^U.3V63YPINM3#$W"6IP M^V'MOJ2P4P<2(=4.EJ$-#3.5A@"+-2[\JIB4 MOR!5BF'\/U-%[R=P!;$^UA[PX7988*0SI>UQH4(.52@)J=\7T#B8V@'1`E>\ M,`U!!7?4YK\@A_J_S3E+PZ0UG"35`0V0H+`?J5`0L@]ER43?*<1JZ=YE2;*4 MD(FH@K@RL6*/R"%A0UT#FWIO]U`(H6ZJ25H&#.YD_+GO:0:-`MWD%//-J63Y MWFMSX)_N?&PR@U)N'38-36;_7,2\/5CLJG:]69[MO45%],2BS:IG60',"EM! M*TW[UQ3AG%NMK5A+&J\U,N'`B\L:PV#>$"5PD83T']C_J/"9_>"A-]0A/X#: MBN#[A28&80-1?F#R`Y+<&ULC)1= M;YLP%(;O)^T_6+XO!AKRI9"J2=5MTB9-TSZN'7,`JQ@CVVG:?[]C'%C2K%MO M$FQ>/W[/%ZN;)]601S!6ZC:G2113`JW0A6RKG/[X?G\UI\0ZWA:\T2WD]!DL MO5F_?[!.B[V"U@6(@88[]&]KV=F!IL1;<(J;AWUW);3J M$+&3C73//902)9:?JE8;OFLP[J=DPL7`[A<7>"6%T5:7+D(<"T8O8UZP!4/2 M>E5(C,"GG1@H28G86Z?5KR!*CJ@` M28^0:W1_?)]&Z3Q+LNG_*2PXZ@.\XXZO5T8?"#8-WFD[[ELP62)YB"SX&&-] M+52,T4-N/26G,THP"HOE>5Q/%O,5>\2%+@?9&CQCYJ<>_ M9WVPXL7>BJ^"][8)&\@>O:4O[KU4S!:CY,P)9NCM3KP8*WUR\63QAQO,!*[;\49]X0=\=YODU]"5_L;W#.^ZE@ MXPNOT;``#__P,`4$L#!!0`!@`(````(0"B?CQ3P@,``)L-```8```` M>&PO=V]R:W-H965T&ULE)==;Z,X%(;O5]K_@'P_`9.0-E'( MJ%!U=Z1=:;6?UPXXB57`K.TT[;^?8TR(;9HIO4D"O+SG\;&/?;+Y^EI7P0L5 MDO$F17@6H8`V!2]9T@2=[+FJBX%(<0MD*2LKNI;H*XRA:AC5A#3(. M:S'%@^_WK*"/O#C5M%'&1-"**."71];*BUM=3+&KB7@^M5\*7K=@L6,54V^= M*0KJ8OWMT'!!=A6,^Q4O2''Q[BY&]C4K!)=\KV9@%QK0\9A7X2H$I^VF9#`" MG?9`T'V*'O`ZQTL4;C==@OYE]"RMWX$\\O,O@I6_L89"MF&>%-G]12M:*%K" MS*%`S\B.\V?]ZC>X%4$0V0ET$/G_)C@D@)I$%G8UV^/5)9P#1`K%F<:->"5V`!GT'-]'J"-))70\=*=4S1 M?#E+[J(Y!GFPHU(],6V)@N(D%:__,R+<6QF3N#>![W/__/,F\]X$OB\F\2R^ M3W"R_!@E-,/J,O9(%-EN!#\'L%X!7+9$KWZ\!N?WTP+YT-H'+4[1'4QL MF`\*!P2R,!U$BV%)6.-=#*Z&S"@6EB)Q%?F/%`X9F$PGT^(4P:B'F5BZ<3.C ML,GN7$4^5ES9'3(HA>ED6NR2W;MQ,Z.PR5:N(A\K;I`M/T.FQ2X9]A>XD=AH MV%_A8\D--BBDZ5G38H_-6^*9D21=82[PTLIZS8_YC(^MN<6G M-^OI?&9KM_EBOVRQT=BQ8[]NW]'KPQ=0>6]9-EM0TFR6D30H0S;MULOGSHW=-OF M\WG!LUYC\\77X#W@Y,,#NEDGCQ_4\?CXB$=U/#X:TZJ20<%/NI7%D/KA[M";]TWS\`"ZW)8*MUV;N.,*^MONYQ'^!%%HNZ(9B/>08``!D```!X;"]W;W)K&ULC)5=;]L@%(;O)^T_(.YKC!O'212G:E)UJ[1*T[2/:X*QC6J,!:1I M__T.IG$39Q^Y20Q^>7G..1R\O'E1#7H6QDK=YIA&,4:BY;J0;97C']_OKV88 M6;*U$`Z!0VMS7#O7+0BQO!:*V4AWHH4WI3:* M.1B:BMC."%;TBU1#DCB>$L5DBX/#PESBH;%)/5LL_/3RGV]N@9V5KO/QE9 M?)&M@&1#F7P!MEH_>>E#X:=@,3E;?=\7X*M!A2C9KG'?]/ZSD%7MH-HI!.3C M6A2O=\)R2"C81$F/P74#`/"+E/0G`Q+"7OK_O2Q/K:91F\34%.=H*Z^ZE MM\2([ZS3ZE<040\UF"1O)M=`__8^B9)92M/I_UU((.H#O&..K99&[Q$<&MC3 M=LP?0;H`YT-D@6.(]6^A`IXWN?4N.`ULRVO=S>7&.(?`A*9-D5(YUT,SZ),@H'$VH^_H@2RT M>N@$)4PE-J)I+.)ZY]LX@9B'V>&&N4W\H1K-K^'FZ?N4#"^@\SM6B4=F*ME: MU(@2+.,H`R@3[HXP<+KK^V^K'?1\_UC#%2_@T,81B$NMW6'@6V+X:*Q^`P`` M__\#`%!+`P04``8`"````"$`TA\X^:D(``#&)P``&0```'AL+W=O\WZOJ]7&[WI?'XJ[_O:CZ?][_]S^W;^7I2_5< M%'6/%([57?^YKE_'=34H7XHC??-8G@[KFCZ>GH;5RZE8;YM&A_W0 M'HVFP\-Z=^QS!?=TC4;Y^+C;%%ZY>3T4QYJ+G(K]NJ;Q5\^[ETJJ'3;7R!W6 MIR^O+W]LRL,+23SL]KOZ>R/:[QTV;O1T+$_KASW-^YLU7F^D=O,!Y`^[S:FL MRL=Z0')#/E"<\\WP9DA*][?;'MGAJYIN291D!O:$*6W*/0V`_O8..Q8:Y)'UM^;ZMMO6 MSW=]9SJ8S$:.1>:]AZ*J@QV3[/V_J7`^1W^93+,O](S"PDZAQON7DH+V<0S@6^" MP`0K$X0FB$P0FR`Q06J"S`2Y`C1GTO;Y'MM(#Z0`,@*2`@D`A(#28"D0#(@N4HT;]/M5?/V^=.&3+?,NG&J M=,:"DXG39H@E$`^(#R0`L@(2`HF`Q$`2("F0#$BN$LUA=)30',9O7`-VLJF? M=YLOBY(?LLXXTJ$;%+]M,1'=CYS8-YT?@7B<.)3RVY!V)D9(^ZV17*(`R`I( M""0"$@-)@*1`,B`Y)_:<355S+=W&?]VU3$1W+2>J:X%XG#AJVG4F1N+U6Z/6 MM4*HF4JSLBN0#MM6W:J-+4,Z:HVD=`S2"4BG;:M.VIG,]!R7M492.E>EM05@ MI:1Z*#L3PU1+R"!FUKJG.5$]#<3CQ!FW@>X#"40KQ:V@$T*K"$@,.@GHI-`J M`Y*K.IK#Z&2O.>RGD@$3T?TH"'6K;/2YOJY+8=1E#.],,VM^HS?SN1$5LJJV M811PHRG5L-T`+&,`*QA`""02O8WXT7QN6Y,;R^@L%C:\$&7'[P1T4D[&E#K: M`<'4,FXT4V_YSG2DSS_G1N].35M>BQR`ZTM5-0V#Y?K/Y0LMG/AP5>)O%/7% M%LC6APTE"AO*7=_N]HTG&DZ["/`%FM$.;_WD6$9&".0@1MJ=!-97#JSK,D04 M"31N'FXT.3"6^M-VCR?8,$64H5:N:>F+PTJ?Z[.5QJ'=5_/Y6\V!,*TZT<&0%M MEHFBH1;0O.%4#4O8Y;YH.->2T]2HHP(YKH]B7(Q5C7$QHU'SK*^)Z$BH3>U+ M>4QVJ88]R*=2ZN(D,V%E3-(XZ^6RQW<([4* M$%8*\A#YB`)$*T0AH@A1C"A!E"+*$.4:TOW*BJM+?KWNSL!+-.I&GM,6[+F8 MGO.7B#R)M)P_-0Z8?F1"/M5@UE@F+6^9JK:;<'Z"!46G;W;RP6%#/902R8 MTD$BS;H9I!(9,S`.")EB)CO(M0[T56$%G;HJ'^0/7O]I[A%E[3Z1NQ[ MB'R!E,-'(!!=Y-!7V#!$%`FD:,4"T45J)=@P190)I&CE`M&%M'3_L7I,]=_/ MW8AY5:>Y5:#+=80EK+HP\212&YZY$?.&>BDQG>KG[4!HO7O@YF6S[+$;1(@H M$LCFY80]=RQK.C(.%K$TZDYB"4JE`GU040@KHZ0PMDLNK-Z=HK[:K)B$U?ZE MFH(I&B=;CHPC&-04PJK;=I[%D593<*37%%.C&`Q$0^O=HXA89^@R%"V5@V`D MD+)]8JFO;D702E$K0ZUDKU`H11:@5"Z1H)=@P192A5JYI:?ZCG:G[[Z=26:.B![1`1D`;6W\I MK92`%NB#FD)8&<=MXT%%(*P^BG$<1=BV5&H*P41-\4XRDPV5L$?Y5$I=KBF$ ME3[)F?E\1/;X[D;6%YR5T.J&,1?\NIJ"PM),80(I!<02D8?(1Q0@6B$*$46( M8D0)HA11ABC7D.Y75CBJ?KVU<&WI+Z5.39(S^%S3D\R.F`9_I>T&3/S?W3V/2/]M@[-*OC#@) M;^K2;T!G^,RE'U20AS.7?@U!GLY<^BD#N3=WZ1<$Y.'GZ(;%+VV0N_+ M%?3(>L2>"3^692T_L`[:-_#N_P4``/__`P!02P,$%``&``@````A`-6^POF" M`@``3`8``!D```!X;"]W;W)K&ULE%5=;YLP%'V? MM/]@^;TX0#Y6%%(EJ[I56J5IVL>S8RY@!6-D.TW[[W>-6TJ:JLM>$+X*-;R.DC6'JU^OAA M>=!F9VL`1Y"AM3FMG>LRQJRH07$;Z0Y:_%)JH[C#I:F8[0SPHM^D&I9,)G.F MN&QI8,C,.1RZ+*6`:RWV"EH72`PTW*%_6\O./K,I<0Z=XF:W[RZ$5AU2;&4C MW6-/2HD2V6W5:L.W#>;]$$^Y>.;N%R?T2@JCK2Y=A'0L&#W-^9)=,F1:+0N) M&?BR$P-E3M=QMEE0MEKV]?DMX6!'[\36^O#%R.*;;`&+C6WR#=AJO?/0V\*' M<#,[V7W3-^"[(064?-^X'_KP%615.^SV#!/R>67%XS58@05%FBB9>2:A&S2` M3Z*DGPPL"'_(:8+"LG!U3M-Y-%M,TACA9`O6W4A/28G86Z?5GP"*>U.!J[=V MS1U?+8T^$&PWHFW'_?#$&1*_[05->.S:@W.ZH`1E+-;O?I4FR9+=8]+B";,) M&'P.F'A`,!0=E%'M?&4/]LJ^*M[*)@3&,B]&CF32_Y'Q8"SKV/SLQ7Y0#ICI M"#-[.T&$G)^@!V,/QM)ID@[$03J`SI#&>1A+^TE+%_]LK]_5>QBJ'"+SL6*: M3`=71X6>'VN^/TD>?"SU%)GVTSJ>$QRWDURF$3I[7\%O.U9XBAPG\[IWX?2& M(Z+`5/`9FL82H??^9"8X]$-TN#36B3?].C[-UOV\LN$#'N:.5W#'325;2QHH MD7(2+3`7$ZZ#L'"Z0^=XI+7#8]R_UGAK`\[]Q"=>:NV>%RC,AO_`ZB\```#_ M_P,`4$L#!!0`!@`(````(0#QJP1RQ`X``"E/```9````>&PO=V]R:W-H965T MO#XGGSNOIX^?=J=_GGW;__]>'' M9OMU][1:[2_(PNONX^73?O\V&PQVRZ?5RV)WM7E;O5+)XV;[LMC3/[=?!KNW M[6KQT"J]/`]&P^%T\+)8OUY*"[/M*38VCX_KY/Z_W?[=&+R]>EK/XR^MFN_C\3,_] MTQDOEFR[_0>8?UDOMYO=YG%_1>8&LJ+XS+>#VP%9NOOPL*8G$,U^L5T]?KS\ MY,R:\?ARA;:#_KE<_=IV_+W9/FQ_A=OV0K5]7U-H4)Q&!SYO-5R$:/PA$ MR@/0#MH(5-N+A]7CXMOSOMG\B%;K+T]["O>$GD@\V.SA;V^U6U*+DIFKT418 M6FZ>J0+T_Q_B=E'&5)VA@I&_3+-J97D^NAZP@C1Q1=I4B_/8HG>A\K(_2KC-QJ6[MH]-OC_8JL:@F9@1N)"%M-KPDUB"XM@;!08BCXP'Q@01`0B`1D!A(`B0%D@') M@11`2B`5D!I(TR5&+&CY?$8LA+09"TFZ@P"(!\0'$@`)@41`8B`)D!1(!B0' M4@`I@51`:B!-EQ@-3\FLT?`BB9$OB>/SD-`S0R#)A#QUWNXWUG!00I0&=X1N M#T)&U436#'6[)7B\9JV:636%WJD;2W4KYPZ'_U`YD7%TL[]W*B43%%K[\#QP M+U)\:D):Z3":(_(0^8@"1"&B"%&,*$&4(LH0Y8@*1"6B"E&-J#&0V5%$LM&- MQ:F=6&R06+U8H?>ZBE2IO:_S"%N+JK<354`'EB0]@,CX\H0!0BBA#%B!)$ M*:(,48ZH0%0BJA#5B!H#F;$0:^DS8B&7WD8L#JMQ/53N`.2)/H3&%I+,TL,YR?"W%`RI@='M89H1H/F(IT[SU:HNU%)M/&&GS*9K/ M6,HT;^UGY%J*S1>,M/D2S5N+MTDE;.Z@^M5;,?%&A;K@1>8SDN;TX=/,1!0J-=>N$+*5[ M4\2(*MOI.M:.:JREN'42-)^RE#:?,=)5S1$5:*MD*6VK8J1MU8@:PY89-9'W MGCXSCF2:W)T9%1KI)ITC\A1RVWLB;:A]1`$KWNBAQTB;CU`Q1I2PHK:5,M*V M,E3,$16LJ&V5C+2M"A5K1`TKMK;,6/1ESN>/($RC1PIU1_M$Y\?R=<9"^H$\ MA28TWQ[&@7.C-XA4'*7UL1CGAT/SL367!,H6/3V/EA`]1B=YC)74<8\)>DS1 M8W:2QYP]CMLK`5-G[(ZNK=VT`OV5Z*\ZR5]]@K_&\&=V)+$=<<:@EKL7QJ"6 MR!C4@+P1(!]1@"A$%"&*$26(4D09HAQ1@:A$5"&J$34&,F-QWA['"/8A\1`&B$%&$*$:4($H198AR1`6B$E&%J$;4&,B,A=A5.&-[*QQW:69J6 M8O,)(VT^1?,92YGF[2Q-2['Y@I$V7Z+YBJ6ZYC%+TU)LOF'4FC?C2K:,N,I[ MDN=F:<**E:5)U&G\^0B0QTBO`GU$@4)&E@:V(JW8G8LA2U.*VF."YE.VI3.K MC)%6S!$5:*MD*6VK8J1MU8@:PY89M?/V3&C9!N&1R%C0`?*4HI&E2:D."I04 M59<[7,A(]^<(;<6($E;4ME)&VE:&BCFB@A6UK9*1ME6A8HVH847,TMS?LL_1 M6C%'$"/JL(<\"K(T%M(/Y"GT3I:FI([G3(&2ZF9IZ#$ZR6-\DL<$/:;H,3O) M8\X>998V=NDDT-KO*]!=B>ZJD]S5[[MK#'?&D';/VWAIQ:W^(O=BJ*?R,)PK MJ0[R$/F(`D0AH@A1C"A!E"+*$.6("D0EH@I1C:@QD!D+>^.E9XN2EJV\1^GB M#HM"W1P-D8?(1Q0@"A%%B&)$":(4488H1U0@*A%5B&I$C8',6(@]A=,7GK3> ML%]U"EDYFK5K-==2/'H\1#ZB`%&(*$(4(TH0I8@R1#FB`E&)J$)4(VH,9(;G MO.T,6C9`>"0RA@H@3REVI'Q$`:(0480H1I0@2A%EB')$!:(2486H1M08R(R% MO9WQ2VMY%WU%(^S@&WI=5K(2+_+(JW8 M-6_M6L=:BLTG;*MGZ69O,/Q:@^&^@RN1T6"`/"4U%:==W^_&SM2U)B5?2_#3 M!&RZVUA@.M**TO1D;"6AL99@TXEAVNQ9(BL_8Q*627PW^W<5ZBYFZ3^6M:XS ML)0.N\>HJXAG#DJ*SK7:Y^U9Z04LHG.ND&UK=Q&CH^YBMB7=36]OW.FMU=$3 MEFG]F:U)QL]I32%N+?4D$KO,G:%F7PYQE90^8_,0^8S$>N;[W;4[VG.BIVNI-!8[__XC.A5V[%E3=&!DIH:]Y@=ZW`A M1(\1F]<>8T:F1^M]D[SGT6QI.TOZM9;&Y&DLD=D/1]:T,6>I;C^4BM/N"@3? M%4IQ.FHGO-ZSVT#)&'U5U4K[B]C247\Q2TE_?;L0B>'.;&0[_;$;^:_-&_73 MWELTG125.I_]#E&HLZ*>(_(0^8@"1"&B"%&,*$&4(LH0Y8@*1"6B"E&-J#&0 M&:/S)EM?VRFJ^>GW<7R\TW\768J5B3'+#\=,W] M>,S?KK%+1I.9.*JD-Q"43*FD71G9)>YH)G8V>G1]N,G/?Z)M>]GAWZVA#]QT<]GAUJ+[D6M&I+F>K,IZP0=2C)G(D4 M$DLH62.=OAI3KD4Z?27T(:1/O=$75>[Q<4_=I5=>=)8>^4_CV2?J]EC9>]&+ M>SB=*<[$<11JT-'B3!Q!80F='5*M^DKH=&CFRQ37:F`ZZYF)PQVT1BU,W&NAW[HV'8FCO>PA$YOJ6Y])70\ M.Q,G>ZA#]U^I==J%J=4&=,.16JL-9VR4]WZ2N@8?2:.6U&'3M-G86\)W6"FMNYK`[K(3&W=5T+W MF>E)^TKHPC*U=5\)W5NFWMM70M>7J77Z2NZIY+ZWA*Z(4^OTZ=!-<6J=OA*Z M"DZMTU="-\*I=?I*Z&+X3%S[QA:E:\74#UJ=P:'ST(?*WA9?5OEB^V7]NKMX M7CW2JVK8'L=OY:?.Y#_V:MGW>;.G;Y2U*\`G^B3=BNXY#\5')!XWFSW_@UP/ M#A^YN_L_````__\#`%!+`P04``8`"````"$`I\C.(@TQ``#R+`$`&````'AL M+W=O+."\@X,_.LELNVHBV50Y+;W?]^OF1F,B\K73+L[H=6]T+F!HB5&\B=0)%? M__>_WO_\XI^/'S^]>_KPSOKE\8.V_/#T\?V;S_J_'W]\_>F7CX]OOK]V>O_SZ_G= MW?KU^S?O/KRT$;[Z^$=B//WPP[NWC[NGM[^^?_SPV0;Y^/CSF\\Z_D\_O?OE MDX_V_NT?"??^S<=__/K+?[U]>O^+0OS]W<_O/O_[&O3EB_=OO^I^_/#T\:MCWW]/PC__MW;CT^?GG[X_$KA7ML#Y6?>O-Z\5J1OO_[^G3Z! M.>TO/C[^\,W+O\V^NLSNUR]??_OU]0S]WW>/OWV*_O>+3S\]_=9\?/?]_MV' M1YUNB3(*_O[T]`_3M/O>('5^C=[U5<'X\<7WCS^\^?7GSY>GW]K'=S_^]%F^ M5_I(YI-]]?V_=X^?WNJ4*LRK^OOTLPY`__WB_3LS-G1*WOSK^N]O[[[_ M_-,W+^<:&W]__/2Y?F="O7SQ]M=/GY_>_S^[<>9"V,YSUWFAH[;;%^M7J_N[ MQ4S[>J[CTG74O[ZC8CRS)X6['J;^=1UF#Z\>5JOE^N'^^5VM74_]ZWK.==C/ M[.K>=="_OL/S9T'GZWIL^M=U6+^:+>_67S@'&]=-__K]K%\MYZO[AR^=O9E& MB95FAHNS]OR'FMT\ZW_X+L]_K)FW:_Z'[_*%O4BB/;!H1#PO=N:'@AFT?W`O M7NDL.%W]L<$P\W+-__![6_W!L^X]SX+H\E!Z;7/LFK*[-Y_??/OUQZ??7NA" MJ!/^Z9Y6V)LK?3)AO7NH3*$$_Z9KSSV]G][.O M7_]3EXFWKLUWA39IBZUO8:X))NPN!U4.ZAPT.6AST.6@S\&0@WT.#CDXYN"4 M@S$'YQQ<(O!:>FZ.-,+_$XY,&./(G]WO/`C2YID0W\)WV>6@RD&=@R8';0ZZ M'/0Y&'*PS\$A!\<D6>5)8]NL="2W M1JM,TJW)S1)(!5*#-"`M2`?2@PP@>Y`#R!'D!#*"G$$N,4FDZ:K^GY!FPNAB MJ=W0(<@(90#"M$Y=6"(7_C1O078@%4@-TH"T(!U(#S*`[$$. M($>0$\@(<@:YQ"0Y\9I7)2?>3M)>F3+C\T_OWO[CNR==BS1[*"3'0I,Q.T4S M05(?CI@H8=:VS'+#-0K3AITE<_T3=L:+8-0D,H1,WC^^>UJ_5`0 M:INHCO7CM$&8%J1+`B_6]\O5,KN0]`@\(,P>Y."(+HUA+$,H0I\0:`0Y.V)/ MQFRY7*P6V2"\Q($3HV:]8X+2:_/4J4<:--$GRR:26]\J2E.BRB&?J*O-DHGJ MVT29RD@M4><[/IM3O6\5P@^,M29E>-K6\5)2Y1Y9$;K8M5 M(75=FSAW?;<0O"7J/'HVRWJ&'WS'$'Y/=/#('OO]9C9;0K$[>^&R<_*]0NR1 MZ.R1NZ2M'K0"FUV671-[6E+%IL"?H-@TS[+8HGA.:]8FU2I".Z**J"9JB%JB MCJ@G&HCV1`>B(]&):"0Z$UT2E+HPA?L$%Z9YYL*BM-9[R&Y#6U.YYWJ`*K:J MB1JBEJ@CZHD&HCW1@>A(="(:BDR%/D&/+>@5ST\COC/+ZNF)WQ+M MB"JBFJ@A:HDZHIYH(-H3'8B.1">BD>A,=$E0ZL)4Z+$+4P_.YZ^$IR[;FTA9 M%EF495%V3=V:1R.IS!U11503-40M44?4$PU$>Z(#T9'H1#02G8DN"4K-F1(_ M-O>%.85=$4BRR*+H[K+5C0TN@"JVJHD:HI:H(^J)!J(]T8'H2'0B&HG.1)<$ MI2Y,_3W!A2O7XRN:12M=V*(I?+9>J97LHJH)FJ(6J*. MJ"<:B/9$!Z(CT8EH)#H371*4NC!U<.SB3RU`SEPU'6>0J\%#>;MUK>8![1Q: MJ$:(\BRKU:O0RD\Y:J*&J"7JB'J']"J*PB=G1V7W?^#L7*.DMV*'HE.Q)=HY MM)A?%W7F=[.LP*Q"@]N)\6&N'\8NQGH4SGL;.IKE(D7.5B>ZT,!'[GV8PFF: M5D_/64\[E)P/VRI".]=J$:ZW%5'M8\5G`+%:=NR(^B16.C2F%9CFW8UL.N:1 MKE+1V,\6E[>^59"W\RCMF"U_5*Z5K%U7!&=W\_LL=NV;A-67QL<.NVL]>G9W MG8_E%GO6Z]5#-K/L?1,NR)AUE.0J]/SDZ=H\2RA;Z*4+,IML>7CK.L[#`-IY MI/Z1!9Q,%]ZN1C9W76^E5L2NM-;6IF[/ME= M.C*GU7,Z&1B9K.=:]/CN)B<;G)G]"$%KYR_6.J"*JB1JBEJ@CZHD&HCW1@>A( M="(:BDPQ-4&/K;WBF>@E2Q54W4$+5$'5%/-!#MB0Y$1Z(3T4AT)KHD*-&SR*O&Y_5IXE"<*D0[ MHHJH)FJ(6J*.J"<:B/9$!Z(CT8EH)#H371*4NIA6FIJ%B.RRY9!H5454$S5$+5%'U!,-1'NB`]&1Z$0T$IV)+@E*79@:]W:'URSI3RT%+DR4 M[&IFT4*53"BQ-]GJP-9UU&4U9)#KJ.MIU#%;A:_8L7;(C+NH8[:LV(16?H^M MCQ76CCJ/PG'UH6,%M;2$?"%&Q=7#JX1],0R'.>6:$=4$=4.Z1]_Z`U1ZSN& M4]IY%`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`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`'U\7? MR>=WF^Q4'+F?$]&8[3K=\=EOY3UOE2SL?%'HM7F:H0YE&9K-K;>^8Y2A#CV3 MH:Y%G*%^;V%X-Q[9^]UU_35+]=8UB>Y)G>\5`O5$@T?%.\Z>80\.10F:S<:08K#4-\2[8@JHIJH<2BZ?[0.Q?G& MCCW1P%A[QCJPXY'H1#0Z%!WJV:'"K99(;O%`%61T9YWO%0+U1(-'=CPO M<6EDX(-#_F/-]5TZZ67MZ(.&79^(1H_LKK/)^-EM+:62*>7_^+W.O)F635X\ MBE/)M0IHQU8544W4.!2-S]:A))6PQYZQ!L;:,]:!'8]$)Z+1H>A0SPZ54LF4 MW!-.O*O0H[]Z-'\P+!?9/2F[$F]=JWC6Z%!:A^4O4%2^552'^3V&H=AX9.]+ M]TNMHV7)W+HFR7W)'7H(U/M``0T>J>0)UXIYEJU[AC\XE'W`;`)X].'#'D]$ MHTL8WZ,LRL9= MOL#A.B;W*;?',!0;U\K=I_2=4_>K+%#KCR"^3R%0[P.%V(-':APE5CZ19_B# M0]D'S"?S/GS8XXEH],@F5K;SL]M:2BRS0##!KUM/B/UBB6&[`MH1540U4>-0 M-%I;AY+$PAY[QAH8:\]8!W8\$IV(1H>B0ST[5$HL3;2GG'C3/)O\690E%JHH MUS%.+(NR<9?=:*J5:Q7?L=P>PU!L7"N_UJ%'[7@SR35)[E@(U/M`(?;@49I8 MV2UYS_`'A](/N,!4$`=Q\GL,!S%Z9!,K2\YSLO-D`7%E"O<)B>56"^+$LDC7 M9K_"M[T&U=>6!+0CJHAJHH:H)>J(>J*!:$]T(#H2G8A&HC/1)4&)B_6T%8MK M\S37'-($].:":$=4$=5$#5%+U!'U1`/1GNA`="0Z$8U$9Z)+@E(7TU8;UEQM M<,@4`^%^N\@FLMO0RAO;$55$-5%#U!)U1#W10+0G.A`=B4Y$(]&9Z)*@5,^T M-8FU71*(5VL=2E+%MHK0CJTJHIJH(6J).J*>:"#:$QV(CD0GHI'H3'1)4.K" ME.%__!:R=E5[N$9]YU"6*EGIM@VM0JK86)&QBJUJHH:H)>J(>J*!:$]T(#H2 MG8A&HC/1)4&IGFEK#FNN.3@4G>4MT8ZH(JJ)&J*6J"/JB0:B/=&!Z$AT(AJ) MSD27!*4N3&$](55<'1ZGBD7Z$RN?!-LUT,XA\[0KNO=DQ6P56OE8M4=A$:]A M^-:W2L-GE6H76OGPO4?7\.F9,35L?&;^U-\&KFTEG%SG+4I.&-#.==3?\YEW MK@I?A!4:^`]3.Z0G4!XUOE6PTWKT>Y&[T,"'Z9/(Z6DR!61\FIY_2KEV]68X MGN\]XC95^9E,`3?C,MEY* MQH!#Z7C-5A^V:]8(W?L6'$KWT\JC:_/L)-F* M*1M*V>K.UG6,AQ)1Y9'5/3-O;Z9+]K4_@&@D^4[12"+J/+*A]2)F'KI/0J_]ZW*(RD:=7#/:L'A]*1M,R.8.M;!=T[HLHC-Y)66B;,`M6N2;1.V/A> M(79+U'ED8\\?]%.O6>P^B9V.I7P6_Z?F1_>+>V;ZXN%GE]D'[%V;:)5\8;!6Q\I!.\\TFPWS&F769'8)^'3,VBFR7]\ M&F%^("M;R78HNAAMB79$E4/QPQ^'DE%D]QB%;QFK8ZP^B95^YO_(K%H_^(Q3 MX5`Z:K("8^L[QJ/&=C3ON]XL>Y'Q.GJ?F_SS]HGO?E]XHO.=Q,IF\I8E"Y? MY;]AM74=(YD[HHJH)FJ(6J*.J"<:B/9$!Z(CT8EH)#H371*4FIM6M-S;"B6N M_AR*3OR6:$=4$=5$#5%+U!'U1`/1GNA`="0Z$8U$9Z)+@A(7#]-*HVOS-%4< MRE(EJ_NVH96?6NR(*J*:J"%JB3JBGF@@VA,=B(Y$)Z*1Z$QT25"J9UI1]F`K ML#A5'(I3A6A'5!'51`U12]01]40#T9[H0'0D.A&-1&>B2X)2%]-JOP?6?@Z9 M=V)N,Z5Y_D<1V]`JI(J-I8X>56Q5$S5$+5%'U!,-1'NB`]&1Z$0T$IV)+@E* M]4RK.A]8=3J4I(IM%:$=6U5$-5%#U!)U1#W10+0G.A`=B4Y$(]&9Z)*@U$6I MM/U3<[,'EK<.93><_.VCT,JGS(ZH(JJ)&J*6J"/JB0:B/=&!Z$AT(AJ)SD27 M!*7FII74#RRI'8I29DNT(ZJ(:J*&J"7JB'JB@6A/="`Z$IV(1J(ST25!J0M3 M^_[QY8T'5RJ'!9;O',I2)5^1#:U"JMA8D<2*K6JBAJ@EZHAZHH%H3W0@.A*= MB$:B,]$E0:F>?)'@^0=W#UP,<"@ZRUNB'5%%5!,U1"U11]03#41[H@/1D>A$ M-!*=B2X)2EWDBP%?<,&*_Z%8\>?K\J%52)5;1X\JMJJ)&J*6J"/JB0:B/=&! MZ$AT(AJ)SD27!*5ZIE7\#ZSX'4I2Q;:*T(ZM*J*:J"%JB3JBGF@@VA,=B(Y$ M)Z*1Z$QT25#B8C.MXK\V3RM^AZ(3OR7:$55$-5%#U!)U1#W10+0G.A`=B4Y$ M(]&9Z)*@U,6T\G[#\MXAN8A*ROP)S3:T\M>H'5%%5!,U1"U11]03#41[H@/1 MD>A$-!*=B2X)2O5,J_@WK/@=2E+%U?)AFK9CJXJH)FJ(6J*.J"<:B/9$!Z(C MT8EH)#H371*4NIA6WF]8WCN4I4K^6#2T"JF"18"*K6JBAJ@EZHAZHH%H3W0@ M.A*=B$:B,]$E0:F>O.)_?@*V85GO4)(JME6$=FQ5$=5$#5%+U!'U1`/1GNA` M="0Z$8U$9Z)+@E(7TVKX#6MXA[)4R1[,;T.KD"HV5F2L8JN:J"%JB3JBGF@@ MVA,=B(Y$)Z*1Z$QT25"J9UI9OV%9[U!TEK=$.Z**J"9JB%JBCJ@G&HCV1`>B M(]&):"0Z$UT2E+J85L-O6,,[E*5*_MI$:!52Q<:*)%9L51,U1"U11]03#41[ MH@/1D>A$-!*=B2X)2O5,*^LW+.L=BL[REFA'5!'51`U12]01]40#T9[H0'0D M.A&-1&>B2X)2%]-J^`UK>(?2QU_Y7\-O0ZN0*J[2CQY_L55-U!"U1!U13S00 M[8D.1$>B$]%(=":Z)"C1,[N;5M?;]FEA[UF<+06V*["JP.H":PJL+;"NP/H" M&PIL7V"'`CL6V*G`Q@([%]@E99F>O-3_TZ\KS>ZX#.!9=AO*W\*(FMV2J\`D MT^XB&@B2"2:98)())IE@D@DFF6"2"2:98)())IE@D@DFF6"2&;-,YK2%`?V. M.MXP\RPZQ=L"4ZYAO4!ZP*0'3'K`I`=,>L"D!TQZP*0'3'K`I`=,>L"D!TQZ MP*0G9IF>?*W@+^0:UQ%F=[?U@'C-+?^3F:A9E&NWKIY))IAD@DDFF&2"22:8 M9()))IAD@DDFF&2"22:89()))IADQBR3.6UE87;'I07/TESCXD*AG?2@G?2` M20^8](!)#YCT@$D/F/2`20^8](!)#YCT@$D/F/3$+-,S;;%A=L?5!L^RB6'^ M1D?4S">/KHYNP2&:&A:8C*&=C(')&)B,@L"D!TQZP*0'3'K`I`=,>L"D!TQZ MP*0'3'K`I`=,>F*6Z,.D!DQXPZ0&3'C#I`9,>,.D!DYZ897JFK6G, M[KBHX5FD0O-XMV`1/>,K,.E!.^D!DQXPZ0&3'C#I`9,>,.D!DQXPZ0&3'C#I M`9,>,.F)6:IG-G%)X]H^6])P+)M;Y._US$(S?VW;%5A58'6!-076%EA78'V! M#06V+[!#@1T+[%1@8X&="^R2LLR8J9G_^"N+LYFML>,_6/`L22C7+F+2$]?G MUY\TE!XPZ0&3'C#I`9,>,.D!DQXPZ0&3'C#I`9,>,.D!.Q>8],3M,CVF9IZB MQ];8J9Y;W1U-(/)?,]K.9K=F44*!R1B8C(')&)B,@L"D!TQZP*0'3'K` MI`=,>L"D!TQZP*0'3'K`I`=,>L"D)V:9'E,83]%C"VE%]%GQW6SFBFN5!.&O M@M;Y>RE1,]]5QFY=/9,Q,!D#DS$P&0.3,3`9`Y,Q,!D#DS$P&0.3,3`9`Y,Q M,!F+66;,%,93C-E".C7FBNM@40D%)CU@T@,F/6#2`R8]8-(#)CU@T@,F/6#2 M`R8]8-(#)CU@T@,F/3'+])C">(H>6TBG>F[%=9Q0^=LK,WU1@_FS[W1.`29C M8#(&)F-@,@8F8V`R!B9C8#(&)F-@,@8F8V`R!B9C8#(6L\R8J7ZG&+/5L"D!TQZP*0'3'K`I`=,>L"D!TQZP*0G9JD>?=M6JN?/K\]>0V7K%8[I MKA3G6O;5-5M](9J.(KMYD56%=G6!-076%EA78'V!#06V+[!#@1T+[%1@8X&= M"^R2LDRFJ94GY)J^FBC_JIB98]$\0GKB&OR:?[L"DQZTDQXPZ0&3'C#I`9,> M,.D!DQXPZ0&3'C#I`9,>,.D!DYZ897I,83Q%CRVDDTNA?G3[FBGIS0MOQH1F MX>9%)F.W<+Z=C(')&)B,@2/+X4XIVF^:V9GTY()IAD@DDFF&2" M22:89()))IAD@DDFF&2"22:89()))IAD@DEFS#*9IIR.97[I4FC+[]28*\GC M5=TYF/2`20^8](!)#YCT@$D/F/2`20^8](!)#YCT@$D/F/2`20^8],0LTV/* MZ2EZ;/F=ZKF5Y'%"X<4E_0H"YQ9@,@8F8V`R!B9C8#(&)F-@,@8F8V`R!B9C M8#(&)F-@,@8F8S%+C2WR58XO)-2U?;:4X5AR\R+;S;,;Z9 M(H1F]^$[P+,#,Z7AE`.SI61Z8*Z\C"_$"S"-&S"-&S"-&S"-&S"-&S"-&S"- M&S"-&S"-&S"-&S"-&S"-&S"-&S"-&S"-FYAE>DQI.$6/+253/;?R,AX0>%ZM MG^?!A9A,QM!.QL!D#$S&P&0,3,;`9`Q,QL!D#$S&P&0,3,;`9`Q,QF*6&3/U MWQ1CMEY,C<4UI"OR]#M`U`,F/6#2`R8]8-(#)CU@T@,F/6#2`R8]8-(#)CU@ MT@,F/6#2$[-,CZG_INBQ]6*JYU9#Q@F%Y]6+6[-0*I#)&-K)&)B,@N/O\D$TPRP2033#+!)!-,,L$D$TPRP2033#+! M)!-,,L$D$TPR8Y;)-"5A+/-+580M(5-C<5GIL"D!TQZP*0'3'K`I`=, M>L"D!TQZP*0'3'K`I`=,>L"D!TQZ8I;I,?7?%#VV7DSUW&K(.*'PO'IQ:^:3 M1\;`9`Q,QL!D#$S&P&0,3,;`9`Q,QL!D#$S&P&0,3,;`9`Q,QF*6&M/O#4TR M=FV?U7V.K>YO[Z!N9V2[`JL*K"ZPIL#:`NL*K"^PH<#V!78HL&.!G0IL++!S M@5U2ENF96)8O"V6Y8]&M1WILNXA)#YCT@$D/F/2`20^8](!)#YCT@$D/F/2` M20^8](!)#YCT@$E/S#(]IC"><+U;VD(ZN=XY)A7Q]0ZO$X1FX7I')F-QK7Z] MN\D8F(R!R1B8C(')&)B,@8LP6TJFQ MN+AV$PC]Q!VJ7S+I03OI`9,>,.D!DQXPZ0&3'C#I`9,>,.D!DQXPZ0&3'C#I MB5FFQQ3&4_380CK5L"D!TQZ MP*0'3'K`I`=,>L"D!TQZP*0'3'K`I`=,>F*6Z3&%\10]MI!.];CB.EG7O\>3 M9_-[C>:-*MTNHW7]\#PM.S!3Y$TY,%L4I@<6%XI^W(!IW(!IW(!IW(!IW(!I MW(!IW(!IW(!IW(!IW(!IW(!IW(!IW(!IW(!IW(!IW,0LTV.*O"EZ;%&8ZKD5 MBO&`P/.@Y:U9="$&DS$P&0.3,3`9`Y,Q,!D#DS$P&0.3,3`9`Y,Q,!D#DS$P M&8M99LP4>5.,V:(P-187BCZAP)108-(#)CU@T@,F/6#2`R8]8-(#)CU@T@,F M/6#2`R8]8-(#)CTQ2_68IZ*)GC^_#'D-E=7@CJ55Q$-XJ.IDAF8AU\BJ&5E= M8$V!M076%5A?8$.![0OL4&#'`CL5V%A@YP*[I"R3:4K"";EF[HGYTW+'HA)\ M.R/;%9CTQ"7I5:WT@$D/F/2`20^8](!)#YCT@$D/F/2`20^8](!)#YCTQ"S3 M8^J_*7ILO9A<"E>NADPF/0]X*.V;Z6#"I.DR9,T6/+8M2/;=2*1X0>!ZTNC6++L1@,@8F8V`R!B9C8#(&)F-@,@8F M8V`R!B9C8#(&)F-@,@8F8S'+C)G*9XHQ6RFEQN+JR2<4F!(*3'K`I`=,>L"D M!TQZP*0'3'K`I`=,>L"D!TQZP*0'3'K`I"=FF9Z\^OP+DYY"86J^@\G^#4^< M:WA4%)I%N7;KZIED@DDFF&2"22:89()))IAD@DDFF&2"22:89()))IAD@DEF MS#*9IEJ,.D!DQXP MZ0&3'C#I`9,>,.D!DQXPZ8E9IL>4AE/TV%(RU1.7E_Y2""8]8-(#)CU@T@,F M/6#2`R8]8-(#)CU@T@,F/6#2`R8]8-(#)CTQR_28TG"*'EM*IGINY65\O<.C MHM6MF;^VR1B8C(')&)B,@Z:^UOOWZFBA_FUW;9V6Y8YIS>A5; MWRYBNP*K"JPNL*;`V@+K"JPOL*'`]@5V*+!C@9T*;"RP>**4'=C$ZG-=J#X=B\:(QHVK2,-8TK@!T[@! MT[@!T[@!T[@!T[@!T[@!T[@!T[@!T[@!T[@!T[@!T[@!T[@!T[B)6:;'U'_Q MN/GS<]*U+273(74K+Z,A]8"'):YK)%@R;UW]Q4(RP2033#+!)!-,,L$D$TPR MP2033#+!)!-,,L$D$TPRP20S9IE,4QK&,K]TC;:E9&HL+B_=I&<-)CU@T@,F M/6#2`R8]8-(#)CU@T@,F/6#2`R8]8-(#)CU@T@,F/3'+])C2<(H>6TJF>EQY MF5RCN1"W=LW2:_3O/7UO()!28]8-(#)CU@T@,F/6#2`R8]8-(#)CU@ MT@,F/6#2`R8]8-(#)CTQR_28,B?6\QE]^_CN1P/5\`OSU7L3*U=GF=3%R88GDZYK9%@V;UU] M`LHFF&R"R2:8;(+))IAL@LDFF&R"R2:8;(+))IAL@LDFF&S&++-I*LGXRODE M8[;R3"Z/]W$UZFYL9-*#=M(#)CU@T@,F/6#2`R8]8-(#)CU@T@,F/6#2`R8] M8-(#)CTQR_28VG"*'EM+IGHLBS)%UT(PZ0&3'C#I`9,>,.D!DQXPZ0&3'C#I M`9,>,.D!DQXPZ0&3'C#IB5FFQ]2&4_386C+5,7")]2MF;^VR1B8 MC(')&)B,@+AY5*)128](!)#YCT@$D/F/2`20^8](!)#YCT@$D/F/2`20^8](!)#YCT MQ"S38XKF*7ILD9WJN17><4+A%97[6[,HH//__\Z<7; MIU_-HR/S^EK$7WQ\_.&;E]\ISE?78#KCMSZW;7=FVYUYDL1M,[-M5MXV-]OF MY6T+L^V:IXRY--N6Y7XKL^WZQ![]UB:FUFQ+Q[DV,;5@6-QF/KL6A8K;[LVV MZQ^8XC:S/SU3+&U; M&W]Z(%C<9ASIH45IV]+$U)O%I6TK$U./KXK;S)C0,"MN,X[LA`?G^^BMO,_O071L5M9G_Z\Y;B-N-(?\)0W&8< MZ67YTK:%\:XOC"AN,S'U_0/%;2:F_OB]N,TXTI]9E[8MC2/]/71QFW&D/S`M M;9N;F/I&M=*VA8FIKSDK;C,>])5-Q6W&@[X-`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` M36*-#Z\EL<:'5Y)8K'D=B=4#7D74`:P/-8_5H<:Q-B)E/S&/APD$JW.&PO=V]R:W-H965T&ULC%3);MLP%+P7Z#\0 MO$>4O":"Y#0UL[T!7H9+JF63-%TPQ65'(T-N MSN'0524%W&AQ4-"Y2&*@Y0[]VT;V]L2FQ#ETBIO]H;\06O5(L9.M=(^!E!(E M\KNZTX;O6LS[(9MQ<>(.AU?T2@JCK:Y<@G0L&GV=\Q6[8LBT7I42,_!E)P:J M@FZR?#NG;+T*]?DMX6A'[\0V^OC9R/*K[`"+C6WR#=AIO??0N]*'\#)[=?LV M-."[(254_-"Z'_KX!63=..SV'!/R>>7EXPU8@05%FF02;`C=H@%\$B7]9&!! M^$-!)R@L2]<4=+I(YLMTFB&<[,"Z6^DI*1$'Z[3Z$T%9,!6Y@K4;[OAZ9?21 M8+L1;7ONAR?+D?CD*3(,+M\SB>X\R<:S%'1)">I;+.S].EM)8J0\Q/U8&S2<^F7-8Z@,Z1Q8,;2(?E9\NXPGJKM MKP430[F?(F/);)F^R#>N1)P[!::&3]"VE@A]\.,^P8$9HL,F;B:^IR_CLWP3 M5H,-'W!#>E[#-VYJV5G20H64:;)$8R;N6#PXW8=IWVF'NQ%>&_P5`HYOZA.O MM':G@]_BX>>Z_@L``/__`P!02P,$%``&``@````A``")M'8:!```Q!```!@` M``!X;"]W;W)K&;.>.889WOSDF?. M,ZM$RHN=2Q9+UV%%S).T..[[/_Y]/VPJLG M<6),.N"A$#OW)&6Y\3P1GU@>B04O60&_''B51Q(>JZ,GRHI%B5J49QY=+D,O MC]+"U1XVU10?_'!(8W;/XW/."JF=5"R+).0O3FDI&F]Y/,5='E5/Y_)SS/,2 M7#RF62I?E5/7R>/-]V/!J^@Q`]XO9!7%C6_UT'.?IW'%!3_(!;CS=*)]SFMO M[8&G_39)@0&6W:G88>?>DLV=3UUOOU4%^B]E%]'Y[H@3OWRMTN1'6C"H-NP3 M[L`CYT\(_9Z@"19[O=4/:@=^54["#M$YD[_YY1M+CR<)VQT`(R2V25[OF8BA MHN!F00/T%/,,$H!/)T^Q-:`BT1IY_KA(KA:^@3@SB,3\B%%EZX3 MGX7D^?\:1%12VI=*[3Z2T7Y;\8L#^PUH44;8/60#CIN M=NZ5ZT!\`95]WI-@N?6>H1IQC;G3&/A\P[0(#[)I4X(TNBD-EZ>)C&",C.7" M5.ZTH1N&#H?QYX1!,-2[FWQ`6K\ZLL:L.IB@11@$`3*=(()A<\S0=FTU:$)H M:)3IH1&L0K?%K2W0^F^;&(S4-YP3"L%FJ-JBN[?;'M!E70JJ8Z^7BRO([?U6 MP85FC-K2;182^,.;ABK<&93W0R'8#%5;^G36IM_I='"A&:.VF'16PW0([.%T M/@IM!FM,?48$$ICA&M&6Z]IDMMG(,)%953:IVF22NAHA M-4L02%\1&M,`J0%-H/X43GU-(+7)Y'0]PFF6*I"^+#0F<,KYJHDT%:T6BP&.%G*@)S\"><^W![M3F],YO3:1Z2^,^J+6VKS:V^PWKM+W"'+*,C^QE5Q[003L8.X%.+4:5OH?I! M\A(*!#=)+N'VJ+Z>X-\"!K>J);[S'#B7S0.\:7CM_P_[OP```/__`P!02P,$ M%``&``@````A``8'5*-,"0``E2T``!@```!X;"]W;W)K/\O2U>BV*\PPB'*O5 M_/5\?KM?+JO-:W%85W?E6W&$D>?R=%B?XONK;I$.VS&A#NL3U_?WQ:; M\O`&(9YV^]WY1QUT/CML[G][.9:G]=,>YOU=A>O-)7;]0R?\8;37_I.YSF\R7CP^U0'_OBH_*^_]9]5I^ M_/NTV_Z^.Q:@-N3)9>"I++\ZZ&];]RMX>-EY^DN=@3]/LVWQO'[?G_\J/_Y3 M[%Y>SY#N"&;D)G:__?&YJ#:@*(2YTY&+M"GW0`#^/3OL7&F`(NOO]7\_=MOS MZVIN[%T4!T8!?/945.NUJ<(<79!/+LIJ'L]G M,(L*\O/M407J8?D---T0)NO!<$1^0;A4`+V&(\SVT7$:0-A3$`AGXE3RT`U#3-R#P'.(Z`"02%#3.AAHH9!/8U\",$X M0A"?XS`W!U[-08!&'!48_N8,,4F=UD5H3!BJA$-R!M$&YA?:!L+80;W[[,8I MZ!Z2"H9-?$PS8H!(,Q.IX!""<;2DUD;7 M5%/00:;+5C\E.0H*&8&0I(F31$PBYX`T5JVR++/*]>;)J:V?DAQ%;64$PN3I ML$T?+@X:IN(,M&[;$V?HNKC'<#C!"GL^:WQ*O#HCD"PKXH41D)<.K@KG^O9X M6MCE.:TV)5AX"D'XYH6R*DA4)Z\,H^/0JK0M#BZ<:][C&6*KA_!-GU5*NIE" MT%`S'H1P?L(R;B06N[ROH&DKA@1$#*4N,;)AYVYO!^N?:BXTL6I;.NPGSPW[/5,.K$J,\W\`':`2=R1SH?H(/&TY>1<M-&,0%1Q4:ILI-N1SCM%I M&L9)JRV73MC%N-./1D>`]'B6VVI`$B((A&I`8OGD%*/53PC-D^6<$ZJ\J5'`0PGD*SQC) ML^L=RCLFX`(QOC/`KB0)5"KJ(&>8-`EB$U_)MA'N,9(H.@1KAEKNL>K0C8W` MN;&I-U(3@V!5P+FS'>=2NG;NM>F1#-$$.,/V#22E[Q0@91Q''@MBZ6-`2FNN M?=4PKKE/)^J>XH:LM/25.O1%2@4?5G0HO2=G&!O#;MJS'ZZH\)>1BO;XC!;- M+S,(PIP"1WFBRAG`I*$*PM:'.,N?\AB#]L'S+CV&0%1YH%,8:(').096D#7> MUQK.=)++&'09**O&X)307"ML9MNH:+9:T::L<>P^!^JWZ MRB#3+!06S_G)@TDA!!%V+P-Z,X$3T\)\PP-6<&XZDYM*PS MN0Y"!"$UI50)'L(^^Q! M;@,(A"_O98=1$#!(;I(SA'W.()3)"'2E[C""'&2"1<(-QNV?ZJ?$(<2(74=& MH/ZBPI4Q".$\)SE$A`[!ZTZ>?@F$>4OAXXK8T[/QQ(9M-^+,7",?W>G_`^=9)JOD^D8<37@IQ&,:G*OR7!>4VR!]MC#YUE0"#DM>@2PQB7-7R=V21[ ML#WVT-EL$JB_VJX,;W&P2:*@%#T(X3]>L/:NX46W8VGES MD[LYBR!,6PQ_$)*N3P`I+NO&^5Z%QP#=9M M7O"V7F2C0&Q%W3W9%@`W^;QK2\@1;\'B)=%#<7HI\F*_KV:;\MW=<-5PQZKY M;7/[]I-V]RW%[S.XE5M?85TV`W`I]FW]4ORQ/KWLCM5L7SQ#R.`NAGH[X;5: M_.%&PO=V]R:W-H965T&ULC)39CMHP%(;O*_4=+-]/G(0=$48#B':D5JJJ+M?&.4FLB>/( M-L/,V_+]^_6QRT>;(5@"-(:&Q&*^?:.6-65*"XC70+#9X4VBCN M<&E*9EL#/.]>4C5+XWC,%)<-#82YN86ABT(*V&BQ5]"X`#%0Z(I M<0M.DC9$@SU[)K;2AP]&YI]D M`YAL+),OP$[K)R]]S/T6OLRNWMYV!?AB2`X%W]?NJSY\!%E6#JL]PH!\7//\ M=0-68$(1$Z4C3Q*Z1@/X2Y3TG8$)X2_=_T'FKLKH8!R-)O$@03G9@75;Z9&4 MB+UU6OT,HN2("I#T"!F@^^-Y&J7343(:_Y_"@J,NP`UW?+DP^D"P:?!.VW+? M@LD(H65U+DDO%^J3P ME4!WO44,_-SBGY-^V"AO([JVE;^Z]5DQFO>3""2;H=B=>C(4^ MNWCV&QN\!O@F;:%7.8C"># MRW,<-\$YTD\G(Z'O2`8"],4FDV!*6$-=6V)T'L_*2F"^]U^B!]27[@W^RL< M[FX46'^`P]7R$CYS4\K&DAH*1,;1!*?)A/$,"Z?;KL5WVN%8=8\5?D4!&R.. M4%QH[4X+WW;]=WGY"P``__\#`%!+`P04``8`"````"$`(H0Z,UD#``!F"P`` M&0```'AL+W=OA*;!!:Y27+"*Q.8;X>;M[O.G[9$U3SPG M1!C`4/'8S(6H-[;-DYR4F%NL)A7$V--B04\-@>;UPW!J3I4%O9ZM?+M$M/* MU`R;9@D'RS*:D`>6/)>D$IJD(046$#_/:%.DIE$FFV^'BC5X7T#>K\C%R8E;/;56!_E)RY(//!L_9\4M#T^^T(E!M\$DZL&?L24*_ MI?(K.&S/3C\J!WXV1DHR_%R(7^SXE=!#+L!N#S*2B6W2MP?"$Z@HT%AK3S(E MK(``X-4HJ6P-J`A^5>]'FHH\-AW?\H*5@P!N[`D7CU12FD;RS`4K_VD0:JDT MR;HE@?>6!*VM=>@AS_^8Q=81J00?L,"[;<..!G0-:/(:RQY$&V!^/R-(16+O M)%@=@6`YV/"R!UBI.Q5RMKC*\J@B)_!7_O*T-PPYQE'SG0C9>K+@^-(W!1 MT/'K"#2FC<`+'"_J$:/G;+&++`[N$99@B?*P=1NC=$I>WYXWFXY_P>7:YG=\M`X@KG=&J,C6ZWQISL=AW/.=-H"/IZF/QE:86>:(?]X-".MZ`% MEJ/KQIJ>6>/I,C5=4<9FF[D7N6M1]8P;Q3VLZ-U7(.6.'[5 M8),_WK-6[TO:BH]&F^.=O^?HJN&FT..JO^.X'F^ZZD&$D-N'-Z[Z5>,-MJ1Y MXK-N&PTX+PR]J;;>E/0B4>,#^8&;`ZVX49`,?M)65@"E:_2>I!\$J]7BL&<" M]AOU,8=]EL!6L;(`G#$F3@]R$^LVY-U_````__\#`%!+`P04``8`"````"$` M[(VUYZX"``!;!P``&0```'AL+W=OA;%2UPD-@PDEHDYU)NLBH;]^WEVM*+&.UQFO="T2^BPL MO=Y^_+`Y:O-@2R$<`83:)K1TKHD9LVDI%+>!;D0-7W)M%'?P:@IF&R-XU@:I MBD63R8(I+FOJ$6)S"8;.E*B=!S&BX@[RMZ5L[`N:2B^!4]P\')JK M5*L&(/:RDNZY!:5$I?%]46O#]Q7H?@IG/'W!;E].X)5,C;8Z=P'`,9_HJ>8U M6S-`VFXR"0JP[,2(/*&[,+Y94[;=M/7Y+<71#IZ)+?7QLY'95UD+*#:T"1NP MU_H!7>\S-$$P.XF^:QOPW9!,Y/Q0N1_Z^$7(HG30[3D(0EUQ]GPK;`H%!9@@ MFB-2JBM(`*Y$29P,*`A_:N]'F;DRH1%,QEY8=R<1BI+T8)U6?_S'L(/PP5$7 M#/+H(YLO)-`2N=T"83Z35=U]4X74,,\#*EQ M3*/9"F?RG0YC8)M&7^C.,B2=1LOSBA=CVG\/$SJ/J3K+K#V"PU&!B7LK9SI; M!^^JP;@Q16<9JUF=5X,[^^*C@ZM_0[=1=B#M_99O&MW*^L_P&YK>"&^<5/( MVI)*Y``Y"9;0&>.WHW]QNH',84EI!]NM?2SA)R;@)$^PC;G6[N4%B%G_6]S^ M!0``__\#`%!+`P04``8`"````"$`F(S9([$$``"_$```&0```'AL+W=OROZQ]_6-Y8_=J<*6TM\%`U M*_O";(ZO+M(7;^N0TEYJFA\ZH+!S/=4.G3//*YAZB M^AD?['C,,[IGV;6D5>71GHKLV?KU\R5AY`19&W M'YU3VRJSZ-NI8G7Z4H#N=^*GF?3=W1CNRSRK6<..[03<.3Q04_/"63C@:;T\ MY*``TV[5]+BR-R1*2&`[ZV67H+]R>FL&GZWFS&X_U?GAE[RBD&VH$U;@A;%7 MI'X[(`3&CF&==!7XK;8.])A>B_9W=ON9YJ=S"^4.0!$*BPX?>]IDD%%P,_&Z M,#)60`#PWRIS7!J0D?2]N][R0WM>V=YL,@\"/YS/P,T+;=HD1Y^VE5V;EI5_ MUNQFP=('-)1.!$EH?GLB_8 MO]4+4HQ.-NAE9<]L"RK1P")[6T_]<.F\P<+(!&=K@%9EG9\']0 MFID:])9S`@BD)P4J9==3>F$&$AM(,D04;?!Z?((V]`(+%Y[2QVVN.TYZ**ZG M].(,)#:09(@HXN`EUL5-IQ-L5]_Y6J&C3I^,:\N10%4\UVK5DZ39WD!B`TF& MB"('VL)0SGCGEIT`R6K('(&0930[`]D;2&P@R1!1XH.V\WQ\2%;C$PAL.`:+ M:*&E5)`6O8C]B!F9:V8Q)WENUQ*]`/Y4OXD@=--*$87[GT%??IQT)*NB..(I MZR1PU8?O!,F_BS*0F"-^-^2[IIQPA(1HI82\^)Z0D:R&+)`YSY5+]`XDOA^4 MP$!BCHA\3Z>SA>8D$00SWP1V-L\GO&.KX0L(4H[CSW.)-O]VDC!(MPG%$@KX M%!V1(!@C!2`X#9]>-!U;T\#'*>EKH`V*G;09%,&$8@$]*(-DC-0!I^'S&OCL MA`D@F\N6<.A>![T[2L*P#L+F#L62)>O@A]IN)1&,L3K@V'M>`[*U.@BHKX/6 M5W8X\M!F6`<#B@5+UH',`BT7B62,U`&GVT`#WQAV0ZP]Y]GKED&WA.4RTICP M#1#;0CXBE?)P2.M,6FYW1+#N!=D+*+Q+C@4TX^T5MO*AZZLM+A&4L2+AO/O? M`OG05`0*"-ID/T_(5.O[.SP"Z07DD`]S[FYH3!1AZ,]X?R`S/]3:.A[GT+UO\```#_ M_P,`4$L#!!0`!@`(````(0#62NWI4@0``-4.```9````>&PO=V]R:W-H965T M&V_8VI_W?S\T^I.VA=ZP9A9H-#0M7UA[!H[ M#LTON,[HC%QQ`T].I*TS!K?MV:'7%F>%&%17CN>ZD5-G96-+A;A]1H.<3F6. M#R2_U;AA4J3%5<8@?GHIK[13J_-GY.JL?;E=O^2DOH+$L:Q*]BY$;:O.XV_G MAK39L0+?;RC(\DY;W!CR=9FWA)(3FX&<(P,U/2^=I0-*FU51@@.>=JO%I[6] M17&*?-O9K$2"_B[QG0Y^6_1"[K^T9?&];#!D&^K$*W`DY(53OQ4<@L&.,3H5 M%?B]M0I\RFX5^X/$H&K$O$6 M/RP2*!&X*A$T6X1A$"WFST<"3&$'KDKD:3>.S(Q(]"%CV6;5DKL%LQ>\TVO& MUP**(]OJ,BSST>?\OU(.N>8B6ZZRMN>V!=FD,$]>-X&[7#FO4-M<<78F!XT9 M^X[!"\EE#SJ0Z$`Z`!QPU-N"8GV"+:[";74![3K@X=/3/'2,;LA!!Q(=2`?` MR(/_*1ZX"LS[86F0.PYZ)SDA!-+7+QQ3]CVE-V8@B8&D0V3D#=;!)]2'J\#$ MA;?T<0=(FU4[2?K07$_IS1E(8B#I$!F9@_4Y-#?=K;JEP\G"0_?NG4)@$^M= M^8&VFO:*M.SGYF%B&%IHPQ))\ERQ1KT0_L9U3A5!M,"1*6@.SYOBY+$IB7C# M4OFA-@_WBA0\3!E((I%`;!RB2Z0201$?-0H9^M'S(7/R.&2%+&2N7*0O"?5\ M4`(#222B\NW[\Z4FDBJ"F6]^AADTYH\G$2>/@Y<(Y)LW8\]%T;C.>_5\D&H# M2102"HVIX"5A(O/+'PF>D\?!*Z3/_%P+7CT?9-Y`$HE\D'E%,#./X)SR?.H% M>QR^@A[)7VCQ=X1!]DTHZ:`N_T&DM;94,28*@/C&^/3T$6S-@]Q945\#K9/L MNS&#(IA0HJ"N#&@>:KE(.\9$'?C&./`@SR8S?F!BES)_V1'HCQ#FQ-+@TUZ= M3.3N*D^I`MHA"6F]2,OMOF,-:R0'1@_+B6+-94.%8V7D!N-BIXHR522^/?YO M@W*/'1E4$"S/?@=!OM;I]WS;Y.ONX>:@H``ZZF.@L8=TK+GL"V@>1%HCYQ\% M7-L;%%4>\N79L\;M&>]Q55$K)S=^@(]`JT?[CXNMQWNZAN_X1\<4[L5PE)K@ M^S&<0TQ\&\1;B--\L`MBV-L!=_HWPT?%-3OCW[+V7#;4JO`)8G;%5&SE9XF\ M8>0JIN21,/B<$#\O\/F(X3#KSF#>G@AAW0U_0?]!NOD7``#__P,`4$L#!!0` M!@`(````(0#:2'3V(`L``,LT```9````>&PO=V]R:W-H965T/W6OK>W$X;LO]7=NYZK9;Q7Y3/F[W MSW?M__XG_.NZW3J>UOO']6NY+^[:/XMC^^_[/_^X?2\/7X\O17%JD<+^>-=^ M.9W>_$[GN'DI=NOC5?E6[.G(4WG8K4_TY^&YNWM[\V MY>Z-)+YL7[>GGY5HN[7;^,GSOCRLO[S2=?]PO/5&:E=_@/QNNSF4Q_+I=$5R M'7ZB>,TWG9L.*=W?/F[I"EBSMP[%TUW[P?'SWK#=N;^M&NA_V^+]J'UO'5_* M]^BP?\?(^+[?/+ MB=+=IRMB%^8__@R*XX9:E&2N>GVFM"E?Z03H_]9NR[H&M%U=29GHM-Y5I=`GPV7<,9Q(!SI4X;\]*73.*J"TZ<,?G7= M[WN#ZR&=SYG@-\*1/F7PF\NNUZ%.PG/&>HO(QZ=/W)%)8U^$RJ!.VID3=UP9 MGKX(QQXUX3D7V=*.WM2JF2[L9LY01J8O(O)0:^WS,AW>\ZN!%*Q/Z_O;0_G> MHMF)^O;Q;\T>#?"9H0VCFDQEA9LI#+9P`83&X0VB&P0VR"Q06J#J0TR&\QL,+?!P@9+ M&ZQLD&N@0^FIZMOR-I3(8F M2PI3)\3K#JVL<:.S6:M-ZJP!F0`)@41`8B`)D!3(%$@&9`9D#F0!9`ED!237 MB9$U6D<866M>VLG;$+.NDB,;=<2)Z]:SWAA(P(E'=[\ZI6[7,U,ZJ8VD="C( M32T=@71<>^G2U@!.:B,IG8+T%*2SVDN7MCKBK#:2TG.07H#TLO92THYKW1M6 MM9&4SG5I(XFT\#&2R!<95VR1>'K9;KZ.2FIXNOLU)->EQ01?8C`1,[>&G<11(LOB99<$BV%:%.( MEET2;2:B>54),W`\MS>\-B]_#K$6$&MY2:S5Q[%R/9;1:RA#1J\Y/UR9M=D] M.-&'*Y``R`1(""0"$@-)@*1`ID`R(#,@H'ZVI($48!H@BA$%"&*$26(4D131!FB&:(YH@6B):(5HMQ`9BY8P:QO7IP? M!0ZOKVGI+F_/(X$H%VHN<[O6B!\K*^D8()H@"A%%B&)$":(4T111AFB&:(YH M@6B):(4H-Y"9'E8^?R(]O-HVTL.1,50`!6P/CZ8WS6J"*$04(8H1)8A21%-$ M&:(9HCFB!:(EHA6BW$!F+EA9_(E<\"K:R`5'^FJ;%<'4\!H*!/J@EE)6?-%HU%`@D%YQ(0JEHU9S2:3ZBU\;0;RP-E(DD#[:H01C MSX38TEQ=4"#0!T68L/J@"A-6>AF&$>.+(B8714PQXA0C9A=%G,F(O!KS7+?; MLW;EYAAN@>&6%X5;?1PN-\*9W8@5^'HW^F!(\_T`H[^(+0+5%<;LF9\]I`%- MT"I$%"&*$26(4D131!FB&:(YH@6B):(5HMQ`9BYHR'TF%\S0F0M62>OC@D^O\HGY MY0^8>45.`T:M#CR[4AO1/%HEB2J">@UA[;:/E8U<002()HA"1!&B&%&"*$4T M190AFB&:(UH@6B):(H-#;&,[`M?=QE86\FE"@GMY8(!TK1R[=]ZP2*5$64CHUI,V> MQ>IW?8HX?^OL\7)?OW5*1%-T/>SI'2ZSPHI275UOPSHD ME":J(HBDM@H72W0V7"*U>+C!S;4[N+$Z>BIMJGAF:[*B_!.MR6MXHS4YZNE3 MK>NX=FL**_4T)V`>;+FBT$0B]NCH^_W0[3G=H36J0F%#:RO962+III1B1(E$ M7-RCER_IGWF:J2%N-I1=.G_0[;!&I@NM%@YZ.EW'6J*.I97J!P&BB4`LKW47 MQJH4&KY:,V4T44$8_[%G3QIC>6K:FLD"@`=T/ZP9KN%=PQT'OWY\@ MAD+)Z*L0+[XH7B*M>+RF&CDUPO%&YF]4\Q=!=\7AN1@7KZ_'UJ;\QMZ6IO>6 M[F]KS%_E'CE=/Z=',31%PQ%ZRYN>`C0=Z=&17N.1:SI2K3(LM0?GQG^@,VY2 MNR&?JNM;/K0X]-G2#WUH7>>S51L>H?41^32=-2UOR*?I"+W._M!\-71B#3%& M=/F-]JZ?5Z/'NHX'SW]H;)21Y^?5+&8YT":SS_8G\?)HK]EG>Y)XA#:3Z6R; MCM!VH3^AC3+THH8TY.H.F([2+3VI-#1`['AUI.C?: MP/?91B_&H7U\G^WWXA':SJ=S:SI"^_4^V^I%G[SOY]4ZQ&KI8.C3RRIH'P]] M>OD$>3;TZ642Y,NAOVKB(SHCMN>.'F,ZPK;>\0@];*%\-1VAIRD^VW5''WJH MXD>-1]*^3V\KH<>T[],[2\@S2GP3G_=]>EL)[1=]G]Y90KZD;M+$1WU_U,3' M?7_BV>:/+L5@7>@?\8A?]Q*M^H@J,?E)0G^A%)]?6%?C14T-MHW2NZ9SZ5 MY4G^P0+4/T.Z_P<``/__`P!02P,$%``&``@````A`.\;7@4F!```H!```!D` M``!X;"]W;W)K&ULE%C?;Z,X$'Y?Z?X'Q/N&&">D MB9*LVJMZN]*>=#K=CV<*3H(*.,).T_[W.V,#Q<:D\)*6R7B^^6;&'W:VW]Z* MW'MEE_,^%_V__V97OE MU8LX,28]B%"*G7^2\KP)`I&<6!&+&3^S$KXY\*J()3Q6QT"<*Q:G:E&1!^%\ M'@5%G)6^CK"IQL3@AT.6L$>>7`I62AVD8GDL(7]QRLZBB58D8\(5'&&$,]9GLEW%=3WBF3SXUCR*G[.@?<;6<1)$UL]],(765)QP0]R!N$"G6B? M\SI8!Q!IOTTS8(!E]RIVV/GW9/-`0S_8;U6!_LO8573^]\2)7_^HLO1G5C*H M-O0)._#,^0NZ_DC1!(N#WNHGU8&_*B]EA_B2R[_Y]3O+CB<)[5X"(R2V2=\? MF4B@HA!F%BXQ4L)S2``^O2+#T8"*Q&\[/P3@+)6GG4^CV7(UIP3]!N\Q3G&Z2$;"-SDI".T60XE"=EA MD'N,LO-7O@?X`BK[NJ=TO@U>H1I)[?.@?>"S]2&M1P#9M"E!&MV4W.5ID-$9 MD;%WH;#1>#7(4'I!PV=@?99='R6[@S`93Q1=(8F MF=!VC;73"&@8F/'0Z*R@VR)K2P1_VF92.E#G:`H4.IM0VA)%:HJ[8P+3UJ6@ M)I?M@EWKM6GQF1RB@8:A7N[`WQ[\`AZ6YQJ MDX,3)-\-C8U:ST?L)'Q[V2BUR>2T&N`T21M(7QQJ4W37'SY+'CXI5U\32"T* ML&$[&G!A>?SH*6^34V/J1C%22VT4)SZ,'!P@.O?%$ZU&%!\^]1G_[X^Z/N@ MOG05K#JRWUF>"R_A%[SKA7!;:JWM/?1>74-M^V)SK^^G0?L-W`_/\9']&5?' MK!1>S@X04[^Z*WW#U`^2GZ$L<$OD$FZ&ZM\3_!+`X,8TQ[/+@7/9/.#)M/UM M8?\+``#__P,`4$L#!!0`!@`(````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`/]%+O. MK]CUV8Y^BMW5L-?+^L,SACY@$?K)(MWAV?-'&7T8`?UDD?ZO#&#$9O13VNY' MTWYBRA(*5A\[+FHY+LX??-*&(/U%9#I1%WXQ"!.)0O<7T4DCG5-#D>!+0O2- M@@=.64K`)5'$I<'T5SLO<91$@10EXJD>2/0D(7R2+/0`3:_]&G!84J:WK[/EVZU;]Y":A.)+%Q$NTR\M;JPLM*T[EHY-Y?TF]H87CA9;$ M/SZDH^S=]1^TC-TQ9XR<1#,FPG!KEI.=6B"W0&&!F05*"U06J"W06&!N@84% MEA9866!M@8T%MA%P3>YI?43!_4_XR,DX'\GLC@4(3NL:APA#3*86R"U06&!F M@=("E05J"S06F%M@88&E!5866%M@8X%M!"B'T(KQ3SC$R=#FJY*FISTP]IP> M]:3-+$.9M)362X#D@!2`S``I`:D`J0%I`)D#L@!D"<@*D#4@&T"V,:*<1HOU M/^$T)T.+)373.B0=]8W7/.FDUUI*ZS5`LR( M4Y$-*QF8#6O"I+!B3CW2C?>Y9&#R,6])TEK!0OUVZ9V!=-E:Q3TR<56U))&N M0;H!Z7EK%4L/=,@N6I)(+T%Z!=+KUBJ6'FKI34L2Z6TLK=Q-1R'E[B-NI5.] M^-6QM5\9H8-,Y->1[L^$2:/6'5-`S3#+J=^B/EBF8XN]%[K@R`YD2 MD$H+]P9I;V1<48-P`S)S0!9L%>\4R=#T>0G2*Q!:`[)A*YZ,S-T5]5QL8UWE M4$J5,QSJV-JA'NG&RVTRM.=&)AWNW/[@"$C.B`N>/S[T^L,C#O44.HY+G,Y` MI@2D4L)I?Y#U,K.0U"#<@,P@L@9DHW3[:39*S**WC765/ZD*<(8_'5O[ MTR,F0\WZ,&%2E*&`Y(QP4*:](QGJ*7&&@DP)2,7(R42J0;H!H3D@"T9\GP>C M),FL/T%W!2IK0#9*M]<;4GW)K+BQKO*GJ]$HA_[=*[W3.;@ZK#^IW:O&A];> M7YX\Z@:.+*Q3A'*$"H1F")4(50C5"#4(S1%:(+1$:(70&J$-0EL%:4>Z>@#6 M9LX\^[I:F\E8AD9IN]%-$)HBE(M66$\+AH9T@(]V*;.9S`)+(J!$J$*H1JA! M:*X@/8?N"O__GT.GHE<]5W$D2,TA0%-DY0Q1EV4J"H:&?A7I=A*S>LX"06Q* MA"I4K@/+G7I(V>RS32"(\EQ!>C+=W3J>S-.GT.SR\V#$#6GI]S=(<^8"J2';=:;%;.B8:\9BOJU$8BVQ78*LX[9\+?, M\L/60>%NB'%0_&1WYTMH['V^8P9H0GT^+*@!FC)$%5R9AAQ9A;#"XCP35JC/ ME,BJA!5:K)'5""MHS9&U$%;06@HK]'Z%K+6P0N\WP@HM;A5+^\+=[L[P!5\& M0S_'B8?(SR$:Z/RGDV#"+.J(^&+*T&AP*)311QOV")"C41%:$YT90UR>Z8YZ M288[6]M),:M0O$;Q1L2[ATYVKGIF\YBCS0*5EPSQ6+-DV(?4XYD-$[1&Z0U# M=%)SQVPSR5MEH-Q,DW..FP]T?0UAB(XBL9M-TD^8134:F>` M'(V*T)KHS(0E59M.FIG+7XE6E5B%#M7(:H35/_31[")S-%B(09!=,L3CS)*1 MK6"LT&B-TAMA^;Y8%RL#[6)[B3^]JG;QMLZ0R603\!,Q#($Z94BBF\II)BYR M-"I":\'%OD\TQD-T]P<]NY>B4872-;(:ACAQP,.^X6B+7J#LDB$9)EYR5VBT M9BB2WC#T1A(K`^UA=^W_];7:7>?\X5,R026+S(<*$62J)N>+@DYC..'WC MF1R-BM":=&`F+)_$1PJO)1I58A22K496(RR?-_TKL\K,T60A)D%XR5";Q<.A M.1JNT&B-TAMAO9'%?CK]O4[[V-4:SO"Q+TW$]WM7'R>WFRPV$3]A5KP?,^1Z MWA[KNATS_!P-B]!B\+/O!&=R1I\3#&&Q;OLI5A5JUZC=,$3]/'S`=F6&-D>3 M!0HO&0K);.O>*S1:H_2&(>X-+-?Q(+6CSROD=+&0PY!)9C/-$V91-V6:IPQ) MC'RJ)V=DLR^VJ&SVD,EF,\\3 M]_RQ6^K#;$P9DOCN#+NP)X-1P4;19C5C2/9D>@*?_NC#?8EF%4-1CVID-2+N M4]GL0W,T6*#LDB$9:#*R=:85&JU1>L/06XG<^H'"7_O858;.\+$O)"D?>\@D MLKD@3%RID'RL$ME#$M['?`Q&!>M$X3T3:9_(??IC%H02C2HQ"NE6(ZL1EL\< M\'`[XX+]N3$ MI-&$65'.3!F2X*8O/9@IS-&H"*W)K,X8.IW%;2?%K$+Q&L4;$><-62\..7""[$(,XCSU+ M!MI-[25BA49K[,M&6&_D<=P7[6-78CG#QUR1"2,8=]LR4G1$MA]U3IBE\M@; M2G@GW^J*77@Q4:K1F*CAT;AM[*X[@ORL?I>86N`UT7NA@R>6S.C1-FQ7DL$.TC MX?Z4V/5:6"&JBM"B.&PF+)_+]#VU).W83S=*M*O$+JC7R&J$Q0E$7][3/IJC MS4)L@O*2(*I7WA*AJ_OK:FO@`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`9OO#%!.6+MKX0)YQ9PB>I9ZF$8XAB-MP/[9,J M.1H6#$6A.!.63[I!1H5!D_(E6E5B%7*C1E8C+-U/D]-S-%R(89!?"J2US)%S M):Q@N$;YC;!X,=`IO%4&VN6N6'"&RWUM0;F>U M(L,2615JU%36,%PC?(;8?GT,RF\50;:Y:[B$>]^ M?_.K%!G75V+'9_;;^6-FG?PJ1>"$X/#B9"90CJP"H1E")4(50C5"#4)SA!8( M+1%:(;1&:(/05D':D>Y"CXX\\ZL4F2\+Q*<;@<):.D%HRE#T/8"J)<^2">J-,?U[MO;[AG9T+ZC1F* M3@\3A*8,10M3+JSPZ'V!K)FP0HLELBIA!:U:L?28:8DY9\R.;L;L(7)5M+"G M9IN?9&P8O#=E2!G"%_YR9G'AM9_8YPJ+("-+P`P;*P,K]!(:JW[66!UDJ#$] MD>XJ?$;P\"T\N'*<>4@?4%.S8$^8%878-!C*#.3"XMJ*>V^F\4B!5C.Q"ITJ MD54)RVMG2<^6;6IEI&?)767/F"5_\U4IYB$5-5W[:I!)QH9QN+6&898\U#[< M`H\O%:RCUB&0+I%5,?2V=*V,]"2Y:UT[273Q^[I$'V#+D)K8C1#Z1)9E;"\-#W58:5K9:0FJ:T&B&TB6R*BV=N;<"Z?FOE9&> M)'6%^ODDX16JYR$=29GIP819<20%PS!)7DLBJ4>';R-4H-4,M4MD5<+RH=0= MTHMNC7:MK/0TJ=L-39,_ZIYY0G)G5[,W,J1#+#,5L8D8QB'FM>)#$[/H^')X M>CVE%YW8(1:A/9GT&8J7#$7BE8C3D:8M,68=4YJHE;R>0759^'F@M7<"Z>>X MQU#G\&;IPR<$$\946'E:?'825CCO%`Q%K)FPPBI9(JL25M"J%4L/6AVL_W;8 MX,&:7LWM(FE`^=)ZHYO94A6SXJ?%Q)"BIS6$4T[.+-JE723UDRR%ER@4HA1> M]C##]DIAG6ROTNUE:=KI0F3QB`_-^4GV+Q?W;P)^W#U_V4UV#P\O%W?[[^[% MX?1@_8=W+2QO->___\;K_1@<,>CW]_I5> M27_XZU?Z7Q#LZ+6+]/7?RXO/^_VK_(,Z>]W^3PT^_)\`````__\#`%!+`P04 M``8`"````"$`0Z_N=F8"``#&!0``&0```'AL+W=O6CZLD#&"OU4-$TF5$"@]"U'-J*_OIY<_:)$NOX M4/->#U#1)[#TF M978TP.MP2?4LF\W.F>)RH)&A-*=PZ*:1`JZUV"H87"0QT'.'_FTG1WM@4^(4 M.L7-_78\$UJ-2+&1O71/@902)W;T(!OAM20\.WO?NA=U]!MIW#:B\P(!]763]= M@Q684*1)LF!#Z!X-X$J4])V!">&/X;F3M>LJFA7)HICE*<+)!JR[D9Z2$K&U M3JL_$91Z4Q-)MB?!YYXD/S^5A$5#(;YK[OAJ:?2.8,^@I!VY[\"T1.+W`T(3 M'KOVX(H6E*!7BT5X6.5%NF0/F#FQQUQ%#*X3YAG!4'121K73E3W8*_M\>"M7 M\>!8)IN,O)#)_T?&@RN*ZV0^+YYYHW+$S(\PB_>5$7)Z@!Z,-7@I_9RY*!U! M)TAC4QU+^W:=+Y+BGQU[*+"_%UQ,>=Z?'&OF1?XJX#@WL:\4F!8^0]];(O36 MST2&G3*=3N.ZSGPQ7Y_/RW68'S9]P#$:>0MWW+1RL*2'!BEG(183!S%NG!Y# M-V^TPP$*KQW^+P&;999@%(W6[K!!83;]@5=_`0``__\#`%!+`P04``8`"``` M`"$`@-1VQ6E?'.I3>3W^7K;C/V]^_^WJM6Z^M,]EV8W`X=1>CY^[[NQ.I^WN MN3P6[:0^ER?XRV/='(L.OC9/T_;]>-C MM2N]>O=R+$\=-VG*0]%!_]OGZMRBVW'W&;MCT7QY.?^QJX]GL'BH#E7WO3<= MCXX[-WHZU4WQ<(!Q?[,6Q0Z]^R_$_ECMFKJM'[L)V$UY1^F8-]/-%)QNKO85 MC("%?=24C]?C6\O-;6L\O;GJ`_2_JGQME=]'[7/]NFVJ?5J=2H@VY(EEX*&N MOS!IM&<(&D])ZZ#/P%_-:%\^%B^'[C_U:UA63\\=I'L)(V(#<_??O;+=043! M9F(OF=.N/D`'X.?H6+'2@(@4W_K/UVK?/5^/[?7$62X7*V<--@]EVP45\QR/ M=B]M5Q__SU7]D`876[C`)[IL)LOU;&[!12\UG(N&\"D:6NN)M9BM/FBW$.W@ M4[2;3Q;V^,2&JT_U="4:PB<.48G3A=BL14.8<3\TQ(UH!Y_8 M4QCMA0M94#P\EY"L'[J4A?ECO^#%/A=/"S/(?A%-G4\%U,(\ M=ONIX!5=<7/5U*\C6%]@O.VY8*N5Y3(WG`0\6,.T>&]6P'1@+K?,YGH,^8)Z M;V$J?[V9+^VKZ5>8?CNAN:,:2U?#9(@P(3XA M`2%;0D)"(D)B0A)"4D(R0G*5:,&&Q>!7!)O9P.("EQD"29<&+KH8[4$R1)L0 MGY"`D"TA(2$1(3$A"2$I(1DAN4JT:,--E43;MB?#%N#3*S$SZN.-<;KCQ(&[ MKY*!N5',@PB;>83XA`2$;`D)"8D(B0E)"$D)R0C)5:*%%P:OA??M/1[>S9A: MCR$G$$,,SSTA'B$^(0$A6T)"0B)"8D(20E)",D)RE6@!@UNY%C"^+YBPC6WW M7.V^W-503'#3>R.0<[C_\UT!,]'C*,A"QE$0OBGN;_J<.#!5E'I=Z/7J#R), M2$#(EI"0D(B0F)"$D)20C)!<)5IHV?F1;KE^,+3,1`^M($IH!5%"RXG#DBCW M:<9]S1]$0V@)V1+K<-"HUBL]:]$@0NN8D(18IX-&M39NV-D@0NM<)5H"X%B@ M)>"-&H8S%!8Q4^N1%D2)M"!*I#EQY([-)R0@9$M\0J%QA@D3$1(3DA"?5&AD M?S)"T$>5 MOODP5`&JM`7',CJQI9T(L:$MDR/08MV?@1:.;2TWEG'!&-O)`DJH>XJJBT/, M4*4-<373`Y&CZKTAZMEF9QFR0,%17RS]?]=GR*+X\JG[@,4<4(D9Q.,2)9 MI(E`2N]35$FO#)'TRA'U7GINV-%(SN:;2X\>..VK\?FXE8RY&/7-DU+-Y M)F?'(&BH5(0GT!H6WZ$LWUC)>$,'%N)!-5\9F_@`O3XH<=*)$!MNAJ*(!%K9 M%UZR\V2(F5`90S3V?3EZO3=$/=OLN'4IV[B4?3"+F(V1 M;HZT6214,A8>>Z`&#;59Q)$VBXAJ*QI:TBND7I%`BE=,50GU2JDJHUZYIM+C MRLY9E^+ZN;L"TK.PRD74%\B!U5N9'\;.-L"&,JQ; M@13[$%72/D(DU^@8D?1*J%>**NF5(9)>.:+>2X\T.Z#]^TCS8Q[,'0SKG<61 M5L!")4?D"94CUWP?$DEB;2PE_>/K6BHU317*?:14"T@Q8J]<8Z(A4J9 M6`FU3P52[#-$>N^-K4*NV>OY8*,54EJ))>*55EJ))>N:;2X\<.96K\?N[^RUR,E8.C MCTX2HJ$,JP?UV"\F%[?9/JJTNED991F@"A9T6;ST)$$Z$6)#.<\B@<1)PG;F MEK6:&?N)&-O):98(!!\XUU-471QBABI]B&1JB'"]-T0]V^Q$2;+]KTX2_(RJ M32B.C)T7.4EPE3;'1$-9N+XE$,P^F<"5<48(4`6AD"J:9G+%$!O**T:(Y-T@ M1B0SF`BD]#Y%E?3*$$FO'%'OI>7&-L_TEU>R7JY/.8'46PBJ9-<]5,D2]052 M]BT!56VI5TA5$?6*J2JA7BE59=0KUU1Z_-A!D=3V\@403H=;G$:2=";*B<)`02)XEW5C)L)RLG MH>XIJBX.,1,J?8AK\YD(>KTW1)YM_O8(_Y?YL6R>ROOR<&A'N_J%O1D"&[>; MJP$/KZW<]NNXP>_@=9;^T&UR&UYS88NUR>PM]IW^X6[CP_Z4W M^-*%?XR\P5ZX09\>HZ.AX\)C7*I/'1>>P5+N;5QX]$EY MN''A42;EZ<:%1Y/`I\.%X36<<_%49D7S5)W:T:%\A&3,^KG7\!=Y^)=./*IZ MJ#MX_P;R!2\XP`M7);Q;,&//LQ[KNL,O[`+#*UPW_P```/__`P!02P,$%``& M``@````A`*S>PQSI!0```1D``!D```!X;"]W;W)K&ULK%E;CZLV$'ZOU/^`>#\AAB20*,D1%VU[I!ZIJGIY9HF3H`T0`7LY_[Z? M,1C;N.E)VI?=S7AF_,TWXQG'N_W\45RL-UHW>57N;#*;VQ8ML^J0EZ>=_S/^Q]_V+Y7]4MSIK2UX*%L=O:Y;:\;QVFR,RW2 M9E9=:8F58U47:8N/]VMS#IOX>']7QF&MS9 M(=DDKF\[^VU'T)\Y?6^DOZWF7+W_5.>'7_*2@FWDB67@N:I>F.J7`Q/!V)E8 M/W49^+6V#O28OE[:WZKWGVE^.K=(]Q(1L<`VAV\);3(P"CA^O^>']KRSO=5LZ<\]`G7KF3;M4\Y4E2#9P#$+S`,]'(8(]9\B18C,2(#UO>\]?;)TW4)KU.M%4AZ@:\:#!^&-N$TG@`*\`[4Y!LVS<"9IY M8:"'[:)!,$;A:@@'C<$DD00*0F^*D-%JKI>!168$^A46ERJ"B.LLL:^@6E.) MA8I`*4L4F,BXGOT'B&1>4#\R<++4J(NXTDW@0D4`ER4*<&1[`IRXL_N+@#GJ ML`][1EP2K"2&/7^EIB$62H-9(DL4J'`D0[U=`DQ9A<,ERZX_=:&$S46MZSQ0=\R+ M5G>>'X@=.[8BKG2S[H2*2*8L48`C.AVX'\Q\)/_.YL,ZV:>1YTAH$01J>A9:]?1SPF;[_?FFO`I@0B&?:->I&8[F`Q$;@BMP3`9 M#2%2`;,NKP-^`"P?%AK=>C=GRZC?VW0+G1&]+%+1LU:OH7B$SPR%;"Y2 MR"9+K5'$O:%"MC"H%T'8R*T1L"R2`7,AHL.&.'=V70)GU%:;6OWIZC7NDUW M/_]MT27'N1'H]Y7>$%HCV\)P4MQLIDSP MWL\V'TT:V^.-@,]GPK5NLRUT1O2R2&';U>8>N_0L'ZKMSI,Z$WN1QK;>2D8M M@5<1J7C_GS'I&L>D=G^(>JV;;(\Z(WKN'&9ZK;B&,?G8C:CSI+$MYI]4VVMM M],>]H=RX%9'*-IM`4FW?OA6Y?%[)YZT7R;>BJ2A11"H`PZ!;/=(+W.F@ZT7J M=Y>U?JL8M<;\[OO.S6I-UW>Y$&5KMHQ*/6");[,H%E M`T0#^\!4=OD<4AO76I_*O=;MH\0]\7/#WS1&L\E1,@RYAZY`>`F;D,U%RDPF M*ZT7Q[VA726%GURE[`O"7>?X2X?YYS5YL0SN%" M6XFPDH`2TXH_O.EI-J%+X*U[9M-6T-Y@T\VXR8J+E:Y]358\K'17\\G*`BL+ M([8E5DP(0N)O0@Q;0SQ827"U,*T$6#'9A&2-2+O;OXX-*PE&I\&;.PYR3[@P&@3DB6\&3.'E03'SH"-(-M&FS"`,Q/H"-R8J(D0OS%\ M@O"-GD*"LL'7)Q,LE`V^"9I64#9&&[PXAV9?,#!Y8O5GDH-Y4_&%BTUH+!;D MPYA"<-Y1[H@,X@'ZFI[HU[0^Y65C7>@1QW/>/5;4_`F;?VBK*\8NGJ&K%D_/ MW9]G_*N!X@5VSNZHQZIJAP^@R!'_O-C_#0``__\#`%!+`P04``8`"````"$` M?%<:^3$!``!``@``$0`(`61O8U!R;W!S+V-O&UL(*($`2B@``$````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M````````````````````````````````````G)%!3\,@&(;O)OZ'AGL+=,8H M:5FB9B>7F#BC\8;P;2,62@#M]N^E75=G].21O"\/S_=1S7>FR3[!!]W:&M&" MH`RL;)6VFQH]K1;Y%'GSKP$<-(4LD&YAT M-=K&Z!C&06[!B%"DADWANO5&Q'3T&^R$?!<;P"4AE]A`%$I$@7M@[B8B&I%* M3DCWX9L!H"2&!@S8&#`M*/[N1O`F_'EA2$Z:1L>]2S.-NJ=L)0_AU-X%/16[ MKBNZV:"1_"E^6=X_#J/FVO:[DH!XOY]&A+A,JUQK4#=[OGOS31;"ML*_LTK) MP8Y)#R*"RM)[[&!W3)YGMW>K!>(EH1@&07^ M33P"^.#]\\_Y%P```/__`P!02P,$%``&``@````A`(-3PHSW`@``(@D``!`` M"`%D;V-0&UL(*($`2B@``$````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M````````````````G%;1;MHP%'V?M']`>6]#"YJF*J1R@X%L)&&Q0]6]6&XP M)6I(D.VB=E^_&S(@K":J^F;[GGM\[CV.;IS;UW7>V0JILK(86%>77:LCBK1< M9,73P$KHZ.*[U5&:%PN>EX486&]"6;?NUR_.3)8;(74F5`WK;O>;+5ZU*!9B<;$Y$%HU MX\U6?Y9T4::5/C6G;QL0[#IHL\FSE&NHT@VR5):J7.H.?DU%[MC-H`/JB$A? M9*;?W*YC-[<.27DN/"!VESQ7PK&/!\Y$\*II,YY)Y3I;?;,5J2YE1V5_H&W7 M5N>1*U')&5A;+C->:)!5P>K-;IUOE);N?2F?U4H(K1P;`/7A;MG$-M=9W^WU M=PA8G2(KAEH)!$XUTDSG0D7+&9?:(+G7;VK>J:@5UX+V+C)X&PP7&OK%_*)V M.RN;R@\UW*$I"CW,R`1C2CX`82`-'LI*:/`.C#HP58VK91"**`YP2`F+1BR: MX1A1/PK-[.?`]3T?X/<0F;#1-+HW\R-&DB!`\4.EA?CCT!_Y'@HI0YX7)4;^ M.Q;B^SH>4C\&'&Q,F;`96`J&&J,^](N"4$(8>`U/"<5FFA_@Q1V!Y@`5P_.SA(A% M\1B%_N_=NV&5Q(:)1@U&`QCEC_`Y&1/.^K!+,J8GG+UB9SK3^3TC#GGC:B:\(D4T?RCF:XYOI,W" M=R@6!*+/>9]H/H;F->_/.Y5_[+;Z\*@;YPY]O'GQOT+ M``#__P,`4$L!`BT`%``&``@````A`!HS&57:`0``,18``!,````````````` M`````````%M#;VYT96YT7U1Y<&5S72YX;6Q02P$"+0`4``8`"````"$`M54P M(_4```!,`@``"P`````````````````3!```7W)E;',O+G)E;'-02P$"+0`4 M``8`"````"$`_GO?E-(!```<%0``&@`````````````````Y!P``>&PO7W)E M;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"+0`4``8`"````"$`<]PQ?(8#``#; M"@``#P````````````````!+"@``>&PO=V]R:V)O;VLN>&UL4$L!`BT`%``& M``@````A`%W^%RBQ!```"A$``!@`````````````````_@T``'AL+W=O&UL4$L! M`BT`%``&``@````A`,/Y:^]_`@``W04``!D`````````````````!!8``'AL M+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A M`&>0+)&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`$>*0"``!R!@``&0````````````````!W.``` M>&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`*_I8;(2!@``8AD``!@````````````` M````O#X``'AL+W=OF%R;3@,```L+```8``````````````````1%``!X;"]W;W)K&PO&PO&UL4$L!`BT`%``&``@````A`-],6&^(`@`` MYP4``!D`````````````````$K,``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`$PS M0]"A`@``>08``!D`````````````````R;D``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`/&K!'+$#@``*4\``!D` M````````````````.L@``'AL+W=O&PO M=V]R:W-H965T&UL4$L!`BT`%``&``@````A`)SA#%AF`@`` MH04``!@`````````````````>`@!`'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`-8]$72``@``W`4``!@````````````` M````YA@!`'AL+W=O&UL4$L!`BT`%``&``@````A`.R-M>>N`@``6P<``!D````` M````````````+!\!`'AL+W=O&PO=V]R M:W-H965T&UL M4$L!`BT`%``&``@````A`-I(=/8@"P``RS0``!D`````````````````@BL! M`'AL+W=O M!28$``"@$```&0````````````````#9-@$`>&PO=V]R:W-H965T&UL4$L!`BT`%``&``@` M```A`$.O[G9F`@``Q@4``!D`````````````````,D\!`'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`'Q7&ODQ`0`` M0`(``!$`````````````````O6`!`&1O8U!R;W!S+V-O&UL4$L!`BT` M%``&``@````A`(-3PHSW`@``(@D``!``````````````````)6,!`&1O8U!R A;W!S+V%P<"YX;6Q02P4&`````"L`*P"?"P``4F XML 11 R33.htm IDEA: XBRL DOCUMENT v2.4.0.8

I. NET LOSS PER SHARE (Details) (USD $)
3 Months Ended

Dec. 31, 2013

Dec. 31, 2012

I. Net Loss Per Share Details

Net loss – available to common shareholders $ (5,451,865) $ (2,310,246)

Less: Gain on derivative instruments (1,610,817) (2,746,198)

Net loss - diluted $ (7,062,652) $ (5,056,444)

Weighted average number of shares - basic and diluted 48,215,919 28,311,602

Earnings per share - basic $ (0.11) $ (0.08)

Earnings per share - diluted $ (0.15) $ (0.18)

X

- Details

Name: CVM_I.EarningsPerShareDetailsAbstract

Namespace Prefix: CVM_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: CVM_LessGainOnDerivativeInstruments

Namespace Prefix: CVM_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 55

-Paragraph 52

-URI http://asc.fasb.org/extlink&oid=32703322&loc=d3e4984-109258

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.23)

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 18

-Article 7

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 20

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 21

-Article 9

+ Details

Name: us-gaap_EarningsPerShareBasic

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 18

-Article 7

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 20

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 21

-Article 9

+ Details

Name: us-gaap_EarningsPerShareDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1377-109256

+ Details

Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Net Income or Loss Available to Common Stockholders plus adjustments resulting from the assumption that dilutive convertible securities were converted, options or warrants were exercised, or that other shares were issued upon the satisfaction of certain conditions.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1505-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1377-109256

+ Details

Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).

+ References

No definition available.

+ Details

Name: us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 R25.htm IDEA: XBRL DOCUMENT v2.4.0.8

C. STOCKHOLDERS EQUITY (Details 3) (USD $)

Dec. 31, 2013

Sep. 30, 2013

C. Stockholders Equity Details 3

Series A through E $ 6,106 $ 6,106

Series N 531,255 41,501

Series F and G warrants 12,667 12,667

Series H warrants 12,000 36,000

Series Q warrants 24,000 48,000

Series R warrants 157,500 288,750

Series S warrants 5,339,750

Total derivative liabilities $ 6,143,278 $ 433,024

X

- Details

Name: CVM_FairvalueofDerivativesLiabilitiesWarrantsAndOtherOptionsDetails1Abstract

Namespace Prefix: CVM_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Custom Element.

+ References

No definition available.

+ Details

Name: CVM_FairvalueofSeriesAthruEWarrants

Namespace Prefix: CVM_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Custom Element.

+ References

No definition available.

+ Details

Name: CVM_FairvalueofSeriesFandGWarrants

Namespace Prefix: CVM_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Custom Element.

+ References

No definition available.

+ Details

Name: CVM_FairvalueofSeriesHWarrants

Namespace Prefix: CVM_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Custom Element.

+ References

No definition available.

+ Details

Name: CVM_FairvalueofSeriesNWarrants

Namespace Prefix: CVM_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Custom Element.

+ References

No definition available.

+ Details

Name: CVM_FairvalueofSeriesQWarrants

Namespace Prefix: CVM_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Custom Element.

+ References

No definition available.

+ Details

Name: CVM_FairValueOfSeriesRWarrants

Namespace Prefix: CVM_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: CVM_SeriesSWarrants

Namespace Prefix: CVM_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Custom Element.

+ References

No definition available.

+ Details

Name: CVM_TotalFairvalueofDerivativeLiabilities

Namespace Prefix: CVM_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 14 R9.htm IDEA: XBRL DOCUMENT v2.4.0.8

C. STOCKHOLDERS EQUITY
3 Months Ended

Dec. 31, 2013

Notes to Financial Statements

C. STOCKHOLDERS' EQUITY
Stock options, stock bonuses and compensation granted by the Company as of December 31, 2013 are as follows:

Name of Plan Total Shares Reserved Under Plans Shares Reserved for Outstanding Options Shares Issued as Stock Bonus Remaining Options/Shares Under Plans

Incentive Stock Option Plans 1,960,000 1,573,597 N/A 145,703

Non-Qualified Stock Option Plans 5,680,000 3,674,544 N/A 1,443,537

Stock Bonus Plans 1,594,000 N/A 958,325 634,919

Stock Compensation Plan 1,350,000 N/A 791,145 558,855

There were zero and 1,437,466 options granted to employees and directors during the three months ended December 31, 2013 and 2012, respectively.

In December 2012, the Company offered employees and directors holding options that expire on April 1, 2013 the opportunity to forfeit these options and have new options issued with an expiration date of December 17, 2017. All twelve employees and directors eligible for this offer accepted the terms. This resulted in the cancellation of 387,466 options priced at $2.20 per share and the concurrent issuance of the same number of options at $2.80 per share. In accordance with ASC 718, the Company recorded the incremental compensation cost of the options. The incremental compensation cost is the excess of the fair value of the replacement award over the fair value of the cancelled award at the cancellation date. At the cancellation date, the incremental compensation cost was $477,879.

Stock-Based Compensation Expense

Three Months Ended December 31,

2013 2012

Employees $ 510,278 $ 966,585

Non-employees $ 214,720 $ 107,818

At December 31, 2013 and September 30, 2013, respectively, non-employee stock compensation expense excluded $55,362 and $57,553 of prepaid consulting expenses.

Derivative Liabilities, Warrants and Other Options

Below is a chart showing the derivative liabilities, warrants and other options outstanding at December 31, 2013:

Warrant Issue Date Shares Issuable upon Exercise of Warrant Exercise Price Expiration Date Reference

Series N 8/18/08 2,951,420 0.53 8/18/14 1

Series A 6/24/09 130,347 5.00 12/24/14 1

Schleuning (Series A) 7/8/09 16,750 5.00 1/8/15 1

Series B 9/4/09 50,000 6.80 9/4/14 1

Series C 8/20/09 – 8/26/09 463,487 5.50 2/20/15 1

Series E 9/21/09 71,428 17.50 8/12/14 1

Series F 10/6/11 1,200,000 4.00 10/6/14 1

Series G 10/6/11 66,667 4.00 8/12/14 1

Series H 1/26/12 1,200,000 5.00 8/1/15 1

Series Q 6/21/12 1,200,000 5.00 12/22/15 1

Series R 12/6/12 2,625,000 4.00 12/6/16 1

Series S 10/11/13-12/24/13 25,713,095 1.25 10/11/18 1

Series L 4/18/07 25,000 7.50 4/17/14 2

Series L (repriced) 4/18/07 70,000 2.50 4/2/15 2

Series M (modified) 4/18/07 500,000 1.00 4/20/14 2

Series P 2/10/12 590,001 4.50 3/6/17 3

Private Investors 7/18/05-6/30/09 740,938 5.60-8.20 1/26/14 - 7/18/14 4

Warrants held by Officer and Director 6/24/09-7/6/09 349,754 4.00 – 5.00 12/24/14 – 1/6/15 5

Consultants 2/15/05-10/28/13 200,750 0.85-20.00 5/20/14 - 12/27/17 6

1. Derivative Liabilities

See below for details of the balances of derivative instruments at December 31, 2013 and September 30, 2013.

December 31,

2013

September 30,

2013

Series A through E warrants $ 6,106 $ 6,106

Series N warrants 531,255 41,501

Series F and G warrants 12,667 12,667

Series H warrants 12,000 36,000

Series Q warrants 24,000 48,000

Series R warrants 157,500 288,750

Series S warrants 5,339,750 -

Total derivative liabilities $ 6,143,278 $ 433,024

The Company reviews all outstanding warrants in accordance with the requirements of ASC 815. This topic provides that an entity should use a two-step approach to evaluate whether an equity-linked financial instrument (or embedded feature) is indexed to its own stock, including evaluating the instrument’s contingent exercise and settlement provisions. The warrant agreements provide for adjustments to the exercise price for certain dilutive events, which includes an adjustment to the number of shares issuable upon the exercise of the warrant in the event that the Company makes certain equity offerings in the future at a price lower than the exercise prices of the warrant instruments. Under the provisions of ASC 815, the warrants are not considered indexed to the Company’s stock because future equity offerings or sales of the Company’s stock are not an input to the fair value of a “fixed-for-fixed” option on equity shares, and equity classification is therefore precluded.

In accordance with ASC 815, derivative liabilities must be measured at fair value upon issuance and re-valued at the end of each reporting period through expiration. Any change in fair value between the respective reporting dates is recognized as a gain or loss.

Series A through E Warrants

The Company accounted for the Series A through E Warrants as derivative liabilities in accordance with ASC 815. These warrants do not qualify for equity accounting and must be accounted for as derivative liabilities since the warrant agreements provide the holder with the right, at its option, to require the Company to a cash settlement of the warrants at Black-Scholes value in the event of a Fundamental Transaction, as defined in the warrant agreement. Since the occurrence of a Fundamental Transaction is not entirely within the Company's control, there exist circumstances that would require net-cash settlement of the warrants while holders of shares would not receive a cash settlement.

In June 2009, the Company issued 1,011,656 Series A warrants exercisable at $5.00 per share in connection with a financing. The cost of the warrants of $2,775,021 was recorded as a debit to additional paid-in capital and a credit to derivative liabilities. As of December 31, 2013, 130,347 of these warrants remained outstanding. As of December 31, 2013 and September 30, 2013, the fair value of the remaining Series A warrants was $1,303.

In July 2009, the Company issued 16,750 warrants to a private investor. The warrants were issued with an exercise price of $5.00 per share and valued at $43,550 using the Black Scholes method. The cost of the warrants was accounted for as a debit to additional paid-in capital and a credit to derivative liabilities. As of December 31, 2013, 16,750 warrants remained outstanding. As of December 31, 2013 and September 30, 2013, the fair value of the remaining warrants was $168.

In connection with a loan received and fully repaid in a prior period, the Company issued 50,000 Series B warrants with an exercise price of $6.80 per share. As of December 31, 2013, 50,000 Series B warrants remained outstanding. As of December 31, 2013 and September 30, 2013, the fair value of the remaining Series B warrants was $0.

In connection with an August 2009 financing, the Company issued 539,222 Series C warrants exercisable at $5.50 per share. As of December 31, 2013, 463,487 of these warrants remained outstanding. As of December 31, 2013 and September 30, 2013, the fair value of the remaining Series C warrants was $4,635.

In September 2009, the Company issued 71,428 Series E warrants with an exercise price of $17.50 per share to the placement agent in connection with a financing. As of December 31, 2013, 71,428 Series E warrants remained outstanding. As of December 31, 2013 and September 30, 2013, the fair value of the remaining Series E warrants was $0.

For the three months ended December 31, 2013 and 2012, the Company recorded a gain of $0 and $332,436, respectively, on the Series A through E warrants.

Series N Warrants

In October 2011, the Company sold 1,333,333 shares of its common stock to private investors for $4,000,000, or $3.00 per share. This financing triggered the reset provision in the Series N warrants, which allows for adjustments in the exercise price if subsequent equity sales are offered at a lower price. As a result, the outstanding 389,078 Series N warrants issued to investors in connection with a prior year financing, were reset from $4.00 to $3.00. In addition, the investors were issued 129,693 warrants exercisable at $3.00 per share at an initial cost of $220,478. The cost was accounted for as a debit to loss on derivatives and a credit to derivative liabilities.

On October 11, 2013 and December 24, 2013, in connection with public offerings of common stock on those dates, the Company issued the Series N warrant holders 2,432,649 additional warrants as required by the warrant agreements. As of December 31, 2013, 2,951,420 Series N warrants remain outstanding. As of December 31, 2013 and September 30, 2013, the values of the Series N warrants were $531,255 and $41,501, respectively. During the three months ended December 31, 2013 and 2012, the Company recorded a loss of $489,754 and a gain of $311,262 on the Series N warrants, respectively.

Series F and G Warrants

In October 2011, in connection with a financing, the Company issued 1,200,000 Series F warrants exercisable at $4.00 per share at any time prior to October 6, 2014. The Company also issued 66,667 Series G warrants exercisable at $4.00 per share to the placement agent for this offering. The Series G warrants are exercisable at any time prior to August 12, 2014. The initial cost of the warrants of $2,146,667 was recorded as a debit to additional paid-in capital and a credit to derivative liabilities. As of December 31, 2013 and September 30, 2013, the fair value of the Series F and G warrants was $12,667. During the three months ended December 30, 2013 and 2012, the Company recorded a gain on the Series F and G warrants of $0 and $640,000, respectively.

Series H Warrants

In January 2012, in connection with a financing, the Company issued 1,200,000 Series H warrants exercisable at $5.00 per share at any time prior to August 1, 2015. The initial cost of the warrants of $2,400,000 was recorded as a debit to additional paid-in capital and a credit to derivative liabilities. As of December 31, 2013 and September 30, 2013, the fair values of the Series H warrants were $12,000 and $36,000, respectively. During the three months ended December 31, 2013 and 2012, the Company recorded a gain of $24,000 and $600,000, respectively, on the Series H warrants.

Series Q Warrants

In June 2012, in connection with a financing, the Company issued 1,200,000 Series Q warrants exercisable at $5.00 per share at any time prior to December 22, 2015. The initial cost of the warrants of $2,160,000 was recorded as a debit to additional paid-in capital and a credit to derivative liabilities. As of December 31, 2013 and September 30, 2013, the fair values of the Series Q warrants were $24,000 and $48,000, respectively. During the three months ended December 31, 2013 and 2012 the Company recorded a gain of $24,000 and $600,000, respectively, on the Series Q warrants.

Series R Warrants

In December 2012 the Company sold 3,500,000 shares of its common stock for $10,500,000, or $3.00 per share, in a registered direct offering. The investors in this offering also received Series R warrants which entitle the investors to purchase up to 2,625,000 shares of the Company’s common stock. The Series R warrants may be exercised at any time before December 7, 2016 at a price of $4.00 per share. The initial cost of the warrants of $4,200,000 was recorded as a debit to additional paid-in capital and a credit to derivative liabilities. As of December 31, 2013 and September 30, 2013, the fair value of the derivative liabilities totaled $157,500 and $288,750, respectively. During the three months ended December 31, 2013 and the Company recorded a gain of $131,250 and $262,500, respectively, on the Series R warrants.

Series S Warrants

On October 11, 2013, the Company closed a public offering of 17,826,087 units of common stock and warrants at a price of $1.00 per unit for net proceeds of $16,400,000, net of underwriting discounts and commissions and offering expenses of the Company. Each unit consisted of one share of common stock and one Series S warrant to purchase one share of common stock. The Series S warrants are immediately exercisable, expire on October 11, 2018, and have an exercise price of $1.25. In November 2013, the underwriters purchased an additional 2,648,913 warrants pursuant to the overallotment option, for which the Company received net proceeds of $24,370.

On December 24, 2013, the Company closed a public offering of 4,761,905 units of common stock and warrants at a price of $0.63 per unit for net proceeds of $2,790,000, net of underwriting discounts and commissions and offering expenses of the Company. Each unit consisted of one share of common stock and one Series S warrant to purchase one share of common stock. The Series S warrants are immediately exercisable, expire on October 11, 2018, and have an exercise price of $1.25. The underwriters purchased an additional 476,190 units of common stock and warrants pursuant to the overallotment option, for which the Company received net proceeds of approximately $279,000.

The initial cost of the S warrants of $7,321,071 was recorded as a debit to additional paid-in capital and a credit to derivative liabilities. As of December 31, 2013, the fair value of the derivative liabilities totaled $5,399,750. During the three months ended December 31, 2013, the Company recorded a gain of $1,921,321 on the Series S warrants.

1. Series L and M Warrants

In April 2007, the Company completed a $15 million private financing. Shares were sold at $7.50, a premium over the closing price of the previous two weeks. The financing was accompanied by 1,000,000 warrants with an exercise price of $7.50 and 1,000,000 warrants with an exercise price of $20.00. The warrants are known as Series L and Series M warrants, respectively. The warrants issued with the financing qualified for equity treatment in accordance with ASC 815. The cost of Series L and Series M warrants were recorded as a debit and a credit to additional paid-in capital.

In November 2011, the Company reduced the exercise price of 160,000 Series L warrants to $3.40. The additional cost of $86,826 was recorded as a debit and a credit to additional paid-in capital and was a deemed dividend. In March 2012, 60,000 Series L warrants were exercised at a price of $3.40, and the Company received proceeds of $204,000.

In April 2012, the 25,000 Series L warrants were transferred to a consultant exercisable at a price of $7.50 per share and were extended for two years from the current expiration date. The additional value of $43,910 was accounted for as a credit to additional paid-in capital and a debit to general and administrative expense. In June 2012, 10,167 Series L warrants with an exercise price of $7.50 per share, expired. In April 2013, 100,000 Series L warrants were repriced to $2.50 and extended for two years to April 2, 2015 in return for a reduction in outstanding warrants to 70,000. The additional cost of $59,531 was recorded as a debit and a credit to additional paid-in capital and was a deemed dividend. This cost was included in modification of warrants and increased the net loss available to shareholders on the statements of operations. As of December 31, 2013, 70,000 of the Series L warrants at the reduced exercise price of $2.50 and 25,000 warrants at the original exercise price of $7.50 remained outstanding.

In February 2011, 600,000 Series M warrants, exercisable at a price of $6.00 per share were extended for two years to July 31, 2014. This cost of $661,457 was recorded as a debit and a credit to additional paid-in capital and was a deemed dividend.

In November 2011, the Company reduced the exercise price of 600,000 Series M warrants from $6.00 to $3.40. The additional cost of $238,794 was recorded as a debit and a credit to additional paid-capital and was a deemed dividend.

In October 2013, the Company reduced the exercise prices of the Series M warrants from $3.40 to $1.00 in exchange for a reduction in the number of warrants from 600,000 to 500,000. The additional cost of $76,991 was recorded as non-employee stock compensation expense. As of December 31, 2013, 500,000 Series M warrants at the reduced exercise price of $1.00 remained outstanding.

3. Series O and P Warrants

In March 2009, as further consideration for its rights under a licensing agreement, Byron Biopharma LLC (“Byron”) purchased 375,000 Units from the Company at a price of $2.00 per Unit. Each Unit consisted of one share of the Company’s common stock and two Series O warrants. All Series O warrants were exercised by September 30, 2012.

On February 10, 2012, the Company issued 590,001 Series P warrants to the former holder of the Series O warrants as an inducement for the early exercise of the Series O warrants. Series O warrants entitled the holder to purchase 590,001 shares of the Company’s common stock at a price of $2.50 per share at any time on or prior to March 6, 2016. The Series P warrants allow the holder to purchase up to 590,001 shares of the Company’s common stock at a price of $4.50 per share. The Series P warrants are exercisable at any time prior to March 6, 2017. The warrants were accounted for as an equity transaction using the Black-Scholes method to value the warrants. The fair value of the warrants was calculated to be $1,593,000. This cost was recorded as a debit and a credit to additional paid-in capital. As of December 31, 2013, 590,001 Series P warrants remained outstanding.

4. Private Investor Warrants

In February 2011, 132,500 warrants issued to an investor with exercise prices between $5.60 and $8.20 were extended for three years. The additional value of $406,912 was calculated using the Black Scholes method and was accounted for as a debit and a credit to additional paid-in capital. As of December 31, 2013, 132,500 warrants remained outstanding.

In January 2009, as part of an amended lease agreement on the manufacturing facility, the Company repriced 300,000 warrants issued to the lessor in July 2007 at $12.50 per share and which were to expire on July 12, 2013. These warrants were repriced at $7.50 per share and expire on January 26, 2014. The cost of this repricing and extension of the warrants was $70,515 and was accounted for as a debit to the deferred rent asset and a credit to additional paid-in capital. In addition, 78,750 additional warrants were given to the lessor of the manufacturing facility on the same date, exercisable at a price of $7.50 per share, and will expire on January 26, 2014. The cost of these warrants was $45,207 and was accounted for as a debit to the deferred rent asset and a credit to additional paid-in capital. As of December 31, 2013, 378,750 warrants remained outstanding.

Between March 31 and June 30, 2009, 229,688 warrants were issued at $7.50 to the leaseholder on the manufacturing facility in consideration for the deferral of rent payments. As of December 31, 2013, 229,688 warrants remained outstanding.

3. Warrants Held by Officer and Director

Between December 2008 and June 2009, Maximilian de Clara, the Company’s President and a director, loaned the Company $1,104,057 under a note payable. In June 2009, the Company issued 164,824 warrants, exercisable at $4.00 per share, to Mr. De Clara. The warrants are exercisable at any time prior to December 24, 2014. These warrants were valued at $65,796 using the Black-Scholes method. In July 2009, as consideration for a further extension of the loan, the Company issued 184,930 warrants, exercisable at $5.00 per share, to Mr. De Clara. These warrants were valued at $341,454 using the Black-Scholes method and can be exercised at any time prior to January 6, 2015. The first warrants were recorded as a discount to the loan and a credit to additional paid-in capital. The second warrants were recorded as a debit to derivative loss of $831,230, a premium of $341,454 on the loan and a credit to additional paid-in capital of $489,776. The warrants and premium are fully amortized. As of December 31, 2013, 349,754 warrants remained outstanding. See Note E for additional information.

4. Options and Shares Issued to Consultants

As of December 31, 2013, 200,750 options issued to consultants as payment for services remained outstanding, of which 191,250 options were issued from the Non-Qualified Stock Option plans. On May 22, 2013, 3,000 options previously issued to a consultant from the Non-Qualified Stock Option plans expired.

On October 15, 2013, the Company entered into a consulting agreement for services to be provided through October 14, 2014. In consideration for services provided, the Company agreed to issue the consultant 100,000 restricted shares in three installments – 34,000 upon signing, 33,000 on January 15, 2014, and 33,000 on March 14, 2014. Accordingly, during the three months ended December 31, 2013, the Company issued the consultant 34,000 shares of restricted stock at the fair market value of $0.80 per share. The aggregate fair market value of $27,200 was recorded as a prepaid expense and will be charged to general and administrative expense over the period of service.

On October 20, 2013, the Company entered into a consulting agreement for services to be provided through October 19, 2016. In consideration for services provided, the Company agreed to issue the consultant 34,164 restricted shares each month of the agreement, with the first three months being issued in advance. Accordingly, the Company issued the consultant 102,492 shares of restricted stock at the fair market value of $0.82 per share. The aggregate fair market value of $84,043 was recorded as a prepaid expense and will be charged to general and administrative expense over the period of service. On December 28, 2012, the Company entered into a consulting agreement with this same consultant for services to be provided through December 27, 2013. In consideration for the services to be provided, the Company issued the consultant 50,000 shares of common stock and 50,000 options to purchase common stock at a price of $2.80 per share. The common shares were issued at the fair market value on the agreement date of $2.80. The aggregate fair market value of $140,000 was recorded as a prepaid expense and was charged to general and administrative expense over the period of service. The fair value of the options issued, as calculated using the Black-Scholes method, was determined to be $98,150 and was also charged to general and administrative expense over the period of service.

On October 28, 2013, the Company entered into a consulting agreement for services to be provided through April 27, 2014. In consideration for services provided, the Company granted the consultant 60,000 options to purchase common stock at a price of $0.85 per share. The fair value of the options issued, as calculated using the Black-Scholes method, was determined to be $24,294 and was recorded as a prepaid expense and will be charged to general and administrative expense over the period of service.

During the three months ended December 31, 2013 and 2012, the Company recorded expense of $137,729 and $1,985, respectively relating to these consulting arrangements. As of December 31, 2013 and September 30, 2013, the Company recorded $55,362 and $57,553, respectively, in prepaid consulting expenses.

X

- Details

Name: CVM_NotesToFinancialStatementsAbstract

Namespace Prefix: CVM_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Custom Element.

+ References

No definition available.

+ Details

Name: CVM_StockholdersEquityTextBlock

Namespace Prefix: CVM_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

EXCEL 15 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%\P-SED93@U8U\S-V(S7S0S.69?86%F-E]E-&8Y M-&-D-#=B,#`B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7 M96(@4&%G92P@86QS;R!K;F]W;B!A'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I7;W)K#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I% M>&-E;%=O#I.86UE/@T*("`@ M(#QX.E=O#I%>&-E M;%=O#I.86UE/D5?3$]!3E-?1E)/35]/1D9)0T52 M/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D=?0T]-34E4345.5%-?04Y$7T-/3E1)3D=%3D-)13PO>#I. M86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DE?3D547TQ/ M4U-?4$527U-(05)%/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U#I% M>&-E;%=O#I.86UE/@T*("`@(#QX.E=O M#I%>&-E;%=O#I.86UE/D%?3U)'04Y)6D%424].7T%.1%]354U-05)9 M7T]&7SPO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-? M4U1/0TM(3TQ$15)37T5154E465]486)L97,\+W@Z3F%M93X-"B`@("`\>#I7 M;W)K#I7;W)K#I%>&-E;%=O#I%>&-E;%=O#I7;W)K#I7;W)K#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I7;W)K#I%>&-E;%=O#I%>&-E;%=O M#I.86UE/@T*("`@ M(#QX.E=O#I%>&-E M;%=O#I.86UE/DA?4$%414Y44U]$971A:6QS/"]X M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O#I%>&-E;%=O#I. M86UE/@T*("`@(#QX.E=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O6QE#I!8W1I=F53:&5E=#X-"B`@ M/'@Z4')O=&5C=%-T#I0#I0#I0&UL/CPA6V5N9&EF72TM/@T* M/"]H96%D/@T*("`\8F]D>3X-"B`@(#QP/E1H:7,@<&%G92!S:&]U;&0@8F4@ M;W!E;F5D('=I=&@@36EC'1087)T7S`W.61E M.#5C7S,W8C-?-#,Y9E]A868V7V4T9CDT8V0T-V(P,`T*0V]N=&5N="U,;V-A M=&EO;CH@9FEL93HO+R]#.B\P-SED93@U8U\S-V(S7S0S.69?86%F-E]E-&8Y M-&-D-#=B,#`O5V]R:W-H965T'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS M<&%N/CPO'0^)T-%3"!30TD@0T]24#QS<&%N/CPO2!#96YT3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)S`P,#`W,C4S M-C,\'0^1&5C(#,Q+`T*"0DR,#$S/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)S(P,30\ M3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\P-SED M93@U8U\S-V(S7S0S.69?86%F-E]E-&8Y-&-D-#=B,#`-"D-O;G1E;G0M3&]C M871I;VXZ(&9I;&4Z+R\O0SHO,#'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO2!U'0^)SQS<&%N/CPO6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA'!E;G-E'0^)SQS<&%N/CPOF5D(#(P,"PP,#`@'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO3PO'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T* M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'!E;G-E'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[ M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@ M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E M>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO7!E M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@ M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'!E;G-E'0^)SQS<&%N/CPO'!E;G-E65E'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO6%B;&4\+W1D/@T* M("`@("`@("`\=&0@8VQA'0^)SQS M<&%N/CPO6%B;&4\+W1D M/@T*("`@("`@("`\=&0@8VQA'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'!E;F1I='5R97,@9F]R(&EN=&5R M97-T(&5X<&5N'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQP('-T>6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM M97,@3F5W(%)O;6%N+"!4:6UE'!E8W1E9"!F;W(@ M=&AE(&5N=&ER92!Y96%R+CPO<#X-"@T*/'`@6QE/3-$)V9O;G0Z(#AP="]N;W)M M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE2!O9B!3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S M.CPO=3X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM M97,@3F5W(%)O;6%N+"!4:6UE'!E;F1I='5R97,@87)E(&-A<&ET86QI>F5D(&%N M9"!A;6]R=&EZ960-"G5S:6YG('1H92!S=')A:6=H="UL:6YE(&UE=&AO9"!O M=F5R('1H92!S:&]R=&5R(&]F('1H92!E>'!E8W1E9"!UF%T:6]N(&ES M(&UA9&4N)B,Q-C`[)B,Q-C`[06X@:6UP86ER;65N="!L;W-S(&ES(')E8V]G M;FEZ960@=VAE;B!E'!E8W1E9"!T;R!R97-U;'0@9G)O;2!T:&4@=7-E(&]F('1H M92!A6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE0T*;65T:&]D(&]F(&%C8V]U;G1I;F<@9F]R M(&EN8V]M92!T87AE2!M971H;V0L(&1E9F5R"!A"!C;VYS M97%U96YC97,@871T&ES=&EN9PT*87-S971S(&%N9"!L:6%B:6QI=&EE&%B;&4@:6YC;VUE M(&EN('1H92!Y96%R'!E8W1E9"!T;R!B92!R96-O=F5R960@;W(@"!A2!R96-O2!T:&%N(&YO="!T;R!B92!R96-O9VYI>F5D+B`F(S$V M,#M!(&9U;&P@=F%L=6%T:6]N(&%L;&]W86YC90T*=V%S(')E8V]R9&5D(&%G M86EN"!A6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE M2!H87,@96YT97)E9`T*:6YT;R!F:6YA;F-I M;F<@87)R86YG96UE;G1S('1H870@8V]N=&%I;B!E;6)E9&1E9"!D97)I=F%T M:79E(&9E871U2!T:&5S92!P87)T:65S+B8C M,38P.R8C,38P.U1H92!#;VUP86YY(&%C8V]U;G1S(&9O2!A8V-E<'1E9"!I;B!T:&4@ M56YI=&5D(%-T871E2!AF5D(&%S(')E;G0@97AP96YS92!O M=F5R('1H92!L96%S92!T97)M+B!);G1E6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE'!E;G-E(&]V97(@=&AE M(')E<75I6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O;6%N M+"!4:6UE2!I;G-T65E2U"87-E9"!0 M87EM96YT'0M M:6YD96YT.B`P+C5I;B<^)B,Q-C`[)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS M1"=F;VYT.B`X<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E M'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P M/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0O;F]R;6%L(%1I;65S($YE=R!2 M;VUA;BP@5&EM97,L(%-E2!T:&4@6QE/3-$ M)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE65A'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0M86QI9VXZ(&IU3X-"CPO:'1M;#X-"@T*+2TM+2TM/5]. M97AT4&%R=%\P-SED93@U8U\S-V(S7S0S.69?86%F-E]E-&8Y-&-D-#=B,#`- M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,#'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^)SQS M<&%N/CPO2!A6QE/3-$)V9O;G0Z(#AP="]N;W)M M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#AP M="!#86QI8G)I+"!(96QV971I8V$L(%-A;G,M4V5R:68[('=I9'1H.B`Q,#`E M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET92<^#0H\='(@6QE/3-$)V)O6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$ M)V)O6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT M97([(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!C M;VQS<&%N/3-$,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@ M'0M86QI9VXZ(&-E;G1E6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE M/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S M='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&QI;F4M:&5I9VAT.B`Q,34E M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=B M;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@'0M86QI9VXZ(&-E M;G1E6QE/3-$)V9O;G0Z M(#AP="!4:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UE'0M86QI9VXZ(')I9VAT M.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@6QE/3-$)W=I M9'1H.B`Q)3L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@ M/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@;&EN92UH96EG:'0Z(#$Q-24G/B8C M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@;&EN92UH M96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I M9'1H.B`Y)3L@=&5X="UA;&EG;CH@6QE/3-$)V9O M;G0Z(#AP="!4:6UE'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U M)2<^/&9O;G0@6QE/3-$)VQI;F4M:&5I M9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W M(%)O;6%N+"!4:6UE6QE/3-$)VQI;F4M M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L M:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^ M)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE M/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S M='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\ M=&0@6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U M)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H M=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP M="!4:6UE6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT M9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q M-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R M:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z M(#AP="!4:6UE6QE M/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S M='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\ M=&0@6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF M(S$V,#L\+W1D/CPO='(^#0H\='(@6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E M)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^ M)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE M/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S M='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\ M=&0@6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U M)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$ M)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL M93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@ M6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@ M,3$U)2<^/&9O;G0@6QE/3-$)V9O;G0Z M(#AP="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE65E6QE M/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE'!I&-E6QE/3-$)V9O;G0Z(#AP="]N M;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE'!E;G-E/"]U/CPO<#X-"@T* M/'`@6QE/3-$)V9O M;G0Z(#AP="!#86QI8G)I+"!(96QV971I8V$L(%-A;G,M4V5R:68[('=I9'1H M.B`Q,#`E)SX-"CQT6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF M(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$-B!S='EL93TS1"=B;W)D M97(M8F]T=&]M.B!B;&%C:R`Q<'0@'0M86QI9VXZ(&-E;G1E M6QE/3-$)V9O;G0Z(#AP M="!4:6UE6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E M)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@6QE/3-$)VQI;F4M:&5I9VAT.B`Q M,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H M=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L6QE/3-$)V)O6QE/3-$)VQI M;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N M/3-$,B!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X- M"B`@("`\=&0@;F]W6QE/3-$)VQI;F4M:&5I9VAT M.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE M:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L6QE/3-$)W9E6QE/3-$)W=I9'1H.B`X)3L@=&5X="UA;&EG;CH@6QE/3-$)W=I9'1H.B`Q)3L@ M;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE M/3-$)W=I9'1H.B`Q)3L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^ M#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@;&EN92UH96EG:'0Z(#$Q M-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@ M,3$U)2<^/&9O;G0@6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@ M(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT M.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)VQI;F4M:&5I M9VAT.B`Q,34E)SXF(S$V,#L\+W1D/CPO='(^#0H\+W1A8FQE/@T*/'`@6QE/3-$)V9O M;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O;6%N M+"!4:6UE65E('-T;V-K(&-O;7!E;G-A=&EO;B!E>'!E;G-E(&5X8VQU9&5D M("0U-2PS-C(@86YD("0U-RPU-3,@;V8@<')E<&%I9"!C;VYS=6QT:6YG(&5X M<&5N6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@ M3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#AP="]N;W)M M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#AP M="!#86QI8G)I+"!(96QV971I8V$L(%-A;G,M4V5R:68[('=I9'1H.B`Q,#`E M)SX-"CQT6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B M;&%C:R`Q<'0@'0M86QI9VXZ(&-E;G1E6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)V)O&5R8VES92!O9B!787)R86YT/"]B/CPO9F]N=#X\+W1D M/@T*("`@(#QT9"!N;W=R87`],T1N;W=R87`@6QE/3-$)VQI;F4M M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$ M,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@'0M86QI9VXZ(&-E;G1E6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$ M)V)O6QE/3-$)W9E6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^ M)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L6QE/3-$)VQI;F4M:&5I M9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!N;W=R87`],T1N;W=R M87`@6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D M/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[ M/"]T9#X-"B`@("`\=&0@8V]L6QE/3-$)W9E'0M86QI9VXZ(&-E;G1E6QE/3-$)W=I9'1H.B`Q,24[('1E>'0M86QI9VXZ M(&-E;G1E6QE/3-$)V9O M;G0Z(#AP="!4:6UE'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T M9#X-"B`@("`\=&0@6QE/3-$)W=I9'1H M.B`Q)3L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D M('-T>6QE/3-$)W=I9'1H.B`Q,24[('1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)V9O;G0Z(#AP="!4:6UE M6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)W9E6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE M:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$ M)W1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@ M6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@ M;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4 M:6UE6QE/3-$)W1E>'0M M86QI9VXZ(&-E;G1E6QE M/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)VQI M;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS M1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT M('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)W1E>'0M86QI9VXZ(&-E M;G1E6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^ M)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)W1E>'0M86QI9VXZ M(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@6QE/3-$ M)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL M93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/B8C M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R M:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z M(#AP="!4:6UE6QE/3-$ M)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)VQI M;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS M1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/CPO M='(^#0H\='(@6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\ M+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN M92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE M6QE/3-$)VQI M;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS M1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT M('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T* M("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T M9#X-"B`@("`\=&0@6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E M)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS M1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)W1E>'0M86QI M9VXZ(&-E;G1E6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT M9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q M-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@ M,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$ M)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL M93TS1"=T97AT+6%L:6=N.B!C96YT97([(&QI;F4M:&5I9VAT.B`Q,34E)SX\ M9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE M6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT M9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q M-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$ M)VQI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@ M5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE M/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H M=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP M="!4:6UE6QE M/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S M='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G M/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\ M+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&QI M;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM M97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H M=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP M="!4:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L:6YE M+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O M;G0@6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\ M+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q M-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@6QE/3-$)VQI M;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS M1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/CPO M='(^#0H\='(@6QE/3-$)VQI;F4M M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L M:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T* M("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&QI;F4M:&5I M9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W M(%)O;6%N+"!4:6UE6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\ M+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN M92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE M6QE M/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H M=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T* M("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T M9#X-"B`@("`\=&0@6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L M:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@6QE/3-$)VQI;F4M M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T M97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T M>6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)VQI;F4M:&5I9VAT M.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O M;6%N+"!4:6UE6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)W1E>'0M86QI M9VXZ(&-E;G1E6QE/3-$ M)V9O;G0Z(#AP="!4:6UE6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T* M("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG M:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)VQI;F4M M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T M97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T M>6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D M/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH M96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$ M)V9O;G0Z(#AP="!4:6UE6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@ M,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@ M(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X- M"B`@("`\=&0@6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L:6YE M+6AE:6=H=#H@,3$U)2<^/&9O;G0@6QE/3-$)VQI;F4M:&5I9VAT M.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE M:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE M/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@ M6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T M9#X-"B`@("`\=&0@6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L M:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@6QE M/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S M='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G M/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)V9O;G0Z(#AP="!4:6UE M6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H M=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP M="!4:6UE6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U M)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)VQI;F4M:&5I M9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT M+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^ M#0H@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS1"=L:6YE+6AE:6=H M=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)VQI M;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS M1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P M.SPO=&0^#0H@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS1"=L:6YE M+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE M/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S M='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\ M=&0@6QE/3-$)VQI;F4M:&5I9VAT M.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O M;6%N+"!4:6UE6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)W1E>'0M86QI M9VXZ(&-E;G1E6QE/3-$ M)V9O;G0Z(#AP="!4:6UE6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T* M("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG M:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)VQI;F4M:&5I M9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT M+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE M/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H M=#H@,3$U)2<^/&9O;G0@6QE/3-$)W9E6QE/3-$)W1E M>'0M86QI9VXZ(&-E;G1E6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)V9O;G0Z(#AP="!4:6UE M6QE/3-$)VQI M;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS M1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT M('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@ M;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4 M:6UE6QE/3-$)W1E>'0M M86QI9VXZ(&-E;G1E6QE M/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)VQI;F4M:&5I M9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE M+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/CPO='(^#0H\ M='(@6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE M/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H M=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP M="!4:6UE6QE/3-$ M)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL M93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@ M6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\ M+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&QI M;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM M97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H M=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP M="!4:6UE6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U M)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)VQI;F4M:&5I M9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT M+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^ M#0H@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS1"=L:6YE+6AE:6=H M=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)VQI M;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS M1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P M.SPO=&0^#0H@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS1"=L:6YE M+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE M/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S M='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\ M=&0@6QE/3-$)VQI;F4M:&5I9VAT M.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O M;6%N+"!4:6UE6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)W1E>'0M86QI M9VXZ(&-E;G1E6QE/3-$ M)V9O;G0Z(#AP="!4:6UE6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T* M("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG M:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)VQI;F4M:&5I9VAT M.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE M:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT M9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&QI;F4M:&5I9VAT.B`Q M,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H M=#H@,3$U)2<^/&9O;G0@6QE/3-$)W9E6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D M/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[ M/"]T9#X-"B`@("`\=&0@6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT M.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@;F]W M6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^ M)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)W1E>'0M86QI9VXZ M(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\ M=&0@;F]W6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@ M,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)VQI;F4M M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T M97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO M=&0^#0H@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS1"=L:6YE+6AE M:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E M6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)VQI;F4M:&5I9VAT M.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE M:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$ M)W1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@ M6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D M/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&QI;F4M M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@ M3F5W(%)O;6%N+"!4:6UE6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@ M,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)VQI M;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@ M,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)VQI;F4M M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L M:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$ M)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL M93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@ M6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT M9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@ M("`\=&0@6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE M:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@;F]W6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/CPO M='(^#0H\='(@6QE M/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E M6QE/3-$)V9O;G0Z(#AP M="!4:6UE6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@ M,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@6QE/3-$)VQI;F4M:&5I9VAT M.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE M:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE M/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@ M6QE/3-$)VQI;F4M:&5I9VAT M.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE M:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$ M)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL M93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@ M6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT M9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@ M("`\=&0@6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T* M("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T M9#X-"B`@("`\=&0@6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L M:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@;F]W6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\ M+W1D/CPO='(^#0H\='(@6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@ M(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X- M"B`@("`\=&0@6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L:6YE M+6AE:6=H=#H@,3$U)2<^/&9O;G0@6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@ M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z M(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE'0M:6YD96YT.B`P+C5I;B<^ M)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0O;F]R;6%L(%1I M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT M.B`X<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)V9O;G0Z(#AP="]N;W)M M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#AP M="!#86QI8G)I+"!(96QV971I8V$L(%-A;G,M4V5R:68[('=I9'1H.B`Q,#`E M)SX-"CQT6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\ M+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=B;W)D97(M8F]T M=&]M.B!B;&%C:R`Q<'0@'0M86QI9VXZ(&-E;G1E6QE/3-$)V)O6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O M;6%N+"!4:6UE6QE/3-$)W9E6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!N;W=R87`],T1N;W=R87`@6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT M9"!C;VQS<&%N/3-$,B!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q M-C`[/"]T9#X-"B`@("`\=&0@;F]W6QE/3-$)VQI M;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@6QE/3-$)W=I9'1H.B`W."4[(&QI;F4M M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@ M3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)W=I9'1H.B`Q)3L@;&EN92UH96EG:'0Z(#$Q-24G/B8C M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@;&EN92UH M96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I M9'1H.B`Q)3L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O M;G0Z(#AP="!4:6UE'0M86QI M9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@6QE/3-$)W9E6QE/3-$)V9O;G0Z(#AP="!4:6UE M6QE/3-$)VQI;F4M:&5I9VAT M.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L M:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$ M)V9O;G0Z(#AP="!4:6UE6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@ M(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X- M"B`@("`\=&0@6QE M/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T* M("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG M:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)VQI;F4M:&5I M9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT M+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE M/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)W9E6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R M:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z M(#AP="!4:6UE6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT M9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q M-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)W9E6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O M;G0@6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D M/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[ M/"]T9#X-"B`@("`\=&0@6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT M.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@6QE/3-$)VQI;F4M M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE M:6=H=#H@,3$U)2<^/&9O;G0@6QE/3-$)VQI;F4M M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T M97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T M>6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UE M6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)VQI;F4M:&5I9VAT.B`Q M,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T M=&]M.B!B;&%C:R`Q<'0@'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@ M,3$U)2<^/&9O;G0@6QE/3-$)W9E6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT M9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@ M("`\=&0@6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T* M("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T M9#X-"B`@("`\=&0@6QE/3-$)V9O;G0Z(#AP="!4 M:6UE6QE/3-$)V)O6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\ M+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q M+C5P="!D;W5B;&4[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS M1"=F;VYT.B`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`D-2XP,"!P97(@ M6QE M/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE2!R97!A M:60@:6X@82!P2!I6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O M;6%N+"!4:6UE&5R8VES86)L92!A="`D-2XU M,"!P97(@&5R8VES92!P2P@;VX@=&AE M(%-E6QE M/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE M2!S;VQD(#$L,S,S+#,S,R!S:&%R97,@;V8@:71S#0IC;VUM;VX@&5R8VES92!P2!S86QE6QE/3-$ M)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE2!I M6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W M(%)O;6%N+"!4:6UE2!T:6UE('!R:6]R('1O($]C=&]B97(@-BP@,C`Q-"XF(S$V,#LF(S$V,#M4 M:&4@0V]M<&%N>0T*86QS;R!I2!T M:6UE('!R:6]R('1O($%U9W5S="`Q,BP@,C`Q-"XF(S$V,#LF(S$V,#M4:&4@ M:6YI=&EA;"!C;W-T(&]F('1H92!W87)R86YT2!R96-O6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE0T*:7-S=65D(#$L M,C`P+#`P,"!397)I97,@2"!W87)R86YT&5R8VES86)L92!A="`D-2XP M,"!P97(@2XF(S$V,#LF(S$V,#LF(S$V,#M$=7)I;F<-"G1H92!T:')E92!M;VYT M:',@96YD960@1&5C96UB97(@,S$L(#(P,3,@86YD(#(P,3(L('1H92!#;VUP M86YY(')E8V]R9&5D(&$@9V%I;B!O9B`D,C0L,#`P(&%N9"`D-C`P+#`P,"P@ M6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE2!T:6UE('!R:6]R('1O($1E M8V5M8F5R(#(R+"`R,#$U+B8C,38P.R8C,38P.U1H92!I;FET:6%L#0IC;W-T M(&]F('1H92!W87)R86YT2XF(S$V,#LF(S$V,#LF(S$V M,#M$=7)I;F<-"G1H92!T:')E92!M;VYT:',@96YD960@1&5C96UB97(@,S$L M(#(P,3,@86YD(#(P,3(@=&AE($-O;7!A;GD@6QE/3-$ M)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE28C,30V.W,@8V]M M;6]N('-T;V-K+B8C,38P.R8C,38P.U1H90T*4V5R:65S(%(@=V%R2!R96-O6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@ M5&EM97,@3F5W(%)O;6%N+"!4:6UE'!I2!R96-E:79E9"!N970@<')O8V5E9',@;V8@ M)#(T+#,W,"X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@ M5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O M;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O;6%N M+"!4:6UE2!E>&5R8VES86)L92P@97AP:7)E#0IO;B!/8W1O8F5R(#$Q+"`R,#$X M+"!A;F0@:&%V92!A;B!E>&5R8VES92!P6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@ M3F5W(%)O;6%N+"!4:6UE6QE/3-$)W9E6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UE2!C;VUP;&5T960@82`D,34@;6EL;&EO;B!P M2XF(S$V,#LF M(S$V,#M4:&4@=V%R6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@ M3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O M;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE'1E M;F1E9"!F;W(@='=O('EE87)S('1O($%P2`R,#$Q+"`V,#`L,#`P(%-E M&5R8VES86)L92!A=`T*82!P'1E;F1E9"!F;W(@='=O('EE87)S('1O M($IU;'D@,S$L(#(P,30N)B,Q-C`[)B,Q-C`[5&AI6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@ M5&EM97,@3F5W(%)O;6%N+"!4:6UE2!R961U8V5D('1H92!E>&5R8VES92!P6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O;6%N M+"!4:6UE2!R961U8V5D('1H92!E>&5R8VES92!P6QE/3-$)W9E6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)V9O;G0Z M(#AP="!4:6UE2`Q,"P@,C`Q,BP@=&AE($-O;7!A;GD@:7-S=65D(#4Y,"PP M,#$@4V5R:65S(%`-"G=A28C,30V.W,@8V]M M;6]N('-T;V-K(&%T(&$@<')I8V4@;V8@)#(N-3`@<&5R('-H87)E(&%T#0IA M;GD@=&EM92!O;B!O28C,30V.W,@8V]M;6]N('-T;V-K(&%T(&$@<')I8V4@;V8@)#0N-3`@<&5R M('-H87)E+B8C,38P.R8C,38P.U1H92!397)I97,@4"!W87)R86YT6QE/3-$)V9O;G0Z(#AP="!# M86QI8G)I+"!(96QV971I8V$L(%-A;G,M4V5R:68[('=I9'1H.B`Q,#`E)SX- M"CQT6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT M.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE2`R,#$Q M+"`Q,S(L-3`P('=A&5R8VES92!P'1E;F1E9"!F;W(@=&AR964@>65A6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O M;6%N+"!4:6UE2`R,#`Y M+"!A2P@=&AE($-O;7!A;GD@'!I2`R-BP@,C`Q-"X@5&AE(&-O'1E;G-I;VX@;V8@=&AE('=A0T*;VX@=&AE('-A;64@9&%T M92P@97AE6QE/3-$)V9O;G0Z(#$Q<'0O;F]R;6%L($-A;&EB6QE/3-$)V9O M;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O;6%N M+"!4:6UE6UE;G1S+B8C,38P.R8C,38P.T%S#0IO9B!$96-E M;6)E6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@ M5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)W=I9'1H.B`T.'!X M.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE M&EM:6QI86X@9&4@0VQA28C,30V.W,@4')E2!I&5R8VES86)L92!A="!A;GD-"G1I;64@<')I;W(@=&\@1&5C96UB97(@ M,C0L(#(P,30N)B,Q-C`[)B,Q-C`[5&AE&5R8VES960@ M870-"F%N>2!T:6UE('!R:6]R('1O($IA;G5A6QE/3-$)W9E#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP M="!4:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O M;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#AP="]N;W)M M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE6UE;G0@9F]R('-E2`R,BP@,C`Q,RP@ M,RPP,#`@;W!T:6]N6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@ M5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O M;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE2P@9'5R:6YG('1H92!T:')E M92!M;VYT:',@96YD960@1&5C96UB97(@,S$L(#(P,3,L('1H92!#;VUP86YY M(&ES6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@ M5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O M;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE'!E;G-E(&%N9"!W87,@8VAA2!E;G1E'!E;G-E(&%N9"!W:6QL#0IB92!C:&%R9V5D('1O(&=E;F5R M86P@86YD(&%D;6EN:7-T'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS M1"=F;VYT.B`X<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E M2P@:6X@<')E<&%I9"!C;VYS M=6QT:6YG(&5X<&5N'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2!I;B!A;B!O2!C M=7)R96YT(&UA'!E8W1A=&EO;G,@=VET:"!R97-P96-T('1O('1H M;W-E(&9U='5R92!A;6]U;G1S+CPO<#X-"@T*/'`@6QE/3-$)V9O;G0Z(#AP="]N M;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE2!G:79E M2!T;R!A8W1I=F4@;6%R:V5T2!T;R!U;F]B0T*8VQA0T*87)E(&%S(&9O;&QO=W,Z/"]P/@T*#0H\<"!S='EL93TS M1"=F;VYT.B`X<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E M6QE/3-$)W9E6QE/3-$)V9O;G0Z(#AP="\Q,34E($-A;&EB6QE/3-$)W9E'0M86QI9VXZ(')I M9VAT)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE2P@96ET:&5R M(&1I6QE M/3-$)W=I9'1H.B`Y-G!X.R!F;VYT.B`X<'0O,3$U)2!#86QI8G)I+"!(96QV M971I8V$L(%-A;G,M4V5R:68[('1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S M='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE28C,30V.W,@87-S97-S;65N="!O9B!T M:&4@2!A9F9E8W0@=&AE('!L86-E;65N="!W:71H:6X@=&AE(&9A:7(@=F%L M=64@:&EE6QE/3-$)V9O;G0Z M(#AP="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O M;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#AP="]N;W)M M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)W9E6QE/3-$)V)O6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U M)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L'0M86QI9VXZ(&-E;G1E M6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U M)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L6QE/3-$ M)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS M<&%N/3-$,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@'0M86QI9VXZ(&-E;G1E6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)W9E6QE/3-$ M)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!N;W=R M87`],T1N;W=R87`@6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF M(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=L:6YE M+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@;F]W6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D M/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[ M/"]T9#X-"B`@("`\=&0@8V]L6QE/3-$)VQI;F4M:&5I9VAT.B`Q M,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!N;W=R87`],T1N;W=R87`@6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)V)O6QE/3-$)VQI;F4M:&5I9VAT.B`Q M,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H M=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)V)O M6QE/3-$)VQI;F4M:&5I M9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE M+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE M/3-$)V)O6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@ M(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)V9O;G0Z(#AP M="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$ M)V9O;G0Z(#AP="!#86QI8G)I+"!(96QV971I8V$L(%-A;G,M4V5R:68[('=I M9'1H.B`Q,#`E)SX-"CQT6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=B M;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@'0M86QI9VXZ(&-E M;G1E6QE/3-$)V9O;G0Z M(#AP="!4:6UE6QE/3-$)V)O6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O M;6%N+"!4:6UE6QE/3-$)V)O6QE M/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S M='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\ M=&0@8V]L6QE/3-$)VQI;F4M:&5I M9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S M='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\ M=&0@;F]W6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@ M,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L6QE/3-$)VQI M;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!N;W=R87`] M,T1N;W=R87`@6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V M,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=L:6YE+6AE M:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@;F]W6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/CPO M='(^#0H\='(@6QE/3-$)VQI M;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`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`Q,34E)SXF(S$V,#L\+W1D/@T* M("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T M9#X-"B`@("`\=&0@8V]L6QE/3-$)VQI M;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS M1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L M6QE/3-$)W9E6QE/3-$)V)O6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U M)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\ M+W1D/CPO='(^#0H\='(@6QE M/3-$)W=I9'1H.B`W."4[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL M93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE M/3-$)W=I9'1H.B`Q)3L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^ M#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@;&EN92UH96EG:'0Z(#$Q M-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@ M,3$U)2<^/&9O;G0@6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)VQI M;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS M1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT M('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H M=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP M="!4:6UE6QE M/3-$)W9E6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE M:6=H=#H@,3$U)2<^/&9O;G0@6QE/3-$)VQI;F4M:&5I9VAT M.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L M:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$ M)V9O;G0Z(#AP="!4:6UE6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E M)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4 M:6UEF5D(&%N9"!U;G)E86QI>F5D(&=A:6YS/"]F M;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@ M,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)VQI;F4M:&5I9VAT M.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE M:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F M;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SX\9F]N M="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT M9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q+C5P="!D;W5B;&4[ M(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@ M5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)V)O6QE/3-$)V9O;G0Z(#AP="!4:6UE'0M86QI9VXZ(')I9VAT M.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM M97,@3F5W(%)O;6%N+"!4:6UE2!D97)I M=F5D(&9R;VT@=F%L=6%T:6]N(&UO9&5L28C,30V.W,@7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A'0^)SQS M<&%N/CPO'0^)SQP('-T>6QE/3-$)V9O;G0Z(#AP="!4 M:6UE2<^/&(^5#PO8CYH90T*0V]M<&%N>28C,30V.W,@4')E2!D=64L(&%N9"!I;B!A8V-O0T*:7-S M=65D($UR+B!D92!#;&%R82!W87)R86YT28C,30V.W,@8V]M;6]N('-T;V-K(&%T M(&$@<')I8V4@;V8@)#0N,#`@<&5R('-H87)E+B!4:&4-"G=A&5R8VES86)L92!A="!A;GD@=&EM92!P2`V+"`R,#$T+B!!="!-28C,30V.W,@8V]M;6]N#0IS=&]C:RX@5&AE(&YU;6)E2`V+"`R,#$U+B!/;B!-87D@,3,L(#(P,3$L('1O(')E8V]G;FEZ92!-2!D871E(&]F('1H92!N;W1E('1O($IU;'D@-BP@,C`Q-3L@ M:&]W979E2!D96UA;F0@<&%Y;65N="!U<&]N M(&=I=FEN9PT*=&AE($-O;7!A;GD@82!M:6YI;75M(#$P(&1A>2!N;W1I8V4N M/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE'0M86QI9VXZ(&IU'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE2<^/&9O;G0@2!A;F0@:VYO=RUH;W<@7-T96TL('!A=&5N="!A<'!L:6-A=&EO;G,L M(')E2!H87,@9G5N M9&5D('-U8V@@8V]S=',@=VET:`T*<')O8V5E9',@9G)O;2!L;V%N2!M=7-T(&-O;7!L M971E('1H92!D979E;&]P;65N="!O9B!I=',@<')O9'5C=',L(&]B=&%I;B!T M:&4@87!P2!A<'!R;W9A;',@86YD(&]B=&%I M;B!S=69F:6-I96YT#0IR979E;G5E'0M86QI9VXZ(&IU M6QE/3-$)VQE='1E6QE/3-$)V9O;G0Z(#AP="!4:6UE M2<^/&9O;G0@2!R=6YN:6YG(&$@;&%R9V4@;75L=&DM;F%T M:6]N86P@4&AA'0@='=E;'9E#0IM M;VYT:',@86YD(&)E;&EE=F5S('1H870@:70@:&%S(')E861Y(&%C8V5S2`D,3DN-"!M:6QL:6]N(&EN(&YE="!P28C,30V.W,@8V%S:"!R97%U:7)E;65N M=',@=&AR;W5G:"`R,#$T+B!4;R!F:6YA;F-E('1H92!S='5D>2!B97EO;F0@ M=&AE(&YE>'0@,3(@;6]N=&AS+`T*=&AE($-O;7!A;GD@<&QA;G,@=&\@2!F:6YA;F-I;F=S M+B!4:&4@0V]M<&%N>0T*8F5L:65V97,@=&AA="!I="!W:6QL(&)E(&%B;&4@ M=&\@;V)T86EN(&%D9&ET:6]N86P@9FEN86YC:6YG('-I;F-E($UU;'1I:VEN M92!I2!O;B!A8V-E<'1A8FQE('1E2P@=&AE($-O;7!A M;GD@=VEL;"!E:71H97(@:&%V92!T;R!S;&]W(&1O=VX@;W(@9&5L87D@=&AE M(%!H87-E($E)22!C;&EN:6-A;"!T6QE/3-$)V9O;G0Z(#AP="!4:6UE'0M86QI9VXZ(&IU2!L875N8VAE9"!I=',@4&AA2!A=F%I M;&%B;&4@:6X@=&AE($-O;7!A;GDF(S$T-CMS(&-O;G1R86-TF%T:6]N2X@270@:7,@=&AE'0O:F%V87-C M3X-"B`@("`\=&%B;&4@ M8VQA6QE M/3-$)V9O;G0Z(#AP="!4:6UE2<^/&9O;G0@2!E;G1E2!W:6QL(')E:6UB=7)S92!!<'1I=B!F;W(@8V]S=',@:6YC=7)R M960N($EN($UA>2`R,#$S+"!#14PM4T-)(&UA9&4@86X@861V86YC92!P87EM M96YT#0IO9B`D-#`P+#`P,"X@26X@3V-T;V)E6QE/3-$)V-O;&]R.B`C,T0S1#-$)SYI;B`\+V9O;G0^/&9O;G0@ M6QE/3-$)V9O;G0Z(#AP="!4:6UE3L@8V]L M;W(Z(",R.3(Y,CDG/B8C,38P.SPO<#X-"@T*/'`@6UE;G1S+"!U<"!T;R!A('-P96-I9FEC M(&UA>&EM=6T@86UO=6YT+B!4:&4@0V]M<&%N>2!A8V-O=6YT960-"F9O&EM M871E;'D@)#(L,#$W+#`P,"!R96QA=&5D('1O($5R9V]M960F(S$T-CMS('-E M0T*)#8S-"PP,#`N($1U2!R96-O'0M86QI9VXZ(&IU2!E;G1E'0M86QI9VXZ(&IU2!C;VUM96YC960@87)B:71R871I;VX@<')O8V5E9&EN9W,@ M86=A:6YS="!I;E9E;G1I=B!(96%L=&@@0VQI;FEC86PL($Q,0R`H:6Y696YT M:78L(&8O:R]A(%!H87)M84YE="P@3$Q#*2P-"G1H92!#;VUP86YY)B,Q-#8[ MF%T:6]N+B!4:&4@ M87)B:71R871I;VX@8VQA:6TL(&EN:71I871E9"!U;F1E2!D:7-M:7-S960@:6Y696YT:78@86YD M(')E<&QA8V5D#0II="!W:71H($%P=&EV(%-O;'5T:6]N6QE/3-$)V9O;G0Z(#AP="!4:6UE2<^3VX@1&5C96UB M97(-"C$R+"`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`[/"]P/@T* M#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE M'0M86QI9VXZ(&IU2!O9B`D-"PU.3$@86YD("0S+#DY,BP@6QE/3-$)V9O;G0Z(#AP="!4:6UE2<^5&AE($-O;7!A;GD- M"FQE87-E2X\+W`^#0H-"CQP('-T>6QE/3-$)V9O M;G0Z(#AP="!4:6UE2<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT M.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE'0M86QI M9VXZ(&IU2!L96%S M92!P87EM96YT(&ES("0Q+#`R-2X@5&AE(&QE87-E(&)E87)S(&EN=&5R97-T M(&%T(&%P<')O>&EM871E;'D@,38E('!E6QE/3-$)V9O;G0Z(#AP="!4:6UE2<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL M93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE'0M86QI9VXZ(&IU'!I6UE;G0@:7,@)#(Y.2X@5&AE(&QE M87-E(&)E87)S(&EN=&5R97-T(&%T(&%P<')O>&EM871E;'D@.24@<&5R(&%N M;G5M+CPO<#X-"@T*/'`@3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R M=%\P-SED93@U8U\S-V(S7S0S.69?86%F-E]E-&8Y-&-D-#=B,#`-"D-O;G1E M;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,#'0O:'1M;#L@8VAA6QE/3-$)V9O;G0Z(#AP="!#86QI8G)I+"!(96QV971I8V$L(%-A;G,M4V5R M:68[('=I9'1H.B`Q,#`E)SX-"CQT6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE M/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)VQI M;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS M1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@ M,3$U)2<^/&9O;G0@6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF M(S$V,#L\+W1D/CPO='(^#0H\='(@6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@ M,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H M=#H@,3$U)2<^/&9O;G0@6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E M)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@6QE/3-$)VQI;F4M:&5I9VAT.B`Q M,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H M=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE M:6=H=#H@,3$U)2<^/&9O;G0@6QE/3-$)VQI;F4M:&5I9VAT.B`Q M,34E)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@6QE/3-$)VQI;F4M M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B M;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@'0M86QI9VXZ(')I9VAT.R!L:6YE M+6AE:6=H=#H@,3$U)2<^/&9O;G0@6QE/3-$)W9E6QE/3-$)V)O6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/CPO='(^ M#0H\+W1A8FQE/CQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T* M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE2<^5&AE($-O;7!A M;GDF(S$T-CMS#0IB87-I8R!A;F0@9&EL=71E9"!L;W-S('!E&EM871E;'D@.#8U+#`P,"!A;F0@-3'0M86QI9VXZ(&IU6QE/3-$)W1E>'0M86QI9VXZ(&IU6QE/3-$)W!A9&1I;F6QE/3-$)W9E2<^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L2<^)B,Q-C`[/"]T M9#X\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L6QE/3-$)W1E>'0M86QI9VXZ M(&IU6QE/3-$)W=I9'1H.B`U)3L@<&%D9&EN9RUB;W1T;VTZ(#(N-7!T)SXF M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[(&)O6QE/3-$)W=I9'1H.B`U)3L@<&%D9&EN9RUB;W1T;VTZ(#(N-7!T)SXF(S$V M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[(&)O6QE/3-$)W=I9'1H.B`Q)3L@<&%D9&EN M9RUB;W1T;VTZ(#(N-7!T.R!T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D M/CQT9"!S='EL93TS1"=W:61T:#H@-24[('!A9&1I;F'0M86QI9VXZ M(&QE9G0G/B0\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,3$E.R!B;W)D97(M M8F]T=&]M.B!";&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT M)SXH,"XQ,3PO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@<&%D9&EN9RUB M;W1T;VTZ(#(N-7!T.R!T97AT+6%L:6=N.B!L969T)SXI/"]T9#X\+W1R/@T* M/'1R('-T>6QE/3-$)W9E3L@<&%D9&EN9RUB;W1T;VTZ(#%P=#L@<&%D9&EN9RUL969T M.B`U+C1P="<^1V%I;B!O;B!D97)I=F%T:79E6QE/3-$ M)W!A9&1I;F6QE/3-$)V)O6QE/3-$)W!A9&1I;F'0M86QI9VXZ(&QE9G0G/BD\+W1D/CQT9"!S='EL93TS1"=P861D:6YG M+6)O='1O;3H@,7!T)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B M;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@'0M86QI9VXZ(&QE M9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)V)O6QE/3-$)W!A9&1I;F'0M86QI9VXZ M(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F6QE/3-$)V)O6QE/3-$)W9E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C M,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L M:6=N.B!L969T)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@'0M86QI9VXZ M(&QE9G0G/B0\+W1D/CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!";&%C M:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT)SXH-RPP-C(L-C4R M/"]T9#X\=&0@'0M86QI9VXZ(&QE M9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)V)O'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I M;F'0M M86QI9VXZ(&QE9G0G/BD\+W1D/CPO='(^#0H\='(@6QE/3-$)W1E>'0M86QI9VXZ(&IU6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C M,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V M,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\ M+W1D/CQT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L M:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N M.B!R:6=H="<^)B,Q-C`[/"]T9#X\=&0@6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/"]T6QE/3-$)W1E>'0M86QI9VXZ(&IU6QE/3-$)W!A9&1I;F6QE/3-$)V)O6QE/3-$)W!A9&1I;F'0M86QI9VXZ(&QE M9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F6QE/3-$)V)O'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=P861D M:6YG+6)O='1O;3H@,7!T.R!T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D M/CPO='(^#0H\='(@6QE/3-$)W1E>'0M86QI9VXZ(&IU6QE/3-$)W!A9&1I;F6QE/3-$)V)O'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT.B`X M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T M>6QE/3-$)V)O6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P M.SPO=&0^/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N M.B!L969T)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@6QE/3-$)W1E>'0M86QI9VXZ(&IU6QE M/3-$)V)O'0M86QI9VXZ(&QE9G0G/BD\+W1D/CQT9"!S='EL93TS1"=P861D:6YG M+6)O='1O;3H@,BXU<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$ M)V)O6QE/3-$)W!A9&1I;F'0M86QI9VXZ(&QE9G0G/B0\+W1D/CQT9"!S='EL93TS1"=B;W)D97(M8F]T M=&]M.B!";&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT)SXH M,"XP.#PO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&IU'0M86QI9VXZ(&QE9G0G/B8C M,38P.SPO=&0^/'1D('-T>6QE/3-$)V)O'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=P M861D:6YG+6)O='1O;3H@,7!T.R!T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\ M+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T)SXF(S$V,#L\ M+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!";&%C:R`Q M<'0@'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T M>6QE/3-$)V)O6QE/3-$)W!A9&1I;F'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/"]T M3L@<&%D9&EN9RUL969T.B`U+C1P M="<^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^#0H@ M("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^ M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/CQT M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9#XF M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T M)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^ M)B,Q-C`[/"]T9#X\=&0@6QE/3-$)W9E3L@<&%D9&EN9RUB;W1T;VTZ(#(N M-7!T.R!P861D:6YG+6QE9G0Z(#4N-'!T)SY$:6QU=&EV92!L;W-S('!E6QE/3-$)W!A9&1I;F6QE M/3-$)W!A9&1I;F6QE/3-$)W!A9&1I;F'0M86QI9VXZ(')I9VAT)SXR."PS,3$L-C`R/"]T9#X\=&0@6QE/3-$)V)O6QE/3-$)V)O'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE2<^/&9O M;G0@3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\P-SED93@U8U\S-V(S M7S0S.69?86%F-E]E-&8Y-&-D-#=B,#`-"D-O;G1E;G0M3&]C871I;VXZ(&9I M;&4Z+R\O0SHO,#'0O M:'1M;#L@8VAA2!/9B!3:6=N:69I8V%N M="!!8V-O=6YT:6YG(%!O;&EC:65S(%!O;&EC:65S/"]S=')O;F<^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0M86QI9VXZ(&IU'0M:6YD96YT.B`M,"XU:6XG/E1H M90T*86-C;VUP86YY:6YG(&-O;F1E;G-E9"!F:6YA;F-I86P@2D@87)E('5N M875D:71E9"!A;F0@8V5R=&%I;B!I;F9O6QE/3-$)W9E6QE/3-$)W=I9'1H.B`P)SX\+W1D/CQT9"!S='EL M93TS1"=W:61T:#H@,"XU:6XG/CPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI M9VXZ(&IU6QE/3-$ M)W=I9'1H.B`P+C5I;B<^/"]T9#X\=&0@2<^26X@=&AE(&]P:6YI;VX@;V8@;6%N86=E;65N="P@=&AE(&%C M8V]M<&%N>6EN9R!U;F%U9&ET960@8V]N9&5N'!E8W1E9"!F;W(@=&AE(&5N=&ER M90T*>65A'0M86QI9VXZ(&IU'0M86QI9VXZ M(&IUF5D(&%N9"!A;6]R=&EZ960@=7-I;F<@=&AE('-T MF%T:6]N(&ES(&UA9&4N($%N(&EM<&%IF5D('=H96X@97-T:6UA=&5D(&9U='5R92!U;F1I6EN9R!V86QU92!O9B!T:&4@87-S970N#0I4:&4@86UO=6YT M(&]F('1H92!I;7!A:7)M96YT(&QO&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#XG/'`@&5S/"]I/B`M/&9O;G0@6EN9R!A;6]U;G1S(&]F(&5X:7-T:6YG(&%S69O&%B;&4@ M:6YC;VUE(&EN('1H92!Y96%R"!A M'0^)SQP('-T>6QE/3-$)V9O;G0Z(#AP M="!4:6UE2<^/&9O;G0@F5D(&%S(&5I=&AEF5D(&EN(&5A M2!A;F0@:7,@:6YC;'5D960@:6X@9&5F97)R960@ M'0^)SQP M('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE2<^/&D^4W1O8VLM0F%S960-"D-O M;7!E;G-A=&EO;CPO:3X@)B,Q-3`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`@("`\=&%B;&4@8VQA2!486)L97,\+W-T M6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT M9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&QI;F4M:&5I9VAT.B`Q M,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS M1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@'0M86QI9VXZ M(&-E;G1E6QE/3-$)V9O M;G0Z(#AP="!4:6UE6QE/3-$ M)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)V)O6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)V)O6QE/3-$)W9E6QE M/3-$)W=I9'1H.B`Q)3L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^ M#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@;&EN92UH96EG:'0Z(#$Q M-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Y)3L@ M=&5X="UA;&EG;CH@6QE/3-$)V9O;G0Z(#AP="!4 M:6UE'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^ M/&9O;G0@6QE/3-$)W=I9'1H.B`Q)3L@;&EN92UH96EG:'0Z(#$Q-24G M/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@;&EN M92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$ M)W=I9'1H.B`Q)3L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@ M("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Y)3L@=&5X="UA;&EG;CH@6QE/3-$)W=I9'1H M.B`Q)3L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^/"]T6QE/3-$)V9O M;G0Z(#AP="!4:6UE6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D M/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH M96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)VQI M;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS M1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT M('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H M=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP M="!4:6UE6QE/3-$ M)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL M93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF M;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)W9E6QE/3-$ M)W1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@ M6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D M/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[ M/"]T9#X-"B`@("`\=&0@6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT M.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@6QE/3-$)VQI;F4M:&5I M9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE M+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O M;G0@6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H M=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP M="!4:6UE6QE/3-$)V9O;G0Z(#AP="!4 M:6UE6QE/3-$)VQI M;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS M1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT M('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H M=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP M="!4:6UE6QE/3-$ M)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL M93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF M;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^ M)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)VQI M;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/CPO='(^#0H\+W1A8FQE/CQS M<&%N/CPO'0^ M)SQT86)L92!C96QL<&%D9&EN9STS1#`@8V5L;'-P86-I;F<],T0P('-T>6QE M/3-$)V)O6QE/3-$)V9O;G0M9F%M M:6QY.B!4:6UE'0M86QI9VXZ(&-E;G1E'0M86QI9VXZ(&-E;G1E6QE/3-$)W9E6QE/3-$)W=I9'1H M.B`Q)3L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E M'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS M1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE65E3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE M6QE/3-$)W=I9'1H M.B`Q)3L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E M6QE/3-$)W=I9'1H.B`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`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE'0M86QI M9VXZ(&-E;G1E'0M86QI9VXZ(')I9VAT)SX\9F]N="!S M='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$ M)W!A9&1I;F'0M86QI9VXZ(&QE9G0G/B8C,38P M.SPO=&0^/"]T6QE M/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&IU6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P M.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\ M+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D M/CQT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N M.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R M:6=H="<^)B,Q-C`[/"]T9#X\=&0@3L@<&%D9&EN9RUL969T.B`U+C1P="<^ M)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)W=I9'1H.B`Q-24[('1E>'0M86QI9VXZ(')I9VAT M.R!P861D:6YG+6QE9G0Z(#4N-'!T)SXX+S$X+S`X/"]T9#X\=&0@'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T M>6QE/3-$)W=I9'1H.B`Q,R4[('1E>'0M86QI9VXZ(')I9VAT)SXR+#DU,2PT M,C`\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,24[('1E>'0M86QI9VXZ(&QE M9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`R)2<^)B,Q-C`[ M/"]T9#X-"B`@("`\=&0@6QE/3-$)W=I9'1H M.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@6QE/3-$)W=I9'1H.B`R)2<^)B,Q M-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)W=I9'1H M.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R M('-T>6QE/3-$)W9E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C M,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXQ,S`L M,S0W/"]T9#X\=&0@6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0G/B8C,38P.SPO=&0^/"]T6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT)SXQ-BPW-3`\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T M)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS M1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T M97AT+6%L:6=N.B!R:6=H="<^-2XP,#PO=&0^/'1D('-T>6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^#0H@("`@ M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!P861D:6YG+6QE9G0Z M(#4N-'!T)SXQ+S@O,34\+W1D/CQT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S M='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S='EL M93TS1"=T97AT+6%L:6=N.B!R:6=H="<^,3PO=&0^/'1D('-T>6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/"]T6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A M9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^ M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXU,"PP,#`\+W1D/CQT M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9#XF M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T M)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^ M-BXX,#PO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P M.SPO=&0^/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT.R!P861D:6YG+6QE9G0Z(#4N-'!T)SXY+S0O,30\+W1D M/CQT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N M.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R M:6=H="<^,3PO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C M,38P.SPO=&0^/"]T6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C M,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXT-C,L M-#@W/"]T9#X\=&0@6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT)SXQ/"]T9#X\=&0@6QE/3-$)W9E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXW,2PT,C@\+W1D/CQT9"!S='EL M93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\ M+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V M,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^,36QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT M)SXQ/"]T9#X\=&0@6QE/3-$)W9E6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!P861D:6YG+6QE9G0Z(#4N M-'!T)SXQ,"\V+S$Q/"]T9#X\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO M=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P M.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXT+C`P/"]T M9#X\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO M=&0^/"]T6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXQ/"]T9#X\=&0@6QE/3-$)W9E6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT.R!P861D:6YG+6QE9G0Z(#4N-'!T)SXQ+S(V+S$R/"]T9#X\ M=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0G/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(')I9VAT)SXU+C`P/"]T9#X\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXQ/"]T9#X\=&0@6QE M/3-$)W9E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO M=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXQ+#(P,"PP,#`\ M+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D M/CQT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N M.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R M:6=H="<^-2XP,#PO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G M/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(')I9VAT.R!P861D:6YG+6QE9G0Z(#4N-'!T)SXQ,B\R M,B\Q-3PO=&0^/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT)SXQ/"]T9#X\=&0@6QE/3-$)W9E6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!P861D M:6YG+6QE9G0Z(#4N-'!T)SXQ,B\V+S$R/"]T9#X\=&0^)B,Q-C`[/"]T9#X- M"B`@("`\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^ M/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT)SXT+C`P/"]T9#X\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0G/B8C,38P.SPO=&0^/"]T6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C M,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT.R!P861D:6YG+6QE9G0Z(#4N-'!T)SXQ,"\Q,2\Q M.#PO=&0^/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT)SXQ/"]T9#X\=&0@6QE/3-$)W9E6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0G/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS M1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D M/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@<&%D9&EN M9RUL969T.B`U+C1P="<^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X-"B`@ M("`\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/"]T6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('!A9&1I;F6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(')I9VAT)SXR/"]T9#X\=&0@6QE/3-$)W9E M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C M,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT)SXQ+C`P/"]T9#X\=&0@6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/"]T6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T M97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/@T* M("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D M/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X\ M=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C M,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V M,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\ M+W1D/CPO='(^#0H\='(@6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT.R!P861D:6YG+6QE9G0Z(#4N-'!T)SXR+S$P+S$R M/"]T9#X\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^ M#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!P861D:6YG M+6QE9G0Z(#4N-'!T)SXS+S8O,3<\+W1D/CQT9#XF(S$V,#L\+W1D/@T*("`@ M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT M9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^,SPO=&0^/'1D('-T>6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/"]T6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G M/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT M+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/@T*("`@ M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@<&%D9&EN9RUL969T M.B`U+C1P="<^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@ M6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/"]T6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('!A9&1I;F6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT)SXW-#`L.3,X/"]T9#X\=&0@6QE/3-$)V9O;G0Z M(#AP="!4:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C M,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT.R!P861D:6YG+6QE9G0Z(#4N-'!T)SXQ+S(V+S$T M("T@-R\Q."\Q-#PO=&0^/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(')I9VAT)SXT/"]T9#X\=&0@6QE/3-$)W9E M6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^#0H@ M("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^ M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/CQT M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9#XF M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H M=#L@<&%D9&EN9RUL969T.B`U+C1P="<^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[ M/"]T9#X-"B`@("`\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO M=&0^/"]T6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C M,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@ M3F5W(%)O;6%N+"!4:6UE6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/"]T6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO M=&0^/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ M(')I9VAT)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L M969T)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL M93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@<&%D9&EN9RUL969T.B`U+C1P="<^ M)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)W!A9&1I;F6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO M=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P M.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S M='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO M=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXV/"]T9#X\=&0@ M'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT M.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE M/3-$)V)O6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/"]T M'0M86QI9VXZ(&QE9G0G/B0\+W1D/CQT M9"!S='EL93TS1"=W:61T:#H@,3(E.R!T97AT+6%L:6=N.B!R:6=H="<^-BPQ M,#8\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,24[('1E>'0M86QI9VXZ(&QE M9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`X)2<^)B,Q-C`[ M/"]T9#X-"B`@("`\=&0@6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT)SXU,S$L,C4U/"]T9#X\=&0@6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/"]T6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/"]T6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXS-BPP,#`\+W1D/CQT9"!S='EL M93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@ M6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^#0H@ M("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^ M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXT."PP,#`\+W1D/CQT M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CPO='(^ M#0H\='(@6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT)SXQ-36QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F'0M86QI9VXZ(')I9VAT M)SXU+#,S.2PW-3`\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@ M,7!T.R!T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS M1"=P861D:6YG+6)O='1O;3H@,7!T)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S M='EL93TS1"=B;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@'0M M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)V)O6QE/3-$)W!A9&1I;F'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/"]T6QE/3-$)W1E>'0M9&5C M;W)A=&EO;CH@=6YD97)L:6YE.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!P861D M:6YG+6QE9G0Z(#4N-'!T)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/@T* M("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D M/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X\ M=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C M,38P.SPO=&0^/"]T3L@<&%D9&EN M9RUB;W1T;VTZ(#(N-7!T.R!P861D:6YG+6QE9G0Z(#4N-'!T)SY4;W1A;"!D M97)I=F%T:79E(&QI86)I;&ET:65S/"]T9#X\=&0@'0M86QI M9VXZ(&QE9G0G/B0\+W1D/CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!" M;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT)SXV+#$T,RPR M-S@\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[('1E M>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I M;F6QE/3-$)W!A9&1I;F'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T* M("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T M9#X-"B`@("`\=&0@8V]L6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF M(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=B;W)D M97(M8F]T=&]M.B!B;&%C:R`Q<'0@'0M86QI9VXZ(&-E;G1E6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF M(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=B;W)D M97(M8F]T=&]M.B!B;&%C:R`Q<'0@'0M86QI9VXZ(&-E;G1E M6QE/3-$)V9O;G0Z(#AP M="!4:6UE6QE/3-$)V)O6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\ M+W1D/CPO='(^#0H\='(@6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^ M)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L6QE/3-$)VQI;F4M:&5I M9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!N;W=R87`],T1N;W=R M87`@6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D M/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=L:6YE+6AE:6=H=#H@ M,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@;F]W6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT M9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@ M("`\=&0@8V]L6QE/3-$)W9E6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B M;&%C:R`Q<'0@6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)VQI;F4M:&5I9VAT.B`Q M,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T M=&]M.B!B;&%C:R`Q<'0@6QE/3-$)V9O;G0Z(#AP="!4 M:6UE6QE/3-$)VQI;F4M:&5I M9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D M97(M8F]T=&]M.B!B;&%C:R`Q<'0@6QE/3-$)V9O;G0Z M(#AP="!4:6UE6QE/3-$)V)O6QE/3-$)V9O;G0Z(#AP="!4:6UE M'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@ M6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D M/CPO='(^#0H\='(^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C M,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P M.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO M=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^ M#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@ M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@ M/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D M/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C M,38P.SPO=&0^/"]T6QE/3-$)W9E6QE/3-$)V)O6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@ M,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L'0M86QI9VXZ(&-E M;G1E6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@ M,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L6QE M/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!C M;VQS<&%N/3-$,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@ M'0M86QI9VXZ(&-E;G1E6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)W9E6QE M/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!N M;W=R87`],T1N;W=R87`@6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=L M:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@;F]W6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\ M+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q M-C`[/"]T9#X-"B`@("`\=&0@8V]L6QE/3-$)VQI;F4M:&5I9VAT M.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!N;W=R87`],T1N;W=R87`@ M6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)V)O6QE/3-$)VQI;F4M:&5I9VAT M.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE M:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$ M)V)O6QE/3-$)VQI;F4M M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L M:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)V)O6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT M9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@ M("`\=&0@6QE/3-$)V)O6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\ M+W1D/CPO='(^#0H\='(^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D M/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C M,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P M.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO M=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^ M#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@ M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@ M/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D M/B8C,38P.SPO=&0^/"]T6QE/3-$)VQI;F4M:&5I9VAT.B`Q M,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H M=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D M/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[ M/"]T9#X-"B`@("`\=&0@8V]L6QE/3-$)W9E6QE/3-$)V)O6QE/3-$)VQI M;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS M1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L M6QE/3-$)VQI;F4M:&5I M9VAT.B`Q,34E)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@6QE/3-$)W=I9'1H.B`W."4[(&QI;F4M:&5I9VAT M.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O M;6%N+"!4:6UE6QE/3-$)W=I9'1H.B`Q)3L@;&EN92UH96EG:'0Z M(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q M)3L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP M="!4:6UE'0M86QI9VXZ(')I M9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@6QE/3-$)V9O;G0Z(#AP="!4:6UE M6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D M/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH M96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)VQI M;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS M1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT M('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)W9E6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT M9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q M-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$ M)VQI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@ M5&EM97,@3F5W(%)O;6%N+"!4:6UEF5D(&%N9"!U M;G)E86QI>F5D(&=A:6YS/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$ M)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL M93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@ M6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT M9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@ M("`\=&0@6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E M)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE6QE M/3-$)V)O6QE/3-$)V)O6QE/3-$)VQI;F4M M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@ M3F5W(%)O;6%N+"!4:6UE6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B M;&%C:R`Q+C5P="!D;W5B;&4[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S M='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#AP="!4 M:6UE6QE M/3-$)V)O6QE/3-$)V9O;G0Z(#AP="!4:6UE'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@ M'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQT86)L92!C96QL6QE/3-$)V9O;G0Z(#AP="!#86QI8G)I+"!( M96QV971I8V$L(%-A;G,M4V5R:68[('=I9'1H.B`Q,#`E)SX-"CQT6QE/3-$)V9O;G0Z(#AP="!4:6UE M6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D M/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[ M/"]T9#X-"B`@("`\=&0@6QE/3-$)V9O;G0Z(#AP M="!4:6UE6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@6QE/3-$)VQI M;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@6QE/3-$ M)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL M93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@ M6QE/3-$)V9O;G0Z M(#AP="!4:6UE6QE/3-$)W1E>'0M86QI9VXZ M(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@6QE/3-$ M)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@6QE M/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S M='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\ M=&0@6QE/3-$)V9O M;G0Z(#AP="!4:6UE6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@6QE M/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@ M6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T* M("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@'0M M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@6QE/3-$)W9E6QE/3-$)V)O6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E M)SXF(S$V,#L\+W1D/CPO='(^#0H\+W1A8FQE/CQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U% M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O M:'1M;#L@8VAA6QE/3-$)V9O;G0Z M(#AP="!#86QI8G)I+"!(96QV971I8V$L(%-A;G,M4V5R:68[('=I9'1H.B`Q M,#`E)SX-"CQT6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V M,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,3`@6QE/3-$)VQI;F4M:&5I9VAT.B`Q M,34E)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@6QE/3-$)VQI;F4M:&5I9VAT M.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE M:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V M,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=B;W)D97(M M8F]T=&]M.B!B;&%C:R`Q<'0@'0M86QI9VXZ(&-E;G1E6QE/3-$)V9O;G0Z(#AP="!4 M:6UE6QE/3-$)V)O6QE/3-$ M)W9E6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\ M+W1D/@T*("`@(#QT9"!N;W=R87`],T1N;W=R87`@6QE/3-$)VQI M;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N M/3-$,B!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X- M"B`@("`\=&0@;F]W6QE/3-$)VQI;F4M:&5I9VAT M.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE M:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L6QE/3-$)W9E6QE/3-$)V9O;G0Z(#AP="!4 M:6UE6QE/3-$)W=I9'1H.B`Q)3L@;&EN92UH96EG M:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H M.B`Q)3L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D M('-T>6QE/3-$)W=I9'1H.B`X)3L@=&5X="UA;&EG;CH@6QE/3-$)W=I9'1H.B`Q M)3L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T M>6QE/3-$)W=I9'1H.B`Q)3L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO M=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@8F]R9&5R+6)O='1O M;3H@8FQA8VL@,2XU<'0@9&]U8FQE.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O M;G0@6QE/3-$)W=I9'1H M.B`X)3L@8F]R9&5R+6)O='1O;3H@8FQA8VL@,2XU<'0@9&]U8FQE.R!T97AT M+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE M/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)W=I9'1H.B`Q)3L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T M>6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE M/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@'0M86QI9VXZ(')I M9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\ M+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q M-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U M)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D M/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[ M/"]T9#X-"B`@("`\=&0@6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^ M)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@ M,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS M1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT M9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q+C5P="!D;W5B;&4[ M(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@ M5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)V9O;G0Z(#AP M="!4:6UE6QE M/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q+C5P="!D;W5B;&4[(&QI M;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM M97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL M93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O M;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE M/3-$)V9O;G0Z(#AP="!#86QI8G)I+"!(96QV971I8V$L(%-A;G,M4V5R:68[ M('=I9'1H.B`Q,#`E)SX-"CQT6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT M9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@ M("`\=&0@8V]L6QE/3-$)V)O6QE/3-$)W9E6QE/3-$)V)O6QE/3-$)VQI;F4M:&5I9VAT M.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE M:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L6QE/3-$)VQI;F4M:&5I M9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@'0M M86QI9VXZ(&-E;G1E6QE M/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)W=I9'1H M.B`V-R4[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT M9"!S='EL93TS1"=W:61T:#H@,24[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[(&QI;F4M:&5I M9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T M:#H@."4[('1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^ M)B,Q-C`[/"]T9#X-"B`@("`\=&0@;F]W6QE/3-$ M)W=I9'1H.B`Q)3L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@ M("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@;&EN92UH96EG:'0Z(#$Q-24G M/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@;&EN M92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$ M)W=I9'1H.B`X)3L@=&5X="UA;&EG;CH@6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT M.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)VQI M;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS M1"=L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE M:6=H=#H@,3$U)2<^/&9O;G0@6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT M9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@ M("`\=&0@6QE/3-$)VQI;F4M:&5I9VAT.B`Q M,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H M=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$ M)V)O6QE/3-$)VQI M;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM M97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)VQI;F4M:&5I9VAT.B`Q M,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT M9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q M-24G/B8C,38P.SPO=&0^#0H@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!S='EL M93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@ M6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T* M("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG M:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D(&YO=W)A<#TS1&YO=W)A M<"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X\+W1R M/@T*/'1R('-T>6QE/3-$)W9E6QE M/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S M='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G M/B8C,38P.SPO=&0^#0H@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS M1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@ M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z M(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!S M='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\ M=&0@6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D M/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH M96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D(&YO=W)A<#TS1&YO M=W)A<"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X\ M+W1R/@T*/'1R('-T>6QE/3-$)W9E6QE/3-$)V9O;G0Z(#AP="!4:6UE M6QE/3-$)V)O6QE/3-$)V9O;G0Z(#AP="!4:6UE'0M86QI M9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B M;&%C:R`Q+C5P="!D;W5B;&4[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\ M+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q M+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@ M,3$U)2<^/&9O;G0@6QE/3-$)V)O6QE/3-$)V9O;G0Z(#AP="!4:6UE'0M86QI9VXZ M(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@6QE/3-$)V9O;G0Z(#AP="!4 M:6UE6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@ M3F5W(%)O;6%N+"!4:6UE3X-"CPO:'1M;#X-"@T* M+2TM+2TM/5].97AT4&%R=%\P-SED93@U8U\S-V(S7S0S.69?86%F-E]E-&8Y M-&-D-#=B,#`-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,#'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C M:&%R'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0O:F%V87-C3X-"B`@ M("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO7!E.B!T M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT M96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^075G(#$X+`T*"0DR,#`X/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$&5R8VES92!O9B!787)R86YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$;G5M<#XR+#DU,2PT,C`\'0^075G(#$X+`T*"0DR,#$T M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^2G5N(#(T+`T*"0DR M,#`Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$&5R8VES92!O9B!787)R86YT M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,S`L,S0W/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M&5R M8VES92!0'!I&5R8VES92!0'!I'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^4V5P(#0L#0H)"3(P,#D\ M'!I'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'!I'0^075G(#(P+`T*"0DR,#`Y/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^ M075G(#(V+`T*"0DR,#`Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^4V5P(#(Q+`T*"0DR,#`Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$&5R M8VES92!O9B!787)R86YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M M<#XW,2PT,C@\'0^075G(#$R+`T*"0DR,#$T/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^3V-T(#8L#0H)"3(P,3$\&5R8VES92!O M9B!787)R86YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV-BPV M-C<\'0^075G(#$R+`T*"0DR,#$T/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^2F%N(#(V+`T*"0DR,#$R/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$&5R8VES92!O9B!787)R86YT/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$;G5M<#XQ+#(P,"PP,#`\'0^075G(#$L#0H)"3(P M,34\&5R8VES92!O9B!787)R86YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M;G5M<#XR+#8R-2PP,#`\'0^1&5C(#8L#0H)"3(P,38\&5R M8VES92!O9B!787)R86YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M M<#XR-2PW,3,L,#DU/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$&5R8VES92!0'!I'0^ M3V-T(#$Q+`T*"0DR,#$S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^1&5C(#(T+`T*"0DR,#$S/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^07!R(#$X+`T*"0DR,#`W/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$&5R8VES92!O9B!787)R86YT/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$;G5M<#XR-2PP,#`\'!I'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^07!R(#$X+`T*"0DR,#`W/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M&5R8VES92!O9B!787)R86YT/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$;G5M<#XU,#`L,#`P/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$&5R8VES92!0'!I'!I'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^2G5L(#$X+`T*"0DR,#`U/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^2G5N M(#,P+`T*"0DR,#`Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'!I'0^ M2G5L(#$X+`T*"0DR,#$T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$&5R8VES92!0'!I'0^2F%N(#8L#0H) M"3(P,34\'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^1F5B(#$U+`T*"0DR,#`U/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^3V-T(#(X M+`T*"0DR,#$S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'!I2`R,"P-"@D),C`Q-#QS<&%N/CPO'0^1&5C M(#(W+`T*"0DR,#$W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$&5R8VES92!0&EM=6T\+W1D/@T*("`@("`@("`\=&0@8VQA'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO3X-"CPO:'1M;#X-"@T*+2TM M+2TM/5].97AT4&%R=%\P-SED93@U8U\S-V(S7S0S.69?86%F-E]E-&8Y-&-D M-#=B,#`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`@/&AE860^#0H@("`@ M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E M>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO M'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\P-SED M93@U8U\S-V(S7S0S.69?86%F-E]E-&8Y-&-D-#=B,#`-"D-O;G1E;G0M3&]C M871I;VXZ(&9I;&4Z+R\O0SHO,#'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO'0O:F%V87-C M3X-"B`@("`\=&%B;&4@ M8VQA'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA7!E M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@ M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPOF%T:6]N M(&]F('!A=&5N="!C;W-T3X-"CPO:'1M;#X-"@T*+2TM M+2TM/5].97AT4&%R=%\P-SED93@U8U\S-V(S7S0S.69?86%F-E]E-&8Y-&-D M-#=B,#`-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,#'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R M'0^)SQS<&%N/CPO3X-"CPO:'1M;#X-"@T*+2TM+2TM/5]. M97AT4&%R=%\P-SED93@U8U\S-V(S7S0S.69?86%F-E]E-&8Y-&-D-#=B,#`- M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,#'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R&-L=61E9"!F3X-"CPO:'1M;#X- M"@T*+2TM+2TM/5].97AT4&%R=%\P-SED93@U8U\S-V(S7S0S.69?86%F-E]E M-&8Y-&-D-#=B,#`-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,#&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T M960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA&UL;G,Z;STS1")U&UL/@T*+2TM+2TM/5].97AT4&%R=%\P-SED93@U A8U\S-V(S7S0S.69?86%F-E]E-&8Y-&-D-#=B,#`M+0T* ` end ZIP 16 0001354488-14-000595-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001354488-14-000595-xbrl.zip M4$L#!!0````(`!6"2D2`T0$15((``,@-!@`0`!P`8W9M+3(P,3,Q,C,Q+GAM M;%54"0`#N4'Y4KE!^5)U>`L``00E#@``!#D!``#L7>MSVSB2_WY5]S_@O+FI MF2J]92>QGL'*.K%WZ_#@$U%HJ6*7NYT6YT=)B)/^3(:O]SY=-D<7!Z=GNZP MO__^G__!X,^+_VHVV8D4@7_`CI77/(U&ZI"]YZ$X8'^(2"0\5R!?TIB'K]OK=7J?;9]W.AV[K M>@3DCGD*-^'B;KO3:W>>?>QU#CK[![W.FD12GF8Z)]*Y[M@_9OJ+ZV$2R`/\ MEX&T(GUPK>7+G4F:Q@?M]M755>NJWU+)N-WK=+KM?[U[>^E-1,B;,M(ICSRQ MXV8%,OJR;%YW?W^_37?=T(612-S1Z+?Q]I#K8F5D\(;Q"YS`73_-)Y0'[[7- MS,#+R[FC.TNX._K\+A_OB:"I/=GR5$@CT8=V MG&>@-1UHLMD+,6)DB`<34@_X6].-;UUK?\?>19HO=[0,XP",JNU6,H[B*7#Z MZY1)_^7.2:)"6*#7[':`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`>L)H286<:0BG06X?CWU?0(XE;5]ZWJNWL2E+;QN@ZCOV MZJVJ:^/5_9JJNK\!JKYCK]ZJN@Y>_5&E/*B?IDO;KHE/;Q5=$X\^C3SD[SAVX$@RN>^!]GL2AT?S=W^<:?YX)W+[YFE@!;?Z5BC*]H/CG]_=AX9^G^*7[K9.NCU08 M@YRX,_>RQO>?/C*-YY_D6KWSQZK[U:\`<)_0_3A)5#:>O*[AV>B*O=^U+6SX MVPU6O])D:T(;:4*;][:66U%H^QZ(+6[>FUOOXJD?H^/MY]\WX_/O=Z?Q[1L]ZZ#?[5MY'[^. MMV]M?=SZW1YT/F[];H^:-N--%'>G=R^#?#/'OD\5C5OF_&/3+^W MGLUM(;ONW70+`;V'_@UOO3OPH]4'F%L_VAXUW/0:UEH513?N_5Y#[;V]AM?) MX)&\]^G;#&`37OYT[Q;P2-X1]&T6L`DO"KJ[-TULGT9XI&65U?-NLP-9Y^[# MS9GM!NXL9WZ87R/]_8GGG#'^I`+N(7[]>:6`N[O87.EG7M8"G"M[?:P!^(9^ MUU;E]UBN;T;;*XND,9-/E\<+J@\%UUDB?I=:[?:ZSPY@C%O,W:J2P-56K'\Y MX8G0*TE8(="@;Z8!_)VOH./+*=C:^-7ZZ]?MFS5ZY6)C>`NSZ..`GX>&TR(QYH82A4 M%BBO?)0E"5Z6VN/!OP5/OG8O39?8W;3:H@'\4P3!GY&ZBB[!NE4D_%.M,X#X M=R:HK1>V+5$!IDZ40E M\B\PO[6DN8*]'H:&SBH&YTG]",;F97=GC!&X?9^T;N''4/A>7M84T`_CY2Q+ ML9+R`2)_IG!*9'X(5S]&3#=P=:3"4$5W"61K4/QA3'XSA'T?DS\4O)YV[)^E MW-V&$5_-U9H6]VU_FZGN_>TDB3=0&Q>8._%%60] M"G(XN'F>J`A^]`1F!7H0^4<3'HT!=Z+R&!EY,@Z$_@@\OPJ`R-JIQR]!>A@S MGLD"DJ4B:.N8>L'7`FIU6%Z\C)TT>R#%,^=],IW(TV_EEG!Y^G`CP&Q#' M+W_K]@\CQ30,D2/I067&(B#.\SVRN"((EDYXRJY4%OA,AD`OA2OD@KZ(-%C6 M"(I.$`H/8&_@.#2IA9MMQTBYL)D?(6VG07HSO^*11HD77W'I#MGN1SN=UIZ, MOEXW2'I(2B*IT8\3HRA\C2F/9K_P,#[\6W?WZ:%F@/F:VF@-!D;-.//MUWHV MV#M^+4,92!Z!H["C@">\P0*0$F@)=6978T^ZC6YGM]'9>]9B8!@TA(U`..Q= MTLJGLB'DQ)K8D"!#()LRL(3NWG^S&`JT&=PE#J1F6G@91"$VG`$_@1014Q'3 MV9#ZF6`9`5P/`J9&93;*F^):"[`:XL9QZ2N0?*12-N%3(PV):))[43I2H2!(! M+*,2Y.E8>*:)V]MM,`3[%CN-"L$UJAJ=WUM)\B-`H)T,4V]KY$%^`XX4R,KY%;3Q$:.2"AXB2N-LRO\0"#"5EP=8U M&V4)#*>&"N)&0J]$=L)C5G`D5$VBJ`@;?_`HXXE3ZUZ+G47@G3/6[=.%;@,'`;\*XMI?8I7&C<&"=$&,D="T M'W(P_`$0"UP0>ZB"322!CW`.;B4LT:YCEW:[G:,+EP?X8@A;T(`I2>K$`@"7 M!N3'Q,-RKR[A"EP,>9HED-(P'SFRZSBF2C:^=\@FZDH`^3GUH37[(D3V`-Z0 MFK&V,1A2-,XQU1&'"8"'81:R;@=HSI`6J*@4S&F*^><>XZ51Y]/.X88Q=@S: M,MYI18MV!4:?3C0S6LW!K]\ES?7)=/#$MVH&,9<^N,5>H]$'N@3F"EQEO+^7,GM*`AEIBO)8I#1(43%`K()`( MM:2B(I9S[_\RJ25=!%<&L:<)%*! M&L]HY)=(737!Z<$@`DY9N\6I208BA$0]S&@T,!N`,8S(-O1,0W[>L#09C_'T MTRBV@98E*-G!Y7W\PAP5$SX9N/(1&O`D!VW/[+Y!,25-,L]M*N``H'@"-6,C M$&P`NT5%$CP"XA(S:0+Y%A0(N1-7DCZ4]R@C7]$9,&/$C$)T$O&$\+7)5C%B M&_#%G4"XB0JR\CB MUY/CP6]HAHF:PE)Y3F*U9CG6-L>Q-@E[0S62/C'5A(E#KB%:PW]83Y);M8B9 M3P&D$""-8%9%UQ"`H;JQDKT[>W'4&\SNB9PX-CZ)QI6(<1888W=;,,9HQ^L, MT56Z@&^5H4VB$>,1CK5+C:B$7@0UE,%J1"J'6AL4W]8%T;D`_X`FB?08VUXRX=?]SRI-/3T_G'(9L?2*X@7UP*PBB6/HE M!0Y@[ACAT>3'UY\'N%`2I:@@;'7&9@E#:G6T$,!U?A4V":. M3`E?183?99"CUIP]JCS8$Y.A2M!%>&0!X!I*CBL1V(K<)C?(R5)2"6QQAJ6M M3;6QTX1H"E#CR.L)M9;,Z@A<"2!LB]E<:D2GNI\V`7#H?!XIH5S!E_! M6EJ92ERG!D#L]F.NTQ9[XZJXE-JUL!RR'"GLCV6)U0*O*#/?&*1+Z&6CC$2* MXG8E7GF/9"`49V$9\ULNF2F7@1-/F8*BYA1DM^8F)#.T!%;I05#.)$ZKV4/> MP"N2IFH285H8U#@`^Q%S49KX$I*:%]@")*`*(.7UU15F4"#_P#8`5\(L&@N$ MW7+F'A@#`0@'`PCF(0\;SX%)/:G]@.E_2@9@!6/LF#J1+BU$,8*L6^QG1[OO M:"W/A>3A!L;C2VE1IA)M`PY)W00;<:"H0L]%%,W=M&H]Z'!0*ILRIX+(W4:_ MTVET.AU4+IC>8DUN.WFFL6Y+$)>IBYM!T@WP'"J75<&5(BRE9#LB% MD;J,$&9-\EWD,(7C6S!:VN#$)^L@';8--%O4'KGM7+BJY2P9\TC^9=T)VQ6( M=K@X91,\XF,79^>TB1+$IIMIFEKLXQ#F*(X-C:>#2FUQ#`(54:*"P#318'4! M)F6WY6$GS:,3)8;!Q*0H(:$9`0J4IQCW&X#'(<5=TYH%J@A80^(6M@30D2J? MSUKLE%"`S$SE&#BBG*I20F\%"M^:6[LNR0V"9 MYJ=J5%]"60B%B#Z&9"I0^`SI1O9N/!6HY(#]K;>/?W/\DOC#@J&1`@:NB:I) M:/(>46T9\YO:IYRO?);P?FH@T!U_S26\3%#;T9Z.E,^H3/TRB%,Y990\[Y7#H1YOT.+9"HA-:@>AA5X@^ULR)H2-[`@VEILVP`8A,,L`00\V;6@C+//`$/H M)&MQA=+9"B(/YI;!_)IT]-%S(#^?.RQ34/\8_^X4AK3.I))644RV1C"L^#DJ M>2`224#+`16^EAM0V=?R\J2[1SNWI6R442W@N3*$JK;BK!"*D;PR*5]]1F=< MRZ)X@SD*#I!]`8!MLCD//RU"7PB,20!W&6%"^0*>16]J'^:Q`LT@3B#OO@UH M8//-4[\R$F8Q4D2BURAX3VV8LBE4$4 MXUB>CO&048[!F"$YP"\XYV/*8H`Y;&A$PHA&S7B0SAS>@'+--CBF41[60Z#F M:SKP,Z58%4CM(T%6(BX!_BH5+'FN87!YQ)YWGC,GK&>0Z@?VX`"/%@;8[AC; MJ&['/#]S2VX!3JEKN.E^MN;+SN`9&?A"VBF7BQ+)-7,[57KT&(#9!,AU;F9K'N5W) M>9RH;$E@'W7`XD!0U%PRI1#['%7BZ=(:I`K/WTK&C2"8QV!/>J-J('@RE.Y$UQYM8$\>3(CC:0MH[C-:[)2]$9"-3/*>48.] M?7O$?G6W&VS4_M+F]J3KO4CI_F\+1PIE",1L"GM%"[6D*G6A3.I0YA*R?QDV M[+.?:*29RPV1B#M5OLB"XJ&V`5S%]K%)5DMK#;16,-P\1LB#0(QATJ_R-S9, MR!KI2,/TSAIP'6Z,$I[Y+A^4D9]Y-O]$LX81,,0>`@7\RHPV][007T"L)LH& M`HIA]F2O4_80GX>0",X]1SN"G-`WW<&R$.SA1`.C*P"9BX8[C%EL5KY-4;3:=E$A!YUN'W;["I1P MV1*Q@H^P&0WFNC*6AU4;EA&)=3MR$HR=BQ[B@HQ[;M*U5)SU4\1-F;7]7LGT M34G@S+_$&_"TP%>HIL82K7V5FE+`(;!51%(_*P] M!!^-I5=CX=C"/#U*]0^CKH,I&7&J+W&C"?49M*D9`OD%\V.5I9YM1Z=XIEN& MTY]AE]\6QN02L[S/SNNMO+X56(IO4*_XP?DZ0G0VA@LV<>X\J^(T.B1Y^C"3 M`3VA'N$#&Z\X/H!%%?,[\)4`W-B$IGS8%95!H?)%(%9^"F+%`^6NAV&/FK3* MS_KMV5&FBW.CTA-M(*0,CW^RI'S&[]H;-[9RJJ=W>1"D1^KR+B,^Z"9M$3HM M.#@Y'MC/GI`Y2FV[.?1P(,Z]`MN+N/^`Z'7?TQT!R7@GV=[9"/FMV[=NVVVY9V(_ M74!D2<(T"'``4++FUS^9606@0`(D0(`D2.%N=UN6R*JLK'S/K$S^'B=1S!^+ MZM^+"P6,^&;&I0"Y,*3!)8BI-@`KVT`.`K3N=R0@,-Y$S0$(K;FWG,/O,*\) M_@?]-O7S51$"6;A>&F.G6M9$U'_*IX:=P\="S$Q57%YW!!0P%8\Q0E$&+ZP' M_")=#WAD\.L+.BEO=<-K&?(G"9FQF%%8\3D/_FAH?`5:>#]B]>08?#6XQODR MIYHT=$ZHA%\_`,5S!Q!CC81.^#FGT`I.3O7\I?*/>U;(-5.1$B<,\0:!Q^0Q M?WX#E([+9``)CJ(+5`NA_;QD%]@[+8PC2BO*>45T0(6"L#3C MM;\4LR-9SG]`$2JH@>?Q<]D)-R,]9>%RA.+&DF^X$LK%%T\QN%:J;O-727P7 MK*KB`1%1IBP@GG'(AIO?\>;%M1=JWU!VF@E M;.]B8;=++U9]-#)XH3I8!9R";I<@K=)S<-65&@.YQN1"-Q(OP*A\R9'(LC+_ M62&@UJNDTJ"V2(/.TK<1=!C?DYX&O+!4>Z+S]TBF.ID8:N$]TL`![3D@I!=9 M5!K^+R#@!`O`4XHWG0T43P]HQ27;FZE=6:-T7LUT"&K/SK!&Z=R:EJC]Q4@= M.]9^*%VIH/*LS`/83'-L3NJZH5KZ0.L=TOHLI7-4TUS"IT2>EH4+Z9"S5$ M4.1F",7\IN[PU@CHL,T'"NDJ+9-E;Z$OC=]ZF4Y:AV)MA*20HW'7Z#. M/'^).A+0$:M,>+B&R2Y^T.1H,>.S>L:X./V:*R.165?WANB\+(I?1H# MT'D1MTQXXPLJ;*?G'EB$"<1UD4'+J!9\_\\L]BME^2N:*?/]!3[,">[^]H/V M`_U;;$+_%L#?T$/ABRE62"UB]HN2_O1*>?1FR?TOBJYI/[Y2:AZR6#F:1.DV MU+@";,+T1#=ADH3S_-/(PO2-6?J-FN=/9ND=Y5\5Q[[@F\`)RE^-BJ^N;`_G M!S0%?_M!UW\H@V5*-1RO%(&X=(_7/E:UPDY*#`)G)O@8>>EWSDOO*GBI>(B7 M270^(O`32(^/(#WZ#N>JD&W"+/]@Z,\`:>`B2_S-%3XDO6,*;RY'!UAF M]%&02CU&R<(WS=]@X&M[YNTNQ"2_[CW M$M90"ZY#K6^2A;]B35*(S3RIGQ&FI?9C6!2]C0K#87+NS9DGV;W-W.=]-TP^%`_3Y0 M?]3U%N?E;1JJK.F_=&/4=6_)[6Z]C53-,53'-IJ=N;76/BSF=E4\'3D<'7L9 MYT>%X$-4N\?'=AP&E3UHN+,_4']4]D8/^WEZ-_[N^1#\+J4[:F3/N`W0+CDR M>*6#7W]J&.R5D3"(P;V*P4(.?!!U?;B;`Z3LAZOJF(W2>H3#7LOQC=3!A1L. MU-<#]=*,Z;)ZY/SB7H9JZIIJ6$ZS,P_1UPR%QAA0J*N.UDT`^YE&7[7Q7@CP M^/IZ*-O87K9AJ"/+4?5)?1H8RC:&\,[I8+!7=M'@0`P'ZNN!^J.NA[*-K47E MFNVHEF4-CL/@.!RS;.,PCL-+>H2)O\K?-6]YF;SZD/EZ>1.S?RU9D+Q[P+?0 MV0=/X0DS;KWK-&3VX/I+ZO\19RB@(6M)<:`AS2SG;2S%9#WLX93WL'_$"7>B M0RAU^Y';^8NGTD$H;<*;]*0;N4G:Y(DZKO-GYY5O@_-KKKRWU0O&4%+\^?:* M#T$`M'"".*T'Z^*77C!CN.,%K5"X6FS31I>+W5UP7@UV/D9#<<(PP1=)-[M$'`T-7UU@PT8^+!GWX>,-TX;"?*\_`SH`35V@ MHXL6T/QQ^@V.!@OG7H*?62RC>.GRQHS4OH8Z1TM=RNDAO>A%<#[0`2P?G_&!:2SMMBYWQ2A.N$PG3Z0H7&`K+3Y7''EI!B1/ M_(CM+_]B:\/@\H]CUUJ`PV)<8_\#%5KCP`M'F(Y<=O`M(0=3G(GH+/Z."VB?'E&A) M*CJAME=W"I7'O9_-J",D-CQ!/]"W.] M5!@P["X6OL>D@0-*3\9]3< M^2%MB)[MR@>E9B.NTRVQN;N8S(E"_[*.#,H-PWKVWJJ5^$4T3?X"])!R<]&=44?U^Q#4/!P3NURO]%57 M+I3"1*VUOEV>W(R/C]@57@`(@*D8RA&+AH.!#M1H+Q[UK80[!ELPYAV!B1"6]_Q M-B-2%_L&*RD7K'8YO`3$(&&D`VGS=MI<:LY"X@,F];_.U^:70NNG,]Y)&CVB MG,KG6GXC\^H[S3;$'L;TX8@]>.R1Y@&#K!6])8'+>)-&:O$L'#!J7AX\%<[# MU_"(I@LC:GO;="EG[!HLNLK5OX;A#%M)PZ<_@#(*[G#*[Q4AH@?^WU8F_N(F M:_S(?\=I!C0-.@F5:OZ3F"2EF4PT%_@C$FQP MYV83_J(\^G/-!>&UGH@&4I.$LV&3=CT/@C]\.X)E^1S:Z9>-%W. M04L%-$"6+I:^C<$*VEIF4;Z9&-`&#F':1S^W9C*'DYB-+R*:Y7LA=9(7..*& M"HT(F0%S7P5B<]ZU&,/)4@/5E%5S^7&[I#$$.$`^EH(_HSV#2R:FD8JPN'S>2.N&$SH1A&9@@)'TCK<`Z6Q2?-T MJ!X9#RMG>TQ=/>Y^XDQ+G`D%OTD>F6CP+AT6+V5],]&",5X!2!Y[/BEE[/I< MNLK?J7*";TK#'M]Q>]I:6SH5F,_Q)MTLM]D6TQMDW2*-?;PLNX0:J%S% M_H<`I]Q\<[_W0);NC')^",XG."]#1G#=\&JAT3(-V2LR1=Y\.Y6WM[+UCW:O M1V#PD1UBQFTF4ZL74O/^Q_#-3,5+GZ3P%)D-F>C"[82\PB^ADT&!5!IIFO!! MN>3#)Z&(Z*7R("X(A!*O(F=]+F_(>F/?P8>AWU6`QPTD+Y(:,Q-D.(8BSE@A M[X)-7X"_D^BB'>%(-,3W$ABF'C[F8,0MHTPS@NW&93-\*Z)`H22N.0C@?M'8 M&?@(84?E)D'*9LF2J#&WX[#S2R,L2QZ$GB MI_8?[Y69MK.M<]ODK(M8)`*7G:BHP"B.*Y]`J$0^>R?M,,[=,V'*QI5A8]95*K!\.+9JC5N+=S*@X"&EN8YPZU!E7:B;05&0QK[#JP'(S]M5 MIODPD9JOG*Q]-DK@\EQK"4(Y.C+)YLA/1"E\J[WGV&[J=KVP_6;;+KK` M3B(/FWQ/Y\+-6-+`/LT92/@=;GV:Y:+U+H9BPZV;NBV.[5.IDF-==$&X=7L` MYI+M])9TTZX_72P7-.'#^'XP'-"$#[U^?WH_(1_.>G_K78V',';S1(^M-5-F M]K=)(L_%VT'?]0MYRFKI7LL3*COG[+Z(E=/Q$5.?ZI8>S9Y5ZWUJ9U6AYF`Q MH:V$8-4@U7%.J8Y`E0N`(S_V)'?L3,9MF3=AIFO5I>M2G88_9Z((:0':%;3% M&P9E%O*]W;G.)5B[<;!?U:J;!]W400QH^V'F4GA-B[1=\^%BV)OW\T1!T^OK M47_(4@7-V'GM[)Y\U5N<_![R'*>8M"5-=I0_'R5[-\%8%X(S(&Q>P64.2#JF8QIHN.B MO!/>7#%S*V2.K[&ZW9LLW2K5O-%BI@MIL-P#M[U52+V#E%F\=^@\+TMEHV1NC,%6SXDIU*`!:AL`]V>U[E=+W&21`]=EZU MF"K:8EJWBI3L,M,",>UV@MHFT/3Z>CBG;Q#H8Q%.ZRJ:7[K6:MAV^PPO76O$ M07#)#*/447,6S:D?EA2RSOTO8U_K3?A5H'PHV>1KV=,1.B^0K%D'=!(GXSB1 M:(OM9A.R.SC4?TJ?KL/XRRA:Q\DS6PUJGH8UUK89A=:Q2O48-$-5YS/+?GC; M-%SE_$RU@=4>15,E&Q-8.85*&[O[GKSO]%I<3&ZF;#\:9-EN9JG2_W9=#SJCPX//3M2JI"JDOTG4A6<]B)_ MF"1QTH^3!*_8,\0:OZY;$583A.Q1N49ND`[Z8!B\!VB.QU41J"B#A;:Q4E"M M&/1+6=!_PV#S!'^I]=HDCLB?JV)2B?RB+M62F M8S3?N#Z\7#"]Y8B5:?>BJW=H,ORY,?3/IQ/R=YXTZC2QQ^RBY5,<^CA):#X7SQ6Q:DOOP;C.'TV@L2 M]A;O($A789QNY>^QF:G8'/Y,P->'-96\9D MC8YKMBEG4:4":+[IAK3!.W3=&\W1Y][X?HCNACVZ3WBZ&6\<>Q%[?#>_N)&0 M:7L4O>"4:*NF/C,U6W-@ETJ4DZ&)CG,B=03*O2SS#HVGOC26_2)UXXC.F.ID4)LFJ=$;.U!8[H+M-NJ-7X6AW+L#D= M[E6]^O38J0#G+#T$-;G%'E=2Y=UT+`D5KI]'4KX6W1 M6C<>W[QCB11'R_Q:!)W#^U.V+S*<0-P/+S?]C7>_>04W>]TRX.*=[;8T&-)I M(2IVK4N-(XZ1BG1BHDL(U3=VDX!Q%P>*CYU;ER.5=DDH=7B(3!DLKW1CU_V@0R=5B^.F>9BH:?C[9QNDT>?2BX)]Y\&?D M+[;/SU[R.ETK0V`T7O$1R[6V87;,9JBVU8Y1J',*'[LF@GBI>O&(E(^*'T#3 M-:K]!!(Y]^4?,$;;*R\-TNFZU1BO9FZCJ;+-<;A;A>J#LIFF+\J#* M*%ZC&4T#%F5'N1=_'$;.DGB#D^QU%M).&OE5"I71\\8+$D$:NDZ:-KG8H2IU M(AJH@6&A.=8V!>?U_'/Y&1NJM-F'[)8SC4M!I+`D?H$4*WT3Q_Z7(`S9J6`S M([+9V-FE`)N<[5ZQ.G7-M<$PN#-D+C%[OD$$@Y>UE)`#_(+#F'6GXM&,O#Z2 M=C#2M,G$#E6I4]!`#0SWS+$J1\^:+NH?([WZT9X`B)_QTOMJ-B+*Q2TG^%>" M;N7S%\J"X9<&H."Z-1%'1![*\F2`D^"%.*ZWGW:6Y%_!YEL M3#-7MTFQKI6J4\Y4%PP%.P+FTT24@F@4D67Y%I`/.,!KG"28QMLGC]C0[],I MV26B206:]%-I`"*=`4R>:KD2FM-Y]%OF`OX.!M/881%9LY,:Q<_4.<@??-\4 MVUMDW":021^AJ[!4Z>7M59+5??3]J]K88>]>#!CV[H^=.^VA-SO.65&H7A8, M5L^2($YF9("/_3E>A5Z:LGU35LWJ>?`!3E=)P.HNW8+H6HS=/:#]*MG<$.I6 M!A@F[PF<7^PT=6W=0:-IAE1G1GH5A[?1A.`55](:\LX9U`&DZ'):31/EJBC7 M/0UU5D_8WX:8_6P^3J?L[ZLXVJ8X#S_$79$T9%T3"F M_;)]V"NK%62Z;W4=)SO?ITAOVDL2>ILY#^,-&2SJ#*W%3A+;_;IBIQ&LOVN# M1]Q@L>I0NVSNADON`HCS$0%"[;FQI,!"#X#Q\R:,7W$QB$1Q=+[[)!]D5D=< M."BGS_JVT#CP'H(PR`*<_NS1QF!!_%,RF"7%D*H8>;L69'NRW*^B[3FR6RG. M.\+!T!5;@[4RSE!92GZP3,M!14$NV-O+JMO(W1NDH0R$I8(*&3*SIOD6V,C# MY9*<>@_;T$N0O[O>1D94?\?+<%<:\C*TIDD-7FB!)V%B!?<.>Q0,FSVTBU@C M+5OV1.E1/LNM>D MJ6?S@!^#B%Y@8ZXUS8O,NB/16A$')\$A?9V3YKBM==[G^G2U3:E&6HN0W]8P MHH""3-&W8QK/A#X>?/BJNOVJ]8LDV=BXWM), M\LA[IH%0_SS=EMH$9WDPWSA.Z6UCF@LCCMCNH7;@ZZ!K+9U\U^I46>5-%9WS MTG%<[5B:F[%UKRJ+Q]=. M13GG]G'P"U).$7>Q&Y,)666J M$&"#@`T).+P2P>(/T`LA]`L3@Y+NH(0U#B($G^V#[94@D[8P0$5,J22@L>2 M-C0%4Z@H8K)0Z"(\`*X=%U^]\H?)7[S$GVR?'W!2G""GO6WV%"?!/['?*0;U MH-]Q'T5\A&;2QQ@?\"-PNLJ):B9$3!W4U-$K[0E+V21=!_Y9.9FTB+56#X%2>K(,6S)%CA.6V^LHFFVRPE"TVZAR:.:+#^Z^X[Z,F:5-]M MC_[3P#OSJ>K+3::MSKV.DYKN:2,SV$^/TG2+_5X>@EEO`5%$@$[#6@R&&?0J M\$(M[IR*YA@E],G5D)?FH=T`+[,<:\I\\8*0+D^NXX1%!I]XAN9_SOTL<+Q& M.X6WUOXMYYW+4@7YX\%G+XAJ8_C[HJ\>T7TSO*@SP!G!G%YVNJK#*[F[K".K M@/RZ3EO#.0L[P32\LE-HHTL80_RP"(Q>$$^&^$.2_E:+UJ8GZ(\1]:[R.W`L M3KOO;0*RZJ&?]IYIZBY)=S[9KUG-Y7O:)FOD`#[-3SGO6';JQSUA4UX".-'[ MUE%URT!<$='IF(&2O?>M32NP>]]:I^&<:9U@\N];UVZ.J$ASPM&F3V\)3]?% M!8!I,@\>G[+>UT"X#2`5_O6#54N\X.0A3O%8T?7U4+D)E6K04[%"!\4)8EKH M%ZH'93.;\Q?H*^FZ'.(:);MG(B85:)Z/J#2@$<\(+;=D/\'+H,)9)-\4\#+\ M03"0U;^T-2OP@,K1?_<-B%&>@\-%DE`!-"`2)]Z9HPO-^TT*I2R/P!+^ZM`!(21Y;@4 M@W%ZVNZ[^Z6"?4K/NO< MOTK,B:_<`BETF0L9(!:7`E,[T*@0MF!W[ZN1W4LQ-W9O@A3;/9.4:Y('A\Y,IT/./_>.I> ML"!UHDE]GI+ML*R)NA7$&@XXJX(NH*)('!K#%!BY344FBGJ(",?;QR=T\-NW M9E29=&')!`!!.,!2;DQ@TZ(-3\*(B1T>7'N1?].%"RT%9WP0`I=RHB$-DQH.*\X31@+!_"V"TUN`5"$`RREQRUL:K3A26AQ:YD0G[H0XA,` M0G"`I83X!)L0;7@20GPZ/2%8NJ9I`6NN(81,V'H"1BE@+N\B)PF&$$IX$D+, M3TN(_%<6"A9P$M8B&L30JNB%YM<@C"S&)+'LXK2697=9A6OHVA):4`=#/5LL MZ%2-DAM&2B`8TP6I^+:R.+TOD(#*?:\`%5LY[+Y/.HKR@/%6\YWJ1][$A3-E M`QWEFIGP%YSWF9-6J]W!"MGJ]9(L;CU/X`<)7I&^\R_2W:[C9(T#FA&.[JGN M3@)/W0,-?O%NF1=/:Y,J7;-,C,5EJG097V%2F766_>Y(>6*Z^EN3?:?Z$[C+.3_<$K:F4MM4?#""7M%:(@F"G'E^;9-7[.-E. MA;E:3`F&9U5;EL5I.HUV_R^9Y%0*;MYVEP$7O^;>EG;.+6.(;7JQ[+-D6#K6 M9LNQ"77C!5$G0O$*;@@E`RXF5%L:(*$D$-N$HF+'))1R$JOEIE(,M@TIVY.6 M`&)[LJJ).+>[&I=TU MYX'6=;*<=IC@MXM%/JY0RA8_%!!+4@A$0#!!CDOQ]F.Y"7^PYRHT^!RO,/D5 MMNPK*5E&\;:WYPSD;9'`"'9)!Z4P"&*8(!0\7\1T\D5T.2J0U7*A9LN-Z&5S M[&]7V&_$B4_7%^\^?F&./LR>Y(55 MK$0;=C&`3&F_H27:X^@T"1Z#R`NY:OWA>].&41;AE*4&E5/25*$/EZ=ZT%V( M&A>EB9GZA^]/<[$X>L%I1L\CVH,^JXSPKK%6Q=KU8T/PU8UDC3P(IAF"E#"K M19Y3W6:EN^$T^5U"M^OCI!]'Z3;,:*?8G7D)ZF:L:?'F:Y>JU.[#FJB!X%,W MK(*[L^SD(RG4V1'(JBH`>;L23O.49((W7N#O(!>`1-L'"EEK3TKJX%;/2LH$ M07!&AZ[-DD*^3HSBR,Q5GL)JQ^/JM?KS-L`)*>+IE3U^*DM::*8)+X-A1]S" MW1ZF=(8JM2.E,E3O#M9?6]=T4JK;IJ=]3[*[NYH3*K%+B\RJU+K3QK"-NQ?9E$!$Z M;QFS[8UDAI?\#?2Q&CF/6=8UV>ML MCK#8G."=-K=P]6,3B/-.#*'VHD2$=#P`$MUEN6D6.,O"?""%8:L&H'_AH4'0 M\`['AQJ:_ZV#!-\$_.7;2@+F6.%/6Y6G\88TB'44Y5'XHZA\K=ZPS3N5Z+*W M[E%U57?K4!S8_M*]#GS<2?Z\$KNPN(V2\G\?24'I[J@BB%!9$)K7/L3%A_96 M;$-VT-MQN=928W!E8?DQ_I/69^$CUW3CVHI0&7TW7 MZV"%DV)?84(/V.@NEF(?J8NRM8/5SA6JSE:--4&PJC-+.>6>.D5M4%AK5 MC49V;)O%Z"YYAWR,B"N:>(Z.;*D;T(\C>GJ,B=>,TZO7B4?O6LI.:I4*\`YH MS>`*K^8TU,Y0KF9P.'M":]'7YND9<2_R!_1P.=[0^;1@HLA:2@5XUC*#RWNF MN5:>2F.G5_8W&*/XF#A`F%1L3I#1Z,6&S5KM()&U.7(KX=8I)A0$,UJKT`EN MJ2=9\,_\]GF\9O&A/BXN$B='"+8ZUF'[)DZ#+.VE*<[2"3$E6=;QH7]Z<;N' MZ6K0S<-SL2P84FD`\N,3&8O\7(,&^@_O>?,G-&B.-">^_67*!\=L,.*">R8H M'!L=0#Z`YB0D.-;$DZZ28)._PC[&9,#"='IMAC27+[&SB5>VL[Q727:GJ[VK MVIS).A?C?`P['#N7,(MMK[`\++E?'E)INHGLXP1Y:)67D7]\^N!VLES?!2$I M=OAD@M;"VI5`JYAVH91S%FFAM4ER^PX5\N4V'(Q![SJ(@@R/Z8W;$5E"1(_! M0XASQZ^^7JAV@YZ]@-)ZNKX.TI47_HVL3&5'-,HQV_&:HG'<=GBQSNE^ M_+IP27H)J3%ZCJ/L*:4OZM'#D04Q&'Y^((/HQXLS1`A\\,5:%WUF@K]FRR\X M?,%WK'9':5J^4+@]1=8`^W>2=HEOM'](JM'N&K372+O$P3=X770)6J/EE_@H MC5B5!;<#M*J[/^^+@MXHW9OH.['\]V^6Y71:.U[KY:4!9WJ]R@=RG1;UEME> MP]^)[W]XJWR_)BU^M.;+"X/-]GJ%#R,[+>D-<[T&OQ/5__AFJ2Y/0KIO8<"I M+DE>NE]);YGJ\J2G2JK_\!:I/H_#D&Z*KC.<')7VXH+A=@%50QRPWR,H]8UV M#455^-T>G&"/"IXF7EJ.>X(S]AZ48#_72,M:Q+1Y%:J0:;T*I'-#<[C"![TL M')Z8Q$EK-=P"1E&;^+8 M_Q*$TC#=;F58#8K>IWJ-,.DN!3AGZB&HN9Q7C+@HJ(I"JR81R7[<^Z?.5 ME+2+3LDF-B6@,,^8Q@Z@)"-SG[5G%ZHDB]T;OR[MP,)^Q6JCY,P4#' M6FI04_A5;E"=@G/^=$')W?MXAXBCAMC#,403,563Z(83=G`":!2MXF?VZDWO MA2"A-Z>7<3]^?HXC]NI7<1&:WA)=B7I\QR(LWS)0#0+[(F\;EEHUI%;]CW__ MXX?+RS\AKRR+WNI9L=)06KM4?I+!@L9DM9^:J5UP%Q!9JV%KH#"$7@X3&G'G M_#+'R#TJ1;1^1.5+0/Y)TJ<=Q[4Q[SN#(-QFW",2!Y1CTP':NYK[C9!%(()UNZ_3Q=LYFYEF6>#?_T$IJ2ROL6 M9I//AU6X3NK]2@+#[(/@?]`2RI>]];V@!,R MH.V[2OTZH2"\.Z)JF-Q%_S(7R8:8A]FF-`T08R"G?>/4]2&N[O%+H"ES(^IO357 M?\<=\Z.YOV4[(40X."^1(;Q>XY7R3M>)!LM3/'3?'E9/\1N_^O'*&L'(;['M M!H9/,!"?L()MSO6W:49X-RED8=E(C.PG%7R$P&FAVJ*:!DCJHJHKAMCL:>CZ*0N M&>#:`L#,(4;'MW\EYZB5R2(ZH\?-DSC#Z2YUL+31E?+0;&`"5F"24@TQ/;13 M=&&C`5XE=.`=13W?#VA=O7#F!63@+8;EWD]BP%ET#YJ;OJU/WNZ4,8 M/+(Z[#SOGGK!L7=!0*V[7RT@&[B>@$MNO;H44-,((*J&V"J9V-R9"79X^WF> MPQF-J(RY5:!<$I@I-#"E^=Q8#LA"!14ZKDW2,:4>5$.T$4(=.]JL052X>O!]`A"UH/,U"`: MQ1`S7%/-DH!_9JCQ)?NL;.-"!FY3-P%";_$@TK=X+@.X MQ1L`(;9XD"$9JP.S2!3-(4P4)J]S`RS`7Q=+Z&EK3 M"[`IFSAQW,;#R*=8Y:U<"`!MYR8ZT"V]R+PD4[=U)0*TM=OX`+:W\#%'F2NO M%`9E`Q.D;6M0'<244%W+J56FZ]I%%MFII%H:IEU44.'-L378>;S=W,`6+4FH M=A##A&F#%PHY+B#WLJ=D.U090B$.SAIZK&_`)->D/]\86Z0A#=L@(JAOP!ZW MQK:X?1MV:,-\`S:8&-M@\C9LT(;Y!FSPR=@&G]Z&#=HP`=H@B+QH12\1$:T? M2KC%]+:,A^*S&C,M6+;I`IE;-QJ1;R-V"Y#>-,BO[M&K!9+@?HTX*'.88>5?7B^TBKL7N1Z[;N%DJ4[P ME#&4S6-UT=T?@;G,E:$9KS-RD+U+7(OK.&E&3QA;CM-\&V:3P19TOUV\=ROZ M`Y%"4"MJ_`L MP1OR57F)V90`!D6]"2:8UZ,+)8(=)>I<0$7)J"S:+3G$T?#TR7?ZNC6@*H^V$H!J%0ZCJ?_5QUVWS"\/DS.[4[54(4/-UKX'*O+O2 M4*TX6'?I=G4O!ODBG$9AYI8@4%.*4:K,5L%I5H?#:M_":Z]V\A@.EA8>KNA M^2V\YGT#=QKR4P<"\8.P<=DW\!JV#@M@HX[Q"PXOQ5$G]>]`-:P`&+SQ@('\ MH&C9#U!;]L-;:-F/BI;]"+5E/T)OV=B+V,%&OF^:]"(_W_"(DR7^FEV%@G,X M$QU8EC`'#,]"-'7?NI&\3[2$$4N!LH(28KO=Z\*NG6@Q<-F21BW]!BRB6=I` MLLPDCCYMO9#@P;Y97*U>`Y2%C.%RC_P1XU2:0")LIQN<7Z=.R0!C@-?2,/4^^7^JZ+KJ@S+,'\+;E\B*`9JS+ MP7&^6/$Q0%/`/<8O#@IV&7MDX4=205C-K4$)T0`T1`V7ZZ+2JY-L%*FE@9G" M`.J;L8=D>TDM_1;L`7T+2@);LBFEEGX+]H"^<26!W/UBLGK"_#:7IAK,J75/; M,N::H,S4&?:;LUFU*QKYT^P))\6CNQWM)RGE+=E2706X=JUMFZ;L[ZLXVI*5 M&*E'_57<&UHY[%^]T@^]B'MWX\#B0%KZL+H`-#F.`I;UM_'JH=@94 M*$1+Y%ESGI)X^_@T5'OG2F%@MM`CA6J,OJKQ^V`;NZ]LW"*[4M]=LTKR7S6^ M!-BLZFQ61;,ZR5=5Y&GLU?(TJII8(`BPN>4H)4U_S2XSWC@]72^@*UL?;HL; MM;*[9KU1->L-V&:],6G6&W?->JMJUENPS7IKTJRW#IO59"B^!3\,BQ'*FAO` MX/O3%X-V;PD!;'6S2OF.'S3K'&WIIVEN*N6:>J9IV";=;IF^#L3-6X,["-.S/A[,Q=LWY2->LGL,WZ MR:19/SEL5I,%X2?P"T(Q0EES`U@0SE7M/0?;SG/H0S#+,\.R-CR$^'X31[N7 MHXO5*-?D>A58AC#&R]&?::)2%5%=5"K3*V"%NA/#5ET(4G@V4..&-6\N8)H$7O-0@O6_3MD[W M$D`9;6_X0&TY_.MPWA\MAM/KP7`^^MQ;CCX/QZ/>U6@\6HZ&"Z'U-#KP[&4& M&*B%:D]X">/DA";2*<&SD2%BJ$:*$_/TEWH-@.8Q@-NV#5-D:?G`95MDT/9, MN=A%%YXA#TN^F)L4?`I&!E/LF]>^@F<=UF&!D&"5UFKP;:C%#M>$2_+O=(V3!/O+.-_ZDIE+(`K2 M-'*<\,QPU-0;'W\-'T)KYFC4J&8&0Y"2&]42-3BFV2\+!VC3M$$:FN8#--/L MEY`#M&G:(`U-\]&):;;I^:/G;7[MI2G.TOZ6C,#-LU.AP*\?G!M`C:O=YKG4 M&2KDG#:RO'7!-:NF/1TUXP#GGL*<9JLC_PV$A.6E`#6O`ER[J4M1-&>9]9BP MHX:OG2"E##*\"U&[XFZGK@D)Q7";Z&V=0F;>RH:?DP`E$+\U*`&EH! M3AB,4HC^%N7"J)=E2?"PS5BT4!:CF0>#ZKW(-[..3@>0K8RA*GH*\B*_L)TC M(Q7YD\5I/Z5"@,P@Q]9N]TJR>E_849N/H@R39L@*&*(6;XD`:F\9,OZ=X%RN M;&Q0CSZV%ZF*$WT8"U0#@+*7T'@5,"\YM,T@>:@"A@DTX%2O->S$0;S3S+&? M?W0:1I,K@/'#35O4T>#^,PX>GS+L]U[(;/.()UNZ%31=YSVO=FYQY:7!2C3T M=RH`T,2P'V[NJ+HH!17%H+P<%*^+("E4*^H,L<)@67H0A%OR*5?O#K:6%0'? MVEKD!]J[*-^9X[9*:*CS`.?_'45YME2ZW!(ZSDH%0-8TP\F/N;DT^K;4^QT* M(E13!6.G(A9/Z7&K=4!;2P+5T&!EH*(;3UU>*WJN$F5Q(MDK4RJ`-I<(IZ&M M:JI@[*2XZ&*L!-I>,JR&-FN_F`/)<,D6^YH]:1,]Z.:3P36W("T!N=_DYFLW MV.)E7`1TMG%>6(_N6MR:7<6_UCVV08(*8H,M>Z07CC'":G@YLGB4'M.;:@.R[!VC^<;J\ M"-ICBT)0650F/>_@)*"<=\B!R4_W'!XMU998U1'CS`L(K8K$$.V31XJ:?QQKSV*`&.U0 M]'R4X%[E_:M<^(=AU`Y`A3?#E:IPM@YT:30ZJ@*:[KHB-MTEJ`H!L!?4\_]G MFV:E^RT>+-B+82*3&BL#,FIWS%RT^ZX$MN[8I>"@A5`+%\6<(5;0OU(V(D`C MJRE4X=BJ40;D!P4E*6DP4#T42.B6[E<*$+,>"-[4"5(7YRS!BE%TFT(4P!AK MBE#8)4$$NW69)0J(_'ID[T(`F/!P[`=,ET6!R-EJ1+MNT@="[E$$`+,?BKSS M`M1YK.4NAY?6I!(Q(&;3H1,.MB":OUP?22=H=G::#P::-'('%`7$^3E<+ MT#W*=$J'9BB:PM@M07"FE.&3&ZJE\:^Q83HNZE3Z96[5`( M.`/O@UUNZPZE.=M*;Z#H-GT:ZD*:0;M"%F^QFQ4":5`6/45A/"Z+E,'UW"Z8 MC4=G42G_6YY3@6'@`X`+^VZGHB#U8./>"F2XU>,S[H6N>IRP$P%IWB86\?L+ MOPSPVMN&&1I3O?\&DWAJ$F>X]Y!FB;<2QNVK-0`8H"-0H^145!/]4NJZ,M8N M@H<^M/.9/K0S%3RT(\Q.9:H+R("=(?.G05S$T^L9HH4A5MH9NDGB--U]Z>3H M;Y>#46A`J1`0'T"-399'LB'MH-FO@RC("(5>J&/1O/4QP9EP@C%0`=!YNB)M M&\A`5V"N^D=C\A?YN/R(_.N!^`WDD_\/4$L#!!0````(`!6"2D1=7[9^C"D` M`!.0`@`4`!P`8W9M+3(P,3,Q,C,Q7W!R92YX;6Q55`D``[E!^5*Y0?E2=7@+ M``$$)0X```0Y`0``[5U;=^,VDG[?<_8_<'M>9LY9R[=.,MV3[!Q9%UL36U)+ MZL[,ON30%"1CAR(5DK+;^?4+D)1$D010(`D!)FX;!59]'ZZ%0N''OW]= MN=8S"D+L>S^]NVQ=O+.0Y_AS["U_>O=Y>M:>=@:#=U88V=[<=GT/_?3.\]_] M_7_^\S\L\K\?_^OLS.ICY,X_6EW?.1MX"_]OUM!>H8_6+?)08$=^\#?KB^UN MR&\^_7/@1>1W3H2?$?EM\M6/UG7KN[EU=@:H<^IO`@?M*G2>5];EU?7EU<7E MM75Y\>FR]75!/M>U(_)'\LOWYQ=7YQ<_S*XN/EY\^'AU`?Q(9$>;1BZ\7 MZ?\2\1]=[/W[(_V_1SM$%L'/"S]^#?%/[YZB:/WQ_/SEY:7UOSK3J[ MFLE?,:=\1I,0?PQC]>Y]QX[B9B#\C,4L0?]UMBUV1G]U=GEU=DV8">?OMN#' M"`:^BR9H8='_?IX,=E]UD'L6.KCE^*MS^K=SPL]FA;RH[SFA;H&V"?O!/$-'H=4T:=8A7:Y?`<5Y-QQO;I7!.GQ"* M0H%2I66;UV)L!\3R)Q1AQW9E5"H5;$0_VK,0Y2,<+49K.CH0'D1P\844ZB4# MH$0-C6OYRW' MOHL=C$2*RE;33-]I#=%+YAN![Y$?G00P4?>!R#:B9:S9^^W M#1G3!,KQ1!K1J=OJVSB(9\L'9(>;`(290*H1S7JM>]_VPG[@KT8+THI0(%"* M+="(/OW6?FSH8X\,N:2U"%3BRC2BU6VKXZ]6.(KQ)S-EQX];,5D&BKLJ2+81 M+>]:8S)\B=M5H5PC7Q^0'A[=^V$X1L'TB0SK`BV8Y1O1YA]D@'P,T6\;8F?O M&0`*6Z"A<7\4+&T/_QXW4](,8.,W>#IHI'9EX^_,?G2%1H@%58[%(!5!LLWV M99!>C-)J^C5((X&4LI;619&-W2I-+2>I6L/+ZBI>'DO'J^HZ7AU+Q^OJ.EX? M2\>A'=#ER;-H2I2I0N58".M$,.$CZ"GJ2D!I1>MIR38`KT#]RE92]4IU-3M; MPEHNJ[@27:#H">74S.8PQ$1B2G6#(@B6YVF[#E!(6(@7TO?D%P]B!Y5E"A.BI:7S"N:;0GMP+'\@,S*A*IM MG7;@'/!?]/2G)<[7L9/SS'G"[J[I+,@`+XEDBIHOL",++M'@Z`QTB"&![0Y( M1_GZ,WKE45`H"N3@TC@2&$;K8&%KQXQ46P[^80D@YE<&85YFHDZHR82#?6+! MG)ZK\C'/%06"?VT@^*5&ZV"A3;294XWZKKTL1S]7!(CZ>X-0+S52!]J=34`M M[./0L=U_(3O@-GMV:2`'WQG$@R=H M[0?4+Y$$,7&7IPP)("=_-8X3/@3ZJ(F;2(>,I$L_X&X8<@6!1'PPCHA2@S5V M#7^U\KW8^1P[3L+1)HKC&3,'Z:4=A"L'WLP91P\$#YW[C60%DBS`^^1WC%&, M4QS*C4D[;:'U^BFABT(P(9G"4#I,W(0S+"\AX\?S4A>K*O]K>13ISN%Z99U9 MNX`_\O--^[X][/2LZ5VO-YM6$P];?MX MCUP$!:>\-LF&R_NL,27TN8HEINPQ8:;T:7(!AA'Z!X_H_F` MH.@M,5GR)39R21+)Z?,8R_`$LU[Y!$.^-5K(SC*E0OJ1FMP8YDG@R4066[2FD:F"P:[6W>NNW&]BOUV8$] ME?GR4+Z4[55K\L7'P1BN@@T9]`M-BTL72P3*F++M;7W&^&B805IW@V9^>HTO M'`59,\7.3H`LE$9E^]J:-,+Q,8C/"7+)_#X?VP&H%_)DP`=Q)O/'Q<,0WK*N M2O)?S#UD*):%\J1L@UR7)Z;]E3<6SRAX]$.D?VO1L=>8[G&0':+1HXN722(@ M8;\4R4$Y5[8?K\DY#!DT'(F-%!]Q/(,_)X$4B%@E":E'EC&ILZ#RPWC9;MO`[K M6CPI*&&F.E\@F)C!'F.&AE`($(7R:*I3!HR.&61NXWN$YSWP$X@K4[TO>5O- M8"!C%&CU".?!5/=)B<6GOEX$Y$HM&0UY0M``6F5[]QK'0>#,L;K[7I43O0;. M\*Z5;>AJD'8JIW;C[?@0*RRX65!:&,J2LBV8](C)L=D,4C(W3T5W/0HEH70H M//B67>,QK#6#B_9\'O=WTO-M/!]XZ8J4<^#&$H`RHVQ/)7_`QK?=#((F-+^? MA^8]._#(Q!BV'6>SVL2G$607B!V>FQ\B"Z5-V19*FC8X(F8PR'YW`;)>@#.D M;"1;*`Z2&:0K,G_IM"Q)GM^086"6] MI3FN)R`49O"6.1J0G]]`PMHOF]S(KO'RU^Z+;O'W.;?X=-:> M]1YZP]G4&O6MT;@W:<\&HZ'.=+0#CUB%=DJ*'0M,`8U]9Q0]H2!1C*WX02'- M#F\!ZKE.46*>&6-6VO:]99J&$'#RP!'1[4N4)$5DNQD430B&1`>:;+6+GI'K MQT[L5&=>``573'?>4C'X^<@)``IF$)8]G,B=2;#IX@KI=O?*D@5`P`RJ;I%' M+'.ICO,5]N)W&NF5+V'O$@KJ=LW*4@9$P@S:"L9)S%;Z':^RU#"M/?6(I)UA MR;Q-GP8&$)DMK-O'5YG*HL5*\A'>VM@;>?NKK`./J!>_"E*&-)'@"FCWR('A M%EEBTF!&LQ^'\262I%$,O`@18`4IGLLEM'MV9#N$R'A3*$JT$BX+"@6AA!BS M=&.8*C_5?$BF&@\MJ1-<_V0S1!%DFLD5TY[J3I:_4C/U+11*9R7JO*6!J:/% M_AI#XBLLGY1XY;5G2I.9D\2&Z^QGI5P]^'.\P$Z,YVCQBQW0A^P9/+'*:D^# M)L,1WV#C^!EX\XT3>[OXW)25TY[>3*KO,`U]8W-3^]G&+LUS.?,S9RGI$.:W6_`:'ZM2WRML+8]LX`K&;GBVA/1N7G)M>9+H96X2\EH*. MRBBN/6F6$&P^-ZP^9Q`Q7>QN(E[8!%-`>ZJLFN3D+#>#GE\07C[1V/UG,@\L MT7"S>D3!:%$('1`/>/(U:4_!)#<05H7JM(@6#)R2U6A/Y529M&K<-[/H,>8B M!$8,--QXCH+L$-Z.^`H5X&W85^&Z%?.D*0S)C1 M92*03G0$SX:"P*)?]-]&KA/NPEET:1P$Z2O=?==_*8EP_9X[['7:TSNK?S_Z M16>$:^:VZ:]ZUNK83X>E7$3$S]CYJSQY5$54#=;DS2:TYY/YOD\0?A/2E%,?W'.RB`X5G M?F.]5'DWT_F*+@ M&3MD>QUT7!NO.`._9#6ZP\&/V!(J`:PDE+(\+B"YAYC1128RHD18=]CX,:B5 MP<.DSAZWP-$ZSBWEVIXP&)!57G?\^1&[+Q\R)?TT$PA`$[('^)$Z.F?^^XO+ MGZD.Y1U4+*4[`\B1>B84/C.Z)`WRII:/O"X.UVD"JM$BGR.,W4?!%>B^:7#$ M3BL)JFDM86J[9+EPD/T/D$L1*@]L!\J.A;2T`PBD9C2#TOL>0S_JHA`OO3A) M8'B'YLOX"LZNP-92`B-O#1&;);#H/)XL7?SOM5U9YRIS)U'*/,[G'C`*UM/`= M^1KW,3F!&+0!*/.@-=\`2F!YB^R+7^CDR6B_J-D\[V8^X\FQ,_NF2IW5<&D] M4((5IN!M58F6.@!F%^9:NK MC@^F948IV`P/[0"(:K\`KJYM`*(U3K1)P#%K8K(PX"9P8XU$'KDWNL!(WRQL M9('!K0L:LV_2.7YUS`Q98`2^@]`\[!,L]N'CF;A&SI0A%H4RJNQ@OP8]^>?& M@#B90>L$K=,Y;K3HHD>ZWNG8:TR'&;KC&CVZ>&D?O.)2]B8"O`XHTJJ!GQAA1KGF;X!($KP2"^/%%6<(+XE"FE9U6*F::@5?E M06$=MQRR]@PB4X>&9IO(KU?P1G+L?:*B1D)-;J29]#P%69%WZ]GMW4+._NX@ M,7>Q//2VK1%[.($MS0S=C$34^^.I;>1_YNSC<))EAAEYE^;&,R?*1;!1G^*E<&9;#Y/9F_ANP(.AN8K;[WWS>STY],KF&`4N/0'* MC#$QHPCS[?(#S>'U0/EI?H=6GQ]9M/0L`/*F\1BL7!F4QN;W4%5IK(F;<>_) MS.A:('+@Y#;&L`M'P[#%1^\K"AP<(NKQ+]EA\%<@8&$HH4:DGI,Q MS"079UG\9XGR;`\6N`(HG4JV7[+>U_HX_*8MDH"P:<3\28,\1-JJ'HP'>C@;\72E3 M"$J`DBTH$,WB]E.`P5'WFKNO4VNRME3P-8OJ@K*E9*EN4* M@/-I&D$EP';C^"J^O2IP87/*0]DR9<\HMMV,;2)DG9M:P'3=22R9F2'Y/4(J5<3U3Z'Z$O@]=J2(HZVI.#<&L5S7/4,[C&03**[,PE#LENSXI M[@3V&L=/:3!]WP_21%[\3/%@82A_INSW)%$YZ@GE;AF=.6V#L56G0BB#BL\L M872(#RXE0#2OR^YL.LRV)Z2]4!Q*JN(3S.JD,@`P\Z"RUE`K5P,X_[]9Q%:! MR3!OZ9BT'R_J^&$4DF;J;N8TJCF7:(N_'Y6K`&V] MLPD";BH(B2J@O"K9HU8B29P9E(N6ZC74H?89"X6+)8XDE"4E>\HZ+($M5$A. M/-I#C.#,B#!Q*$U*MH\U:9)&R;CUZB[32YU94;H2*.>F;#DKHJ1XV)P0T$CE M](95DN>/E_#H8%#A24*Y4;*9K`ITV<@IAL>XK0ASV"=+[$-H)"?&$GDHSTKV METWR#(7*N+$W$UA?FD5AZ'M.>G,23KQ45>"WR$QO`Q4`-*[S)V%(,%!X45K0 M&J#D-W\=M1'RJ\!EW!"0;;?;S&M[*VP(Z9)50%E7EHU&,IA`\% M?-Z5K`=*?_,7;QN@OSIPAIT(D(TA"K"WK++:@LI"F5:6SD5RQI7#1.E4*Q57 M+10"O[BKHLM)HEJ<+W7$5S.'>R%]ILYI7%F*3@32I+;5&;B MP*[3?[9DNEFOW7A,IO-H,B8/O(4?K!(>A#F$P15`Z5;VCF6%Q,&2Z)AR!!TA M@FU$1V?N\]^%@E"*U#T>(8EW_C2YU/`25GX\+]AW3WZQ_6OI'P]J0U\CY,WW M4=0'(#C(/0L=W'+\5=+;VZWI9K6R@]?18HJ77GQ/PHO2L88,0F/?Q4[V+B^. M:'47%Q<_6&=6%X>.ZX>;`)%_M%O6]//#0WOR+VO4MZ:#V^&@/^BTAS.KW>F, M/@]G@^&M-1[=#SKTKF!CH_G0CU`X\]/$>S0@+NU+@FL3$#F=HQ^/C1DA^<;E M9M>&R@,[EHJ)#LY^7 M@VXT&0W)SYW>0V\XJ]:9&KH(L[.J\V1[2T1?4>L%@1]T?++B<.)$U^*96JX6 MK5FRF3S2')Z)\KNU6EP&D[9-9@Y(GVVF=ET]NA*7I?V[293U]_Y.*_NL(#V- MB5Z+G?Y#OM-WR'0Z&W5^OAO==WN3J=7[]'DP^]<;GC=+M2Q"Q^M'1((K<%*3 MG<@84]IWM]6W<1"G*7Y`-FV]Y?/:Y46^B7=;5K\]F%A?VO>?>]9#KSW]/-$^ MH^V,V:L*F,'X4AIGK#+%`%.10$SS'`/A*#>G@'#0WYEZK7O?]N*DQ.F[M,5^ M=)GO1[V6=3]J#Z=6?S)Z()LOLNWJ3?YH,T4>-[)22-[:\@/!E`&3/+6Y0P8/ M_>V^WTI?7B6KPUT._6+3O\HW_7[+&HU[D_9L,!I._]OJ#X;M88?LD/YHK7^/ M'N%Y!Z"@X0N%3JW-`U'0W]QO6_1N&(YV>QH_WL<@K]37=GF=;_:W+:LS>G@8 MS.+5DM4>=LF_8]=`;UC9O=;0"R!LP_8FB!=4DM7H?/($HBE@R25;C^8U6"6> M\V^?5().?_>]:R476DJZZOM\5[UK6>/VS!@WW=9-*N.4*\HT?=^4$2ZV^Z,Q M/BT6?(4;HKRK9T=NK8/6$$7W?DC?&(OS*!=;[7?Y5CN@+N<9V59,IQ997UG3 MN_:D]T=OP,V8TK,#C^BT8R-6CNO62B6%@B?32Z`&F=*#_M&:;AY#]-N&U-=[ M+A_XO\]WH7_0\]";:>_39S+X6[TOFJ>`O`60^`F6A-:HD$.E($>A;!'-/4;$ M22'F0V"[_I[2;HV"I>WAWQ,(O3DLO(`99G!9%F8PFMRVAX/_C3?]\=X''G=@ M_7G[TU^:3GXS`CS M&@?^&@71Z]BEEGOSW0VTP6IMXX!Q^SJ5!@D#R583*:N0;0GDS*#ZUO?G+]AU M8^_R87X4<`^7J0-(O)K`7(7$R^-H!O^9!`)=](QROX([-EH`^/79JI(HP,H/)_>,?X02M_8`:FGT2)'V[ MFM-SX36`GR$[,:9E,32%^>0F2.?)#I8(/D6+Y,"O`IPQ!CGYV_BT(GP+%1O-V9;$W@_#DGUBBJ8JK?1U<6D#RC=PI+W&^% MNPCE8S]> MW-)$^FA^\TI_:7ME@R\UH&ZE&OU@4,JR$<[-8&C&,+LU)L[\O-.9WN/M^\%^ M$DD30;3IRPK+-*;)C=6BL\JB?+:);P/?Q(ZA&%3(N8<>=73ZYF1;H%ZDFFF[ MW+&)\=+C[B$0;QX_QYGV//Z0)%N73E]=C:&H&F0Z6&Q'NZCV2LP=R.OTLS7/ M5@DT^A=>C)LRK+57X4H8^[Z,@O471U7^$@PD:,*-F$QS256=CSRREM\$-/U& M?/`F?UC^RXDF#&:7Q5N/^X#@Q6,W@?*0-YK,6F$WL_M^;-0 MLOC:GI3*[X(D*M,X.G.98^Y;I('2WV,*8]KH(;8'!Q(SI;/AR7CL0./9[&[B9"<_D.)UFASMMFLDPS.V(E$/5WQC*? M-Z]%ASBU9&^.-Z?.[J&]0EU_96/. M:;*:KYG1!DK;+RBPH*[]^W52HUF.DQB'S$%='.[P@%:/^R0EA5S'?"%MC@RE M^!=\U4#PC$N4//2]3QO;Q0N,YC*\0^2T'0X=EWHXA,:QOS^&%Q+.**KM2.FX M''.!>@-YN*EY60"IE]SZ+"BE'^4[KO`#-WF[*+Q:HHFW$P5VY>7N?/'B$C/Y'VOJ+`P2$: M!]A!$PK'UN31)@HCVYO3X'QFB`L77P4*:%_UUFMQRBA1$T(3:SL(PPV:M\/" M<,Q8SXB$M*]>A11"K#"_^\N/;L\V=M,G;N-@4?532?&+VM>]QYY26*`;?:YQ M63S8*.39$QQL6)=*`]ZWBLJ&O!?E=*8[6JU=_Q6A*0J>R5S`:'*9,%H:ZK'T MZ,R2W*Z(`VC3E[SH;]LK>F&#W:^5?="HR'I6V\BG6%*+OI(I>^A[*%4[+%>8 MZ782RID5G"XB$6C4"0RV5\7!MI`I43387C4XV&:N[XICO$$'S/5J-.&X\^1. MGIL@\=N1M&''H@8?27?H+<_1(FU@HV""ET\1_WB:(W)"G'"L,./8NE1!T>DS M5\@,=H0M#D*4RG-ALJXD0^Z0>SAT6$2W]PO05+(^E#+[#/&8Q*JUA2ZXDX"\W0.'&HS-UGERTH?&;(G!IW!NSM&[_CUP3%UEM4FN_@;7V&U-.&JNV M]ILCM/;D2QWQT-V11%/9&[Q5AN[.T9#LB9'L22+9?+ZD&DCVCH9D7XQD7Q+) MYG,.U4"R?S0D;\5(WDHBV7RBGAI(WAX-R3LQDG>22'XP"$V.!N54#.54%DH3-E%%[95#>2^&\EX62D/V2J4& MJH1R@M8T@F8.@#1?%`JM"9L?MA7*(7YX\.=X@1<0C(MEH2`;M2=BF:P0Y;$8 MW+$LID;MCL9'@'(<'W>A[3.NW)!\5EDHN(9LF/@F*T%Y>WYXA]SYX^O^]=PN M#I!#JN"A#I6%LF#(9DL.$C6^6=\+-VY$M>`Z98O%H%@;LAUC&FJ('[80X4%? MZ@4\)B:0TWTL!(^9!`%@W&VN)`R8V'A5WG&R?]=]1@2$V"]57N529A=03<_* M/Z]];QOF/EJ\)+V;L<"!".H^-9)&70(.)70 M/;+J9#?07!'=AT/5T,R;J+B_"UIH:4'=9T4U^OUQVNK^>RF;(G!WQ70?'M6` M-F>J^DG_`7MXM5D!YOY=2>TG2O76`#F+CP"Q_14*\;:D]I.FFA`?6FSTM8KK MG9:[:Q7?R5ZKN&XX:?@SS?'K9]*RPX/S!3?=FJN]N@DUOJXG0 MD'(AW1F>F^0PT\^`8"D9U0K?'DIR-)2F1\G+%L>DIP#1<9CIV][\5I*=G(S. MURR.R5`I5,=AZ4Z2H3MI=I0\_WI,=@H0'8>93Y+,?))F1LESK<=DI@"1,F;B M)P]&Z65T M`$6U^:;4DB0%G-&;UB'%@"I>W+Q^+[MYW=75X"9VFS/C!GEH@2.:SRJO.7^? M*E6!";?*3^[F?P6*OEWT/P(U;^2B_[?<\UK:_K?<\]]RSYN9AOR]NN,V@_.0 MFY;0XUNJE:U7V31FOJ5:.5:JE9_3R#I^/O[RHKJCM:K;G(D.O::B\7G4#>&R-N M*+^=Q#=F7:4]ZRW\Z$1@`R"I45AP;ZF#". M\BU1#K>"!#E71@T")YTAY]J0)=<;R)!S;=0L?](9J%45 MP^#3RIGSWJ@\6AIRYD#V`P(1*-2&+!-``!P3^LL*V%_*@F_(&08,`N.2A3#4 MOJK`W)4L=20`K4!_5C,E^+Z-MM/W@P7"T8:^=.O- M]^DNCM"<`)\^G<1YQZ)!R420O'O:^^JXFSF:]PD*F9_M_L\9HGHS]Y('"@%1MN&D&W9$TJ2U!1 M1G=X:P6"6(8K':Q&FR@D"_TY]I;\0>J@H.Y05JG!J<1$U1?\,Y\$7_(OE=&? MM!``-,QP)9@7+SXSYMK2@KI#@$'HVA]"`JH-:K M2G9+-^)D.*5@S/MQA`_U)M,&L??OE#,`%H82H7=[+(F%HH-WM+;Q?/_A5"G& M@I137/O%!Q#F0GOUI\/IMG8KY@=DT^0V\=WN-&G)3L]=(IP?\HEPNBVKWQY, MK"_M^\\]ZZ'7GGZ>]!YZP]ETEPRGX3RN+&7%.5K%DB9D6#FYI#Y4L@N,/<2,6#TOH/GQK M!%AV>&+#P'(#"@]+Z#Z6:018=O1@PZE1>;@>%-!]3%`7UA)KU1[19/6LL(R5$">,T&(*IX)+Q!2^QYV%O>V*[ML=[1!(KJBG:%HPD;)UF@F#%> MEJG\"XZ>/GO^8XB"9[JO'7CK3112+[3GD`$B9H#\:Q,$L54A#@<>P603FQM' MBL=W&P=>'()YD+4[?I,0LOT_KCK:9N&JC4TO7'_@!CQ%$9DOXH+&M.(#G8Q; ME)C9E$MX-+,]STHM>(5$0E[CX#GP(D3(CG:!$ZX=T?L_`6_#SQ72 MN`N1YRPW``+0T-^C;EL=?[7"4>+`\&C@!8VZ0&2&1Z&P M!K-DH]X>=LF_A[/!\+8W[`QZ4[7]3,(6?H>K5)$)I^\G%PE1@[)O@1&&';4; M'!A!%YL'C>OF=6C3FX;\>`B!V`EQ([#$C.B'0R53!46Q#EPA,Q@"M3XN83FS M5(0O=-,SADG<@=/#"-X9)E=`]U$QH"D=W-(1VMZD?R)$3FOI/Y_/$4XZ!_DA MWR?(KWZ]1TO;[1$CHE?&.$5*%0J9T>;YHU*9WDT^B@-%./D^ MH*F6:/"+OZ9=,MV2LED0B)U**AR0]3K3AS5#\CVR0_IT')V]Z&TM`;F,XN;' MPO#U-ZG;==':#S'9TH8ABL*A[U''-RJ]-[6+#F%)F)_N16B"0G?^I%NZ=BM? ML3(+ZXX8A=UQYINJZ(8^&-QZT.J]=@8%]D0GB"X*G0#'N;=&BWM$^B>B@^CA M/<:P8Z\Q&5#CX97C$ZE4F>[MH,0@5ADJ_=[\N]:8F,FYC'A]F7?8W[6L<7NF MZO+AH3I\GSNKK,YH`.SA"-W3Q!(#PI"WI.\<)--;>^4'$?X]F[UL@N@V@;3C MT:)/(+;=?Y'%)RD/N,'GPO>N+% MBM2L5V>4*=<:' MJ68]"]FI\M[W-XTM`O;UZ8PT4\QZ%K"3)9V;^;)J?=HV44<@W;B4II(K5M]U MZ1YQ$:&@Z0907K>V8Q'%2W\.D&KB@=GJ#5$47VTMWZ^"!+5=[06S!+5$B2], MLW^$$]EX!7"4*(EA9&@HXSLQ*S9QL%K;.*!NL]$BW[R2_/"DO]_Z_OP%NV5= M;1M.*U>-,8X1<+AP%9C,F"JSPWA1>3:E(CES?!E0$F%(Z'<4#UID8*>7;\8H MB&]G,1W&U_EQ<-"RAKV9=3^:3JUQ;V)-[]J3G@K?\:"UO0^44Y(_%`+$-'85 M`OO`(S3$^?S;ST0O&ATU\VD8M._%[V*D%^7H'2F'W7>D*](X((*9S/6FBF`I M2I43AOD4_YGKCN5M42BD+^.U!`>M5Z]/IG*M*?3WL MS.`_;[E@"F44U^E8JU_+3CU\I@"+JN4P!G?Z8ILAE][T3=,FP=B(K=K_@ MIC#(,34@W"!R[%^_$O'MVKCDZHL,$2[3D'$'<&GPF%-AT'ZK"ZU6C3Z7 MMN=H(.Y0N[.$7G_0ZW=[`Z'7O>JU'S;X<2,5X4I<^*;3[7>Z[U?][FGWXVF_ M6_,A2$6>&S^D^]`-_]5K/C5<+6[\X;OYS7W_L#"^W`+XP9NH7\;:9_5BNES/ MT>.WA\'G;W\_N-;']Y=74-T\WL.OORQN+A_/[7>_2!=?%Q_$X)&?7&T++%7` MRH'NV16=7 M1TX'/>Y`!Q.U,!5P#"UN5]THVP!C(,5T='X-!=WP9AK3:\!LN9K1UFS+IR3. M@3W8!!:`:&P[U@AL5,_$FOCNJ::Q,8!^(B#5N06(&*^[4S50WEGD`"J$-O83 M[+]A"2G;[0SL"+C@'Y^(Q9P2@:XP;('\N%[(U*Y)70<[D4I MCCT7Z`K\S?^]0=;:(+=P^EBB)EB"4[KDX$6=#25A>2M)J>?3"G*L.9FL+D('!4B2; MK6>+>5`J9N&G3#\_'Z/88^FXRD;9D;0#/RPT9D8=6]QOKL25-)5F6-3* M6%#FTD)>9:G.H[)9&K<0YTZ:BK,13;,]G$;`V[EM&IH!0LG7 MIF8KXSU)5_!O92IY= M"'-E(@]EZ2A5=-Z>@?N4C!T;XI]:X`'A^%M*PE;&A[PRSMO"3/J'? MP\!ACE'^P_82V=K?6]O4\=1>^N[A[#H0.[6&+>V/>6D/L>FOE.&?E\ID)"V6 M@G1U+:^^'J.,1^VQ:CC^ZL(4J$0\*>MF53(EW>OF)3UJ"V-17@@WXN1:$J:2 MN+Q>'*]%2^V)K4)W[-B6LL$Q'#B!H"GE;!GW\C*6VL)$$7'V,EXH4QS+<127 M%L%/&ZG\L3_"&-YAN=,.$X?HYPOVD/; ML@SD1P,1ZD/;'_T`3!*6;E>MH4YSL:/-!#+.&]#$]MUY\!9;O&<+Y!DL9@MT;=Y MBY@?Z2ZQ4THY6[SO\N+]@TQ7 MSIJ--,Y7%A3B3O_EC MIQ_!Z\\[A9^B7T>Y&$.;Z*S4M1GIL:2>K:+"Y),^'1)^"GHZ2L$SICYIV9>3 ML,5?F(VRYTA'K8(XK4D+/5_(%'._,!5-,IZC%FLAQTF+EU7)%G-A-DI-@XY: MXK0@/0)(-Z@4OZ#$OD7IK]5\A_\D']6NC/5(0N2=Z!2#PDE M6Q^%^7*5/N).CU(OC.0],RQ7T+!U49@#EV7XQSPZETNX5T<-96-T8:);0P]' M.DX7WT#1HU0-.K8^"C-?ZINK'R&JQEL6NG;V:\)4U*`P=ZYZ"_-#9[DUB\Q` M4BAE2[XPG4ZO6ASS4)&78<[RV=5L61`?7CHE1V+.3ES#VIGDJ)%? MMG7`YNQ$N[-:T9F5OS!G[0?+C"A(SR5GEWR5YH41/C?J0G6T0B^%LU6X$WL' M'(2'\DZ$/>H`&8@TGZ<>(Y#G8$?M/`/'IKK>EV/#J"=)]0"1BV`]$U.X`$'YO M+M#:M_8=5JJ1.07(0$%M0WZTDL9UGU]ZL++L^=2&'6`B-RIY(IKBHP$.1Z))>0H\2F.,8:MK_Q(J'M.>.XSB(S!\=M3W;94 M`\H(6(0,L^*M71R"/$)ZX=C>[NPDZ,O`)"4@ATMM:P(/XGEV`$W,XBVI;QIZ M@&=(D^^0,Y`2#:3$&<@Q#>28,Y`7-)`7G(&\I(&\Y`SD%0WD%6<@)S20$]Y` M+L`.CPQ`IX(M5/(!>CJU=?_*`QKH8B4?H.4TE(JF MP0:F_.=]*%R:G1K.0#]%49Z&)ETZ!Q#+PC*UD8P\Q&`+LA0@%) M(596T37-B@PU_*=Q!_P=2,J.M)^;*LQIHIJL:49F-KR*+J(JYZ469=/L^,#. M;>BY%`Y8E8V#]OUU07/B!6<@PR1]4YK";[C+X14:6H4;D!-P!\Q>%F.NC`N( M?0K$/E\0!Q2(`VX@KFRDFEF$V:*F`2H>(B]JR&VC69BTBJ;!2@_`T0R78,B" MI54T#3::B#[2XHJEH'=\YBKL#:0%F6+!L"I#J/S\O4#"!E M4\T9G8Q/]BZP;2MP!/PH9-SA.(2MP0OO7@M8*R?9P^9R?&E87"_'F.RZ'GF. MLA%UW=_&I9K^[M28KU**P]EZ474%2P'!+A=E$PT6$4?,6DZYD:'N!7=4YCFA MUG#*!5WJQ+J`/K8=/`[=&1JH4!*-G%-^R=$>&_K+?N1D8MI]PD<2XRMGRZ44;!6Y(APT3ZT8@4 MS8C)VS#'MHKLI-X<'-28UT$N,<5D")NKAB[#H;HSD&J6B^/PYKP*I$3UKY.- M?&K"=ETV);\NG!HBBBZ:K>165;#"AU)L!(-\D=,]6O(JALI0DC?/K"P.;\[I MH.N_@,#I7/4TI!8EKVH/WPE@T-0!-1^M:I/S%K)\)4E?I,507DK*>"0MY!MQ M)=]($UD\ER?R2I:6&856T_*J4OK\)*_)*BK>%!@%VVQX,:+PDH_);#)>U<:* MH#%VHK&TOFIE@I6M>15'\`*X=+6DG(17QHHK(X64L(2"-[>L'/?92T2'->4Y M76#SRJ[FUDSC;":5Q>(L9^Z`'592?E&L-CEO!LQ*XN/`F4K?6;P_J0MN#2#F M*L0L/>P`=&EL%PFX]M+]+'O/-KRJ,WCC.[1=Y&+%F9X.<*`-+V9WY^HC`9T? MB/9KP[%G9R&GV**X`*Q+ MS:OW5ZSQ5I/Q:LQ,IZST6HZ9\OTLXW3\^I%_9F%EA^??R`J^68LQAC? MOE!@J)J,`U[B3X:F%XGV3"%>3,Y/^1AA/@0\4V>O($KXG]3*LU]-QQUGVA;H MGIF^5L!-3K>#X")[BRQ2JT'76(-`/W\DA2I\C!E_$+$!&.G1OQF$>H* MV@(G9#,O@KU;\\^YB.*O@-3D-MN"`PY+/A>9=^):I+SY<>;+C/27$MSS,`,( M)_.V!<*+UU2'GC+[UC473#`Q')`!"'D4JR M^D?(,FP$_;[`P!]]^JAZZ"]2\J:D&9XD6CO3?@3`]35QCN?1.DU/M2@YG<`F M`Y1;/1XS?/!I??"F]\#?\*#03^]%B4L.>`^+."(QMA#782T#FBYLT"]\^ES@> M(((F8[7ITL8A2E#/2#%?V"3`1*,%0=*K^``;2J\(-:EH%FC*F:<&-"S/HCIZ M4M>TOZ=!J0]LP'%=LX#)?.R.S,?LS2'#<"%3>[[^>!O74YR%]S^AK>-)^9VU MU60'W]OPLJ]-"L!GE:S-7B%78S5UNRV3LSS5:^'NLI*SRU?(U54E5U>O@RM_ MY4L),2]H7#$I..4JO!0ISTJQF%/\P6%)VJ"5&K,R+Y-K$'/*JQ0N,IP#"#8& M(E=FY+^L6-B2^;6FDI+(>%IP7&MC/VD.>`:`_] MRCX'<^"0Z[*`'L\]7JAO3BTG\N,5_M\-KBA9V<%"7"20]XI$J%/WIN89 MRE8UN^*1&B%2L$K&$3H5IU96#*>Q==&K..5C`32`D?I1(9)Z-/F++RBH(GI% M'B.B!2`G"?7,#%?9=-N#-R7>5-&L64^CXE40F/^B6H M\^ M>$,ICQ1B7H=T*G[)'[OJ<)JGY)5-J9W?GULY^]VC!6\63+;K&"@('61_H+\I M%$"R%;2*[8.:\L;_8D3]Q$&`Q0````( M`!6"2D1CQ]MD"@\``-.X```4`!@```````$```"D@9Z"``!C=FTM,C`Q,S$R M,S%?8V%L+GAM;%54!0`#N4'Y4G5X"P`!!"4.```$.0$``%!+`0(>`Q0````( M`!6"2D1VW8LJ]!$``*/P```4`!@```````$```"D@?:1``!C=FTM,C`Q,S$R M,S%?9&5F+GAM;%54!0`#N4'Y4G5X"P`!!"4.```$.0$``%!+`0(>`Q0````( M`!6"2D0///)W2$H``--%!``4`!@```````$```"D@3BD``!C=FTM,C`Q,S$R M,S%?;&%B+GAM;%54!0`#N4'Y4G5X"P`!!"4.```$.0$``%!+`0(>`Q0````( M`!6"2D1=7[9^C"D``!.0`@`4`!@```````$```"D@<[N``!C=FTM,C`Q,S$R M,S%?<')E+GAM;%54!0`#N4'Y4G5X"P`!!"4.```$.0$``%!+`0(>`Q0````( M`!6"2D27/.]'-D550%``.Y0?E2=7@+``$$)0X```0Y`0``4$L%!@`````&``8`%`(` '`)(I`0`````` ` end XML 17 R29.htm IDEA: XBRL DOCUMENT v2.4.0.8

E. LOANS FROM OFFICER (Details Narrative) (USD $)
3 Months Ended

Dec. 31, 2013

Dec. 31, 2012

E. Loans From Officer Details Narrative

Interest expense paid to Mr. de Clara $ 55,203 $ 41,402

X

- Details

Name: CVM_E.LoansFromOfficerDetailsNarrativeAbstract

Namespace Prefix: CVM_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of interest expense incurred on a debt or other obligation to related party.

+ References

No definition available.

+ Details

Name: us-gaap_InterestExpenseRelatedParty

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 18 R28.htm IDEA: XBRL DOCUMENT v2.4.0.8

D. FAIR VALUE MEASUREMENTS (Details 1) (USD $)
3 Months Ended 12 Months Ended

Dec. 31, 2013

Sep. 30, 2013

D. Fair Value Measurements Details 1

Beginning balance $ 433,024 $ 6,983,690

Issuances 7,321,071 4,200,000

Settlements

Realized and unrealized gains recorded in Earnings Recorded in earnings (1,610,817) (10,750,666)

Ending balance $ 6,143,278 $ 433,024

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: CVM_FairValueMeasurementsBeginningBalance

Namespace Prefix: CVM_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: CVM_FairValueMeasurementsDetails1Abstract

Namespace Prefix: CVM_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: CVM_FairValueMeasurementsEndingBalance

Namespace Prefix: CVM_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of realized and unrealized gain (loss) included in earnings, which have arisen from the use of significant unobservable inputs (level 3) to measure fair value of assets, liabilities, and financial instruments classified in shareholders' equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)

-URI http://asc.fasb.org/extlink&oid=25499696&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarnings

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of issuances of financial instrument classified in shareholders' equity measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)

-URI http://asc.fasb.org/extlink&oid=25499696&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInstrumentsClassifiedInShareholdersEquityIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of settlements of financial instrument classified in shareholders' equity measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)

-URI http://asc.fasb.org/extlink&oid=25499696&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInstrumentsClassifiedInShareholdersEquitySettlements

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 19 R30.htm IDEA: XBRL DOCUMENT v2.4.0.8

G. COMMITMENTS AND CONTINGENCIES (Details Narrative) (USD $)
3 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Sep. 30, 2013

Research and development expense $ 4,019,541 $ 2,924,722

Rent deposit included in non-current assets 1,670,917 1,670,917

R & D deferred rent liability 4,591 3,992

Deferred rent liability $ 11,065 $ 12,412

X

- Definition

Custom Element.

+ References

No definition available.

+ Details

Name: CVM_DeferredRentLiability

Namespace Prefix: CVM_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: CVM_RDDeferredRentLiability

Namespace Prefix: CVM_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.17)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 17

-Article 5

+ Details

Name: us-gaap_DepositsAssetsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 985

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 20 R31.htm IDEA: XBRL DOCUMENT v2.4.0.8

H. PATENTS (Details) (USD $)

Dec. 31, 2013

H. Patents Details

Three months ending September 30, 2014 $ 25,252

Year ending September 30, 2015 33,795

Year ending September 30, 2016 33,795

Year ending September 30, 2017 33,795

Year ending September 30, 2018 33,461

Year ending September 30, 2019 31,758

Thereafter 125,604

Total $ 317,460

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: CVM_FiniteLivedIntangibleAssetsNetTotal

Namespace Prefix: CVM_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: CVM_PatentsDetailsAbstract

Namespace Prefix: CVM_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of amortization expense expected to be recognized during the next fiscal year following the latest fiscal year for assets, excluding financial assets and goodwill, lacking physical substance with a finite life.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(3)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of amortization expense expected to be recognized in the remainder of the fiscal year following the latest fiscal year ended for assets, excluding financial assets and goodwill, lacking physical substance with a finite life.

+ References

No definition available.

+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of amortization expense expected to be recognized after the fifth rolling twelve months following the latest balance sheet presented for assets, excluding financial assets and goodwill, lacking physical substance with a finite life.

+ References

No definition available.

+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of amortization expense expected to be recognized during the fifth fiscal year following the latest fiscal year for assets, excluding financial assets and goodwill, lacking physical substance with a finite life.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(3)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of amortization expense expected to be recognized during the fourth fiscal year following the latest fiscal year for assets, excluding financial assets and goodwill, lacking physical substance with a finite life.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(3)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of amortization expense expected to be recognized during the third fiscal year following the latest fiscal year for assets, excluding financial assets and goodwill, lacking physical substance with a finite life.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(3)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of amortization expense expected to be recognized during the second fiscal year following the latest fiscal year for assets, excluding financial assets and goodwill, lacking physical substance with a finite life.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(3)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 21 R8.htm IDEA: XBRL DOCUMENT v2.4.0.8

B. NEW ACCOUNTING PRONOUNCEMENTS
3 Months Ended

Dec. 31, 2013

Accounting Changes and Error Corrections [Abstract]

B. NEW ACCOUNTING PRONOUNCEMENTS
There are no significant new accounting pronouncements that would impact the condensed financial statements.

X

- Details

Name: us-gaap_AccountingChangesAndErrorCorrectionsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 01

-Paragraph b

-Subparagraph 6

-Article 10

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 270

-SubTopic 10

-Section 45

-Paragraph 13

-URI http://asc.fasb.org/extlink&oid=6372559&loc=d3e765-108305

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 270

-SubTopic 10

-Section 45

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=6372559&loc=d3e725-108305

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 250

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28359718&loc=d3e22499-107794

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 250

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=28359718&loc=d3e22580-107794

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Direct Effects of a Change in Accounting Principle

-URI http://asc.fasb.org/extlink&oid=6510796

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Indirect Effects of a Change in Accounting Principle

-URI http://asc.fasb.org/extlink&oid=6515603

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Accounting Change

-URI http://asc.fasb.org/extlink&oid=6503790

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Change in Accounting Principle

-URI http://asc.fasb.org/extlink&oid=6507316

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 270

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.10-01.(b)(6))

-URI http://asc.fasb.org/extlink&oid=27015980&loc=d3e46468-122699

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Retrospective Application

-URI http://asc.fasb.org/extlink&oid=6523989

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 250

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=28359718&loc=d3e22583-107794

+ Details

Name: us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 22 R32.htm IDEA: XBRL DOCUMENT v2.4.0.8

H. PATENTS (Details Narrative) (USD $)
3 Months Ended

Dec. 31, 2013

Dec. 31, 2012

H. Patents Details Narrative

Patent impairment charges $ 240 $ 10,223

Amortization of patent costs $ 9,703 $ 23,905

X

- Details

Name: CVM_PatentsDetailsNarrativeAbstract

Namespace Prefix: CVM_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(2)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_AmortizationOfIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 3

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16373-109275

+ Details

Name: us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 23 R2.htm IDEA: XBRL DOCUMENT v2.4.0.8

BALANCE SHEETS (USD $)

Dec. 31, 2013

Sep. 30, 2013

ASSETS

Cash and cash equivalents $ 13,494,028 $ 41,612

Receivables 45,879 74,263

Prepaid expenses 988,699 780,523

Deposits - current portion 150,000 0

Inventory used for R&D and manufacturing 1,347,257 1,016,628

Deferred rent - current portion 585,156 598,717

Total current assets 16,611,019 2,511,743

RESEARCH AND OFFICE EQUIPMENT AND LEASEHOLD IMPROVEMENTS-- less accumulated depreciation depreciation and amortization of $3,010,439 and $2,967,345 463,053 489,336

PATENT COSTS--less accumulated amortization of $1,148,214 and $1,313,046 317,460 318,195

DEFERRED RENT - net of current portion 5,285,781 5,448,381

DEPOSITS 2,120,917 2,070,917

TOTAL ASSETS 24,798,230 10,838,572

LIABILITIES AND STOCKHOLDERS' EQUITY

Accounts payable 1,627,765 1,924,482

Accrued expenses 346,401 113,496

Due to employees 280,464 386,337

Related party loan 1,104,057 1,104,057

Deferred rent - current portion 9,274 8,529

Lease obligations - current portion 11,463 8,212

Total current liabilities 3,379,424 3,545,113

Derivative instruments 6,143,278 433,024

Deferred revenue 126,545 126,545

Deferred rent-net of current portion 6,381 7,875

Lease obligations - net of current portion 24,445 20,925

Deposits held 5,000 5,000

Total liabilities 9,685,073 4,138,482

COMMITMENTS AND CONTINGENCIES 0 0

STOCKHOLDERS' EQUITY

Preferred stock, $.01 par value - authorized 200,000 shares, issued and outstanding, -0- 0 0

Common stock, $.01 par value - authorized 600,000,000 shares; issued and outstanding 55,852,992 shares and 31,025,019 shares issued and outstanding at December 31, 2013 and September 30, 2013, respectively 558,530 310,250

Additional paid-in capital 231,049,613 218,550,408

Accumulated deficit (216,494,986) (212,160,568)

Total stockholders' equity 15,113,157 6,700,090

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 24,798,230 $ 10,838,572

X

- Definition

Deferred Rent Current Portion.

+ References

No definition available.

+ Details

Name: CVM_DeferredRentCurrentPortion

Namespace Prefix: CVM_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Deferred Rent Net Of Current Portion.

+ References

No definition available.

+ Details

Name: CVM_DeferredRentNetOfCurrentPortion

Namespace Prefix: CVM_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Subparagraph a

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccountsPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.3-4)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 3

-Subparagraph a(1)

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 4

-Article 5

+ Details

Name: us-gaap_AccountsReceivableNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.30(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AdditionalPaidInCapital

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.18)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 12

-Article 7

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 18

-Article 5

+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_AssetsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.9)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6801-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 9

-Article 5

+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of capital lease obligation due within one year or the normal operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 30

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6455398&loc=d3e45280-112737

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 30

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6455314&loc=d3e45023-112735

+ Details

Name: us-gaap_CapitalLeaseObligationsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount equal to the present value (the principal) at the beginning of the lease term of minimum lease payments during the lease term (excluding that portion of the payments representing executory costs such as insurance, maintenance, and taxes to be paid by the lessor, together with any profit thereon) net of payments or other amounts applied to the principal, through the balance sheet date and due to be paid more than one year (or one operating cycle, if longer) after the balance sheet date.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 30

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6455398&loc=d3e45280-112737

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 30

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6455314&loc=d3e45023-112735

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CapitalLeaseObligationsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3044-108585

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 25

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 7

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 17

-Article 9

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.17)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.(a),19)

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

+ Details

Name: us-gaap_CommitmentsAndContingencies

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The cumulative difference between the rental payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense over the term of the leased property by the lessor or lessee, respectively.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 20

-Section 25

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=7501430&loc=d3e39896-112707

+ Details

Name: us-gaap_DeferredRentCredit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 20

-Section 25

-Paragraph 2

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=7501430&loc=d3e39927-112707

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.26(c))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DeferredRentCreditNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

+ Details

Name: us-gaap_DeferredRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The carrying amount of the asset transferred to a third party to serve as a deposit, which typically serves as security against failure by the transferor to perform under terms of an agreement.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 17

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 8

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.8,17)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DepositAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The aggregate of all deposit liabilities held by the entity, including foreign and domestic, interest and noninterest bearing; may include demand deposits, saving deposits, Negotiable Order of Withdrawal (NOW) and time deposits among others.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.12)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 12

-Article 9

+ Details

Name: us-gaap_Deposits

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.17)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 17

-Article 5

+ Details

Name: us-gaap_DepositsAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 10

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28364263&loc=d3e13433-108611

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6945355&loc=d3e41228-113958

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=28364263&loc=d3e13495-108611

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 20

-Section 50

-Paragraph 3

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=20225523&loc=SL20225862-175312

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6945355&loc=d3e41271-113958

+ Details

Name: us-gaap_DerivativeLiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amounts due to recorded owners or owners with a beneficial interest of more than 10 percent of the voting interests or officers of the company. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k)(1))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (d)

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph k

-Subparagraph 1

-Article 4

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Subparagraph a

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 12

-Subparagraph a(1)

-Article 6

+ Details

Name: us-gaap_DueToOfficersOrStockholdersCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k)(1))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (d)

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph k

-Subparagraph 1

-Article 4

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Subparagraph a

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DueToRelatedPartiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 35

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6386567&loc=d3e3927-108312

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

+ Details

Name: us-gaap_InventoryNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19-26)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_Liabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.32)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 25

-Article 7

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 32

-Article 5

+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_LiabilitiesAndStockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.21)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 21

-Article 5

+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Assets

-URI http://asc.fasb.org/extlink&oid=6509628

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (g)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6787-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 340

-SubTopic 10

-Section 05

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6386993&loc=d3e5879-108316

+ Details

Name: us-gaap_PrepaidExpenseCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph a

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 8

-Article 7

+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The cumulative amount of the reporting entity's undistributed earnings or deficit.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.31(a)(3))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 24 R6.htm IDEA: XBRL DOCUMENT v2.4.0.8

STATEMENTS OF CASH FLOWS (USD $)
3 Months Ended

Dec. 31, 2013

Dec. 31, 2012

CASH FLOWS FROM OPERATING ACTIVITIES:

Net loss $ (4,334,418) $ (2,310,246)

Adjustments to reconcile net loss to net cash used in operating activities:

Depreciation and amortization 56,699 133,450

Issuance of common stock, warrants and options for services 137,729 54,485

Modification of warrants issued for services 76,991 0

Employee option cost 510,278 966,585

Common stock contributed to 401 (k) plan 37,887 39,711

Impairment loss on abandonment of patents 240 10,223

Loss on retired equipment 0 2,011

Gain on derivative instruments (1,610,817) (2,746,198)

(Increase)/decrease in assets:

Receivables 28,384 143,714

Deferred rent 176,161 139,536

Prepaid expenses (210,367) 471,936

Inventory used for R&D and manufacturing (330,629) 247,585

Deposits (200,000) 0

Increase/(decrease) in liabilities:

Accounts payable (380,943) (192,358)

Accrued expenses 232,905 23,252

Due to employees (105,873) 20,843

Deferred rent liability (749) 688

Net cash used in operating activities (5,916,522) (2,994,783)

CASH FLOWS FROM INVESTING ACTIVITIES:

Purchases of equipment (8,587) (16,093)

Expenditures for patent costs 0 (125)

Net cash used in investing activities (8,587) (16,218)

CASH FLOWS FROM FINANCING ACTIVITIES:

Proceeds from issuance of common stock and warrants 19,380,190 9,807,375

Payments on oblgations under capital leases 2,665 1,025

Net cash provided by financing activities 19,377,525 9,806,350

NET INCREASE IN CASH AND CASH EQUIVALENTS 13,452,416 6,795,349

CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD 41,612 3,941,042

CASH AND CASH EQUIVALENTS, END OF PERIOD 13,494,028 10,736,391

ISSUANCE OF WARRANTS:

Increase in derivative liabilities (7,321,071) (4,200,000)

Decrease in additional paid-in capital 7,321,071 4,200,000

Total 0 0

ISSUANCE OF ADDITIONAL SHARES

Increase in common stock (15,631) 0

Increase in additional paid-in capital (1,101,786) 0

Decrease in additional paid-in capital 1,117,417 0

Total 0 0

ISSUANCE OF COMMON STOCK FOR PREPAID SERVICES:

Increase in additional paid-in capital (55,362) (236,165)

Increase in prepaid expenses 55,362 236,165

Total 0 0

PATENT COSTS INCLUDED IN ACCOUNTS PAYABLE

Increase in patent costs 9,208 8,641

Increase in accounts payable (9,208) (8,641)

Total 0 0

NON CASH RESEARCH AND OFFICE EQUIPMENT PURCHASES

Increase in research and office equipment (12,126) (36,622)

Increase in accounts payable (2,664) 0

Increase in capital lease obligation 9,462 36,622

Total 0 0

CAPITAL LEASE PAYMENTS INCLUDED IN ACCOUNTS PAYABLE:

Decrease in capital lease obligation 26 1,105

Increase in accounts payable (26) (1,105)

Total 0 0

OFFERING COSTS INCLUDED IN ACCOUNTS PAYABLE:

Decrease additional paid-in capital 72,328 0

Increase in accounts payable (72,328) 0

Total 0 0

SUPPLEMENTAL DISCLOSURE OF CASH FLOWS INFORMATION:

Cash expenditures for interest expense $ 56,509 $ 41,878

X

- Details

Name: CVM_CapitalLeasePaymentsIncludedInaccountsPayable

Namespace Prefix: CVM_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Common Stock Contributed To 401K Plan.

+ References

No definition available.

+ Details

Name: CVM_CommonStockContributedTo401KPlan

Namespace Prefix: CVM_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: CVM_DecreaseAdditionalPaidinCapital

Namespace Prefix: CVM_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Decrease In Additional Paid In Capital Additional Shares Issued.

+ References

No definition available.

+ Details

Name: CVM_DecreaseInAdditionalPaidInCapitalAdditionalSharesIssued

Namespace Prefix: CVM_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Decrease In Additional Paid In Capital From Issuance Of Warrants.

+ References

No definition available.

+ Details

Name: CVM_DecreaseInAdditionalPaidInCapitalFromIssuanceOfWarrants

Namespace Prefix: CVM_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Custom Element.

+ References

No definition available.

+ Details

Name: CVM_DecreaseInCapitalLeaseObligationIncludedInAccountsPayable

Namespace Prefix: CVM_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Decrease In Deferred Rent.

+ References

No definition available.

+ Details

Name: CVM_DecreaseInDeferredRent

Namespace Prefix: CVM_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: CVM_EquipmentCostsIncludedInAccountsPayableAbstract

Namespace Prefix: CVM_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: CVM_IncreaseInAccountsPayable

Namespace Prefix: CVM_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Custom Element.

+ References

No definition available.

+ Details

Name: CVM_IncreaseInAccountsPayableCapitalLeasePayments

Namespace Prefix: CVM_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Increase In Accounts Payable For Equipment Costs.

+ References

No definition available.

+ Details

Name: CVM_IncreaseInAccountsPayableForEquipmentCosts

Namespace Prefix: CVM_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: CVM_IncreaseInAccountsPayablePatentCosts

Namespace Prefix: CVM_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Increase In Additional Paid In Capital Common Stock Issued.

+ References

No definition available.

+ Details

Name: CVM_IncreaseInAdditionalPaidInCapitalCommonStockIssued

Namespace Prefix: CVM_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Increase In Additional Paid in Capital Stock Issued Prepaid Services.

+ References

No definition available.

+ Details

Name: CVM_IncreaseInAdditionalPaidinCapitalStockIssuedPrepaidServices

Namespace Prefix: CVM_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Custom Element.

+ References

No definition available.

+ Details

Name: CVM_IncreaseInCapitalLeaseObligationNoncashEquipmentCosts

Namespace Prefix: CVM_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Increase In Common Stock.

+ References

No definition available.

+ Details

Name: CVM_IncreaseInCommonStock

Namespace Prefix: CVM_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Increase In Derivative Liabilities From Issuance Of Warrants.

+ References

No definition available.

+ Details

Name: CVM_IncreaseInDerivativeLiabilitiesFromIssuanceOfWarrants

Namespace Prefix: CVM_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Increase In Prepaid Expenses.

+ References

No definition available.

+ Details

Name: CVM_IncreaseInPrepaidExpenses

Namespace Prefix: CVM_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Increase In Research And Office Equipment,

+ References

No definition available.

+ Details

Name: CVM_IncreaseInResearchAndOfficeEquipment

Namespace Prefix: CVM_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: CVM_IssuanceOfAdditionalSharesAbstract

Namespace Prefix: CVM_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: CVM_IssuanceOfCommonStockForPrepaidServices

Namespace Prefix: CVM_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Issuance Of Warrants.

+ References

No definition available.

+ Details

Name: CVM_IssuanceOfWarrants

Namespace Prefix: CVM_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: CVM_IssuanceOfWarrantsAbstract

Namespace Prefix: CVM_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: CVM_ModificationOfWarrantsIssuedForServices

Namespace Prefix: CVM_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: CVM_OfferingCostsIncludedInAccountsPayable

Namespace Prefix: CVM_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: CVM_PatentCostsIncludedInAccountsPayableAbstract

Namespace Prefix: CVM_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: CVM_Total

Namespace Prefix: CVM_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Custom Element.

+ References

No definition available.

+ Details

Name: CVM_TotalCapitalLeasePaymentsIncludedInAccountsPayable

Namespace Prefix: CVM_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: CVM_TotalEquipmentCostsIncludedInAccountsPayable

Namespace Prefix: CVM_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Total For Issuance Of Additional Shares.

+ References

No definition available.

+ Details

Name: CVM_TotalForIssuanceOfAdditionalShares

Namespace Prefix: CVM_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Total Issuance Of Common Stock For Prepaid Services.

+ References

No definition available.

+ Details

Name: CVM_TotalIssuanceOfCommonStockForPrepaidServices

Namespace Prefix: CVM_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: CVM_TotalPatentCostsIncludedInAccountsPayable

Namespace Prefix: CVM_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3044-108585

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 230

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450594&loc=d3e33268-110906

+ Details

Name: us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_DepreciationAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4C

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5624171-113959

+ Details

Name: us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of gain (loss) on sale or disposal of intangible assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.7,9)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_GainLossOnDispositionOfIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_GainLossOnSaleOfPropertyPlantEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Change during the period in carrying value for all deferred liabilities due within one year or operating cycle.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInDeferredLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The net cash inflow or outflow for the increase (decrease) in the beginning and end of period deposits balances.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 230

-Section 45

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6477933&loc=d3e60009-112784

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3095-108585

+ Details

Name: us-gaap_IncreaseDecreaseInDeposits

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease), during an accounting period, in total obligations owed to the reporting entity's executives and owners.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInDueToOfficersAndStockholders

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in intangible assets (for example patents and licenses).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInIntangibleAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInInventories

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_IncreaseDecreaseInOperatingAssetsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInPrepaidExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInReceivables

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The amount of cash paid for interest during the period net of cash paid for interest that is capitalized.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586

+ Details

Name: us-gaap_InterestPaidNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3536-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e565-108580

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3213-108585

+ Details

Name: us-gaap_PaymentsToAcquireIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3213-108585

+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash inflow from the additional capital contribution to the entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash outflow during the period from the repayment of aggregate short-term and long-term debt and payment of capital lease obligations.

+ References

No definition available.

+ Details

Name: us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The noncash expense that accounts for the value of stock or unit options distributed to employees as compensation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_StockOptionPlanExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_SupplementalCashFlowInformationAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 25 R22.htm IDEA: XBRL DOCUMENT v2.4.0.8

C. STOCKHOLDERS EQUITY (Details)

Dec. 31, 2013

Incentive Stock Option Plans

Total Shares Reserved Under Plans 1,960,000

Shares Reserved forOutstanding Options 1,573,597

Remaining Options/Shares Under Plans 145,703

Non-Qualified Stock Option Plans

Total Shares Reserved Under Plans 5,680,000

Shares Reserved forOutstanding Options 3,674,544

Remaining Options/Shares Under Plans 1,443,537

Stock Bonus Plans

Total Shares Reserved Under Plans 1,594,000

Shares Issued as Stock Compensation 958,325

Remaining Options/Shares Under Plans 634,919

Stock Compensation Plan

Total Shares Reserved Under Plans 1,350,000

Shares Issued as Stock Compensation 791,145

Remaining Options/Shares Under Plans 558,855

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: CVM_SharesIssuedAsStockCompensation

Namespace Prefix: CVM_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (a)(3)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(i)-(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

XML 26 R24.htm IDEA: XBRL DOCUMENT v2.4.0.8

C. STOCKHOLDERS EQUITY (Details 2) (USD $)

Dec. 31, 2013

Series N [Member]

STOCKHOLDERS' EQUITY

Issue Date Aug. 18, 2008

Shares Issuable upon Exercise of Warrant 2,951,420

Exercise Price $ 0.53

Expiration Date Aug. 18, 2014

Series A [Member]

STOCKHOLDERS' EQUITY

Issue Date Jun. 24, 2009

Shares Issuable upon Exercise of Warrant 130,347

Exercise Price $ 5.00

Expiration Date Dec. 24, 2014

CSchleuningSeriesAMember

STOCKHOLDERS' EQUITY

Issue Date Jul. 08, 2009

Shares Issuable upon Exercise of Warrant 16,750

Exercise Price $ 5.00

Expiration Date Jan. 08, 2015

Series B [Member]

STOCKHOLDERS' EQUITY

Issue Date Sep. 04, 2009

Shares Issuable upon Exercise of Warrant 50,000

Exercise Price $ 6.80

Expiration Date Sep. 04, 2014

Series C [Member]

STOCKHOLDERS' EQUITY

Shares Issuable upon Exercise of Warrant 463,487

Exercise Price $ 5.50

Expiration Date Feb. 20, 2015

Issue Start date Aug. 20, 2009

Issue End Date Aug. 26, 2009

Series E [Member]

STOCKHOLDERS' EQUITY

Issue Date Sep. 21, 2009

Shares Issuable upon Exercise of Warrant 71,428

Exercise Price $ 17.50

Expiration Date Aug. 12, 2014

Series F [Member]

STOCKHOLDERS' EQUITY

Issue Date Oct. 06, 2011

Shares Issuable upon Exercise of Warrant 1,200,000

Exercise Price $ 4.00

Expiration Date Oct. 06, 2014

Series G [Member]

STOCKHOLDERS' EQUITY

Issue Date Oct. 06, 2011

Shares Issuable upon Exercise of Warrant 66,667

Exercise Price $ 4.00

Expiration Date Aug. 12, 2014

Series H [Member]

STOCKHOLDERS' EQUITY

Issue Date Jan. 26, 2012

Shares Issuable upon Exercise of Warrant 1,200,000

Exercise Price $ 5.00

Expiration Date Aug. 01, 2015

Series Q [Member]

STOCKHOLDERS' EQUITY

Issue Date Jun. 21, 2012

Shares Issuable upon Exercise of Warrant 1,200,000

Exercise Price $ 5.00

Expiration Date Dec. 22, 2015

SeriesRMember

STOCKHOLDERS' EQUITY

Issue Date Dec. 06, 2012

Shares Issuable upon Exercise of Warrant 2,625,000

Exercise Price $ 4.00

Expiration Date Dec. 06, 2016

Series S

STOCKHOLDERS' EQUITY

Shares Issuable upon Exercise of Warrant 25,713,095

Exercise Price $ 1.25

Expiration Date Oct. 11, 2018

Issue Start date Oct. 11, 2013

Issue End Date Dec. 24, 2013

Series L [Member]

STOCKHOLDERS' EQUITY

Issue Date Apr. 18, 2007

Shares Issuable upon Exercise of Warrant 25,000

Exercise Price $ 7.50

Expiration Date Apr. 17, 2014

Series L Repriced [Member]

STOCKHOLDERS' EQUITY

Issue Date Apr. 18, 2007

Shares Issuable upon Exercise of Warrant 70,000

Exercise Price $ 2.50

Expiration Date Apr. 02, 2015

Series M Modified

STOCKHOLDERS' EQUITY

Issue Date Apr. 18, 2007

Shares Issuable upon Exercise of Warrant 500,000

Exercise Price $ 1.00

Expiration Date Apr. 20, 2014

Series P [Member]

STOCKHOLDERS' EQUITY

Issue Date Feb. 10, 2012

Shares Issuable upon Exercise of Warrant 590,001

Exercise Price $ 4.50

Expiration Date Mar. 06, 2017

Private Investors [Member]

STOCKHOLDERS' EQUITY

Shares Issuable upon Exercise of Warrant 740,938

Issue Start date Jul. 18, 2005

Issue End Date Jun. 30, 2009

Expiration start date Jan. 26, 2014

Expiration end date Jul. 18, 2014

Exercise Price Minimum $ 5.60

Exercise Price Maximum $ 8.20

Warrants Held by Officer And Director [Member]

STOCKHOLDERS' EQUITY

Shares Issuable upon Exercise of Warrant 349,754

Issue Start date Jun. 24, 2009

Issue End Date Jul. 06, 2009

Expiration start date Dec. 24, 2014

Expiration end date Jan. 06, 2015

Exercise Price Minimum $ 4.00

Exercise Price Maximum $ 5.00

Consultants [Member]

STOCKHOLDERS' EQUITY

Shares Issuable upon Exercise of Warrant 200,750

Issue Start date Feb. 15, 2005

Issue End Date Oct. 28, 2013

Expiration start date May 20, 2014

Expiration end date Dec. 27, 2017

Exercise Price Minimum $ 0.85

Exercise Price Maximum $ 20.00

X

- Definition

Custom Element.

+ References

No definition available.

+ Details

Name: CVM_ExercisePrice

Namespace Prefix: CVM_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

Custom Element.

+ References

No definition available.

+ Details

Name: CVM_ExercisePriceMaximum

Namespace Prefix: CVM_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

Custom Element.

+ References

No definition available.

+ Details

Name: CVM_ExercisePriceMinimum

Namespace Prefix: CVM_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

Custom Elemenrt.

+ References

No definition available.

+ Details

Name: CVM_ExpirationDate1

Namespace Prefix: CVM_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: instant

X

- Definition

Custom Elemenrt.

+ References

No definition available.

+ Details

Name: CVM_ExpirationEndDate

Namespace Prefix: CVM_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: instant

X

- Definition

Custom Elemenrt.

+ References

No definition available.

+ Details

Name: CVM_ExpirationStartDate

Namespace Prefix: CVM_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: instant

X

- Definition

Custom Elemenrt.

+ References

No definition available.

+ Details

Name: CVM_Issuedate2

Namespace Prefix: CVM_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: instant

X

- Definition

Custom Element.

+ References

No definition available.

+ Details

Name: CVM_IssueEndDate1

Namespace Prefix: CVM_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: instant

X

- Definition

Custom Elemenrt.

+ References

No definition available.

+ Details

Name: CVM_IssueStartDate

Namespace Prefix: CVM_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: instant

X

- Definition

Shares Issuable Upon Exercise Of warrant.

+ References

No definition available.

+ Details

Name: CVM_SharesIssuableUponExerciseOfwarrant

Namespace Prefix: CVM_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_StockholdersEquityNoteAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 27 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 28 R7.htm IDEA: XBRL DOCUMENT v2.4.0.8

A. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
3 Months Ended

Dec. 31, 2013

Notes to Financial Statements

A. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation

The accompanying condensed financial statements of CEL-SCI Corporation (the Company) are unaudited and certain information and footnote disclosures normally included in the annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been omitted pursuant to the rules and regulations of the Securities and Exchange Commission. While management of the Company believes that the disclosures presented are adequate to make the information presented not misleading, these interim condensed financial statements should be read in conjunction with the financial statements and notes included in the Company’s annual report on Form 10-K for the year ended September 30, 2013.

In the opinion of management, the accompanying unaudited condensed financial statements contain all accruals and adjustments (each of which is of a normal recurring nature) necessary for a fair presentation of the Company’s financial position as of December 31, 2013 and the results of its operations for the three months then ended. The condensed balance sheet as of September 30, 2013 is derived from the September 30, 2013 audited financial statements. Significant accounting policies have been consistently applied in the interim financial statements and the annual financial statements. The results of operations for the three months ended December 31, 2013 and 2012 are not necessarily indicative of the results to be expected for the entire year.

Summary of Significant Accounting Policies:

Research and Office Equipment and Leasehold Improvements - Research and office equipment is recorded at cost and depreciated using the straight-line method over estimated useful lives of five to seven years. Leasehold improvements are depreciated over the shorter of the estimated useful life of the asset or the term of the lease. Repairs and maintenance which do not extend the life of the asset are expensed when incurred. The fixed assets are reviewed on a quarterly basis to determine if any of the assets are impaired.

Patents - Patent expenditures are capitalized and amortized using the straight-line method over the shorter of the expected useful life or the legal life of the patent (17 years). In the event changes in technology or other circumstances impair the value or life of the patent, appropriate adjustment in the asset value and period of amortization is made. An impairment loss is recognized when estimated future undiscounted cash flows expected to result from the use of the asset, and from its disposition, is less than the carrying value of the asset. The amount of the impairment loss would be the difference between the estimated fair value of the asset and its carrying value.

Research and Development Costs - Research and development costs are expensed as incurred.



Income Taxes - The Company uses the asset and liability method of accounting for income taxes. Under the asset and liability method, deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating and tax loss carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company records a valuation allowance to reduce the deferred tax assets to the amount that is more likely than not to be recognized. A full valuation allowance was recorded against the deferred tax assets as of December 31, 2013 and September 30, 2013.

Derivative Instruments – The Company has entered into financing arrangements that contain embedded derivative features. The Company has also issued warrants to various parties in connection with work performed by these parties. The Company accounts for these arrangements in accordance with ASC 815, “Accounting for Derivative Instruments and Hedging Activities.” In accordance with accounting principles generally accepted in the United States (“GAAP”), derivative instruments and hybrid instruments are recognized as either assets or liabilities on the balance sheet and are measured at fair value with gains or losses recognized in earnings or other comprehensive income depending on the nature of the derivative or hybrid instruments. The Company determines the fair value of derivative instruments and hybrid instruments based on available market data using appropriate valuation models, giving consideration to all of the rights and obligations of each instrument. The derivative liabilities are remeasured at fair value at the end of each interim period as long as they are outstanding.

Deferred Rent (Asset) –Consideration paid, including deposits, related to operating leases is recorded as a deferred rent asset and amortized as rent expense over the lease term. Interest on the deferred rent is calculated at 3% on the funds deposited on the manufacturing facility and is included in deferred rent. This interest income will be used to offset future rent.

Stock-Based Compensation – Compensation cost for all stock-based awards is measured at fair value as of the grant date in accordance with the provisions of ASC 718 “Stock Compensation Expense”. The fair value of the stock options is calculated using the Black-Scholes option pricing model. The Black-Scholes model requires various judgmental assumptions including volatility and expected option life. The stock-based compensation cost is recognized on the straight line allocation method as expense over the requisite service or vesting period.

Equity instruments issued to non-employees are accounted for in accordance with ASC 505-50, “Equity-Based Payments to Non Employees.” Accordingly, compensation is recognized when goods or services are received and is measured using the Black-Scholes valuation model. The Black-Scholes model requires various judgmental assumptions regarding the fair value of the equity instruments at the measurement date and the expected life of the options.



The Company has Incentive Stock Option Plans, Non-Qualified Stock Option Plans, a Stock Compensation Plan and Stock Bonus Plans. In some cases these Plans are collectively referred to as the "Plans". All Plans have been approved by the stockholders.

Reclassification – Certain prior year items have been reclassified to conform to the current year presentation.

X

- Details

Name: CVM_NotesToFinancialStatementsAbstract

Namespace Prefix: CVM_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for all significant accounting policies of the reporting entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18726-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18861-107790

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18743-107790

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18854-107790

+ Details

Name: us-gaap_SignificantAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 29 R3.htm IDEA: XBRL DOCUMENT v2.4.0.8

BALANCE SHEETS (Parenthetical) (USD $)

Dec. 31, 2013

Sep. 30, 2013

Assets

Accumulated Depreciation and Amortization for Research and Office Equipment and Leasehold Improvements $ 3,010,439 $ 2,967,345

Accumulated Amortization for Patents $ 1,161,540 $ 1,151,852

Stockholders Equity

Preferred Stock Shares Par Value $ 0.01 $ 0.01

Preferred Stock Shares Authorized 200,000 200,000

Preferred Stock Shares Issued 0 0

Preferred Stock Shares Outstanding 0 0

Common Stock Shares Par Value $ 0.01 $ 0.01

Common Stock Shares Authorized 600,000,000 600,000,000

Common Stock Shares Issued 55,852,992 31,025,019

Common Stock Shares Outstanding 55,852,992 31,025,019

X

- Definition

Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.14)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 14

-Article 5

+ Details

Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_AssetsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Face amount or stated value per share of common stock.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

The maximum number of common shares permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 30 R17.htm IDEA: XBRL DOCUMENT v2.4.0.8

A. ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (POLICIES)
3 Months Ended

Dec. 31, 2013

A. Organization And Summary Of Significant Accounting Policies Policies

Basis of Presentation
The accompanying condensed financial statements of CEL-SCI Corporation (the Company) are unaudited and certain information and footnote disclosures normally included in the annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been omitted pursuant to the rules and regulations of the Securities and Exchange Commission. While management of the Company believes that the disclosures presented are adequate to make the information presented not misleading, these interim condensed financial statements should be read in conjunction with the financial statements and notes included in the Company’s annual report on Form 10-K for the year ended September 30, 2013.

In the opinion of management, the accompanying unaudited condensed financial statements contain all accruals and adjustments (each of which is of a normal recurring nature) necessary for a fair presentation of the Company’s financial position as of December 31, 2013 and the results of its operations for the three months then ended. The condensed balance sheet as of September 30, 2013 is derived from the September 30, 2013 audited financial statements. Significant accounting policies have been consistently applied in the interim financial statements and the annual financial statements. The results of operations for the three months ended December 31, 2013 and 2012 are not necessarily indicative of the results to be expected for the entire year.

Research and Office Equipment and Leasehold Improvements
Research and Office Equipment and Leasehold Improvements - Research and office equipment is recorded at cost and depreciated using the straight-line method over estimated useful lives of five to seven years. Leasehold improvements are depreciated over the shorter of the estimated useful life of the asset or the term of the lease. Repairs and maintenance which do not extend the life of the asset are expensed when incurred. The fixed assets are reviewed on a quarterly basis to determine if any of the assets are impaired.

Patents
Patents - Patent expenditures are capitalized and amortized using the straight-line method over the shorter of the expected useful life or the legal life of the patent (17 years). In the event changes in technology or other circumstances impair the value or life of the patent, appropriate adjustment in the asset value and period of amortization is made. An impairment loss is recognized when estimated future undiscounted cash flows expected to result from the use of the asset, and from its disposition, is less than the carrying value of the asset. The amount of the impairment loss would be the difference between the estimated fair value of the asset and its carrying value.

Research and Development Costs
Research and Development Costs - Research and development costs are expensed as incurred.

Income Taxes
Income Taxes - The Company uses the asset and liability method of accounting for income taxes. Under the asset and liability method, deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating and tax loss carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company records a valuation allowance to reduce the deferred tax assets to the amount that is more likely than not to be recognized. A full valuation allowance was recorded against the deferred tax assets as of December 31, 2013 and September 30, 2013.

Derivative Instruments
Derivative Instruments – The Company has entered into financing arrangements that contain embedded derivative features. The Company has also issued warrants to various parties in connection with work performed by these parties. The Company accounts for these arrangements in accordance with ASC 815, “Accounting for Derivative Instruments and Hedging Activities.” In accordance with accounting principles generally accepted in the United States (“GAAP”), derivative instruments and hybrid instruments are recognized as either assets or liabilities on the balance sheet and are measured at fair value with gains or losses recognized in earnings or other comprehensive income depending on the nature of the derivative or hybrid instruments. The Company determines the fair value of derivative instruments and hybrid instruments based on available market data using appropriate valuation models, giving consideration to all of the rights and obligations of each instrument. The derivative liabilities are remeasured at fair value at the end of each interim period as long as they are outstanding.

Deferred Rent (Asset)
Deferred Rent (Asset) –Consideration paid, including deposits, related to operating leases is recorded as a deferred rent asset and amortized as rent expense over the lease term. Interest on the deferred rent is calculated at 3% on the funds deposited on the manufacturing facility and is included in deferred rent. This interest income will be used to offset future rent.

Stock-Based Compensation
Stock-Based Compensation – Compensation cost for all stock-based awards is measured at fair value as of the grant date in accordance with the provisions of ASC 718 “Stock Compensation Expense”. The fair value of the stock options is calculated using the Black-Scholes option pricing model. The Black-Scholes model requires various judgmental assumptions including volatility and expected option life. The stock-based compensation cost is recognized on the straight line allocation method as expense over the requisite service or vesting period.

Equity instruments issued to non-employees are accounted for in accordance with ASC 505-50, “Equity-Based Payments to Non Employees.” Accordingly, compensation is recognized when goods or services are received and is measured using the Black-Scholes valuation model. The Black-Scholes model requires various judgmental assumptions regarding the fair value of the equity instruments at the measurement date and the expected life of the options.

The Company has Incentive Stock Option Plans, Non-Qualified Stock Option Plans, a Stock Compensation Plan and Stock Bonus Plans. In some cases these Plans are collectively referred to as the "Plans". All Plans have been approved by the stockholders.

Reclassification
Reclassification – Certain prior year items have been reclassified to conform to the current year presentation.

X

- Details

Name: CVM_OrganizationAndSummaryOfSignificantAccountingPoliciesPoliciesAbstract

Namespace Prefix: CVM_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).

+ References

No definition available.

+ Details

Name: us-gaap_BasisOfAccountingPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for deferral and amortization of significant deferred charges.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.17)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 17

-Article 5

+ Details

Name: us-gaap_DeferredChargesPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for derivatives entered into for trading purposes and those entered into for purposes other than trading including where and when derivative financial instruments and derivative commodity instruments and their related gains or losses are reported in the entity's statements of financial position, cash flows, and results of operations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-URI http://asc.fasb.org/section&trid=2229173

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(n)(7))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph n

-Article 4

+ Details

Name: us-gaap_DerivativesReportingOfDerivativeActivity

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-URI http://asc.fasb.org/subtopic&trid=2144439

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-URI http://asc.fasb.org/subtopic&trid=2144471

+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2144681

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 30

-URI http://asc.fasb.org/subtopic&trid=2144749

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 19

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32840-109319

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 954

-SubTopic 740

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 17

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32809-109319

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=21917399&loc=d3e32247-109318

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=21917399&loc=d3e32280-109318

+ Details

Name: us-gaap_IncomeTaxPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for reclassifications that affects the comparability of the financial statements.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755

+ Details

Name: us-gaap_PriorPeriodReclassificationAdjustmentDescription

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for assessing and recognizing impairments of its property, plant and equipment.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6391110&loc=d3e2921-110230

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2155824

+ Details

Name: us-gaap_PropertyPlantAndEquipmentImpairment

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2127266

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Research and Development

-URI http://asc.fasb.org/extlink&oid=6523717

+ Details

Name: us-gaap_ResearchAndDevelopmentExpensePolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (b),(f)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2228939

+ Details

Name: us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 31 R1.htm IDEA: XBRL DOCUMENT v2.4.0.8

Document and Entity Information
3 Months Ended

Dec. 31, 2013

Feb. 04, 2014

Document And Entity Information

Entity Registrant Name CEL SCI CORP

Entity Central Index Key 0000725363

Document Type 10-Q

Document Period End Date Dec. 31, 2013

Amendment Flag false

Current Fiscal Year End Date --09-30

Is Entity a Well-known Seasoned Issuer? No

Is Entity a Voluntary Filer? No

Is Entity's Reporting Status Current? Yes

Entity Filer Category Accelerated Filer

Entity Common Stock, Shares Outstanding 55,940,156

Document Fiscal Period Focus Q1

Document Fiscal Year Focus 2014

X

- Details

Name: CVM_DocumentAndEntityInformationAbstract

Namespace Prefix: CVM_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

If the value is true, then the document is an amendment to previously-filed/accepted document.

+ References

No definition available.

+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition

End date of current fiscal year in the format --MM-DD.

+ References

No definition available.

+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition

The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.

+ References

No definition available.

+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".

+ References

No definition available.

+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.

+ References

No definition available.

+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.

+ References

No definition available.

+ Details

Name: dei_EntityCurrentReportingStatus

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.

+ References

No definition available.

+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.

+ References

No definition available.

+ Details

Name: dei_EntityVoluntaryFilers

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.

+ References

No definition available.

+ Details

Name: dei_EntityWellKnownSeasonedIssuer

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

XML 32 R18.htm IDEA: XBRL DOCUMENT v2.4.0.8

C. STOCKHOLDERS EQUITY (Tables)
3 Months Ended

Dec. 31, 2013

C. Stockholders Equity Tables

Stock options, stock bonuses and compensation granted by the Company

Name of Plan Total Shares Reserved Under Plans Shares Reserved for Outstanding Options Shares Issued as Stock Bonus Remaining Options/Shares Under Plans

Incentive Stock Option Plans 1,960,000 1,573,597 N/A 145,703

Non-Qualified Stock Option Plans 5,680,000 3,674,544 N/A 1,443,537

Stock Bonus Plans 1,594,000 N/A 958,325 634,919

Stock Compensation Plan 1,350,000 N/A 791,145 558,855

Schedule of employees and non-employees stock compensation

Three Months Ended December 31,

2013 2012

Employees $ 510,278 $ 966,585

Non-employees $ 214,720 $ 107,818

Derivative Liabilities, Warrants and Other Options

Warrant Issue Date Shares Issuable upon Exercise of Warrant Exercise Price Expiration Date Refer-ence

Series N 8/18/08 2,951,420 0.53 8/18/14 1

Series A 6/24/09 130,347 5.00 12/24/14 1

Schleuning (Series A) 7/8/09 16,750 5.00 1/8/15 1

Series B 9/4/09 50,000 6.80 9/4/14 1

Series C 8/20/09 – 8/26/09 463,487 5.50 2/20/15 1

Series E 9/21/09 71,428 17.50 8/12/14 1

Series F 10/6/11 1,200,000 4.00 10/6/14 1

Series G 10/6/11 66,667 4.00 8/12/14 1

Series H 1/26/12 1,200,000 5.00 8/1/15 1

Series Q 6/21/12 1,200,000 5.00 12/22/15 1

Series R 12/6/12 2,625,000 4.00 12/6/16 1

Series S 10/11/13-12/24/13 25,713,095 1.25 10/11/18 1

Series L 4/18/07 25,000 7.50 4/17/14 2

Series L (repriced) 4/18/07 70,000 2.50 4/2/15 2

Series M (modified) 4/18/07 500,000 1.00 4/20/14 2

Series P 2/10/12 590,001 4.50 3/6/17 3

Private Investors 7/18/05-6/30/09 740,938 5.60-8.20 1/26/14 - 7/18/14 4

Warrants held by Officer and Director 6/24/09-7/6/09 349,754 4.00 – 5.00 12/24/14 – 1/6/15 5

Consultants 2/15/05-10/28/13 200,750 0.85-20.00 5/20/14 - 12/27/17 6

Tabular disclosure of derivative liabilities at fair value

December 31, 2013 September 30, 2013

Series A through E warrants $ 6,106 $ 6,106

Series N warrants 531,255 41,501

Series F and G warrants 12,667 12,667

Series H warrants 12,000 36,000

Series Q warrants 24,000 48,000

Series R warrants 157,500 288,750

Series S warrants 5,339,750 —

Total derivative liabilities $ 6,143,278 $ 433,024

X

- Definition

Custom Element.

+ References

No definition available.

+ Details

Name: CVM_ScheduleOfDerivativeLiabilitiesAtFairValue

Namespace Prefix: CVM_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Custom Element.

+ References

No definition available.

+ Details

Name: CVM_ScheduleOfDerivativeLiabilitiesWarrantsAndOtherOptions

Namespace Prefix: CVM_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Custom Element.

+ References

No definition available.

+ Details

Name: CVM_ScheduleStockOptionsStockBonusesAndCompensationGrantedByCompany

Namespace Prefix: CVM_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: CVM_StockholdersEquityTablesAbstract

Namespace Prefix: CVM_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the amount of total share-based compensation cost, including the amounts attributable to each share-based compensation plan and any related tax benefits.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (h)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 33 R4.htm IDEA: XBRL DOCUMENT v2.4.0.8

STATEMENTS OF OPERATIONS (USD $)
3 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Income Statement [Abstract]

OTHER INCOME $ 113,144 $ 15,000

OPERATING EXPENSES:

Research and development (excluding R&D depreciation of R&D depreciation of $41,673 and $104,864) 4,019,541 2,924,722

Depreciation and amortization 56,699 133,450

General & administrative 1,971,214 2,001,285

Total operating expenses 6,047,454 5,059,457

OPERATING LOSS (5,934,310) (5,044,457)

GAIN ON DERIVATIVE INSTRUMENTS 1,610,817 2,746,198

INTEREST INCOME 31,757 29,415

INTEREST EXPENSE (42,682) (41,402)

NET LOSS (4,334,418) (2,310,246)

ISSUANCE OF ADDITIONAL SHARES DUE TO RESET PROVISIONS (1,117,447) 0

NET LOSS AVAILABLE TO COMMON SHAREHOLDERS $ (5,451,865) $ (2,310,246)

NET LOSS PER COMMON SHARE

BASIC $ (0.11) $ (0.08)

DILUTED $ (0.15) $ (0.18)

WEIGHTED AVERAGE COMMON SHARES OUTSTANDING

BASIC 48,215,919 28,311,602

DILUTED 48,215,919 28,311,602

X

- Definition

Custom Element.

+ References

No definition available.

+ Details

Name: CVM_GainOnDerivativeInstruments

Namespace Prefix: CVM_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Issuance Of Additional Shares.

+ References

No definition available.

+ Details

Name: CVM_IssuanceOfAdditionalShares

Namespace Prefix: CVM_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_DepreciationAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 55

-Paragraph 52

-URI http://asc.fasb.org/extlink&oid=32703322&loc=d3e4984-109258

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.23)

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 18

-Article 7

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 20

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 21

-Article 9

+ Details

Name: us-gaap_EarningsPerShareBasic

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 18

-Article 7

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 20

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 21

-Article 9

+ Details

Name: us-gaap_EarningsPerShareDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.4)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_GeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_IncomeStatementAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of the cost of borrowed funds accounted for as interest expense.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.9)

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 9

-Article 9

+ Details

Name: us-gaap_InterestExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 7

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.7(b))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_InvestmentIncomeInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e565-108580

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1377-109256

+ Details

Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.

+ References

No definition available.

+ Details

Name: us-gaap_OperatingExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_OperatingExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The net result for the period of deducting operating expenses from operating revenues.

+ References

No definition available.

+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Reflects the sum of all other revenue and income recognized by the entity in the period not otherwise specified in the income statement.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.4)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 4

-Article 7

+ Details

Name: us-gaap_OtherIncome

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 985

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1505-109256

+ Details

Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1448-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Weighted-Average Number of Common Shares Outstanding

-URI http://asc.fasb.org/extlink&oid=6528421

+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 34 R12.htm IDEA: XBRL DOCUMENT v2.4.0.8

F. OPERATIONS, FINANCING
3 Months Ended

Dec. 31, 2013

Notes to Financial Statements

F. OPERATIONS, FINANCING
The Company has incurred significant costs since its inception in connection with the acquisition of certain patented and unpatented proprietary technology and know-how relating to the human immunological defense system, patent applications, research and development, administrative costs, construction of laboratory facilities, and clinical trials. The Company has funded such costs with proceeds from loans and the public and private sale of its common and preferred stock. The Company will be required to raise additional capital or find additional long-term financing in order to continue with its research efforts. To date, the Company has not generated any revenue from product sales. The ability of the Company to complete the necessary clinical trials and obtain US Food & Drug Administration (FDA) approval for the sale of products to be developed on a commercial basis is uncertain. Ultimately, the Company must complete the development of its products, obtain the appropriate regulatory approvals and obtain sufficient revenues to support its cost structure.

The Company is currently running a large multi-national Phase III clinical trial for head and neck cancer with its partners TEVA Pharmaceuticals and Orient Europharma. The Company believes that it has enough capital to support its operations for more than the next twelve months and believes that it has ready access to new equity capital should the need arise. During fiscal year 2013, the Company raised $9.8 million net proceeds from several institutional investors. During the three months ended December 31, 2013, the Company raised approximately $19.4 million in net proceeds through the sale of common stock and warrants in two public offerings. These funds are expected to meet the Company’s cash requirements through 2014. To finance the study beyond the next 12 months, the Company plans to raise additional capital in the form of corporate partnerships, debt and/or equity financings. The Company believes that it will be able to obtain additional financing since Multikine is a Phase III product designed to treat cancer and because it has done so consistently in the past. However, there can be no assurance that the Company will be successful in raising additional funds or that funds will be available to the Company on acceptable terms or at all. If the Company does not raise the necessary amounts of money, the Company will either have to slow down or delay the Phase III clinical trial or even significantly curtail its operations until such time as it is able to raise the required funding.

Since the Company launched its Phase III trial for Multikine, the Company has spent approximately $11,300,000 as of December 31, 2013 on direct costs for the Phase III clinical trial. The total remaining cash cost of the clinical trial is estimated to be about $33,300,000. It should be noted that this estimate is based only on the information currently available in the Company’s contracts with the Clinical Research Organizations responsible for managing the Phase III trial. This number can be affected by the speed of enrollment, foreign currency exchange rates and many other factors, some of which cannot be foreseen today. It is therefore possible that the cost of the Phase III trial will be higher than currently estimated.

X

- Details

Name: CVM_NotesToFinancialStatementsAbstract

Namespace Prefix: CVM_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Custom Element.

+ References

No definition available.

+ Details

Name: CVM_OperationsAndFinancingTextBlock

Namespace Prefix: CVM_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 35 R11.htm IDEA: XBRL DOCUMENT v2.4.0.8

E. LOANS FROM OFFICER
3 Months Ended

Dec. 31, 2013

Notes to Financial Statements

E. LOANS FROM OFFICER AND INVESTOR
The Company’s President, and a director, Maximilian de Clara, loaned the Company $1,104,057. The loan from Mr. de Clara bears interest at 15% per year and is secured by a lien on substantially all of the Company’s assets. The Company does not have the right to prepay the loan without Mr. de Clara’s consent. The loan was initially payable at the end of March 2009, but was extended to the end of June 2009. At the time the loan was originally due, and in accordance with the loan agreement, the Company issued Mr. de Clara warrants to purchase 164,824 shares of the Company’s common stock at a price of $4.00 per share. The warrants are exercisable at any time prior to December 24, 2014. In June 2009, the loan with Mr. de Clara was extended for the second time to July 6, 2014. At Mr. de Clara’s option, the loan may be converted into shares of the Company’s common stock. The number of shares which will be issued upon any conversion will be determined by dividing the amount to be converted by $4.00. As further consideration for the second extension, Mr. de Clara received warrants to purchase 184,930 shares of the Company’s common stock at a price of $5.00 per share at any time prior to January 6, 2015. On May 13, 2011, to recognize Mr. de Clara’s willingness to agree to subordinate his note to the convertible preferred shares and convertible debt as part of the settlement agreement, the Company extended the maturity date of the note to July 6, 2015; however, Mr. de Clara may demand payment upon giving the Company a minimum 10 day notice.

During the three months ended December 31, 2013 and 2012, the Company paid $55,203 and $41,402 respectively in interest expense to Mr. de Clara.

X

- Definition

Custom Element.

+ References

No definition available.

+ Details

Name: CVM_LoansFromOfficerAndInvestorTextBlock

Namespace Prefix: CVM_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: CVM_NotesToFinancialStatementsAbstract

Namespace Prefix: CVM_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 36 R23.htm IDEA: XBRL DOCUMENT v2.4.0.8

C. STOCKHOLDERS EQUITY (Details 1) (USD $)
3 Months Ended

Dec. 31, 2013

Dec. 31, 2012

C. Stockholders Equity Details 1

Employees $ 510,278 $ 966,585

Non-employees $ 214,720 $ 107,818

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: CVM_NonemployeesShareBasedCompensation

Namespace Prefix: CVM_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: CVM_StockholdersEquityDetails1Abstract

Namespace Prefix: CVM_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Represents the compensation cost capitalized during the period arising from equity-based compensation arrangements (for example, shares of stock, units, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (h)(1)(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 37 R19.htm IDEA: XBRL DOCUMENT v2.4.0.8

D. FAIR VALUE MEASUREMENTS (Tables)
3 Months Ended

Dec. 31, 2013

D. Fair Value Measurements Tables

Measured at fair value on a recurring basis

Quoted Prices in Active Markets for Identical Assets or Liabilities (Level 1)
Significant Other Observable

Inputs (Level 2)
Significant Unobservable Inputs (Level 3) Total

Derivative instruments $ - $ - $ 6,143,278 $ 6,143,278

The table below sets forth the assets and liabilities measured at fair value on a recurring basis, by input level, in the condensed balance sheet at September 30, 2013:

Quoted Prices in Active Markets for Identical Assets or Liabilities (Level 1)
Significant Other Observable

Inputs (Level 2)
Significant Unobservable Inputs (Level 3) Total

Derivative instruments $ - $ - $ 433,024 $ 433,024

Reconciliation of beginning and ending balances related to fair value measurements using significant unobservable inputs (Level 3)

(3 month) (12 month)

December 31, 2013 September 30, 2013

Beginning balance $ 433,024 $ 6,983,690

Issuances 7,321,071 4,200,000

Settlements - -

Realized and unrealized gains

recorded in earnings (1,610,817 ) (10,750,666 )

Ending balance $ 6,143,278 $ 433,024

X

- Details

Name: CVM_FairValueMeasurementsTablesAbstract

Namespace Prefix: CVM_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=25499696&loc=d3e19190-110258

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (a),(b)

-URI http://asc.fasb.org/extlink&oid=25499696&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=25499696&loc=d3e19279-110258

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=25499696&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 38 R15.htm IDEA: XBRL DOCUMENT v2.4.0.8

I. NET LOSS PER SHARE
3 Months Ended

Dec. 31, 2013

Accounting Policies [Abstract]

I. NET LOSS PER SHARE
The Company’s basic and diluted loss per share are as follows: For the three months ended December 31, 2013 and 2012, the computation of dilutive net loss per share excluded options and warrants to purchase approximately 865,000 and 578,800 shares of common stock because their inclusion would have an anti-dilutive effect.

Three Months Ended December 31, 2013

Net Loss Weighted Average Shares LPS

Basic loss per share $ (5,451,865 ) 48,215,919 $ (0.11 )

Gain on derivatives (1,610,817 )

Dilutive loss per share $ (7,062,652 ) 48,215,919 $ (0.15 )

Three Months Ended December 31, 2012

Net Loss Weighted Average Shares LPS

Basic loss per share $ (2,310,246 ) 28,311,602 $ (0.08 )

Gain on derivatives (2,746,198 )

Dilutive loss per share $ (5,056,444 ) 28,311,602 $ (0.18 )

X

- Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2144384

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257

+ Details

Name: us-gaap_EarningsPerSharePolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 39 R13.htm IDEA: XBRL DOCUMENT v2.4.0.8

G. COMMITMENTS AND CONTINGENCIES
3 Months Ended

Dec. 31, 2013

Commitments and Contingencies Disclosure [Abstract]

G. COMMITMENTS AND CONTINGENCIES
Clinical Research Agreements

In March 2013, the Company entered into an agreement with Aptiv Solutions to provide certain clinical research services in accordance with a master service agreement. The Company will reimburse Aptiv for costs incurred. In May 2013, CEL-SCI made an advance payment of $400,000. In October 2013, CEL-SCI made the second and final advance payment of $200,000. The funds advanced will be credited back in $150,000 annual increments from December 2014 through December 2017. As of December 31, 2013, $150,000 of the deposit is classified as a current asset.

In April 2013, the Company entered into a co-development and revenue sharing agreement with Ergomed. Under the agreement, Ergomed will contribute up to $10 million towards the Company’s Phase III trial in the form of offering discounted clinical services in exchange for a single digit percentage of milestone and royalty payments, up to a specific maximum amount. The Company accounted for the co-development and revenue sharing agreement in accordance with ASC 808 “Collaborative Arrangements”. The Company determined the payments to Erogmed are within the scope of ASC 730 “Research and Development.” Therefore, the Company records the discount on the clinical services as a credit to research and development expense on its Statements of Operations. Since the Company entered into the co-development and revenue sharing agreement with Ergomed it has incurred research and development expenses of approximately $2,017,000 related to Ergomed’s services. This amount is net of Ergomed’s discount of approximately $634,000. During the three months ended December 31, 2013, the Company recorded, net of Ergomed’s discount, approximately $1,179,000 as research and development expense related to Ergomed’s services.

In October 2013, the Company entered into two co-development and profit sharing agreements with Ergomed. One agreement supports the US Navy with the development of Multikine as a potential treatment in HIV/HPV co-infected men and women with peri-anal warts. The other agreement focuses on the development of Multikine in HIV/HPV co-infected women with cervical dysplasia. Ergomed will assume up to $3 million in clinical and regulatory costs for each study.

On October 31, 2013, the Company commenced arbitration proceedings against inVentiv Health Clinical, LLC (inVentiv, f/k/a PharmaNet, LLC), the Company’s former clinical research organization. The arbitration claim, initiated under the Commercial Rules of the American Arbitration Association, alleges (i) breach of contract, (ii) fraud in the inducement, and (iii) common law fraud, and seeks at least $50 million in damages. The Company filed this arbitration because, among other reasons, the number of patients enrolled and treated in the study fell below the level agreed to with inVentiv. In April 2013, the Company dismissed inVentiv and replaced it with Aptiv Solutions, Inc. and Ergomed Clinical Research Ltd, as noted above.

On December 12, 2013, inVentiv filed a counterclaim, alleging breach of contract on the part of CEL-SCI and seeking at least $2 million in damages. On December 20, 2013, inVentiv moved to dismiss certain claims. Given that this matter is at a preliminary stage, the Company is not in a position to predict or assess the likely outcome of these proceedings.

Lease Agreements

In August 2007, the Company leased a building near Baltimore, Maryland. The building was remodeled in accordance with the Company’s specifications so that it can be used by the Company to manufacture Multikine for the Company’s Phase III clinical trial and sales of the drug if approved by the FDA. The lease is for a term of twenty years and requires annual base rent to escalate each year at 3%. The Company is required to pay all real and personal property taxes, insurance premiums, maintenance expenses, repair costs and utilities. The lease allows the Company, at its election, to extend the lease for two ten-year periods or to purchase the building at the end of the 20-year lease.

The Company was required to deposit the equivalent of one year of base rent in accordance with the contract. When the Company meets the minimum cash balance required by the lease, the deposit will be returned to the Company. The $1,670,917 is included in non-current assets on December 31, 2013 and September 30, 2013.

The Company subleases a portion of its rental space on a month to month term lease, which requires a 30 day notice for termination. The Company receives $5,150 per month in rent for the subleased space.

The Company leases its research and development laboratory under a 60 month lease which expires February 28, 2017. The operating lease includes escalating rental payments. The Company is recognizing the related rent expense on a straight line basis over the full 60 month term of the lease at the rate of $11,360 per month. As of December 31, 2013 and September 30, 2013, the Company has recorded a deferred rent liability of $4,591 and $3,992, respectively.

The Company leases its office headquarters under a 36 month lease which expires June 30, 2015. The operating lease includes escalating rental payments. The Company is recognizing the related rent expense on a straight line basis over the full 36 month term of the lease at the rate $7,864 per month. As of December 31, 2013 and September 30, 2013, the Company has recorded a deferred rent liability of $11,065 and $12,412, respectively.

The Company leased office equipment under a capital lease arrangement. The term of the capital lease is 48 months and expires on September 30, 2016. The monthly lease payment is $1,025. The lease bears interest at approximately 16% per annum.

In October 2013, the Company purchased office equipment under a capital lease. The term of the capital lease is 36 months and it expires on September 30, 2016. The monthly lease payment is $299. The lease bears interest at approximately 9% per annum.

X

- Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for commitments and contingencies.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 460

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6398077&loc=d3e12565-110249

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14435-108349

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 440

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308

+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 40 R14.htm IDEA: XBRL DOCUMENT v2.4.0.8

H. PATENTS
3 Months Ended

Dec. 31, 2013

Accounting Policies [Abstract]

H. PATENTS
During the three months ended December 31, 2013 and 2012, the Company recorded patent impairment charges of $240 and $10,223, respectively. For the three months ended December 31, 2013 and 2012, amortization of patent costs totaled $9,703 and $23,905, respectively. The Company estimates that future amortization expense will be as follows:

Nine months ending September 30, 2014 $ 25,252

Year ending September 30,

2015 33,795

2016 33,795

2017 33,795

2018 33,461

2019 31,758

Thereafter 125,604

Total $ 317,460

X

- Definition

Custom Element.

+ References

No definition available.

+ Details

Name: CVM_Patents

Namespace Prefix: CVM_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 41 R16.htm IDEA: XBRL DOCUMENT v2.4.0.8

J. SUBSEQUENT EVENTS
3 Months Ended

Dec. 31, 2013

Subsequent Events [Abstract]

J. SUBSEQUENT EVENTS
The Company has evaluated subsequent events through the date these financial statements were filed and determined there are no subsequent events that require disclosure.

X

- Details

Name: us-gaap_SubsequentEventsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.

+ References

No definition available.

+ Details

Name: us-gaap_SubsequentEventsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 42 R34.htm IDEA: XBRL DOCUMENT v2.4.0.8

I. NET LOSS PER SHARE (Details Narrative)
3 Months Ended

Dec. 31, 2013

Dec. 31, 2012

I. Net Loss Per Share Details Narrative

Options and warrants excluded from earnings per share due to anti-dilutive effect 865,000 578,800

X

- Details

Name: CVM_I.EarningsPerShareDetailsNarrativeAbstract

Namespace Prefix: CVM_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Antidilution

-URI http://asc.fasb.org/extlink&oid=6505113

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Diluted Earnings Per Share

-URI http://asc.fasb.org/extlink&oid=6510752

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Contingent Stock Agreement

-URI http://asc.fasb.org/extlink&oid=6508534

+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 43 R21.htm IDEA: XBRL DOCUMENT v2.4.0.8

I. NET LOSS PER SHARE (Tables)
3 Months Ended

Dec. 31, 2013

I. Net Loss Per Share Tables

Computation of dilutive net loss per share

Three Months Ended December 31, 2013

Net Loss Weighted Average Shares LPS

Basic loss per share $ (5,451,865 ) 48,215,919 $ (0.11 )

Gain on derivatives (1,610,817 )

Dilutive loss per share $ (7,062,652 ) 48,215,919 $ (0.15 )

Three Months Ended December 31, 2012

Net Loss Weighted Average Shares LPS

Basic loss per share $ (2,310,246 ) 28,311,602 $ (0.08 )

Gain on derivatives (2,746,198 )

Dilutive loss per share $ (5,056,444 ) 28,311,602 $ (0.18 )

X

- Details

Name: CVM_NetIncomeLossPerCommonShareTablesAbstract

Namespace Prefix: CVM_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

+ Details

Name: us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 44 R26.htm IDEA: XBRL DOCUMENT v2.4.0.8

C. STOCKHOLDERS EQUITY (Details Narrative) (USD $)
3 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Sep. 30, 2013

Options granted to employees and directors 0 1,437,466

Amount excluded from non-employee stock compensation expense for future services to be performed $ 55,362 $ 57,553

Series A through E warrants

Gain on warrants 0 332,436

Series A [Member]

Warrants outstanding 130,347

Fair value of outstanding warrants 1,303 1,303

Private Investors [Member]

Warrants outstanding 16,750

Fair value of outstanding warrants 168 168

Series B [Member]

Warrants outstanding 50,000

Fair value of outstanding warrants 0 0

Series C [Member]

Warrants outstanding 463,487

Fair value of outstanding warrants 4,635 4,635

Series E [Member]

Warrants outstanding 71,428

Fair value of outstanding warrants 0 0

Series N [Member]

Loss on warrants 489,754

Gain on warrants 311,262

Warrants outstanding 2,951,420

Fair value of outstanding warrants 531,255 41,501

SeriesFAndGWarrantsMember

Gain on warrants 0 640,000

Fair value of outstanding warrants 12,667 12,667

Series H [Member]

Gain on warrants 24,000 600,000

Fair value of outstanding warrants 12,000 36,000

Series Q [Member]

Gain on warrants 24,000 600,000

Fair value of outstanding warrants 24,000 48,000

SeriesRMember

Gain on warrants 131,250 262,500

Fair value of outstanding warrants 157,500 288,750

Series S

Gain on warrants 1,921,321

Fair value of outstanding warrants 5,399,750

Series M Modified [Member]

Warrants outstanding 500,000

Series P [Member]

Warrants outstanding 590,001

Private Investor Warrants

Warrants outstanding 132,500

Private Investor Warrants

Warrants outstanding 378,750

Private Investor Warrants

Warrants outstanding 229,688

Warrants Held by Officer And Director [Member]

Warrants outstanding 349,754

Consultants [Member]

Warrants outstanding 200,750

Expense recorded for consulting arrangement 137,729 1,985

Prepaid consulting expenses $ 55,362 $ 57,553

X

- Definition

Custom Element.

+ References

No definition available.

+ Details

Name: CVM_AmountExcludedFromNonemployeeStockCompensationExpenseForFutureServicesToBePerformed1

Namespace Prefix: CVM_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Custom Element.

+ References

No definition available.

+ Details

Name: CVM_ExpenseRecordedForConsultingArrangement

Namespace Prefix: CVM_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Custom Element.

+ References

No definition available.

+ Details

Name: CVM_FairValueOfOutstandingWarrants

Namespace Prefix: CVM_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Custom Element.

+ References

No definition available.

+ Details

Name: CVM_PrepaidConsultingExpenses

Namespace Prefix: CVM_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Custom Element.

+ References

No definition available.

+ Details

Name: CVM_WarrantsOutstanding

Namespace Prefix: CVM_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Amount of increase in the fair value of derivatives recognized in the income statement.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4A

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5618551-113959

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4C

-Subparagraph (a),(c),(d),(e)

-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5624171-113959

+ Details

Name: us-gaap_DerivativeGainOnDerivative

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of decrease in the fair value of derivatives recognized in the income statement.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4A

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5618551-113959

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4C

-Subparagraph (a),(c),(d),(e)

-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5624171-113959

+ Details

Name: us-gaap_DerivativeLossOnDerivative

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Net number of share options (or share units) granted during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 45 R5.htm IDEA: XBRL DOCUMENT v2.4.0.8

STATEMENTS OF OPERATIONS (Parenthetical) (USD $)
3 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Expenses

Depreciation $ 41,673 $ 104,864

X

- Definition

The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_Depreciation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_OperatingExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 46 R10.htm IDEA: XBRL DOCUMENT v2.4.0.8

D. FAIR VALUE MEASUREMENTS
3 Months Ended

Dec. 31, 2013

Fair Value Disclosures [Abstract]

D. FAIR VALUE MEASUREMENTS
In accordance with ASC 820-10, “Fair Value Measurements,” the Company determines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company generally applies the income approach to determine fair value. This method uses valuation techniques to convert future amounts to a single present amount. The measurement is based on the value indicated by current market expectations with respect to those future amounts.

ASC 820-10 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to active markets for identical assets and liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement). The Company classifies fair value balances based on the observability of those inputs. The three levels of the fair value hierarchy are as follows:

● Level 1 – Observable inputs such as quoted prices in active markets for identical assets or liabilities

● Level 2 – Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and amounts derived from valuation models where all significant inputs are observable in active markets

● Level 3 – Unobservable inputs that reflect management’s assumptions

For disclosure purposes, assets and liabilities are classified in their entirety in the fair value hierarchy level based on the lowest level of input that is significant to the overall fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the placement within the fair value hierarchy levels.



The table below sets forth the assets and liabilities measured at fair value on a recurring basis, by input level, in the condensed balance sheet at December 31, 2013:

Quoted Prices in Active Markets for Identical Assets or Liabilities (Level 1)
Significant Other Observable

Inputs (Level 2)
Significant Unobservable Inputs (Level 3) Total

Derivative instruments $ - $ - $ 6,143,278 $ 6,143,278

The table below sets forth the assets and liabilities measured at fair value on a recurring basis, by input level, in the condensed balance sheet at September 30, 2013:

Quoted Prices in Active Markets for Identical Assets or Liabilities (Level 1)
Significant Other Observable

Inputs (Level 2)
Significant Unobservable Inputs (Level 3) Total

Derivative instruments $ - $ - $ 433,024 $ 433,024

The following sets forth the reconciliation of beginning and ending balances related to fair value measurements using significant unobservable inputs (Level 3) for the three months ended December 31, 2013 and the year ended September 30, 2013:

(3 month) (12 month)

December 31, 2013 September 30, 2013

Beginning balance $ 433,024 $ 6,983,690

Issuances 7,321,071 4,200,000

Settlements - -

Realized and unrealized gains

recorded in earnings (1,610,817 ) (10,750,666 )

Ending balance $ 6,143,278 $ 433,024

The fair values of the Company’s derivative instruments disclosed above are primarily derived from valuation models where significant inputs such as historical price and volatility of the Company’s stock as well as U.S. Treasury Bill rates are observable in active markets.

X

- Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 21

-URI http://asc.fasb.org/extlink&oid=28364263&loc=d3e13537-108611

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=28364263&loc=d3e13433-108611

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14064-108612

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=25499696&loc=d3e19207-110258

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 30

-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14172-108612

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=28364263&loc=d3e13504-108611

+ Details

Name: us-gaap_FairValueDisclosuresTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 47 R27.htm IDEA: XBRL DOCUMENT v2.4.0.8

D. FAIR VALUE MEASUREMENTS (Details) (USD $)

Dec. 31, 2013

Sep. 30, 2013

Level1

Derivative instruments

Level2

Derivative instruments

Level3

Derivative instruments 6,143,278 433,024

Total

Derivative instruments $ 6,143,278 $ 433,024

X

- Definition

Fair value before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 20

-Section 55

-Paragraph 7

-URI http://asc.fasb.org/extlink&oid=28370219&loc=SL20226000-175313

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 20

-Section 50

-Paragraph 3

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=20225523&loc=SL20225862-175312

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4B

-Subparagraph (a),(c)

-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5624163-113959

+ Details

Name: us-gaap_DerivativeFairValueOfDerivativeLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 48 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.8 Html 70 203 1 false 33 0 false 3 false false R1.htm 0001 - Document - Document and Entity Information Sheet http://cel-sci.com/role/DocumentAndEntityInformation Document and Entity Information true false R2.htm 0002 - Statement - BALANCE SHEETS Sheet http://cel-sci.com/role/BalanceSheets BALANCE SHEETS false false R3.htm 0003 - Statement - BALANCE SHEETS (Parenthetical) Sheet http://cel-sci.com/role/BalanceSheetsParenthetical BALANCE SHEETS (Parenthetical) false false R4.htm 0004 - Statement - STATEMENTS OF OPERATIONS Sheet http://cel-sci.com/role/StatementsOfOperations STATEMENTS OF OPERATIONS false false R5.htm 0005 - Statement - STATEMENTS OF OPERATIONS (Parenthetical) Sheet http://cel-sci.com/role/StatementsOfOperationsParenthetical STATEMENTS OF OPERATIONS (Parenthetical) false false R6.htm 0006 - Statement - STATEMENTS OF CASH FLOWS Sheet http://cel-sci.com/role/StatementsOfCashFlows STATEMENTS OF CASH FLOWS false false R7.htm 0007 - Disclosure - A. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://cel-sci.com/role/A.SummaryOfSignificantAccountingPolicies A. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES false false R8.htm 0008 - Disclosure - B. NEW ACCOUNTING PRONOUNCEMENTS Sheet http://cel-sci.com/role/B.NewAccountingPronouncements B. NEW ACCOUNTING PRONOUNCEMENTS false false R9.htm 0009 - Disclosure - C. STOCKHOLDERS EQUITY Sheet http://cel-sci.com/role/C.StockholdersEquity C. STOCKHOLDERS EQUITY false false R10.htm 0010 - Disclosure - D. FAIR VALUE MEASUREMENTS Sheet http://cel-sci.com/role/D.FairValueMeasurements D. FAIR VALUE MEASUREMENTS false false R11.htm 0011 - Disclosure - E. LOANS FROM OFFICER Sheet http://cel-sci.com/role/E.LoansFromOfficer E. LOANS FROM OFFICER false false R12.htm 0012 - Disclosure - F. OPERATIONS, FINANCING Sheet http://cel-sci.com/role/F.OperationsFinancing F. OPERATIONS, FINANCING false false R13.htm 0013 - Disclosure - G. COMMITMENTS AND CONTINGENCIES Sheet http://cel-sci.com/role/G.CommitmentsAndContingencies G. COMMITMENTS AND CONTINGENCIES false false R14.htm 0014 - Disclosure - H. PATENTS Sheet http://cel-sci.com/role/H.Patents H. PATENTS false false R15.htm 0015 - Disclosure - I. NET LOSS PER SHARE Sheet http://cel-sci.com/role/I.NetLossPerShare I. NET LOSS PER SHARE false false R16.htm 0016 - Disclosure - J. SUBSEQUENT EVENTS Sheet http://cel-sci.com/role/J.SubsequentEvents J. SUBSEQUENT EVENTS false false R17.htm 0017 - Disclosure - A. ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (POLICIES) Sheet http://cel-sci.com/role/A.OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies A. ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (POLICIES) false false R18.htm 0018 - Disclosure - C. STOCKHOLDERS EQUITY (Tables) Sheet http://cel-sci.com/role/C.StockholdersEquityTables C. STOCKHOLDERS EQUITY (Tables) false false R19.htm 0019 - Disclosure - D. FAIR VALUE MEASUREMENTS (Tables) Sheet http://cel-sci.com/role/D.FairValueMeasurementsTables D. FAIR VALUE MEASUREMENTS (Tables) false false R20.htm 0020 - Disclosure - H. PATENTS (Tables) Sheet http://cel-sci.com/role/H.PatentsTables H. PATENTS (Tables) false false R21.htm 0021 - Disclosure - I. NET LOSS PER SHARE (Tables) Sheet http://cel-sci.com/role/I.NetLossPerShareTables I. NET LOSS PER SHARE (Tables) false false R22.htm 0022 - Disclosure - C. STOCKHOLDERS EQUITY (Details) Sheet http://cel-sci.com/role/C.StockholdersEquityDetails C. STOCKHOLDERS EQUITY (Details) false false R23.htm 0023 - Disclosure - C. STOCKHOLDERS EQUITY (Details 1) Sheet http://cel-sci.com/role/C.StockholdersEquityDetails1 C. STOCKHOLDERS EQUITY (Details 1) false false R24.htm 0024 - Disclosure - C. STOCKHOLDERS EQUITY (Details 2) Sheet http://cel-sci.com/role/C.StockholdersEquityDetails2 C. STOCKHOLDERS EQUITY (Details 2) false false R25.htm 0025 - Disclosure - C. STOCKHOLDERS EQUITY (Details 3) Sheet http://cel-sci.com/role/C.StockholdersEquityDetails3 C. STOCKHOLDERS EQUITY (Details 3) false false R26.htm 0026 - Disclosure - C. STOCKHOLDERS EQUITY (Details Narrative) Sheet http://cel-sci.com/role/C.StockholdersEquityDetailsNarrative C. STOCKHOLDERS EQUITY (Details Narrative) false false R27.htm 0027 - Disclosure - D. FAIR VALUE MEASUREMENTS (Details) Sheet http://cel-sci.com/role/D.FairValueMeasurementsDetails D. FAIR VALUE MEASUREMENTS (Details) false false R28.htm 0028 - Disclosure - D. FAIR VALUE MEASUREMENTS (Details 1) Sheet http://cel-sci.com/role/D.FairValueMeasurementsDetails1 D. FAIR VALUE MEASUREMENTS (Details 1) false false R29.htm 0029 - Disclosure - E. LOANS FROM OFFICER (Details Narrative) Sheet http://cel-sci.com/role/E.LoansFromOfficerDetailsNarrative E. LOANS FROM OFFICER (Details Narrative) false false R30.htm 0030 - Disclosure - G. COMMITMENTS AND CONTINGENCIES (Details Narrative) Sheet http://cel-sci.com/role/G.CommitmentsAndContingenciesDetailsNarrative G. COMMITMENTS AND CONTINGENCIES (Details Narrative) false false R31.htm 0031 - Disclosure - H. PATENTS (Details) Sheet http://cel-sci.com/role/H.PatentsDetails H. PATENTS (Details) false false R32.htm 0032 - Disclosure - H. PATENTS (Details Narrative) Sheet http://cel-sci.com/role/H.PatentsDetailsNarrative H. PATENTS (Details Narrative) false false R33.htm 0033 - Disclosure - I. NET LOSS PER SHARE (Details) Sheet http://cel-sci.com/role/I.NetLossPerShareDetails I. NET LOSS PER SHARE (Details) false false R34.htm 0034 - Disclosure - I. NET LOSS PER SHARE (Details Narrative) Sheet http://cel-sci.com/role/I.NetLossPerShareDetailsNarrative I. NET LOSS PER SHARE (Details Narrative) false false All Reports Book All Reports Process Flow-Through: 0002 - Statement - BALANCE SHEETS Process Flow-Through: Removing column 'Dec. 31, 2012' Process Flow-Through: Removing column 'Sep. 30, 2012' Process Flow-Through: 0003 - Statement - BALANCE SHEETS (Parenthetical) Process Flow-Through: 0004 - Statement - STATEMENTS OF OPERATIONS Process Flow-Through: 0005 - Statement - STATEMENTS OF OPERATIONS (Parenthetical) Process Flow-Through: 0006 - Statement - STATEMENTS OF CASH FLOWS cvm-20131231.xml cvm-20131231.xsd cvm-20131231_cal.xml cvm-20131231_def.xml cvm-20131231_lab.xml cvm-20131231_pre.xml true true XML 49 R20.htm IDEA: XBRL DOCUMENT v2.4.0.8

H. PATENTS (Tables)
3 Months Ended

Dec. 31, 2013

H. Patents Tables

Schedule of total estimated future amortization

Nine months ending September 30, 2014 $ 25,252

Year ending September 30,

2015 33,795

2016 33,795

2017 33,795

2018 33,461

2019 31,758

Thereafter 125,604

Total $ 317,460

X

- Details

Name: CVM_PatentsTablesAbstract

Namespace Prefix: CVM_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=14024403&loc=d3e13816-109267

+ Details

Name: us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

C. STOCKHOLDERS EQUITY (Details 3) (USD $)	Dec. 31, 2013	Sep. 30, 2013
C. Stockholders Equity Details 3
Series A through E	$ 6,106	$ 6,106
Series N	531,255	41,501
Series F and G warrants	12,667	12,667
Series H warrants	12,000	36,000
Series Q warrants	24,000	48,000
Series R warrants	157,500	288,750
Series S warrants	5,339,750
Total derivative liabilities	$ 6,143,278	$ 433,024

E. LOANS FROM OFFICER (Details Narrative) (USD $)	3 Months Ended
E. LOANS FROM OFFICER (Details Narrative) (USD $)	Dec. 31, 2013	Dec. 31, 2012
E. Loans From Officer Details Narrative
Interest expense paid to Mr. de Clara	$ 55,203	$ 41,402

D. FAIR VALUE MEASUREMENTS (Details 1) (USD $)	3 Months Ended	12 Months Ended
D. FAIR VALUE MEASUREMENTS (Details 1) (USD $)	Dec. 31, 2013	Sep. 30, 2013
D. Fair Value Measurements Details 1
Beginning balance	$ 433,024	$ 6,983,690
Issuances	7,321,071	4,200,000
Settlements
Realized and unrealized gains recorded in Earnings Recorded in earnings	(1,610,817)	(10,750,666)
Ending balance	$ 6,143,278	$ 433,024

H. PATENTS (Details) (USD $)	Dec. 31, 2013
H. Patents Details
Three months ending September 30, 2014	$ 25,252
Year ending September 30, 2015	33,795
Year ending September 30, 2016	33,795
Year ending September 30, 2017	33,795
Year ending September 30, 2018	33,461
Year ending September 30, 2019	31,758
Thereafter	125,604
Total	$ 317,460

B. NEW ACCOUNTING PRONOUNCEMENTS	3 Months Ended
B. NEW ACCOUNTING PRONOUNCEMENTS	Dec. 31, 2013
Accounting Changes and Error Corrections [Abstract]
B. NEW ACCOUNTING PRONOUNCEMENTS	There are no significant new accounting pronouncements that would impact the condensed financial statements.

H. PATENTS (Details Narrative) (USD $)	3 Months Ended
H. PATENTS (Details Narrative) (USD $)	Dec. 31, 2013	Dec. 31, 2012
H. Patents Details Narrative
Patent impairment charges	$ 240	$ 10,223
Amortization of patent costs	$ 9,703	$ 23,905

BALANCE SHEETS (USD $)	Dec. 31, 2013	Sep. 30, 2013
ASSETS
Cash and cash equivalents	$ 13,494,028	$ 41,612
Receivables	45,879	74,263
Prepaid expenses	988,699	780,523
Deposits - current portion	150,000	0
Inventory used for R&D and manufacturing	1,347,257	1,016,628
Deferred rent - current portion	585,156	598,717
Total current assets	16,611,019	2,511,743
RESEARCH AND OFFICE EQUIPMENT AND LEASEHOLD IMPROVEMENTS-- less accumulated depreciation depreciation and amortization of $3,010,439 and $2,967,345	463,053	489,336
PATENT COSTS--less accumulated amortization of $1,148,214 and $1,313,046	317,460	318,195
DEFERRED RENT - net of current portion	5,285,781	5,448,381
DEPOSITS	2,120,917	2,070,917
TOTAL ASSETS	24,798,230	10,838,572
LIABILITIES AND STOCKHOLDERS' EQUITY
Accounts payable	1,627,765	1,924,482
Accrued expenses	346,401	113,496
Due to employees	280,464	386,337
Related party loan	1,104,057	1,104,057
Deferred rent - current portion	9,274	8,529
Lease obligations - current portion	11,463	8,212
Total current liabilities	3,379,424	3,545,113
Derivative instruments	6,143,278	433,024
Deferred revenue	126,545	126,545
Deferred rent-net of current portion	6,381	7,875
Lease obligations - net of current portion	24,445	20,925
Deposits held	5,000	5,000
Total liabilities	9,685,073	4,138,482
COMMITMENTS AND CONTINGENCIES	0	0
STOCKHOLDERS' EQUITY
Preferred stock, $.01 par value - authorized 200,000 shares, issued and outstanding, -0-	0	0
Common stock, $.01 par value - authorized 600,000,000 shares; issued and outstanding 55,852,992 shares and 31,025,019 shares issued and outstanding at December 31, 2013 and September 30, 2013, respectively	558,530	310,250
Additional paid-in capital	231,049,613	218,550,408
Accumulated deficit	(216,494,986)	(212,160,568)
Total stockholders' equity	15,113,157	6,700,090
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 24,798,230	$ 10,838,572

STATEMENTS OF CASH FLOWS (USD $)	3 Months Ended
STATEMENTS OF CASH FLOWS (USD $)	Dec. 31, 2013	Dec. 31, 2012
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (4,334,418)	$ (2,310,246)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	56,699	133,450
Issuance of common stock, warrants and options for services	137,729	54,485
Modification of warrants issued for services	76,991	0
Employee option cost	510,278	966,585
Common stock contributed to 401 (k) plan	37,887	39,711
Impairment loss on abandonment of patents	240	10,223
Loss on retired equipment	0	2,011
Gain on derivative instruments	(1,610,817)	(2,746,198)
(Increase)/decrease in assets:
Receivables	28,384	143,714
Deferred rent	176,161	139,536
Prepaid expenses	(210,367)	471,936
Inventory used for R&D and manufacturing	(330,629)	247,585
Deposits	(200,000)	0
Increase/(decrease) in liabilities:
Accounts payable	(380,943)	(192,358)
Accrued expenses	232,905	23,252
Due to employees	(105,873)	20,843
Deferred rent liability	(749)	688
Net cash used in operating activities	(5,916,522)	(2,994,783)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of equipment	(8,587)	(16,093)
Expenditures for patent costs	0	(125)
Net cash used in investing activities	(8,587)	(16,218)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock and warrants	19,380,190	9,807,375
Payments on oblgations under capital leases	2,665	1,025
Net cash provided by financing activities	19,377,525	9,806,350
NET INCREASE IN CASH AND CASH EQUIVALENTS	13,452,416	6,795,349
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD	41,612	3,941,042
CASH AND CASH EQUIVALENTS, END OF PERIOD	13,494,028	10,736,391
ISSUANCE OF WARRANTS:
Increase in derivative liabilities	(7,321,071)	(4,200,000)
Decrease in additional paid-in capital	7,321,071	4,200,000
Total	0	0
ISSUANCE OF ADDITIONAL SHARES
Increase in common stock	(15,631)	0
Increase in additional paid-in capital	(1,101,786)	0
Decrease in additional paid-in capital	1,117,417	0
Total	0	0
ISSUANCE OF COMMON STOCK FOR PREPAID SERVICES:
Increase in additional paid-in capital	(55,362)	(236,165)
Increase in prepaid expenses	55,362	236,165
Total	0	0
PATENT COSTS INCLUDED IN ACCOUNTS PAYABLE
Increase in patent costs	9,208	8,641
Increase in accounts payable	(9,208)	(8,641)
Total	0	0
NON CASH RESEARCH AND OFFICE EQUIPMENT PURCHASES
Increase in research and office equipment	(12,126)	(36,622)
Increase in accounts payable	(2,664)	0
Increase in capital lease obligation	9,462	36,622
Total	0	0
CAPITAL LEASE PAYMENTS INCLUDED IN ACCOUNTS PAYABLE:
Decrease in capital lease obligation	26	1,105
Increase in accounts payable	(26)	(1,105)
Total	0	0
OFFERING COSTS INCLUDED IN ACCOUNTS PAYABLE:
Decrease additional paid-in capital	72,328	0
Increase in accounts payable	(72,328)	0
Total	0	0
SUPPLEMENTAL DISCLOSURE OF CASH FLOWS INFORMATION:
Cash expenditures for interest expense	$ 56,509	$ 41,878

C. STOCKHOLDERS EQUITY (Details 2) (USD $)	Dec. 31, 2013
Series N [Member]
STOCKHOLDERS' EQUITY
Issue Date	Aug. 18, 2008
Shares Issuable upon Exercise of Warrant	2,951,420
Exercise Price	$ 0.53
Expiration Date	Aug. 18, 2014
Series A [Member]
STOCKHOLDERS' EQUITY
Issue Date	Jun. 24, 2009
Shares Issuable upon Exercise of Warrant	130,347
Exercise Price	$ 5.00
Expiration Date	Dec. 24, 2014
CSchleuningSeriesAMember
STOCKHOLDERS' EQUITY
Issue Date	Jul. 08, 2009
Shares Issuable upon Exercise of Warrant	16,750
Exercise Price	$ 5.00
Expiration Date	Jan. 08, 2015
Series B [Member]
STOCKHOLDERS' EQUITY
Issue Date	Sep. 04, 2009
Shares Issuable upon Exercise of Warrant	50,000
Exercise Price	$ 6.80
Expiration Date	Sep. 04, 2014
Series C [Member]
STOCKHOLDERS' EQUITY
Shares Issuable upon Exercise of Warrant	463,487
Exercise Price	$ 5.50
Expiration Date	Feb. 20, 2015
Issue Start date	Aug. 20, 2009
Issue End Date	Aug. 26, 2009
Series E [Member]
STOCKHOLDERS' EQUITY
Issue Date	Sep. 21, 2009
Shares Issuable upon Exercise of Warrant	71,428
Exercise Price	$ 17.50
Expiration Date	Aug. 12, 2014
Series F [Member]
STOCKHOLDERS' EQUITY
Issue Date	Oct. 06, 2011
Shares Issuable upon Exercise of Warrant	1,200,000
Exercise Price	$ 4.00
Expiration Date	Oct. 06, 2014
Series G [Member]
STOCKHOLDERS' EQUITY
Issue Date	Oct. 06, 2011
Shares Issuable upon Exercise of Warrant	66,667
Exercise Price	$ 4.00
Expiration Date	Aug. 12, 2014
Series H [Member]
STOCKHOLDERS' EQUITY
Issue Date	Jan. 26, 2012
Shares Issuable upon Exercise of Warrant	1,200,000
Exercise Price	$ 5.00
Expiration Date	Aug. 01, 2015
Series Q [Member]
STOCKHOLDERS' EQUITY
Issue Date	Jun. 21, 2012
Shares Issuable upon Exercise of Warrant	1,200,000
Exercise Price	$ 5.00
Expiration Date	Dec. 22, 2015
SeriesRMember
STOCKHOLDERS' EQUITY
Issue Date	Dec. 06, 2012
Shares Issuable upon Exercise of Warrant	2,625,000
Exercise Price	$ 4.00
Expiration Date	Dec. 06, 2016
Series S
STOCKHOLDERS' EQUITY
Shares Issuable upon Exercise of Warrant	25,713,095
Exercise Price	$ 1.25
Expiration Date	Oct. 11, 2018
Issue Start date	Oct. 11, 2013
Issue End Date	Dec. 24, 2013
Series L [Member]
STOCKHOLDERS' EQUITY
Issue Date	Apr. 18, 2007
Shares Issuable upon Exercise of Warrant	25,000
Exercise Price	$ 7.50
Expiration Date	Apr. 17, 2014
Series L Repriced [Member]
STOCKHOLDERS' EQUITY
Issue Date	Apr. 18, 2007
Shares Issuable upon Exercise of Warrant	70,000
Exercise Price	$ 2.50
Expiration Date	Apr. 02, 2015
Series M Modified
STOCKHOLDERS' EQUITY
Issue Date	Apr. 18, 2007
Shares Issuable upon Exercise of Warrant	500,000
Exercise Price	$ 1.00
Expiration Date	Apr. 20, 2014
Series P [Member]
STOCKHOLDERS' EQUITY
Issue Date	Feb. 10, 2012
Shares Issuable upon Exercise of Warrant	590,001
Exercise Price	$ 4.50
Expiration Date	Mar. 06, 2017
Private Investors [Member]
STOCKHOLDERS' EQUITY
Shares Issuable upon Exercise of Warrant	740,938
Issue Start date	Jul. 18, 2005
Issue End Date	Jun. 30, 2009
Expiration start date	Jan. 26, 2014
Expiration end date	Jul. 18, 2014
Exercise Price Minimum	$ 5.60
Exercise Price Maximum	$ 8.20
Warrants Held by Officer And Director [Member]
STOCKHOLDERS' EQUITY
Shares Issuable upon Exercise of Warrant	349,754
Issue Start date	Jun. 24, 2009
Issue End Date	Jul. 06, 2009
Expiration start date	Dec. 24, 2014
Expiration end date	Jan. 06, 2015
Exercise Price Minimum	$ 4.00
Exercise Price Maximum	$ 5.00
Consultants [Member]
STOCKHOLDERS' EQUITY
Shares Issuable upon Exercise of Warrant	200,750
Issue Start date	Feb. 15, 2005
Issue End Date	Oct. 28, 2013
Expiration start date	May 20, 2014
Expiration end date	Dec. 27, 2017
Exercise Price Minimum	$ 0.85
Exercise Price Maximum	$ 20.00

BALANCE SHEETS (Parenthetical) (USD $)	Dec. 31, 2013	Sep. 30, 2013
Assets
Accumulated Depreciation and Amortization for Research and Office Equipment and Leasehold Improvements	$ 3,010,439	$ 2,967,345
Accumulated Amortization for Patents	$ 1,161,540	$ 1,151,852
Stockholders Equity
Preferred Stock Shares Par Value	$ 0.01	$ 0.01
Preferred Stock Shares Authorized	200,000	200,000
Preferred Stock Shares Issued	0	0
Preferred Stock Shares Outstanding	0	0
Common Stock Shares Par Value	$ 0.01	$ 0.01
Common Stock Shares Authorized	600,000,000	600,000,000
Common Stock Shares Issued	55,852,992	31,025,019
Common Stock Shares Outstanding	55,852,992	31,025,019

Document and Entity Information	3 Months Ended
Document and Entity Information	Dec. 31, 2013	Feb. 04, 2014
Document And Entity Information
Entity Registrant Name	CEL SCI CORP
Entity Central Index Key	0000725363
Document Type	10-Q
Document Period End Date	Dec. 31, 2013
Amendment Flag	false
Current Fiscal Year End Date	--09-30
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		55,940,156
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2014

STATEMENTS OF OPERATIONS (USD $)	3 Months Ended
STATEMENTS OF OPERATIONS (USD $)	Dec. 31, 2013	Dec. 31, 2012
Income Statement [Abstract]
OTHER INCOME	$ 113,144	$ 15,000
OPERATING EXPENSES:
Research and development (excluding R&D depreciation of R&D depreciation of $41,673 and $104,864)	4,019,541	2,924,722
Depreciation and amortization	56,699	133,450
General & administrative	1,971,214	2,001,285
Total operating expenses	6,047,454	5,059,457
OPERATING LOSS	(5,934,310)	(5,044,457)
GAIN ON DERIVATIVE INSTRUMENTS	1,610,817	2,746,198
INTEREST INCOME	31,757	29,415
INTEREST EXPENSE	(42,682)	(41,402)
NET LOSS	(4,334,418)	(2,310,246)
ISSUANCE OF ADDITIONAL SHARES DUE TO RESET PROVISIONS	(1,117,447)	0
NET LOSS AVAILABLE TO COMMON SHAREHOLDERS	$ (5,451,865)	$ (2,310,246)
NET LOSS PER COMMON SHARE
BASIC	$ (0.11)	$ (0.08)
DILUTED	$ (0.15)	$ (0.18)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING
BASIC	48,215,919	28,311,602
DILUTED	48,215,919	28,311,602

C. STOCKHOLDERS EQUITY (Details 1) (USD $)	3 Months Ended
C. STOCKHOLDERS EQUITY (Details 1) (USD $)	Dec. 31, 2013	Dec. 31, 2012
C. Stockholders Equity Details 1
Employees	$ 510,278	$ 966,585
Non-employees	$ 214,720	$ 107,818

J. SUBSEQUENT EVENTS	3 Months Ended
J. SUBSEQUENT EVENTS	Dec. 31, 2013
Subsequent Events [Abstract]
J. SUBSEQUENT EVENTS	The Company has evaluated subsequent events through the date these financial statements were filed and determined there are no subsequent events that require disclosure.

I. NET LOSS PER SHARE (Details Narrative)	3 Months Ended
I. NET LOSS PER SHARE (Details Narrative)	Dec. 31, 2013	Dec. 31, 2012
I. Net Loss Per Share Details Narrative
Options and warrants excluded from earnings per share due to anti-dilutive effect	865,000	578,800

C. STOCKHOLDERS EQUITY (Details Narrative) (USD $)	3 Months Ended
C. STOCKHOLDERS EQUITY (Details Narrative) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Sep. 30, 2013
Options granted to employees and directors	0	1,437,466
Amount excluded from non-employee stock compensation expense for future services to be performed	$ 55,362		$ 57,553
Series A through E warrants
Gain on warrants	0	332,436
Series A [Member]
Warrants outstanding	130,347
Fair value of outstanding warrants	1,303		1,303
Private Investors [Member]
Warrants outstanding	16,750
Fair value of outstanding warrants	168		168
Series B [Member]
Warrants outstanding	50,000
Fair value of outstanding warrants	0		0
Series C [Member]
Warrants outstanding	463,487
Fair value of outstanding warrants	4,635		4,635
Series E [Member]
Warrants outstanding	71,428
Fair value of outstanding warrants	0		0
Series N [Member]
Loss on warrants	489,754
Gain on warrants		311,262
Warrants outstanding	2,951,420
Fair value of outstanding warrants	531,255		41,501
SeriesFAndGWarrantsMember
Gain on warrants	0	640,000
Fair value of outstanding warrants	12,667		12,667
Series H [Member]
Gain on warrants	24,000	600,000
Fair value of outstanding warrants	12,000		36,000
Series Q [Member]
Gain on warrants	24,000	600,000
Fair value of outstanding warrants	24,000		48,000
SeriesRMember
Gain on warrants	131,250	262,500
Fair value of outstanding warrants	157,500		288,750
Series S
Gain on warrants	1,921,321
Fair value of outstanding warrants	5,399,750
Series M Modified [Member]
Warrants outstanding	500,000
Series P [Member]
Warrants outstanding	590,001
Private Investor Warrants
Warrants outstanding	132,500
Private Investor Warrants
Warrants outstanding	378,750
Private Investor Warrants
Warrants outstanding	229,688
Warrants Held by Officer And Director [Member]
Warrants outstanding	349,754
Consultants [Member]
Warrants outstanding	200,750
Expense recorded for consulting arrangement	137,729	1,985
Prepaid consulting expenses	$ 55,362		$ 57,553

STATEMENTS OF OPERATIONS (Parenthetical) (USD $)	3 Months Ended
STATEMENTS OF OPERATIONS (Parenthetical) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Expenses
Depreciation	$ 41,673	$ 104,864

D. FAIR VALUE MEASUREMENTS (Details) (USD $)	Dec. 31, 2013	Sep. 30, 2013
Level1
Derivative instruments
Level2
Derivative instruments
Level3
Derivative instruments	6,143,278	433,024
Total
Derivative instruments	$ 6,143,278	$ 433,024